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Abstract 
 
 
Genetic immunization, also known as DNA or polynucleotide immunisation, is well 
documented to induce broad-based immunity in various animal models of infectious and 
non-infectious diseases. However, the low potency of DNA vaccines has to date 
precluded the development of commercial vaccines. The aim of this study was to 
systematically investigate a number of parameters to improve the potency of DNA 
vaccines for use in chickens, using a low pathogenic avian influenza (LPAI) virus as a 
proof-of-concept for their ability to produce a humoral immune response.        
The index virus used in the study was avian influenza virus A/coot/WA/2727/79 (H6N2), 
isolated from an apparently healthy Eurasian coot in 1979.  Prior to any DNA 
experiments the virus was rigorously characterized. The virus strain was shown to be an 
H6 subtype by haemaglutination inhibition (HI) testing and as an N2 subtype by gene 
sequence analysis. The isolate was shown to be able to grow on MDCK cells in the 
absence of exogenous trypsin. It was further biologically characterized as LPAI with an 
intravenous pathogenicity index (IVPI) of 0.15 and a motif of 
321PQAETRG
328 at the 
cleavage site of the haemagglutinin (HA) protein. It was capable of infecting domestic 
chickens under experimental conditions with a low level of virus excretion via the cloaca 
and oropharynx following intravenous or oral and oculonasal inoculation.  
The full-length HA and nucleoprotein (NP) genes of this H6N2 virus were subsequently 
cloned into the eukaryotic expression vector VR1012 to generate VR-HA and VR-NP 
constructs. Six-week-old Hy-Line chickens were intramuscularly injected with either the 
VR-HA or VR-NP vaccine at different dose rates, with or without lipofectin as adjuvant.   iv
Minimal or no detectable antibody was produced, as measured by HI, ELISA and 
Western blotting-based assay, but high titres of H6-specific HI antibodies appeared 10 
days after homologous virus challenge. In contrast to the empty vector controls, there was 
a significant difference in HI antibody titre between pre- and post-challenge in vaccinated 
birds, indicating some evidence for the priming effect of the DNA vaccines. Using the 
frequency of virus shedding as an indicator of protection, lower doses (50 or 100 μg per 
chicken) of either adjuvanted VR-HA or VR-NP vaccine significantly reduced virus 
shedding in oropharyngeal and cloacal swabs compared to higher doses (300 or 500 μg 
per chicken ) or empty vector control chickens. Although two vaccinations with naked 
VR-HA alone were not sufficient to induce an effective immune response against a 
homologous virus challenge, further repeat vaccinations and incorporation of adjuvant 
did lead to the generation of low to moderate HI antibody titres in some chickens and 
resulted in no or reduced virus shedding after challenge. 
Next, to examine the effect of expression vector, three different DNA vectors, pCI, pCI-
neo and pVAX1 were used to clone the same HA gene and generate three DNA vaccine 
constructs. Once again, direct intramuscular injection of the three DNA constructs did not 
elicit measurable H6-specific HA antibody response in Hy-Line chickens but the 100 µg 
pCI-HA lipofectin adjuvanted vaccine group showed a significant increase in post-
challenge HI titres from the naive control group, indicating that an anamnestic antibody 
response had been induced by the pCI-HA DNA vaccination. Compared with the controls, 
the three DNA constructs showed significantly reduced virus shedding in cloacal swabs 
post virus challenge, suggesting that the three DNA vaccines induced some level of 
immune response in vaccinated chickens. As with the VR-HA construct, the lower dose   v
groups for each vaccine (50 or 100 μg) were more effective at reducing virus shedding 
from the cloaca than the higher dose group (300 μg).  
 To further investigate why the DNA vaccines did not elicit a measurable antibody 
response, the HA gene incorporating a Kozak enhancer sequence was cloned into an 
alternative expression vector, pCAGGS, to produce the pCAG-HAk construct. Three-
week-old SPF chickens were immunized with this construct either by the intramuscular 
route (IM) or electroporation (EP). H6 HI antibodies  were present in some chickens by 3 
weeks after the first IM vaccination and 75% of the chickens vaccinated with 10, 100 or 
300 µg pCAG-HAk were antibody positive by 2 weeks after the second IM vaccination. 
For EP immunization, 87.5% of vaccinated birds seroconverted after the first vaccination 
and 100% seroconverted after the second vaccination and the H6 HI antibody titres were 
significantly higher than for chickens vaccinated by IM inoculation. Another group was 
given a single dose IM vaccination with 100 µg of the pCAG-HAk construct and showed 
a maximum sero-conversion rate of 53.3% with a peak H6 HI titre of 2
7 at 5 weeks post-
vaccination. This demonstrated that optimization of the expression vector and insertion of 
a Kozak sequence could synergistically enhance expression of the H6 HA gene and result 
in a measurable H6 antibody response in SPF chickens. EP was also compared with IM 
inoculation with the 100 μg pCI-HA construct in SPF chickens, resulting in a 50% sero-
conversion rate and mean HI titre of 2
1.3 at 2 weeks after the second vaccination by EP. 
By comparison, only 25% chickens had trace HI titres by IM inoculation. This indicated 
that EP was more efficient than IM delivery for both constructs.  
A codon-optimized complete HA gene from A/coot/WA/2727/79 (H6N2) was then 
chemically synthesized and cloned into a pCAGGS vector to generate the pCAG-  vi
optiHAk construct. SPF chickens immunized twice with either 10 µg or 100 µg of 
pCAG-optHA showed 37.5% and 87.5% sero-conversion rates respectively, with a mean 
H6 HI tire of 2
1.4 and 2
2.6 at 3 weeks after the second immunization, but the differences 
were not statistically significant. There were also no significant differences in either the 
sero-conversion rate or the H6 HI titre between the pCAG-HAk and pCAG-optiHAk 
groups, suggesting that a codon-optimized HA DNA vaccine did not achieve significantly 
better immunogenicity than the pCAG-HAk vaccine.  
In vitro expression of the developed DNA constructs in chicken-, hamster-, monkey- and 
human-origin cells, as measured by Western blotting and immunofluorescence testing 
(IFT), showed the strength of H6 HA expression in the following descending order - 
pCAG-optiHAk/pCAG-HAk, pCI-HAk, VR-HA, pCI-HA, pCIneo-HA and pVAX-HA. 
The in vivo chicken vaccinations also showed that the pCI-HA construct was more 
effective than the pCI-neo-HA, and that the pCAG-optiHA or pCAG-HAk constructs 
were better than pCI-HAk in term of reduction in virus shedding after H6N2 virus 
challenge.  Thus, in vitro HA gene expression directly correlated with the generation of 
immune responses in vivo, indicating that in vitro studies can be used for pre-selection of 
expression plasmids prior to development of avian influenza DNA vaccines. 
Lipofectin as a chemical adjuvant was shown to enhance the DNA-induced immune 
response but is prohibitively expensive for routine use in poultry vaccines. Thus, an 
experimental adjuvant for poultry DNA vaccines (Essai) and a new nanoparticle (Phema) 
adjuvant used for the first time in poultry were compared with conventional aluminum 
salts (alum) adjuvant in the present study. No HI antibody was detected in any adjuvant-
vaccinated Hy-Line chickens following two immunizations. However, in comparison  vii
with the naive control group, the alum- and Phema adjuvanted pCAG-HAk groups 
significantly reduced the frequency of virus shedding in oropharyngeal swabs, but Essai 
adjuvant was not effective in augmenting the pCAG-HAk vaccine efficacy. This pilot 
study also emphasised that the traditional aluminum hydroxide adjuvant, either DNA 
binding or non-binding, may be useful as an adjuvant for enhancing DNA-induced 
immune responses in chickens owing to its low price and safety record.  
Overall, DNA immunization with various HA-expressing constructs was shown to be 
variably effective in inducing immune responses in chickens. The efficacy of DNA 
vaccines could be synergistically improved by taking appropriate approaches. With 
continuing research DNA vaccines have the potential to become an important tool for 
disease prevention and control.  
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Chapter 1 
Introduction and Literature Review  
 
1.1 Introduction  
Avian influenza (AI) is a disease of birds, and occasionally other mammals and humans, 
caused by any type A avian influenza virus (Easterday and Hinshaw 1991). Although 
listed as a notifiable disease by the World Organization for Animal Health (OIE), the 
majority of AI viruses do not cause significant diseases in birds (OIE 2008). The very 
virulent AI viruses, generally restricted to subtypes H5 and H7, can cause highly 
pathogenic avian influenza (HPAI) which was first described in 1959 in Scotland due to 
A/chicken/Scotland/59 (H5N1) (Alexander 2000; Pereira et al. 1965).  
Since late 2003, the apparently unprecedented emergence and worldwide spread of the 
H5N1 HPAI virus and resultant fears of a pandemic outbreak have brought AI to the 
forefront of important animal diseases (Alexander 2007). Vaccination is a powerful and 
cost-effective tool to combat AI for either emergency or prophylactic purposes in large 
scale outbreaks (Capua and Marangon 2007b). Although successful in prevention and 
control of avian influenza epizootics, traditional protein-based vaccines such as whole, 
inactivated or live, recombinant vectored virus vaccines have some inherent limitations. 
These include safety issues due to use of live virus in vaccine production, variable 
immunity due to vector immunity for live recombinant vaccine vectors, and a heavy 
reliance on chicken embryonated eggs for vaccine production (Ben-Yedidia and Arnon 
2005; Capua and Marangon 2007a; Greenland and Letvin 2007; Leitner et al. 1999). 
With the difficulties in controlling the current H5N1 epizootic in multiple countries using   2
existing strategies, including vaccination, there is a clear need to examine alternative 
vaccine strategies. 
Genetic immunization, also referred to as DNA or polynucleotide immunization, 
represents a novel strategy for vaccine development, in which plasmid DNA encoding 
foreign antigens is directly administered to a host and leads to induction of a specific 
immune response to the in vivo produced antigens (Cohen et al. 1998). In contrast to 
currently used vaccines, immunization with DNA confers a cytotoxic T lymphocyte 
(CTL) response via the major histocompatibility complex (MHC) class I-restricted 
pathway, and a humoral response, as well as a helper T lymphocyte (Th) response via 
MHC class II-restricted pathway (Donnelly et al. 2005). DNA vaccines are likely to be 
attractive owing to reduced safety concerns in comparison with the use of live viruses in 
conventional vaccine production, expeditious vaccine development and production, 
relative ease of manufacture in large quantities, and more robustness regarding 
transportation and storage requirements (Donnelly et al. 1997b; Gurunathan et al. 2000; 
Lalor et al. 2008). Thus, DNA vaccines have the potential to address many of the 
shortcomings of current vaccines and show great potential for application to large scale 
vaccination for avian influenza. 
DNA vaccines have been developed to protect against a number of pathogens in a range 
of animals (Donnelly et al. 1997b; Dufour 2001; Liu and Ulmer 2005). DNA vaccines 
encoding different genes of influenza type A viruses have been demonstrated to generate 
variable immune responses in several different species, including mice (Epstein et al. 
2002; Kodihalli et al. 2000) , chickens (Kodihalli et al. 1997; Robinson et al. 1993), 
swine (Heinen et al. 2002; Macklin et al. 1998), ferrets (Ljungberg et al. 2002; Webster   3
et al. 1994), and nonhuman primates (Liu et al. 1997). However, the mechanism of DNA 
vaccines has not yet been fully elucidated. Low immunogenicity and inter-individual 
variability are considered to be the main bottlenecks for development of commercial 
DNA vaccines (Mir et al. 1999) . In this study a comprehensive study has been conducted 
for the first time to develop DNA vaccines against an LPAI virus (H6N2) as opposed to 
DNA vaccines against HPAI viruses, to investigate if this can provide information on 
immunogenicity and variability in DNA vaccines. 
Studies on a DNA vaccine encoding the M2 protein of influenza virus showed 
contradictory results in a mouse or swine model, emphasizing the need to evaluate 
vaccine efficacy in appropriate animal models (Heinen et al. 2002). It is believed that 
DNA vaccines show success in mouse models but are unsatisfactory in larger animals 
and humans (Abdulhaqq and Weiner 2008). This experience emphasizes the need to 
choose the appropriate animal models for evaluation of vaccine efficacy (Kemble and 
Greenberg 2003; Kodihalli et al. 2000). In this thesis the chicken, a natural host for avian 
influenza and one in which DNA vaccines may be used, was chosen to assess the efficacy 
of AI DNA vaccines that were developed. 
For Australian biosecurity reasons, the virus selected for the development of an avian 
influenza DNA vaccine was restricted to a low pathogenic avian influenza (LPAI) virus 
as any research relating to HPAI viruses is restricted to the Australian Animal Health 
Laboratory (AAHL), CSIRO, Geelong, Australia. Avian influenza virus A/Eurasian 
coot/Western Australia/2727/1979 (H6N2) (A/coot/WA/2727/79) was isolated from a 
healthy eurasian coot (Fulica atra) in Western Australia in the 1970’s, as part of an 
international program on the ecology of influenza in Australia supported by the World   4
Health Organization (WHO) (Mackenzie et al. 1984). Thus, this study was conducted as 
a proof-of-concept project for an avian influenza DNA vaccine in chickens. 
Initial characterization of the virus was performed at the Virology Laboratory, 
Department of Agriculture and Food of Western Australia (DAFWA). Development of 
several DNA vaccines using different vectors and adjuvants was conducted at the the 
State Agricultural Biotechnology Centre (SABC) at the Murdoch University. Vaccine 
evaluation studies were conducted mainly in the Animal Houses and Animal Isolation 
House at Murdoch University and partially (Chapter 3) at an AEC-approved free-range 
pen at Jandakot, Western Australia with approval of the Animal Ethics Committee (AEC) 
and Institutional Biosafety Committee at Murdoch University. The chickens used were 
supplied by Altona Hatchery Pty. Ltd., Australia. The flock of origin was avian influenza 
free and the chickens were influenza A antibody negative. 
The study relating to use of an additional pCAGGS vector and codon optimization of the 
HA gene (Chapter 5 and 6) was conducted at the Avian Influenza Reference Laboratory 
at Harbin Veterinary Research Institute (HVRI), China under a placement studentship 
from the Australian Biosecurity Cooperative Research Centre (AB-CRC).  
1.2 Avian influenza virus  
1.2.1 Virus structure, genome and classification 
Avian influenza is caused by avian influenza virus (AIV), which belongs to the genus 
influenzavirus A in the family Orthomyxoviridae (Easterday and Hinshaw 1991). 
Influenza viruses are medium-sized (80-120 nm in diameter), pleomorphic RNA viruses 
with a host-derived lipid bilayer envelope covered with about 500 projecting glycoprotein   5
spikes with haemagglutinating and neuraminidase activities (OIE 2008; Perez et al. 2005). 
The viral genome consists of eight segments of single-stranded, negative sense RNA, 
totaling approximately 14 kilobases, and encodes for 11 viral proteins (Chen et al. 2004; 
McGeoch et al. 1976) (Figure 1.1). Segments 1, 2 and 3, about half of the total genome, 
encode for the three viral polymerases (PA, PB1and PB2). An alternative open reading 
frame (ORF) near the 5’ end of the PB1 gene encodes for the 90-amino acid-long PB1-F2 
polypeptide, which has apoptotic or pro-apoptotic properties and may contribute to the 
pathogenicity and lethality of influenza type A viruses (Chen et al. 2004). Segment 5 
encodes the nucleoprotein (NP). Segments 4 and 6 encode for the two external 
glycoproteins, haemaggglutinin (HA) and neuraminidase (NA), respectively. The two 
smallest segments (7 and 8) encode two genes each with overlapping reading frames. 
Segment 7 encodes two matrix proteins: M1, the most abundant protein in the influenza 
virion, forms a shell surrounding the virion nucleocapsids and initiates progeny virus 
assembly and M2, that has ion channel activity, is embedded in the viral envelope. 
Segment 8 encodes for a nonstructural protein (NS1) that is the only protein which is not 
packaged into the virus particle and which blocks the host’s antiviral response, and NS2 
or NEP (nuclear export protein) that participates in the assembly of virus particles (Palese 
and Shaw 2007; Steinhauer and Skehel 2002; Tamura et al. 2005; Webster et al. 1992). 
The HA protein is a glycosylated integral membrane protein presented in a homotrimer 
form on the surface of the virus, which mediates adsorption and penetration of virus 
during infection. The protein NA is an integral membrane glycoprotein in a 
homotetramer form that promotes the release of virus particles from host cell receptors 
(Palese and Shaw 2007; Suarez and Schultz-Cherry 2000b). Two surface glycoproteins,   6
HA and NA, undergo gradual, continuous minor antigenic changes due to point mutations 
in the HA and NA genes, referred to as antigenic drift. This phenomenon occurs in all 
influenza A viruses due to the lack of a proof reading system for the RNA polymerases. 
Owing to the segmented nature of the viral genome, the exchange of RNA segments, 
called genetic reassortment, between two genotypically different AI viruses infecting the 
same host cell may potentially result in the generation of a novel strain and/or subtype, 
which can lead to major antigenic changes in the HA or NA genes. This is referred to as 
antigenic shift. The emergence of these resultant virus strains with different antigenic and 
other characteristics, including enhanced human infectivity, may result in influenza 
pandemics (Easterday and Hinshaw 1991; Palese and Shaw 2007; Tamura et al. 2005). 
 
 
Figure 1.1  Schematic diagram of an influenza A virus. 
(Modified from http://avianflu.umd.edu/Avian_Influenza_Program/Avianflu.html) 
 
Influenza viruses are divided into types A, B, or C on the basis of the antigenic nature of 
M1 and NP proteins (Suarez and Schultz-Cherry 2000b). Type B and C viruses generally 
only infect humans, but the type A viruses infect humans, pigs, horses, mink, felids, 
marine mammals, and a wide variety of domesticated and wild birds (Olsen et al. 2006;   7
Tamura et al. 2005). Type A viruses are further subdivided into subtypes based on the 
antigenic differences in the HA and NA molecules. At present, there are 16 
haemagglutinin (H1–H16) and 9 neuraminidase (N1–N9) subtypes. Each virus has one H 
and one N antigen subtype. All H and N subtypes of influenza A virus in the majority of 
possible combinations have been isolated from avian species (Alexander 2000; Palese 
and Shaw 2007; Tamura et al. 2005). 
1.2.2 Avian influenza biotypes  
Avian influenza viruses can be subdivided into two biotypes, designated low pathogenic 
avian influenza (LPAI) and highly pathogenic avian influenza (HPAI) (Werner and 
Harder 2006). Infection of poultry with LPAI viruses can be associated with a spectrum 
of clinical signs from asymptomatic infections, mild to severe respiratory disease, growth 
rate and egg production losses. Infection of susceptible poultry with HPAI viruses, 
previously referred to as ‘fowl plague', can cause severe disease with high morbidity and 
mortality. Virus biotypes are determined by pathogenicity tests, e.g. intravenous 
pathogenicity index (IVPI), with strains considered to be highly pathogenic if the 
inoculation of a minimum of eight susceptible 4–8-week-old chickens with index virus 
strains causes more than 75% mortality within 10 days or has an IVPI of greater than 1.2. 
To date, HPAI viruses have only been associated with the H5 and H7 subtypes exhibiting 
multiple basic amino acids at the cleavage site of the HA molecules. This molecular 
characteristic of the HA provides an accurate indicator of virulence or potential virulence 
as multiple basic amino acid motifs at the cleavage site facilitate cleavage by weak 
proteases such as furin, whereas, the LPAI viruses require strong proteases like trypsin 
found in the respiratory and gastrointestinal mucosa. Most H5 or H7 isolates of low   8
virulence show the amino acid motif at the cleavage site of either -PEIPKGR*GLF- or -
PENPKGR*GLF- (Alexander 2008; OIE 2008). Since 2004, due to the risk of a H5 or 
H7 virus of low virulence becoming virulent by mutation in poultry, all H5 and H7 
viruses are now designated as notifiable avian influenza (NAI) viruses. NAI viruses are 
now further divided into highly pathogenic notifiable avian influenza (HPNAI) and low 
pathogenic notifiable avian influenza (LPNAI) according to the HA0 cleavage site amino 
acid sequence and strain virulence for chickens by pathogenicity tests. Non-H5 or non-
H7 AI viruses which are not highly pathogenic in chickens are classified as LPAI 
(Alexander 2000; Capua and Alexander 2004b; OIE 2008) .  
To date all true HPAI are of H5 or H7 subtypes. However, at least two isolates, both of 
H10 subtype (H10N4 and H10N5) were classified as HPAI due to IVPI values >1.2 
according to both the OIE and EU definitions, whereas, they did not have multiple basic 
amino acids at the HA cleavage sites (Wood et al. 1996). These viruses caused no death 
or signs of disease when inoculated intranasally into chickens. On the contrary, four 
viruses containing multiple basic amino acids at the HA cleavage sites showed low 
virulence (IVPI <1.2) (Londt et al. 2007). Other unusual strains are H7N3 HPAI viruses 
(IVPI>1.2) isolated in Chile in 2002 (Suarez et al. 2004) and in Canada in 2004 (Pasick 
et al. 2005), which show the distinct and unusual cleavage site motif of 
PEKPKTCSPLSRCRETR*GLF and PENPKQAYRKRMTR*GLF, respectively. This is 
attributable to intragenic recombination between the HA, NP and M genes to give a virus 
with easily cleaved HA (OIE 2008). 
1.2.3 Viral antigens involved in immunity   9
At least four out of 11 viral proteins are important targets of the host immune response. 
Both HA and NA are the most important protective components among the viral proteins. 
In terms of protective immune responses, HA and NA readily induce antibody responses 
whereas NP elicits cell-mediated immunity (Sasaki et al. 2004; Suarez and Schultz-
Cherry 2000b; Tamura et al. 2005). Anti-HA antibodies block virus attachment to sialic 
acid receptors of the host cells and prevent infection, whereas, anti-NA antibodies bind 
viral NA glycoprotein at the cell surface to prevent the release of new virions from 
infected cells and hence accelerate the recovery from infection. Thus, the antibodies 
against HA and NA constitute the primary defence against homologous virus infection. In 
particular, antibody against the one virus is capable of neutralizing other viruses of the 
same HA or NA subtype, but does not cross-neutralize viruses of different HA and NA 
subtypes (Subbarao et al. 2006; Tamura et al. 2005). It is well accepted that these 
neutralizing antibodies produce immunological pressure and thus promote antigenic drift 
and shift in HA and NA proteins of influenza A viruses (Kodihalli et al. 1994). 
Antibody to HA is the main determinant for protection of the host from influenza virus 
infection. In poultry, vaccination for avian influenza is targeted primarily at the HA 
subtype, which has been demonstrated by subunit vaccines that only contain the HA 
protein (Swayne et al. 2000a). NA protein can also stimulate production of neutralizing 
antibody and NA-specific vaccines provided protection against a HPAI challenge in 
chickens (McNulty et al. 1986). It is thought that the NA protein is less important than 
HA protein in protection (Johansson et al. 1989; Suarez and Schultz-Cherry 2000b; 
Tamura et al. 2005). However, the administration to mice of a plasmid DNA mixture 
encoding HA or NA genes by gene gun (GG) provided almost complete protection   10
against subsequent influenza A/Puerto Rico/8/34 (H1N1) (PR8) virus challenge, 
accompanied by high levels of specific antibody responses to the respective components 
(Chen et al. 1999a). 
In contrast to the highly variable HA and NA proteins, the internal NP, M1 and M2 
proteins show little antigenic variability within influenza type A viruses. These proteins 
are potential candidate antigens for development of vaccines that might provide cell 
mediated immunity and that can give broad cross protection against multiple HA and NA 
subtypes (Kodihalli et al. 1994; Tamura et al. 2005). Antibodies to conserved NP and M1 
antigens have been utilised to detect type-specific antibody using agar gel 
immunodiffusion (AGID) and Enzyme-linked immunosorbent assay (ELISA) in chickens 
(Suarez and Schultz-Cherry 2000b). However, for a vaccine to prevent AI virus infection, 
NP and M1 antigens are not effective as antibodies to these proteins are not neutralizing 
and hence are not protective. The M2 protein has provided broad but limited cross-
protection in mice. This has not been demonstrated in chickens yet (Lalor et al. 2008; 
Suarez and Schultz-Cherry 2000b). 
1.2.4 General features of avian influenza virus epidemiology 
Influenza A viruses have been shown to infect a wide variety of birds and mammals. 
Wild waterfowl, gulls and shorebirds are thought to form the virus reservoir in nature 
(Alexander 2007; Horimoto and Kawaoka 2005; Suarez 2000; Webster et al. 1992). 
LPAI viruses have thus far been isolated from at least 105 wild bird species of 26 
families (Olsen et al. 2006). The actual number of susceptible species is possibly much 
greater (Alexander 2007). Influenza A virus-infected birds, showing no clinical signs, can 
transmit these viruses to other avian or mammalian populations and consequently may   11
seed these viruses to new geographic areas. If these LPAI viruses are introduced into a 
domestic poultry flock, most are either non-pathogenic or mildly pathogenic for poultry. 
However, some LPAI H5 and H7 isolates may undergo rapid spread in susceptible 
poultry and in this process progressively incorporate mutations giving multiple basic 
amino acids at the HA cleavage site or other virulence characteristics, becoming highly 
pathogenic and causing HPAI outbreaks (Alexander 2007; Normile 2005; Olsen et al. 
2006). It is believed that the wider the circulation of LPAI in poultry, the higher the 
posssiblity of mutation to HPAI (Alexander 2007). This is particularly so for H5 or H7 
subtype viruses (Garcia et al. 1996).  
The mechanisms by which influenza viruses are transmitted from one bird to another and 
cause infection are poorly understood, but this appears to depend on the strain of virus, 
the species of bird, and environmental factors (Alexander 2007). Historically, HPAI was 
regarded as a rare disease in domestic poultry with only 17 outbreaks recorded worldwide, 
five in turkeys and 12 in chickens, during the period from 1959 to 1998 (Alexander 2000; 
Capua and Alexander 2004a). However, there were a further eight HPAI outbreaks 
involving 12 countries from 1997 to March 2004 (Morris and Jackson 2005). Since late 
2003, there has been a dramatic increase in the number of outbreaks (a total of 2544 
H5N1 HPAI outbreaks from the end of 2003 to 15 July 2009) and infections have spread 
widely from Southeast Asia to other Asian countries, the Middle East, Europe and Africa, 
so that now over 50 countries have been affected (Lalor et al. 2008; OIE 2009). In 
addition to affecting land-based poultry, recent outbreaks have involved deaths in ducks, 
geese and a range of wild bird species as well as some feline species (Poland et al. 2007). 
In terms of the number of infected flocks and the geographical spread of the diseases, this   12
H5N1 virus lineage has caused the largest HPAI epizootic ever seen in the world (Sims et 
al. 2005; Stephenson 2006). This has not only resulted in tremendous losses to the world 
poultry industries and caused substantial loss of food resources in developing ountries, 
but as the virus has spread directly to humans and caused often-fatal infections, this has 
created fears of a devastating human pandemic outbreak with high mortality. 
Prior to 1997, it was believed that the avian influenza viruses were unable to be 
transmitted directly to humans due to the absence of an appropriate attachment site on the 
HA to bind to human cellular receptors (Beare and Webster 1991; Kodihalli et al. 1999). 
However, a novel H5N1avian influenza virus was transmitted directly from infected 
poultry to humans in Hong Kong in 1997, causing 18 confirmed infections and six deaths. 
This provided the first clear evidence that AI viruses could pass directly to humans (Claas 
et al. 1998; Subbarao et al. 1998). This virus disappeared after the total depopulation of 
poultry in Hong Kong in 1997. However, since then there have been further cases where 
human infections have resulted from contact with poultry during avian influenza 
outbreaks, caused by AI virus subtypes including H5N1 (Capua and Alexander 2004a),  
H7N3 (Tweed et al. 2004), H7N7 (Fouchier et al. 2004) , H9N2 (Peiris et al. 1999) and 
H10N7 (PAHO 2004). From 2003 to mid-2009 these viruses have infected at least 417 
humans in 15 countries and caused 257 deaths (WHO 2009).  
1.2.5 Prevention and control of avian influenza 
With this ongoing H5N1 HPAI panzootic in poultry and the risk of an H5N1 pandemic, a 
comprehensive multi-faceted control strategy needs to be undertaken.  This strategy is 
similar to control programs used for control of other HPAI outbreaks.  However, with the 
rapid onset of geographically diverse outbreaks in countries with variable animal health   13
resources during this H5N1 panzootic,  the OIE/FAO/WHO has recommended the 
following components: (a) enhanced biosecurity, (b) increased surveillance with effective 
diagnostic tests, (c) early detection and rapid confirmation of suspects, (d) rapid and 
transparent notification, (e) quarantine (including containment, management of poultry 
movement, zoning and compartmentalization), (f) stamping-out of outbreak cases, (g) 
vaccination, (h) other measures such as education, communication and mass media 
campaigns to increase public awareness and reduce panic and education of farmers and 
poultry workers on avian influenza control measures (FAO/WHO/OIE 2007; Swayne 
2006, 2009). Stamping out and depopulation plus enhanced biosecurity measures seems 
to be the most effective means of eradication of HPAI and this has worked in developed 
countries in previous H5 and H7 outbreaks and is probably the most effective method for 
limited outbreaks in non-densely populated poultry areas. However, stamping-out 
policies cannot be adopted in developing and undeveloped countries for logistical reasons, 
including loss of food resource, damage to the microeconomy and lack of funds to 
conduct campaigns and compensate poultry owners (Capua and Alexander 2004a). 
Vaccination has proven to be a powerful tool for control of H5N1 HPAI outbreaks, 
supporting eradication programs through increasing bird resistance to field virus 
challenge, reducing virus shedding levels in vaccinated birds and hence preventing virus 
transmission (Capua and Alexander 2004a; Capua and Marangon 2007b; van der Goot et 
al. 2005). Vaccination and companion DIVA (“differentiation infected from vaccinated 
animals”) testing, as well as quarantine and movement control are highly recommended 
by OIE for control and prevention of HPAI (Capua and Marangon 2007a).   14
The origins for the H5N1 panzootic are unknown. Wild birds and waterfowls as 
reservoirs play a potential role in AIV circulation and evolution (Normile 2005; Olsen et 
al. 2006). However, the global distribution and persistence of LPAI viruses in wild bird 
populations is not fully elucidated and is often difficult to get data on (Webby and 
Webster 2003). With lack of knowledge of the sheer magnitude of the animal reservoirs, 
it is impossible to predict if and when outbreaks will occur (Alexander 2007). 
Furthermore, influenza viruses can have numerous antigenic subtypes and rapidly evolve 
due to constant gene mutation and reassortment. All these factors contribute to the fact 
that AI is a difficult disease to eradicate in some circumstances. Vaccination has emerged 
as a useful tool in managing H5N1 HPAI infections with a view to future eradication 
(Webster et al. 1992; Webster et al. 2006). 
1.3 Vaccination against avian influenza and challenges with vaccination 
Vaccines have been widely used as a valuable tool to prevent, manage or eradicate AI 
from poultry or other birds in various countries (Swayne 2009). A wide variety of 
vaccines have been developed in the laboratory for potential use in the field (Kemble and 
Greenberg 2003; Swayne 2006). However, there is no globally-effective or universal AI 
vaccine due to continuous mutations or genetic reassortment of these viruses (Swayne 
2006). 
1.3.1 Inactivated whole virus vaccine 
As early as 1971, inactivated oil emulsion vaccines were used to immunize chickens and 
turkeys against AI virus infection (Allan et al. 1971). Up to now, inactivated vaccines 
against AI in chickens and turkeys have been reported against AI subtypes H1 (Swayne   15
2001), H4 (Abraham et al. 1988; Fatunmbi et al. 1992), H5 (Crawford et al. 1998; Ellis 
et al. 2004; Fatunmbi et al. 1992; Swayne et al. 2001; Swayne et al. 2006), H6 (Cardona 
et al. 2006), H7 (Cherbonnel et al. 2003; Di Trani et al. 2003; Fatunmbi et al. 1992; 
Philippa et al. 2005) and H9 (Pan et al. 2009; Swayne 2006). 
Currently, inactivated whole virus vaccines are the major vaccine type used in the poultry 
industry. They engender a strong humoral immune response and have proven to be 
effective against AI in multiple species of poultry. Nevertheless, they don’t produce a 
strong mucosal immune response. In addition, inactivated oil emulsion vaccines elicit 
antibodies not only specific for the protective epitopes on the HA and NA, but also to the 
internal proteins, NP and M1. Thus, vaccinated birds cannot be differentiated from 
naturally infected birds using the commonly used serologic assays like influenza A 
ELISA or AGID tests (Marangon et al. 2007; Suarez 2005). 
Reverse genetics have been applied to develop improved vaccines against AI (Liu et al. 
2003; Neumann et al. 2003; Tian et al. 2005; Webster et al. 2006). Conventionally 
prepared reassortant H5N1 vaccines developed by reverse genetics are currently being 
used in China (Tian et al. 2005) and other countries in SE Asia (Liu et al. 2003; Swayne 
2009). In addition, H7 and H9 subtype vaccines developed by reverse genetics have been 
used in experimental challenge studies (Chen et al. 2003b; Joseph et al. 2008). These 
vaccines have similar performances to conventional inactivated vaccines, however 
extensive data on their efficacy under field conditions is not available. In addition, this 
technology advancement does not alter the fact that large scale vaccine production still 
relies on egg-based production. This process is cumbersome, lengthy, and costly (Swayne 
2009; Wang et al. 2006).   16
1.3.2 Live recombinant vectored based vaccine  
Protective viral antigens can be expressed in vivo by inoculation of live viral vectors 
containing the gene for the target antigen. These vaccines have been developed for 
poultry using viral vectors such as fowl poxvirus (Swayne et al. 2000a), vaccinia virus 
(De et al. 1988; Yewdell et al. 1985), retrovirus (Brown et al. 1992; Hunt et al. 1988), 
adenovirus (Gao et al. 2006; Hoelscher et al. 2006; Toro et al. 2007), Newcastle disease 
(ND) virus (Ge et al. 2007; Park et al. 2006; Swayne et al. 2003; Veits et al. 2006), 
infectious laryngotracheitis herpesvirus (Veits et al. 2003) and an avian influenza-
Newcastle disease virus chimera (Park et al. 2006).  
Among these vaccines, a recombinant fowlpox virus vectored vaccine expressing 
influenza H5 HA has been most commonly used and is commercially available (Suarez 
and Schultz-Cherry 2000b; Swayne 2009). Recombinant fowlpox vectors expressing HA 
genes from A/turkey/Ireland /1378/83 (H5N3) (Swayne et al. 2000a), A/seal/Mass/1/80 
(H7N7) and A/chicken/Victoria/1/85 (H7N7) (Boyle et al. 2000), and 
A/turkey/Ireland/1378/83 (H5N8) (Bublot et al. 2006) have been reported to be effective 
in reducing virus shedding and in providing clinical protection. Recently, a new 
recombinant vaccine co-expressing both HA (H5) and NA (N1) genes of 
A/goose/Guangdong/3/96 (H5N1) was developed (Qiao et al. 2006; Qiao et al. 2003). 
This vaccine is suitable for use in 1-day-old chickens and in older birds where no 
antibody to fowlpox virus exists. Although any test developed to detect antibodies to the 
virus NP, M, NS1 or NA protein can be used to identify field exposed birds in a fowlpox-
vectored vaccinated population, there is some uncertainty about the efficacy of fowlpox-
vectored vaccines, relating to the immune status of flocks to the vector virus (Swayne et   17
al. 2000a). Thus, these vaccines are likely to be used only in birds that are susceptible to 
infection with the vector virus (Capua and Marangon 2006; Swayne et al. 2000a). 
Moreover, some studies with these vaccines appear to have shown evidence of a period 
of growth inhibition in chickens (Mingxiao et al. 2006). 
Most recently, recombinant Newcastle Disease virus (NDV) vectors expressing HA of 
H5 or H7 HPAI virus, developed using reverse genetics, have been licensed for use in 
China and Mexico (Swayne 2009). This prototype vaccine not only elicited both NDV- 
and AIV-specific antibodies, but also protected chickens from AIV and NDV challenge 
(Ge et al. 2007; Park et al. 2006). However, pre-existing maternal and active humoral 
immunity to ND virus vector or AI virus may limit vaccine replication and thus prevent 
or reduce a protective immune response. Additionally, biosafety and biosecurity of such 
live vaccines has yet to be fully assessed (Swayne 2009). 
1.3.3 Subunit avian influenza vaccines  
Viral proteins such as the AI HA can also be expressed in an in vitro system and this 
crude or purified viral protein can be formulated with adjuvant to form a subunit vaccine. 
This makes the vaccine technically similar to inactivated whole AI vaccines, but 
production of viral antigens does not involve culture of live AIVs and avoids biosecurity 
concerns. In vitro expression systems include eukaryotic cell cultures (such  as 
mammalian cells (Ghendon et al. 2005), plants (Shoji et al. 2008), yeast (Saelens et al. 
1999), bacterial (e.g. Escherichia coli (Davis et al. 1983)) or viral vectors (e.g. 
baculovirus) (Crawford et al. 1999; Johansson 1999; Swayne et al. 2001). Recently, 
Pichia pastoris, one of the eukaryotic expression systems, was used to express HA genes 
from H5, H7 and H9 AI viruses respectively (Xu et al. 2006). The production costs of   18
this type of vaccine may not be compatible with poultry use where cost/dose must be 
substantially lower than human or some other animal vaccines (Suarez and Schultz-
Cherry 2000b). 
1.3. 4 Genetic vaccines 
Genetic vaccines are composed only of DNA (as plasmids) or RNA (as mRNA), which is 
taken up by cells and translated into protein (Leitner et al. 1999). Since there are limited 
reports on RNA vaccines compared to extensive literature on DNA vaccines, genetic 
vaccines generally refer to plasmid DNA antigen-expression systems (Davis 1997). 
Genetic immunization, also termed DNA or polynucleotide immunization, is a novel 
vaccine technology that developed following the first report that direct injection of 
plasmid DNA generated the successful expression of the plasmid-encoded antigen in 
murine muscle cells (Wolff et al. 1990). This unexpectedly successful new method has 
been described as the “Third Vaccine Revolution” (Babiuk et al. 1999a; Dixon 1995) or 
“the third generation of vaccines” (Pasquini et al. 1997).  
1.3.4.1 DNA-based vaccines 
DNA vaccines have been proven to be effective against various infectious diseases (Deck 
et al. 1997; Donnelly et al. 1997b; Dufour 2001). Numerous studies of influenza A DNA 
vaccines have demonstrated that they are capable of inducing humoral and cell mediated 
immune responses and conferred protection against influenza A viruses in a range of 
species via various delivery routes (Babiuk et al. 1999b). However, DNA vaccines 
against AI in poultry have not been as efficacious and consistent as conventional 
inactivated whole virus vaccines (Suarez and Schultz-Cherry 2000a).   19
1.3.4.2 RNA-based vaccines 
To avoid the potential risk of DNA sequence integration into the host genome with DNA 
vaccination, RNA has been proposed as the expression vector (Vignuzzi et al. 2001). The 
mRNA constructs encoding the foreign gene, delivered either intramuscularly (Conry et 
al. 1995), by GG (Qiu et al. 1996), or by liposome-entrapped mRNA injection (Martinon 
et al. 1993), resulted in efficient transgene expression and induced immune responses. 
However, antigen expression sufficient to stimulate effective immune responses has been 
a major problem with this type of vaccine.  
1.3.5 Other AI vaccines 
1.3.5.1 Live attenuated influenza virus vaccines 
A reassortant H9N2 vaccine candidate carrying HA and NA genes from A/chicken/Hong 
Kong/G9/97 (H9N2) virus (Chen et al. 2003b) and a reassortant H5N1 influenza A virus 
vaccine candidate bearing the HA and NA genes of the A/HK/491/97 (H5N1) virus 
(Subbarao et al. 2003) in a background of internal genes from PR8 virus, were developed 
using reverse genetics and showed ability to induce protective antibody responses in 
experimental studies. As the vaccine virus is live, there is potential for reassortment with 
other circulating influenza A viruses with the risk of novel influenza viruses.  To date, no 
genetically engineered live AI virus vaccines are commercially available for use in 
animals. However, cold-adapted temperature sensitive mutant influenza A virus vaccines, 
derived from the cold-adapted (ca) influenza A vaccine donor strain influenza A/Ann 
Arbor/6/60 (H2N2), have been developed by reverse genetics and are safe for use in   20
humans (Chen et al. 2003a; Suguitan et al. 2006). Potentially, a live AI virus vaccine 
could be developed for use in poultry if sufficient safety was demonstrated. 
1.3.5.2 Non-parenteral administration of inactivated whole vaccines 
Mucosal vaccination using existing inactivated whole influenza A virus vaccines induced 
both mucosal and systemic antibody responses and conferred broad cross-protection in 
mice (Takada et al. 1999; Takada et al. 2003; Tumpey et al. 2001). Oral immunization 
with an inactivated waterfowl-origin AI virus has been shown to induce specific antibody 
to this virus, indicating that it should  at least be possible to use oral influenza vaccination 
in poultry (Crawford et al. 1998). 
Altogether, although different kinds of vaccines were experimentally and commercially 
developed for use in the poultry industry, each vaccine seems to have its limitations. To 
date, licensed vaccines, either inactivated whole virus vaccines or recombinant live 
fowlpox or NDV-based vaccines, rely on embryonated chicken egg production. This 
leads to some drawbacks for large scale vaccine production, including strict requirement 
for facilities of a high biosecurity standard for handling live influenza viruses, long 
production cycles, heavy reliance on manual systems for production, the need for readily 
available chicken flocks, inflexibility in quickly altering antigenic composition and 
limited breadth of protection (Dufour 2001; Forde 2005; Rao et al. 2009). Examining 
alternative strategies is necessary for development of improved or more cost-effective 
vaccines.   21
1.4 Characteristics of DNA-based vaccines  
DNA vaccines are composed of simple ring forms of double-stranded DNA that generally 
consist of two components: (1) a mammalian expression cassette (promoter/enhancer, 
antigen-encoding DNA and polyadenylation sequences) and (2) the bacterial plasmid 
backbone (necessary for plasmid amplification and selection) (Gurunathan et al. 2000; 
Miller et al. 2004; Srivastava and Liu 2003). Since its initial development in 1990, this 
technology has been used to generate humoral and cell-mediated immune responses in a 
wide variety of species for numerous viral (Davis and McCluskie 1999), bacterial 
(Strugnell et al. 1997) and parasitic (Kalinna 1997) diseases in a range of animal models 
(Donnelly et al. 1997b; Dufour 2001; Ivory and Chadee 2004). They have also been used 
for genetic therapies against cancer (Benton and Kennedy 1998) and autoimmune 
diseases (Ramshaw et al. 1997). In addition, DNA vaccines have become a valuable 
laboratory tool for a variety of applications ranging from proteomics to understanding the 
mechanism of antigen presentation, the role of cytokines and the effects of bacterial DNA 
in the generation of immune responses (Donnelly et al. 1997b).     
DNA vaccines are prepared using standard molecular biology techniques. First, a gene of 
interest is cloned into a mammalian expression vector using polymerase chain reaction 
(PCR), with a pair of primers and a cDNA template. Secondly, the resultant plasmid 
construct is examined to verify the fidelity of the insert to avoid cloning errors, such as 
frame shifts through sequencing. Following successful sequence analysis, the construct is 
tested to verify correct protein expression by a variety of methods. Generally a cell line is 
transfected transiently with the plasmid and the desired protein expression is detected by   22
Western blotting (WB), ELISA, immunofluorescent test (IFT), or immunoprecipitation. 
Finally, the construct is grown and purified for immunization (Sasaki et al. 2003). 
1.4.1 Immunology of DNA vaccines 
1.4.1.1 Immune mechanism 
Although the ability of DNA vaccines to induce immune responses has been well 
documented, the mechanism by which the immune cascade arises is not yet fully 
understood. Following delivery by various techniques via numerous routes, plasmid DNA 
is taken up primarily by somatic cells (keratinocytes for GG and myocyte for 
intramuscular (IM) injection) (Dupuis et al. 2000; O'Hagan et al. 2004) and to some 
extent by antigen presenting cells (APCs), and the DNA encoded vaccine antigen is then 
expressed (Danko et al. 1997; Donnelly et al. 1997b; Klinman et al. 1998; Lu et al. 1996; 
O'Hagan et al. 2001; Wolff et al. 1990). Endogenously synthesized proteins produced by 
transfected cells after plasmid DNA inoculations are processed in the cytosol by 
multicatalytic proteosomes and resultant peptides are presented via the MHC Class I 
pathway to activate CD8
+ T lymphocytes (Cohen et al. 1998; Tuting et al. 2000). Soluble 
proteins released by transfected cells undergo endocytosis or phagocytosis to activate the 
MHC class II-restricted pathway for antigen processing in CD4
+ T cells, which can 
promote antibody responses in B cells or initiate other T helper (Th) cell responses 
(Cohen et al. 1998; Gurunathan et al. 2000; Tuting et al. 2000). T helper cells, also 
known as effector T cells, secrete different and sometimes mutually antagonistic 
cytokines, which are fundamental for the complete activation of either B cells (Th2-type) 
or CTLs (Th1-type) (Davis 1997). Since the quantity of endogenously synthesized 
antigen was demonstrated to range from picograms to nanograms, the efficient induction   23
of a broad-based immune response most likely involves the immune-enhancing properties 
of the plasmid DNA itself (e.g. CpG motifs) and/or the type of antigen-presenting cell 
(APC) transfected in addition to the “orthodox” antigen processing and presentation in 
the context of MHC class I- or II- restricted priming pathways (Donnelly et al. 2005; 
Gurunathan et al. 2000; Huygen 2005). Thus, how DNA vaccination can induce the two 
arms of the immune response has been an active area of investigation and covers three 
main areas: antigen presentation, the immunological properties of the plasmid backbone 
and the role of cytokines in inducing the immune responses (Donnelly et al. 2005). 
1.4.1.1.1 Mechanism of antigen presentation  
Processing and presentation of antigen following DNA immunization is one of the 
intriguing aspects of the DNA-induced immune response. The exact mechanism by which 
injected or particle-coated plasmid DNA leads to antigen presentation has yet to be fully 
defined (Porgador et al. 1998), but at least three mechanisms are involved, namely direct 
transfection of professional APCs, direct priming by somatic cells and cross-priming 
(Gurunathan et al. 2000). Current data demonstrate that bone marrow-derived APCs (e.g. 
dendritic cells (DC)) play a pivotal role in initiating the immune response following both 
IM and GG delivery of plasmid DNA (Tuting et al. 2000). Injection of plasmid DNA 
results in direct transfection of a small number of DCs that present antigen to T cells, and 
general activation of large numbers of DCs that were not transfected (Akbari et al. 1999; 
Casares et al. 1997; Porgador et al. 1998). The intradermal (ID) deposition of plasmid 
DNA may result in the activation of the APCs present in the dermis (Langerhans cells) at 
a level of 5% of the cellular tissue, but  the situation in muscle is not clear (Condon et al. 
1996; Porgador et al. 1998).   24
Somatic cells (myocytes, keratinocytes, or any MHC class II-negative cells) may also 
directly present antigens to T cells to induce primary immune responses, although they 
alone are not as efficient as the DCs at priming (Agadjanyan et al. 1999; Iwasaki et al. 
1997a). When CTLs destroy somatic cells (mainly myocytes) expressing the antigen 
plasmids can be released from these myocytes and can be phagocytosed by monocytes 
migrating through the muscle (Davis et al. 1997; Egan and Israel 2002; Leitner et al. 
1999). Thus, transfected myocytes may serve as plasmid-depots for continued APC-
transfection (Corr et al. 1996). Additionally, with IM injections, plasmid DNA may gain 
access to the lymphatic or circulatory systems to transfect myocytes away from the site of 
injection (Torres et al. 1997). With GG administration, transfected DCs migrating from 
the epidermis to lymphoid tissues, and transfected non-migratory cells (e.g. keratinocytes 
and Langerhans) remaining in the epidermis, can all present antigen and influence the 
magnitude of the immune response (Akbari et al. 1999; Klinman et al. 1998).  
The resulting proteins are not only presented to T cells by the somatic cells themselves, 
but also cross over into the MHC class I-restricted processing way, allowing APCs to 
activate both CD8
+ and CD4
+ T lymphocytes (Cohen et al. 1998). Such a cross-priming 
process, although contradicting the dogma that only endogenous antigens can enter the 
MHC class I pathway, may provide a principle mechanism by which plasmid DNA is 
delivered to cells such as myocytes and these myocytes effectively shuttle antigen to DCs 
or other APCs to induce CTL and humoral responses (Kumaraguru et al. 2000; Sharma 
and Khuller 2001). 
The presentation by APCs of endogenously expressed antigen and exogenously acquired 
antigen to T cells is not independent (Tuting et al. 2000). Bone marrow-derived APCs are   25
essential for generation of the plasmid DNA-induced immune responses via ID or IM 
routes (Akbari et al. 1999; Casares et al. 1997; Corr et al. 1996; Doe et al. 1996; Fu et al. 
1997b; Iwasaki et al. 1997b). Somatic cells may serve as a reservoir for antigen and play 
a secondary role in the induction of immune response via cross-priming (Gurunathan et 
al. 2000).  
1.4.1.1.2 Role of CpG motifs in plasmid DNA vector backbone 
Unlike inactivated vaccines, naked DNA vaccines without adjuvant can induce effective 
immune responses in experimental studies in animal models. Part of this effectiveness is 
attributable to the plasmid DNA itself, whose backbone contains unmethylated cytosine-
phosphate-guanine (CpG) dinucleotides (termed CpG motifs) (Donnelly et al. 2005; 
Greenland and Letvin 2007; Sato et al. 1996).  
Toll-like receptor (TLR) 9, present on effector cells of the immune system, can bind to 
and recognize such CpG motifs (Hemmi et al. 2000). Interaction of TLR9 with CpG 
motifs activates several signaling pathways and results in an an immunostimulatory 
cascade (Klinman et al. 2004), activating B-cells to proliferate or secrete antibody (Krieg 
2000), eliciting innate immune response characterized by the production of interleukin 
(IL)-6, IL-12 or tumor necrosis factor (TNF)-α, interferon (IFN)-γ and IFN-α 
(Gurunathan et al. 2000; Klinman et al. 1997b), and inducing professional APCs to 
secrete cytokines and resultant activation of natural killer cells (NK). Thus, CpG motifs 
likely play an important role in the generation of a plasmid-expressed antigen specific 
immune response following DNA vaccination (Greenland and Letvin 2007; Klinman et 
al. 1997b).   26
Several lines of evidence demonstrate that CpG motifs in the plasmid backbone of DNA 
vaccines contribute to the immunogenicity of DNA vaccines.  Vector lacking an antigen-
encoding insert was still able to induce cytokine production in vitro (Kojima et al. 2002), 
indicating that the antigen-encoding region of the DNA vaccine was not required for the 
activation of an innate immune response (Klinman et al. 1997b). The immunogenicity of 
a DNA vaccine was markedly decreased by treatment with CpG inhibitors like SssI CpG 
methylase and was significantly increased by co-administration of exogenous CpG-
containing DNA (Klinman et al. 1997b). Co-administering oligodeoxynucleotide (ODN) 
that contained CpG motifs with an antigen elicited an antibody and cellular response 
similar to immunization with a plasmid encoding the same antigen (Davis et al. 1998). 
Re-engineered plasmids containing additional CpG motifs in the plasmid vector 
backbone elicited a higher antibody response, more CTLs, and greater IFN-γ production 
than did the original vector (Klinman et al. 1997b; Krieg et al. 1998a; Sato et al. 1996). 
However, some studies showed that CpG motifs appeared to be limited in their ability to 
increase antibody and cytokine production in vivo and the addition of too many CpG 
motifs to the plasmid backbone may reduce its immunogenicity (Krieg et al. 1998a; 
Weeratna et al. 1998). 
Although CpG-based bacterial DNA may stimulate immune responses in vivo and in vitro, 
coadministration of mammalian DNA can suppress such activation (Gurunathan et al. 
2000). Some studies showed that a subset of nonstimulatory ODNs can block the immune 
activation induced by ODNs containing CpG motifs. An excess of non-CpG ODNs could 
inhibit the uptake of fluorescein-isothiocyanate (FITC)-labeled CpG ODNs and result in 
the inability of CpG ODNs to induce immune stimulation (Hacker et al. 1998). Improved   27
immunogenicity of a DNA vaccine could also be achieved by removing suppressive 
motifs (tandem repeats of GpC) from the plasmid backbone (Krieg et al. 1998a). These 
observations emphasize the complexity of the interaction between DNA sequence motifs 
and the immune system (Gurunathan et al. 2000).  
Other studies have shown that DNA vaccines could induce robust immune responses in 
both TLR9-positive and TLR9-negative or MyD88-negative mice (Spies et al. 2003). 
Also, production of type I interferons and CXCL10 (chemokine) occurred in TLR9-
deficient and MyD88-deficient mice given DNA vaccines (Okabe et al. 2005). These 
observations suggest that TLR9-receptor independent pathways can also contribute to the 
immunogenicity of plasmid DNA vaccines (Wagner and Bauer 2006). 
In summary, a DNA vaccine vector backbone carrying CpG motifs can function as an 
adjuvant or immunomodulator, which may or may not have an adjuvant effect for DNA 
vaccines (Donnelly et al. 1997b). Therefore, it may be possible to tailor the type of 
immune response to a DNA vaccine in vivo towards a given pathogen or tumor by 
selectively engineering stimulatory motifs into the vector backbone (Gurunathan et al. 
2000; Tuting et al. 2000). 
1.4.1.1.3 Role of cytokines or costimulatory molecules in DNA vaccines 
DNA vaccination can induce Th1- and Th-2 biased immune response, which requires 
induction of a number of cytokine or costimulatory molecules that play a crucial role in 
generation of the effector T-cell subsets and in determining the nature of the response 
(Gurunathan et al. 2000; Manoj et al. 2004). These cytokines and co-stimulatory 
molecules, either alone or in combination, have been employed to modulate the immune 
response generated by DNA vaccination (Manoj et al. 2004). They are also termed   28
‘biological’ adjuvants (Cohen et al. 1998; Kelso 1998) or ‘genetic’ adjuvants (Laddy and 
Weiner 2006; Scheerlinck 2001). 
These immunomodulatory molecules have been divided somewhat arbitrarily into three 
groups: (1) cytokines - further subdivided into three groups: a) pro-inflammatory 
cytokines, including granulocyte-macrophage colony stimulating factor (GM-CSF), IL-
1α, IL-1β, transforming growth factor β (TGF-β), TNF-α, TNF-β, IFN-α, IL-12; b) Th1-
inducing cytokines, including IFN-γ, IL-2, IL-12, IL-15, IL-18, IFN-I (αβ) (Bracci et al. 
2006); c) Th2-inducing cytokines,  including IL-4, IL-5, IL-6, IL-10, and IL-13; (2) 
chemokines - including monocyte chemo-attractant protein-1(MCP-1), macrophage 
inflammatory protein-1α (MIP-1α), MIP-1β, regulated upon activation of normal T cell 
exposed and secreted (RANTES)(CCL5), T cell activation protein-3(TCA), and CCL21 
(Yamano et al. 2006); (3) co-stimulatory molecules, such as CD40, CD80, CD86 and 
CD154 (Manoj et al. 2004; Scheerlinck 2001). 
DNA vaccination studies in mice showed that co-injection of plasmids encoding 
cytokines or co-stimulatory molecules with antigen-encoding plasmids usually resulted in 
increased immunoglobulin G (IgG) responses (Manoj et al. 2004; Scheerlinck 2001), but  
in some cases, the response remained unchanged or was even down regulated (Barouch et 
al. 1998).  
GM-CSF has been one of the most studied genetic adjuvants (Scheerlinck 2001). By 
activating and recruiting professional APCs, it significantly enhanced humoral responses 
in mice (Xiang and Ertl 1995), in most cases GM-CSF slightly increased CTL responses. 
However, the GM-CSF-encoding plasmid appears to be less potent in rhesus monkeys 
than in mice (Kumar et al. 2002).    29
DNA vaccines co-administered with plasmids encoding IFN-γ (Chow et al. 1998), IL-2 
(Xin et al. 1999), IL-12 (Kim et al. 1999), IL-15 (Xin et al. 1999) or IL-18 (Sin et al. 
1999) showed a decreased ratio of IgG1:IgG2a, indicating that a bias towards a Th1 type 
immune response occurred. Moreover, co-injection of Th1-inducing cytokines induced 
increased CTL response to plasmid-encoded antigens (Scheerlinck 2001).  
Immunization with antigen expressing plasmids mixed with plasmids encoding Th2-
inducing cytokines such as IL-4 (Sin et al. 1999), IL-6 (Lee et al. 1999), IL-10 (Kim et al. 
1998), IL-13 (Kim et al. 2000) tended to induce immune responses characterized by 
higher levels of IgG1 antibody in terms of both a higher level of total antibody and a 
higher ratio of IgG1:IgG2a Ab. Nevertheless, most of these cytokines (with the exception 
of IL-6) elicited either similar or lower CTL responses to these antigens in vivo 
(Scheerlinck 2001).  
Co-delivery of a plasmid expressing CD40 ligand/trimer (CD40LT) with β-gal-encoding 
plasmid decreased the IgG1:IgG2a ratio (indicating a Th1 bias), enhanced β-gal-specific 
humoral and CTL responses and induced protective immunity to a Leishmania major 
following challenge (Gurunathan et al. 1998a). In addition, a number of chemokine-
encoding plasmids were reported to modulate immune responses to DNA vaccines 
(Scheerlinck 2001).  
The combination of two or more immuno-modulators has been examined to further 
enhance and modulate the immune response to DNA vaccines. Significant enhancement 
of Th1-type immune response (as measured by a lower IgG1:IgG2a ratio) was observed 
when a human immunodeficiency virus (HIV) DNA vaccine was co-delivered with GM-
CSF-encoding plasmid and IL-12-encoding plasmid, whereas, the combination of a HIV   30
DNA vaccine with a plasmid-encoding GM-CSF and a plasmid-encoding IL-4 induced 
an increased Th2 biased response (as measured by a higher IgG1:IgG2a ratio) (Kusakabe 
et al. 2000). The influenza NP plasmid, NPo/B7-1, coexpressing the costimulatory 
molecule CD80 (B7-1) and a suboptimal NP antigen (NPo) had no effect on the CTL 
response in mice, whereas, the NP/B7-2 plasmid coexpressing NPo and the costimulatory 
molecule CD80 (B7-2) increased this response. The combination of either IL-12-
expressing plasmid or GM-CSF-expressing plasmid with either the NPo/B7-1 plasmid or 
NPo/B7-2 plasmid enhanced the CTL response in vivo. Co-administration of GM-
CSF/IL-12 plasmid expressing GM-CSF and IL-12 with the NPo/B7-1 plasmid generated 
a further enhancement of the CTL response whereas co-delivery with the NPo/B7-2 
plasmid did not (Iwasaki et al. 1997a). However, co-administration of a herpes simplex 
virus (HSV) DNA vaccine with both CD80-encoding and CD86-encoding plasmids had a 
marked negative effect on the humoral response (Flo et al. 2000). Thus, optimal 
combination of costimulatory molecules and cytokines may differ for a particular plasmid 
immunogen depending on the type of immune response desired (Iwasaki et al. 1997a).  
The timing between administration of the cytokine-encoding plasmid and the antigen-
encoding plasmid influenced the immune response induced by a DNA vaccine (Manoj et 
al. 2004; Scheerlinck 2001).  
The method by which the cytokines were co-expressed also had an impact on the 
plasmid-induced immune response. Although a co-expressed plasmid encoding the 
antigen and immunomodulator may theoretically be expressed as a fusion protein and 
extend the longevity of action of cytokines or co-stimulatory molecules, co-expressed 
plasmid vaccination did not always enhance the immune response. For instance, a   31
dicistronic plasmid expressing both HIV-1 gp120 and IL-2 produced a weaker gp120-
specific immune response than did the HIV-1 gp120-encoding plasmid alone (Barouch et 
al. 1998). There was little evidence that co- expression of cytokine or immunomodulators 
with antigen gave an advantage in DNA vaccination (Barouch et al. 1998; Iwasaki et al. 
1997a). In contrast, plasmids co-expressing a target gene and IL-2 or IL-4 gene appeared 
to induce stronger antigen-specific antibody responses than antigen-encoding plasmids 
alone (Inoue et al. 2002; Lim et al. 1998).  
Taken together, although the effect of immunomodulators may vary depending on DNA 
vaccine used, delivery regimen (method, route, dose and timing of delivery) and their 
different combinations, it is clear that cytokines, chemokines and co-stimulatory 
molecules can potentially be used as a complementary strategy to improve and/or 
modulate DNA vaccination (Kusakabe et al. 2000; Manoj et al. 2004; Scheerlinck 2001). 
1.4.1.2 Humoral immune response  
Since antibodies to viral proteins were first described after IM injection of DNA vaccines 
encoding HA (HA-DNA) and NP (NP-DNA) of influenza virus (Ulmer et al. 1993), 
DNA vaccination has proven to be an effective means of generating humoral immune 
responses against various viral, bacterial, parasitic, tumor, and eukaryotic proteins 
(Donnelly et al. 1997b).  
As expected, antibody responses against DNA-encoded antigens are generally dependent 
on the dose of DNA (Deck et al. 1997; Ulmer et al. 1994) and the number of vaccinations 
(Deck et al. 1997). However, this dependence is lost in some laboratory animal species 
(Galvin et al. 2000).  In mice, marginal or undetectable antibody was induced after the   32
first DNA injection (Dufour 2001). However, booster immunization did increase serum 
antibody titres, and this was further augmented after a third immunization, but did not 
alter the isotypic profile of the response (Deck et al. 1997; Feltquate et al. 1997). 
In some cases, such as HIV and influenza, a combination DNA vaccine comprising 
multiple plasmids encoding several different antigens of a pathogen may be required to 
induce a broader spectrum of immune responses. In this situation, it is essential that 
coadministration of multiple plasmids or coexpression of multiple antigens does not 
interfere or compete with each other resulting in the inhibition of immune responses to 
one of the components (Donnelly et al. 1997b). Although this has not been extensively 
investigated, a combined DNA vaccine containing seven separate plasmids was shown to 
be effective against influenza virus shedding in ferrets, and antibody responses against 
each of three different HA components were demonstrated (Donnelly et al. 1995a). 
1.4.1.3 Cell-mediated immune response  
DNA immunization via IM, ID, GG or other means has been proven to induce antigen-
specific CTL responses in mice and non-human primates (Donnelly et al. 1997b). CTL 
that are capable of recognizing and killing virus-infected targets have been demonstrated 
against various viruses such as influenza virus (Ulmer et al. 1993), rabies virus (Xiang et 
al. 1995), and HIV (Liu et al. 1996). In studies of influenza NP in BALB/c mice, anti-NP 
CTL was shown to last over two years after immunization with NP-DNA (Donnelly et al. 
1995b; Yankauckas et al. 1993). 
Some studies showed that repeated IM immunization enhanced cell-mediated immune 
(CMI) response to influenza NP (Donnelly et al. 1995b) and HIV Env (Shiver et al.   33
1995). However, in a murine study with three GG immunizations of 4 µg each of a 
plasmid encoding gp120 and 1 µg each of a plasmid encoding Rev, CTL responses 
appeared after two immunizations, while antibody responses were detected only after a 
third dose, but CTL were suppressed (Fuller and Haynes 1994).  The authors suggested 
that the suppression was related to a switch in Th cells from Th1 to Th2, as the 
administration of  anti-IL-4 antibody prevented this loss of CTL responsiveness.       
DNA vaccine studies in mice showed that generation of Th-1 like T immune response 
may be a general property of DNA vaccines delivered via the IM or ID route, 
characterised by relatively high CTL activity, the predominance of IgG2a antibodies and 
γ-IFN production (Donnelly et al. 1997b). However, DNA vaccination using GG appears 
to generate a Th2-like response characterized by increased IgG1 Ab and IL-4 production 
(Feltquate et al. 1997; Mor et al. 1995; Pertmer et al. 1996).  
Intramuscular injection of mice with a plasmid DNA encoding NP from PR8 virus 
induced IgG anti-NP antibodies, a robust CTL response to the H-2K
d-restricted epitope 
147–155, as well as protective efficacy in mice against a heterosubtypic virus challenge 
(Fu et al. 1997a; Ulmer et al. 1993). This protection was shown not to be mediated by 
antibody responses to NP (Ulmer et al. 1993). A further study showed that, although 
CD8
+-restricted CTLs were essential effectors in protection, NP-DNA also induced a 
Th1-type of CD4
+ helper T-cell response. This was indicated by IgG 2 predominance of 
anti-NP antibody and with high levels of interferon-γ and IL-2, modest level of GM-CSF 
and little or no IL-4 or IL-10, although a lesser role of CD4
+ cells has been reported 
(Ulmer et al. 1998). Albeit that there are conflicting results on the relative importance of 
CD4
+ and CD8
+ for protection conferred by NP-DNA, both CD8
+ CTL and cytokine-  34
secreting CD4
+ T cells contributed to the overall protection from influenza virus 
challenge in mice (Epstein et al. 1997; Liang et al. 1994; Ulmer et al. 1998). After 
examination of the roles of T cell subsets in protective immunity induced by DNA 
vaccines encoding NP or M (M-DNA) of PR8 virus. Epstein et al.(2000) found that CD8
+ 
cells were not essential for the anti-viral CTL response in NP-DNA and M-DNA-
immunized mice, as either CD4
+ or CD8
+ T cells alone were sufficient to promote 
survival and recovery after challenge.  
1.4.1.4 Immunological memory with DNA vaccination  
Several studies showed that DNA vaccination was capable of generating long-term 
antibody responses, depending on the type of antigen used in the vaccine (Deck et al. 
1997; Gurunathan et al. 2000; Raz et al. 1994). Others studies showed that DNA 
vaccination can induce long-lived Th1 responses in vivo, as well as long-term CTL 
responses (Akbari et al. 1999; Gurunathan et al. 1998b). 
The possible mechanisms hypothesized for sustained humoral and CMI responses after 
DNA vaccination are as follows: (A) persistence of antigen synthesis in transfected cells 
such as in follicular DCs that could  serve as an antigen reservoir to maintain the immune 
response, though plasmid DNA may not be detected; (B) immune responses elicited by 
DNA immunization are antigen-independent,  although plasmid DNA as well as antigen 
may completely disappear; (C) Memory cells generated by DNA vaccination may differ 
from those achieved by protein-based immunization (Akbari et al. 1999; Gurunathan et al. 
2000). 
1.4.1.5 Mucosal immunization   35
Mucosal immunity is considered an important goal to combat pathogens that enter via the 
mucosal route (Loehr et al. 2000). IM injection and GG delivery (widely used for DNA 
vaccination) of naked plasmid DNA induces limited secretory mucosal IgA responses 
(Srivastava and Liu 2003). However, formulation of DNA vaccines with cationic lipids 
(Mitchell et al. 1995; Wong et al. 2001), monophosphoryl A (Sasaki et al. 1998b), QS-21 
(Sasaki et al. 1998c), poly(lactide-coglycolide) microparticles (Jones et al. 1997) or 
alginate (Mittal et al. 2000) via IM, oral, or intranasal (IN) delivery, induced marked 
secretory IgA response at the mucosal sites. Mucosal immunity induced by DNA 
vaccines was also achieved by administration via intratracheal, aerosol, or genital-tract 
routes (Gurunathan et al. 2000). Some studies demonstrated that serum IgG responses 
induced by mucosal immunization are comparable to those generated by systemic 
immunization with the same DNA constructs (Livingston et al. 1998; Sasaki et al. 1998b; 
Sasaki et al. 1998c), whereas, others showed that mucosal immunization is insufficient to 
induce serum IgG responses (Ban et al. 1997; Fynan et al. 1993b; Kuklin et al. 1997). 
Although the immune effect of mucosal immunization is variable, overall it appears to be 
superior to systemic immunization with regards to induction of mucosal IgA responses 
(Livingston et al. 1998; Sasaki et al. 1998b; Sasaki et al. 1998c). However, in some 
studies mucosal DNA vaccination could not prevent virus replication and persistence at 
the mucosa challenge site, indicating that the immunization regimen for induction of 
sufficient IgA response may be suboptimal or that prevention of viral replication at the 
mucosal site may require immune mechanisms other than secretory IgA for those viruses 
(Kuklin et al. 1998).   36
Plasmid DNA vaccines have been delivered by microparticles and nanoparticles as a 
delivery vehicle for both mucosal and systemic immunisation (Jones et al. 1997; Roy et 
al. 1999). Immunization via a systemic delivery route may not achieve effective mucosal 
immune responses (Gallichan and Rosenthal 1996; Stevceva et al. 2000). However, a 
mucosal prime-parenteral boost immunization approach demonstrated that parenteral 
immunization can prime for subsequent mucosal responses (McCluskie et al. 2002). In 
addition, delivery of plasmid DNA orally with attenuated enteric bacteria such as 
Salmonella or Shigella is being investigated as an alternative strategy for oral and other 
mucosal DNA immunization (Fennelly et al. 1999; Sizemore et al. 1995). 
1.4.2 Advantages and limitations of DNA vaccines 
1.4.2.1 Advantages 
Immunization with plasmid DNA has many potential advantages over vaccination with 
whole inactivated virus, subunit, and recombinant vaccines as summarized in Table 1.1 
(Forde 2005; Gurunathan et al. 2000; Laddy and Weiner 2006; Manoj et al. 2004; 
Sharma and Khuller 2001).  
1. DNA vaccines are able to induce broad-spectrum immune responses based on the 
ability to produce antibody, CMI and mucosal immunity (Babiuk et al. 1999b). CMI 
responses elicited by DNA vaccines against conserved internal proteins of an influenza 
virus, together with antibodies generated to viral surface proteins, have the potential to 
provide cross protection against different virus strains within the same subtype (Donnelly 
et al. 1997a; Epstein et al. 2002; Kodihalli et al. 2000).   37
2. DNA vaccines are inherently safer than currently used protein-based vaccines. DNA 
vaccines are simpler to design, faster, less expensive and more consistent to manufacture. 
High stability and relative temperature insensitivity of plasmid DNA make it highly 
suitable for mass production and distribution in both industrialized and non-industrialized 
countries (Abdulhaqq and Weiner 2008; Dufour 2001; Forde 2005). 
3. DNA immunization allows the use of sequences of interest derived directly from 
clinical specimens or after only limited passage in chicken embryonated eggs or 
mammalian cell culture (Webby et al. 2004). This would avoid the selection of mutants 
due to passages and lead to the development of vaccines to  the protein antigens  encoded 
by the exact sequence of the clinical viral isolate (Katz et al. 1987). In addition, 
endogenous protein immunogens produced by the host administered with DNA vaccines 
would be more similar to those found in pathogens as compared with viral proteins 
produced in Escherichia coli (E .coli), yeast, or insect cells. In theory, this should make 
DNA vaccines more antigenic and show a closer antigenic match with the associated 
pathogen (Donnelly et al. 1997b; Srivastava and Liu 2003). 
4. Due to the simple structure of the DNA plasmid vector, DNA vaccines show less side 
effects to the host than whole virus or protein subunit vaccines. The plasmid DNA vector 
can be used repeatedly without inducing immune inhibition from the host (Mascola et al. 
2005; Ulmer 2002). It has also been reported that maternal antibodies or passively 
transferred antibodies do not interfere with neonatal immune responses induced by DNA 
vaccines (Pertmer et al. 2000). 
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Table 1.1 Comparative advantages and limitations of various type of vaccines. 
 
Factor Sub-factor  Killed    vaccine  Live attenuated vaccine   Subunit vaccine  Live vectored vaccine  DNA vaccine  
Safety 
  Virus involved during 
production 
Yes Yes No  Introduction  of  vector 
virus 
No 
  The product itself   Improperly 
inactivated risk 
Potential to revert to 
pathogenicity 
Safe Individual  differences  Safe 
Immune response 
  Ag Presentation  MHC class   II  MHC class  I & II  MHC class  II  MHC class  I & II  MHC class  I & II 
  Humoral   Strong   Strong   Strong  Strong   Need improvement 
  CTL    None  Strong  None  Possible  Possible 
Design 
 Incoporate  multi-
antigen   
Impossible Impossible Impossible  Possible  Possible 
 Introduction  of  DIVA  Impossible  Impossible  Possible  Possible Possible 
  Cost to develop  Very expensive  Expensive  Very expensive  Expensive  Relatively inexpensive 
Manufacturing 
 Techniques  Cell  culture  or 
embryonated eggs  
Cell culture or 
embryonated eggs 
Cell culture or 
embryonated eggs 
Cell culture or 
embryonated eggs 
Bacterial fermentation 
  Production engineering  Less difficult than 
live virus, more 
difficult than DNA 
Difficult Less  difficult  than 
live virus, more 
difficult than DNA 
Difficult Relatively  simple 
  Lead time  4-9 months  4-9 months  4-9 months  4-9 months  1 month 
  Quality control   More so than DNA  Requires extensive 
quality control  
More so than DNA  Requires extensive 
quality control 
Easy to control 
Cost 
  Cost of vaccine to 
manufacture 
Expensive  Moderate to expensive  Expensive  Moderate to expensive  Relatively inexpensive 
 Storage  costs  Refrigeration  Refrigeration  Refrigeration  Refrigeration  No cold chain requirements 
  Need for adjuvant  Need  Need   Need   Need   Not necessary, adjuvant 
itself 
Side effect 
    Local reaction, even 
lesion 
Less  Local reaction, even 
lesion 
Less No 
 
* Modified from  (Forde 2005; Gurunathan et al. 2000; Laddy and Weiner 2006)  39
5. As DNA vaccines target immune responses to certain epitopes of specific antigens 
(Zinkernagel and Hengartner 2001), they allow the incorporation of a marker antigen in 
the vaccine to enable the differentiation of infected from vaccinated animals (DIVA 
strategy) for disease surveillance serology conducted as part of vaccination programs 
(Babiuk et al. 1999b; Dhama et al. 2008; Lee et al. 2004). Vaccine marker antigens are 
likely to be either exogenous by adding a marker to the vaccine or endogenous by 
incorporating a marker antigen gene to the same plasmid vector (James et al. 2008; Li et 
al. 2008). 
6. The DNA plasmid is amenable to introduction of several ORFs from one or more 
genes, leading to potential capacity to express diverse antigens in a single plasmid vector 
(Abdulhaqq and Weiner 2008; Mumper et al. 2000; Talaat et al. 2001). Thus one DNA 
vaccine can be formulated against different serotypes of one disease or against several 
diseases (Talaat et al. 2001). 
7. DNA vaccines containing unmethylated CpG oligonucleotide sequences in the plasmid 
backbone may have inherent adjuvant activity to improve immune responses (Abdulhaqq 
and Weiner 2008). 
1.4.2.2 Limitations and risks of DNA vaccines   
Although DNA vaccines against numerous infectious diseases in a range of animal 
models are well documented, only three DNA vaccines, against West Nile virus (horses), 
infectious haematopoietic necrosis (salmon) and melanoma (canine), have been licensed 
so far (Laddy and Weiner 2006; Lalor et al. 2008).  Several factors may be responsible 
for their limited application to date.    40
One of the most significant hurdles of DNA vaccine development has been that many of 
the vaccines have been less immunogenic in vivo. For example, a macaque study showed 
that the level of cellular responses induced by IM injection of DNA plasmid-based 
vaccines to HIV-1 was found to be only one-third of that induced by adenovirus serotype 
5 (Ad5) viral vector vaccines (Casimiro et al. 2003). Plasmid DNA-induced immune 
responses have proven to be much stronger in small laboratory animal models (Kodihalli 
et al. 1999; Yang et al. 2004) than in larger animals (Babiuk et al. 2003; Babiuk et al. 
1999b), nonhuman primates (Liu et al. 1997) or humans (Egan and Israel 2002; 
Greenland and Letvin 2007; Wang et al. 1998). 
The second major limitation of DNA vaccines given by IM administration appears to be a 
very high inter-individual variability in the level of foreign gene expression, which is a 
major problem in development of vaccines for clinical application (Mir et al. 1999). 
Although clinical trials have shown that DNA vaccines are safe and well tolerated, a 
number of safety concerns have been raised about the use of DNA vaccines (Huygen 
2005). These include potential integration of plasmid DNA into the host genome via 
either random or homologous recombination between the host and the plasmid (Hasty et 
al. 1991). However, most transfected cells are nondividing, have very limited sequence 
homology between plasmid and mammalian DNA (Donnelly et al. 1997b), and 
investigations in mice that received IM injections with plasmid DNA showed no evidence 
of integration into the host genome using very sensitive PCR tests (Nichols et al. 1995).  
Another theoretical concern is that plasmid-mediated immune responses might result in 
abnormal immune responses such as autoimmune responses (Gilkeson et al. 1995; 
Steinberg et al. 1990), induction of immune tolerance in neonates (Gurunathan et al.   41
2000) or,  via the stimulation of cytokine production, influence the host’s response to 
other vaccines and susceptibility to infection (Donnelly et al. 1997b; Gurunathan et al. 
2000; Klinman et al. 1997a). However, actual studies, including human volunteers 
exposed to plasmid DNA vaccines, indicate that the levels of autoantibodies induced by 
DNA vaccines have not resulted in any evidence of systematic autoimmune disease 
(Gurunathan et al. 2000; Mor et al. 1997). Also, to date, IM administration of DNA 
vaccines in multiple studies has not shown evidence of generation of tolerance in young 
adult animals (Donnelly et al. 1997b) . Despite increasing use of DNA vaccines and 
cytokine-encoding plasmids, there have been no serious side effects indicative of immune 
system disruption reported (Ishii et al. 1999a; Ishii et al. 1999b). 
1.4.3 Approaches to enhance or optimize DNA vaccines  
To overcome the limitations with respect to immunogenicity of DNA vaccines, various 
strategies have been used to improve the level and reliability of gene expression. These 
have targeted various points from in vivo delivery into cells, through to enhancing 
expression of the antigen from the cell and enhancing immune responses by use of 
adjuvants, as discussed below. 
1.4.3.1 Optimization of the plasmid vector 
The DNA vaccine vectors used for expression of the antigen can have a huge impact on 
immunogenicity (Miller et al. 2004). It is generally believed that the expression level of 
antigen-encoding genes in vivo following DNA vaccination correlates positively with the 
plasmid DNA-induced immune response (Donnelly et al. 2003; Greenland and Letvin 
2007; Montgomery et al. 1994).   42
1.4.3.1.1 Promoters 
A promotor facilitates the transcription of a particular gene (Laddy and Weiner 2006). 
Promoter strength remains a critical factor to be considered in plasmid vaccine design 
(Miller et al. 2004). Viral promoters with broad cell type specificity, such as the 
cytomegalovirus immediate early gene (CMV/IE) promoter, simian virus 40 (SV40), 
murine leukemia virus (SL33) and Rous sarcoma virus (RSV) promoters, have been the 
most frequently used vehicles for driving the expression of the vector-encoded gene 
(Hasan et al. 1999; Manoj et al. 2004). In many systems the CMV/IE promoter has 
provided the strongest gene expression in vivo among the above promoters (Lee et al. 
1997). Tissue-specific promoters used in the construction of DNA vectors, such as the 
muscle-creatine kinase (MCK) promoter (Bojak et al. 2002; Gebhard et al. 2000), and 
muscle-specific desmin (Loirat et al. 1999), are expected to be safer than viral promoters, 
but they induced lower levels of antigenic protein expression and weaker immune 
responses (Nettelbeck et al. 2000). Considering the advantages of both viral and tissue-
specific promoters, some new non-viral, synthetic, and chimeric promoters have started 
to be investigated (Garg et al. 2004; Tornoe et al. 2002; Vanniasinkam et al. 2006).  
1.4.3.1.2 Modified plasmid vectors 
Selection of an appropriate vector is one of the most important issues in optimizing a 
DNA vaccine. The DNA vaccine vector is central to high level gene expression and 
subsequent immune response to its encoded antigen (Abdulhaqq and Weiner 2008). Some 
vectors are commercially available, but others with improved properties are being 
developed. Examples of current DNA vaccine vectors are described below. 
1.4.3.1.2.1 Bidirectional and biocistronic plasmids   43
DNA vaccines have the potential to express multiple antigens from one or more 
pathogens in a single vector (Donnelly et al. 1997b). Two kinds of plasmids have been 
constructed. Bidirectional plasmids allowed coexpression of two antigens in vitro, which 
was in accord with increased immune response in vivo (Kwissa et al. 2000). The 
disadvantage of this plasmid was competition for gene expression from the promoters, 
plasmid instabilty due to the presence of more than one expression cassette and possible 
lower transfection efficacy of such plasmids. Bicistronic plasmids can transcribe from a 
single promoter and express proteins from a single mRNA (Barouch et al. 1998; Manoj et 
al. 2003a). However, the disadvantage was variable translational efficiency of the internal 
ribosome entry site (IRES), which may result  in  reduced expression and weaker immune 
responses (Mizuguchi et al. 2000). 
1.4.3.1.2.2 Antibiotic free plasmids 
Antibiotic resistance genes are primarily inserted into the plasmid for selection purposes 
during cloning. Owing to concern regarding the potential for generating microbial 
resistance, the incorporation of antibiotic resistance genes into DNA vectors for 
vaccination purposes is not favoured by vaccine producers or vaccine regulatory agencies. 
Thus novel plasmids without antibiotic resistance genes based on “operator-repressor 
titration” are currently being investigated (Cranenburgh et al. 2001; Williams et al. 1998). 
1.4.3.1.2.3 Simple MIDGE vectors 
The minimalistic immunogenically defined gene expression (MIDGE) vector is another 
example of an antibiotic resistance gene-free plasmid.  These vectors contain the minimal 
gene expression elements including a promoter/intron, gene of interest and   44
polyadenylation signal. Owing to the elimination of bacterial DNA sequences, 
unfavorable side effects (potential integration into host, antibiotic resistance) of plasmid 
DNA are excluded (Manoj et al. 2004; Schakowski et al. 2001). 
MIDGE vectors expressing cytokines together with cytotoxic T lymphocyte antigen-4 
(CTLA-4) have been utilized as adjuvants for vaccination studies (Muller et al. 2002). 
Their potential to replace plasmid vectors is dependent on their transfection efficiency. 
Linking nuclear localization signal (NLS) peptides with the MIDGE vector resulted in 
enhanced antibody responses using IM delivery (Schirmbeck et al. 2001). Thus, MIDGE 
vectors appear to be attractive candidates for DNA vaccines to efficiently prime both 
humoral and cellular antiviral immunity. 
1.4.3.1.3 Codon bias 
The genetic code is almost universal to all organisms, but coding sequences in DNA in 
different species do not use synonymous codons with equal frequencies. This is 
dependent on which tRNA pools are rate limiting in a particular species (Grosjean and 
Fiers 1982; Laddy and Weiner 2006). Generally speaking, there is  a high correlation 
between codon usage, tRNA abundance and the level of gene expression (Duret 2000). 
The genetic composition of the gene appears to impact on the expression of genes in a 
heterologous system, which is attributable to the existing tRNA pool that is available for 
translation of a paticular gene in eukaryotic cells (Saier 1995). Many pathogens have a 
very different codon bias and/or genomic GC content as compared with mammals (Doria-
Rose and Haigwood 2003; Ikemura 1985). In the context of DNA vaccines, this bias may 
result in inefficient translation, low expression levels of microbial genes in transfected 
mammalian cells, and hence low immunogenicity of DNA vaccines (Garmory et al. 2003;   45
Manoj et al. 2004). Thus, optimizing codons in plasmid-encoded genes may become an 
approach for enhancing efficacy in genetic immunization.  A number of studies have 
demonstrated enhanced antibody and CTL responses through the codon optimization of 
the antigen-encoding DNA (Manoj et al. 2004). However, re-engineering the coding 
sequence of a model protein (Thy-1) using ubiquitous HIV codons significantly impaired 
Thy-1 expression, whereas, altering the coding sequence of the jellyfish green fluorescent 
protein (GFP) gene to reflect codon usage in the human genome resulted in increased 
expression in mammalian cells (Haas et al. 1996). Also using HIV codon optimization 
resulted in the removal of inhibitory sequences, which reduce the export of RNA from 
the nucleus as well as translation levels (Haas et al. 1996). 
An additional mechanism resulting from codon usage optimization may contribute to 
increased immunogenicity. Altering the coding sequence of particular genes to conform 
to the preferred mammalian codons resulted in the introduction of multiple CpG motifs 
into the plamid backbone (Doria-Rose and Haigwood 2003). As unmethylated CpG is 
known to be immunostimulatory, CpG-rich plasmids without insertion of foreign gene 
can be used as adjuvants (Klinman et al. 1997b; Sato et al. 1996).Thus, a codon-
optimized gene may have an inherent adjuvant effect due to increased CpG motifs, 
though this is not always the case (Krieg et al. 1998b).  
Apart from codon usage bias, other important factors may also influence gene expression 
at the RNA molecule level (Laddy and Weiner 2006). Sequences rich in G+C content 
probably form secondary structures which can hinder protein translation. Internal splice 
sites can result in the production of incomplete or unwanted antigens. Cis-acting elements 
can inhibit protein synthesis, such as the rev-responsive element (RRE) in the HIV   46
protein Gag. Removal of RRE resulted in high-level protein expression (Indraccolo et al. 
1998; Muthumani et al. 2003). In addition, modifications of native leader sequences, 
which affect mRNA translation and protein secretion, may have marked effects on 
translation efficiency (Kutzler et al. 2005). 
1.4.3.1.4 Kozak sequences 
One control point that can influence protein synthesis from plasmid vectors is at the stage 
of  translation of mRNA transcripts (Babiuk et al. 2003). A comparison of several 
hundred mRNA sequences showed that presence of the CCA/GCCAUGG consensus 
sequence, named Kozak sequence, around the initiator codon was important for efficient 
initiation of translation in higher eukaryotes (Kozak 1987b). A suboptimal sequence 
flanking the AUG initiation codon influences its recognition by eukaryotic ribosomes and 
leads to “leaky scanning” during the translation process (Kozak 2005). Prokaryotic genes 
and some eukaryotic genes do not contain Kozak sequences, therefore, the incorporation 
of a Kozak sequence into a plasmid vector backbone may increase the expression level of 
the transgenes in the context of DNA vaccines (Garmory et al. 2003). 
1.4.3.1.5 Other elements 
Intron and polyadenylation signals can also affect the level of expression of the antigen. 
The addition of an intron, such as the intron A of the CMV/IE gene (Chapman et al. 
1991), and polyadenylation signals, such as bovine growth hormone (Braun et al. 1998), 
β-globin IVS (Collings et al. 1999) and SV40 minor t antigen (Herrera et al. 2000), to the 
plasmid led to increased protein expression. Due to the presence of two potential CpG 
islands in the ampicillin resistance (Amp
r) gene and absence of CpG islands in the   47
kanamycin resistance (Kan
r) gene, Kan
r-expressing plasmids appeared to induce a lower 
immunostimulatory effect than Amp
r-expression plasmids (Sato et al. 1996). 
1.4.3.2 Immunization regimen 
1.4.3.2.1 Delivery methods 
Numerous studies have shown that the method of DNA immunization can affect both the 
strength and the nature of immune responses (Deml et al. 2001). For the purpose of this 
review and this study, delivery methods refer to the use of devices to drive plasmid DNA 
into the host. It can be classified into two categories: syringe and needle, and needle-free 
devices, such as biojecto (Jackson et al. 2001; Williams et al. 2000), powderject (Chen et 
al. 2000a), GG (Fynan et al. 1993b; Pertmer et al. 1996), electroporation  (EP)  (Hirao et 
al. 2008; Selby et al. 2000), and topical application devices (Liu et al. 2001; Watabe et al. 
2001). Needle injection is easily and rapidly performed and the DNA is prepared for 
injection simply by resuspension in a saline solution (Barry and Johnston 1997; De Rose 
et al. 2002; Webster et al. 1994). Needle-free devices for DNA immunization have been 
more efficient in generating immune responses. Studies in mice showed that the amounts 
of DNA required for a comparable antibody response via GG delivery were 
approximately 100-fold less than that for needle injection (Babiuk et al. 2003; Barry and 
Johnston 1997; Doria-Rose and Haigwood 2003; Pertmer et al. 1995). 
Although biojector and powderject have been used to deliver live and subunit vaccines as 
well as DNA vaccines, improvements in the transfection rate of host cells with plasmid 
DNA are still required (Chen et al. 2000a; Degano et al. 1998; Rogers et al. 2001). Use 
of GG and EP has been shown to give efficient uptake of plasmid after immunization 
(Tang et al. 1992; Zucchelli et al. 2000). GG-mediated delivery has been extensively   48
used in DNA vaccination in a number of animal models, but it appears to produce a Th-2 
type immune response, which may not protect the host from infections in all instances 
(Jankovic et al. 2001). Furthermore, owing to limitations in the amounts of plasmid DNA 
that can be coated onto the gold particles, multiple shots by GG are usually required 
(Barry and Johnston 1997; Manoj et al. 2004).  
EP can be combined with commonly used methods of vaccine delivery. Intramuscular or 
ID injections followed by EP resulted in an increased immune response in mice and pigs 
(Drabick et al. 2001; Glasspool-Malone et al. 2000; Mathiesen 1999; Selby et al. 2000; 
Widera et al. 2000). Intradermal injection of naked DNA with EP in the presence of 
nuclease inhibitors synergistically enhanced transgene expression and subsequent 
immune response (Drabick et al. 2001; Glasspool-Malone et al. 2000; Glasspool-Malone 
et al. 2002). 
Nevertheless, the disadvantages of device-dependent delivery methods may restrict or 
limit their future application. These include the limited amount of DNA vaccine 
administered, the requirement for multiple shots, the effect of the noise accompanying a 
GG shot, the requirement for a helium supply as the propellant for the GG, the need for 
an apparatus for generation of electronic pulses, tissue necrosis potentially caused by EP 
and the cost-effectiveness of these methods (Glasspool-Malone and Malone 2002; Manoj 
et al. 2004). The topical application without needle injection has a clinical advantage, but 
complicated operating procedures involved also limit its application (Fan et al. 1999; 
Watabe et al. 2001).  
1.4.3.2.2 Delivery routes    49
A range of routes has been examined for the administration of DNA vaccines. Delivery 
routes can be broadly grouped into two categories: mucosal and systemic. The former 
routes include IN (Fynan et al. 1993b), ocular/orbital (McCluskie et al. 1999), eyedrop 
(Russell and Mackie 2001), oral (McCluskie et al. 1999), sublingual (SL) (McCluskie et 
al. 1999), intrarectal (McCluskie et al. 1999), intravaginal (IVG) (McCluskie et al. 1999), 
intraperineal (IPER)/intravulvomucosal (McCluskie et al. 1999), intratracheal 
(Glasspool-Malone et al. 2002), intrajejunal (Etchart et al. 1997), intrabursal (Fynan et al. 
1993b), and via Peyer’s patches (Schubbert et al. 1997). Systemic routes include IM 
(McCluskie et al. 1999), ID (Fynan et al. 1993b; McCluskie et al. 1999), intravenous (IV) 
(Fynan et al. 1993b; McCluskie et al. 1999), intraperitoneal (IP) (Fynan et al. 1993b; 
McCluskie et al. 1999),  intralymphatic (Maloy et al. 2001),  and subcutaneous (SC) 
(Fynan et al. 1993b).  
The magnitude of DNA vaccine-induced immune responses has been shown to be 
dependent on the delivery route. The delivery routes of plasmid DNA have also been 
shown to influence the type of immune response (Manoj et al. 2004). In many cases, IM 
injections of plasmid DNA by needle elicit a Th1-type response, whereas,, ID 
administration by needle injection generates a mixed immune response. By contrast, GG 
delivery appears to predominantly yield a Th2 response (Feltquate et al. 1997; Leitner et 
al. 1997; Leitner et al. 1999; Manoj et al. 2004). 
Lymph nodes have also been explored as sites of DNA vaccine delivery. Mice given a 
plasmid expressing a CTL epitope of lymphocytic choriomeningitis virus (LCMV) via 
the intralymphatic and intrasplenic routes elicited a CD8 
+cytotoxic T lymphocyte   50
response, which was 100- to 1,000-fold more efficient than that induced by ID or IM 
immunization (Maloy et al. 2001). 
Additionally, tattoo immunization (a new rapid and potent ID DNA vaccination) of 
murine skin with plasmid DNA has been shown to provide a highly transient pulse of 
vaccine antigen that induced strong protective immune responses within a relatively short 
time period (Bins et al. 2005). 
1.4.3.2.3 Delivery dose, number and timing of doses, and volume 
The delivery dose, number, volume and timing of doses of plasmid DNA may affect the 
immune response resulting from DNA vaccination. 
The delivery dose required depends on the delivery method and route used as well as the 
nature of the plasmid vector and its ability to express the antigen in the target cells. 
Typically, in small laboratory rodents, immunization via IM or SC route requires 10 to 
100 μg of plasmid DNA to induce immune responses, whereas, 0.1-1 μg of plasmid DNA 
is required to induce antibody or CTL responses by GG (Gurunathan et al. 2000). In large 
animals, primates or humans, higher doses of DNA appear to be required (Doria-Rose 
and Haigwood 2003; Manoj et al. 2004). However, studies in cattle (Cox et al. 1993) and 
chimpanzees (Davis et al. 1996) showed that, irrespective of the DNA delivery route, it 
may not be necessary to increase the dose proportionate to the body size for larger 
animals (Davis 1997; Leitner et al. 1999). One study with a HIV DNA vaccine in 
macaques showed that increasing the vaccine DNA dose did not generate the expected 
higher immune responses to HIV-1 and other factors such as the use of a strong promoter 
or co-administration of cytokins or other stimulating molecules may be required for 
higher protein expression from DNA vaccines (Galvin et al. 2000).   51
The number of doses also influences the immune response for DNA vaccines. For a very 
immunogenic gene such as the rabies glycoprotein (Lodmell et al. 2001) and influenza 
HA (Robinson et al. 1997), a single dose of DNA vaccine may induce antibody and CTL 
responses, whereas, for less immunogenic genes, it may be difficult to induce protective 
immune responses from a single dose (Doria-Rose and Haigwood 2003). Nevertheless, 
in most cases, the immune responses can be enhanced by successive boosting with the 
vaccine (Gurunathan et al. 2000). For instance, neutralizing antibody to HIV is usually 
detected only after multiple doses of DNA vaccine (Barnett et al. 2001). Besides an 
increase in the magnitude of the immune response multiple immunizations with DNA 
vaccines may alter the type of response induced (Fuller and Haynes 1994). In a macaque 
study using DNA vaccination against simian immunodeficiency virus (SIV), antibodies 
to SIV were reduced after the sixth and seventh vaccinations but were accompanied by 
increased CTL responses (Doria-Rose and Haigwood 2003). 
The time intervals between DNA immunizations may also have an effect on plasmid-
induced immune responses. In a study using the Powderject GG to deliver SIV vaccine to 
macaques, increasing the length of the resting period between immunizations and 
reducing the number of immunizations achieved substantially better responses (Fuller et 
al. 1997). 
Distribution of DNA vaccines significantly influenced their immunogenicity following 
IM injection in mice (Davis et al. 1993b; Dupuis et al. 2000). Larger injection volumes in 
mice appear to result in higher hydrostatic pressure, causing a higher uptake of plasmid 
DNA and generating stronger immune responses (Dupuis et al. 2000). Proportionally 
large volumes simply cannot be administered in larger animals (Greenland and Letvin   52
2007; Liu et al. 1999). Correspondingly, higher dose rates of plasmid DNA in large 
animals appear to be needed to generate immune responses than that in small laboratory 
animals (Doria-Rose and Haigwood 2003). 
Because the immunogenicity of DNA vaccines may be limited by delivery-related 
problems, it is important to optimize the immunization regimens for the target antigen 
and host species. This also requires consideration of the practicality of the method 
including the route, number and volume of doses and their timing. 
1.4.3.3 Co-administration of adjuvants with DNA vaccines  
Naked plasmid DNA immunogens have the potential to elicit potent cellular and humoral 
immune responses against infectious agents. Although plasmid DNA itself can stimulate 
non-specific production of cytokines that augment specific immune responses (Sato et al. 
1996; Srivastava and Liu 2003), DNA-induced immune responses can be further 
enhanced or modulated by the use of immuno-stimulatory adjuvants or improved delivery 
formulations (Greenland and Letvin 2007). Adjuvants for plasmid DNA vaccines can 
broadly be divided into two classes, genetic and chemical adjuvants based on their origin 
(Sasaki et al. 2003). Genetic adjuvants are vectors expressing cytokines or other co-
stimulatory molecules, and are species-specific. As veterinary vaccines work across 
different species and only minimal knowledge of immune modulators such as cytokines 
and interleukins for many species is available, adjuvants dependent on universal 
activation signals of the innate immune response are to be preferred (Scheerlinck and 
Greenwood 2006). Chemical adjuvants can be expected to function similarly in different   53
species and at this time show greater promise for animal DNA vaccines than genetic 
adjuvants. 
1.4.3.3.1 Genetic adjuvants  
A number of studies have demonstrated that  the co-delivery of plasmid DNAs 
expressing immunomodulatory molecules as mentioned in section 1.4.1.1.3, along with 
DNA vaccines can enhance the magnitude and the nature of the immune response to 
DNA vaccines in experimental animal models (Egan and Israel 2002).  
1.4.3.3.2 Chemical adjuvants  
Although naked DNA vaccines themselves can induce immune responses, biodistribution 
studies showed that after IM injection only a small fraction of the injected DNA 
transfected target cells which resulted in poor immunogenicity, especially in larger 
animals and humans (Donnelly et al. 2005).  
Chemical adjuvants can function as activators of innate immunity (Kovacsovics-
Bankowski et al. 1993; Leifert et al. 2004), provide slow release depots, or alter immune 
cell trafficking (Sigal et al. 1999). They can generally be sorted into several categories 
(Table1.2), most of which have shown promise for enhancing the expression and 
immunogenicity of plasmid DNA vaccines in animal models (Greenland and Letvin 
2007). 
Agents that cause muscle necrosis, such as cardiotoxin or bupivicaine, increase immune 
responses to DNA vaccines through increased protein expression in regenerating 
myocytes and recruitment of APCs by inflammatory responses (Coney et al. 1994; Davis 
et al. 1993a).   54
Table 1.2 Applications of chemical adjuvants in DNA vaccines. 
 
Adjuvant  type  Examples  Vaccine and reference 
Conventional adjuvants 
Aluminum phosphate, 
Aluminum hydorxide 
V1JpHA encoding HA from influenza virus 
A/Georgia/03/93; V1Jns/gD and V1Jns/DgB 
encoding herpes simplex virus 2 (HSV-2) gD and 
the amino-terminal 707 amino acids of gB (Ulmer et 
al. 1999) 
Mineral salts  
 
Calcium phosphate  Plasmid encoding an H5 AIV HA gene (Suarez and 
Schultz-Cherry 2000a) 
Tensoactive 
compounds 
QS-21  Plasmid encoding  HIV-1 env and rev gene (Sasaki 
et al. 1998c) 
Monophosphoryl lipid A(MPL)  DNA vaccine encoding the CVS rabies virus G 
(Lodmell et al. 2000) 
Microorganism-
derived 
adjuvants  Cholera toxin  Plasmid pPJV7418 encoding  for hepatitis B surface 
and core antigens, Plasmid pC-Env/T encoding a 
truncated HIV-1 gp120 gene, pM2-FL encoding the 
M2 gene of influenza A/Sydney/5/97 (H3N2) virus 
(Arrington et al. 2002) 
Cardiotoxin   Plasmid encoding hepatitis B surface antigen 
(HBsAg) (Davis et al. 1993a) 
Bupivicaine  Plasmid encoding HIV-1gp160 (Coney et al. 1994) 
Barium chloride  β-galactosidase (β-gal)-encoding plasmid (Wells et 
al. 1998) 
Dimethyldioctadecylammonium 
bromide (DDA) 
Plasmids encoding pseudorabies virus glycoprotein 
B (gB) and gD (van Rooij et al. 2002) 
Others 
Sucrose  Plasmid encoding an H5 AIV HA gene (Suarez and 
Schultz-Cherry 2000a) 
Particulate  delivery system 
Cationic liposomes  Cystic fibrosis transmembrane conductance 
regulator-encoding plasmid (Hyde et al. 2000), 
Plasmid DNA encoding HBsAg (Perrie et al. 2001) 
Anionic liposomes  Tyrosinase-related protein-2 (TRP2)-encoding 
plasmid (Yamano et al. 2006) 
Liposomes/ 
Lipid particles 
DermaVir  Simian-human immunodeficiency virus (SHIV)  
plasmid pSHIV(int-) (Lisziewicz et al. 2005) 
Polyethyleneimine (PEI)  HIV-glycoprotein 120 (gp120)-encoding plasmid 
(Garzon et al. 2005) 
Dimethylaminoethyl 
methacrylates(DEAEMA) 
DNA plasmid (pCMV-S) encoding HbsAg (Bos et 
al. 2004) 
β-Cyclodextrin  Plasmids pGL3-CVencoding for the luciferase gene 
and pEGFPLuc coding for an EGFP/luciferase 
fusion protein (Pun et al. 2004) 
Cationic poly(β-amino esters)  pVRC-HIV-1 Env IIIB gp120 (Greenland et al. 
2005) 
Poloxamers   HIV-1 gag-encoding plasmid (Evans et al. 2004) 
Polymers 
 
Polyvinylpyrrolidone (PVP)  Human growth hormone or bacterial β-gal)-
encoding plasmids (Anwer et al. 1999)   55
Table 1.2 Applications of chemical adjuvants in DNA vaccines.(continued). 
 
Adjuvant  type  Examples  Vaccine and reference 
Poly(dl-lactic-co-glycolic acid) 
(PLGA) 
Plasmid encoding multiple HIV-1 CTL epitopes and 
several Simian immunodeficiency virus (SIV) 
epitopes together with the SV5 Pk tag epitope 
(Sharpe et al. 2003) 
PLGA-CTAB  Plasmid encoding HIV p55 gag (Denis-Mize et al. 
2003) 
PLGA-poly(β-amino ester)  Plasmid DNA encoding firefly luciferase, β-gal, or 
SIY/β-gal fusion (Little et al. 2004) 
Alginate Plasmid  encoding  bacterial  β-gal (LacZ) gene 
(Mittal et al. 2000) 
Chitosan  Plasmid encoding the CTL epitope from respiratory 
syncytial virus M2 protein (Iqbal et al. 2003) 
Nano- and 
microparticles 
Poly(ortho ester) polymers  pCMV-Luc expressing luciferase and pCI-Neo 
expressing the SIY antigen (Wang et al. 2004a) 
Synthetic peptide Trp-Lys-Tyr-
Met-Val-d-Met(WKYMVm) 
pGX10-GE encoding HIV-1 tat gene, pGX10-NP 
encoding the NP gene of PR8 virus, pGX10-HA 
encoding the HA gene of influenza A/WSN/33 
virus, and pGX10-gDsS encoding the S gene of 
hepatitis B virus (HBV) (Lee et al. 2005) 
Ubenimex 
 
Plasmid encoding HIV-1 (Sasaki et al. 1998a) 
Synthetic 
adjuvants 
 
Oligodeoxynucleotides (ODNs) 
containing CpG motifs 
Plasmid encoding infectious bursal disease virus 
(Wang et al. 2003) 
 
Aluminum salts are the most widely used adjuvant for both human and veterinary 
vaccines (Lindblad 2004). Aluminum phosphate possibly acts by recruiting APCs to the 
site of the IM injection, where a fraction of transfected muscle cells expressed a plasmid-
encoded antigen (Donnelly et al. 2005). Formulation of plasmid DNA vaccines with 
aluminum salts has been shown to enhance humoral immune responses in rodents and 
primates (Ulmer et al. 1999). 
Liposomes are synthetic spheres possessing lipid layers that can encapsulate antigens and 
act as both a vaccine delivery vehicle and adjuvant (Petrovsky and Aguilar 2004). These 
delivery vehicles not only protect plasmid DNA from nuclease degradation, but also 
facilitate the transfer of DNA across membranes and release DNA contents following   56
fusion with endosomes (Nakanishi and Noguchi 2001). Either cationic or anionic 
liposome formulations, alone or in combination, can augment immune responses to 
plasmid DNA immunogens (Perrie et al. 2001). Furthermore, the immunogenicity of 
liposome formulated plasmid DNA can be augmented in combination with cytokine 
adjuvants (Yamano et al. 2006). 
A variety of cationic polymers (Greenland and Letvin 2007) have shown promise for 
enhancing the expression of plasmid DNA by facilitating transport of plasmid DNA 
across cell membranes (Ledley 1996), reducing DNA degradation and  facilitating its 
release from endosomal compartments (Lungwitz et al. 2005). The polymer may also act 
in part through a local inflammatory response (Donnelly et al. 2005). Nevertheless, 
formulation with cationic polymer polyethyleneimine (PEI) decreased the immune 
responses generated by intramuscularly administered plasmid DNA encoding diphtheria 
toxin (Anderson et al. 2004). 
Microparticle complexes appear to improve delivery of DNA to APCs by facilitating 
trafficking to local lymphoid tissue and facilitating uptake by DCs (Denis-Mize et al. 
2003; Dupuis et al. 2000). In particular, the copolymer poly-DL-lactic-co-glycolic acid 
(PLGA) has been extensively investigated as a carrier for plasmid DNA immunogens 
(Cui and Mumper 2003b). Poly-lactide-co-glycolide (PLG) delivery of HIV DNA 
vaccines was shown to be effective at inducing antibody and CMI responses in various 
species, including rhesus macaques (O'Hagan et al. 2004). Recently, nanoparticles have 
shown promise for enhancing immune responses to plasmid DNA vaccines (Cui and 
Mumper 2002a, b, c, 2003a; Li et al. 2009; Lori et al. 2007).   57
Conventional adjuvants effective for inactivated whole organism and subunit vaccines 
may sometimes enhance the immune responses induced by DNA vaccines in large animal 
species. However, most studies in the mouse model have shown that formulation of DNA 
vaccines with such adjuvants is usually not beneficial (van Drunen Littel-van den Hurk et 
al. 2004). Hence, there is a need to evaluate new adjuvant formulations and delivery 
systems for DNA vaccines (Greenland and Letvin 2007; van Drunen Littel-van den Hurk 
et al. 2004; Wales et al. 2005).  
1.4.3.4 Antigen targeting to improve DNA vaccines 
1.4.3.4.1 Extracellular targeting  
As APCs play a crucial role in the generation of immune responses, connecting the 
plasmid-encoded antigens with molecules that recognize receptors on APCs is one 
approach to effectively target limited antigens to give effective antigen presentation. 
Molecules to which plasmid-encoded antigens have been linked have included anti-
CD11c, anti-CD40, anti-HLA-DR, anti-MHC II, CD154, cytotoxic T-lymphocyte antigen 
(CTLA)-4, IgG-Fc, L-selectin, p53TCR-PE38 and Troy Bodies (Manoj et al. 2004; 
Scheerlinck 2001). Another molecule used for targeting is C3d, which recognizes its 
receptor CR2 (complement type 2 receptor) or CD21 on B cells. Although this induced 
stronger immune response in some cases (Manoj et al. 2003b; Ross et al. 2001; Smahel et 
al. 2001) 146, 151), this strategy is not always successful (Frleta et al. 2001; Suradhat et 
al. 2001). Interestingly, DNA vaccination using antigen targeting to APCs did not show 
direct correlation between increased antibody level and higher protective immune 
response for Corynebacterium pseudotuberculosis in sheep (Chaplin et al. 1999).     58
1.4.3.4.2 Intracellular targeting 
Ubiquitin has been linked with the antigen-encoding sequences to facilitate plasmid-
encoded antigens being targeted to proteosomes, where antigen is rapidly degraded and 
presented via the MHC class I pathway (Rodriguez et al. 2001). Alternatively, linking the 
antigen to viral protein 22 (VP22) from viruses, such as HSV-1, bovine herpesvirus 1 
(BHV-1) and Marek’s disease virus type 1, effectively transported proteins synthesized in 
one cell to neighbouring cells, which was expected to increase the number of cells 
presenting the antigen (Manoj et al. 2004). These approaches have been shown to 
enhance CTL responses (Elliott and O'Hare 1997; Fu et al. 1998; Hung et al. 2001; Hung 
et al. 2002; Leachman et al. 2002; Oliveira et al. 2001), but are not always effective 
(Vidalin et al. 1999).    
Linking specific protein epitopes with the lysosome integral membrane protein (LIMP-II) 
was used to target lysosomal compartments for the induction of immune responses via 
the MHC class II pathway (Rodriguez et al. 2001). Short peptide sequences linking to the 
protein transduction domain (PTD) resulted in rapid trafficking to the surfaces of 
transfected cells. The plasmid encoding the PTD-linked epitope induced a markedly 
accelerated CD8
+ T cell response (Leifert et al. 2001).  
1.4.3.5 Prime-boost strategies  
A number of studies have demonstrated that in many cases, a combination of two or more 
vaccine modalities generate better immune responses than either vaccine alone (Doria-
Rose et al. 2003; Klinman et al. 1998). Priming with DNA and boosting with other 
vaccines, or vice versa, enhanced either Th1- (Hanke et al. 1999; Li et al. 1998) or Th2-  59
type (Barnett et al. 1997) biased immune responses. This approach can also avoid one 
major drawback for recombinant virus-based vaccines where booster vaccination with 
these vaccines may be ineffective due to an anamnestic responses to the vector itself 
(Restifo and Rosenberg 1999).  DNA vaccines coupled with other types of vaccines have 
conferred some protection against a diverse range of pathogens in animal models as 
discussed below (Doria-Rose and Haigwood 2003). For HIV and malaria, prime-boost 
vaccination regimens have successfully progressed to clinical trials in humans (Giri et al. 
2004; Moore and Hill 2004).   
One combination involves initial use of DNA vaccine followed by a subsequent 
vaccination of exogenous protein with adjuvant and this gives better immunogenicity 
than repeating the DNA vaccination (Tanghe et al. 2001; Wang et al. 2004c). However, 
cattle primed with MPB70 DNA and boosted with MPB70 protein generated a strong 
antibody response and a weak IFN-γ response, but were not protected against bovine 
tuberculosis (Wedlock et al. 2003). 
Vaccination regimes using initial DNA vaccination followed by secondary vaccination 
with recombinant pox-virus (Robinson et al. 1999; Sedegah et al. 2003), vaccinia virus 
(McConkey et al. 2003; McShane 2002; Sedegah et al. 1998), adenovirus (Lo et al. 2008; 
Wang et al. 2004b), live Salmonella typhimurium vaccine (Mollenkopf et al. 2001) or 
live attenuated influenza virus (Huber et al. 2009) have all conferred potent and 
promising immune protection. 
Regimes where DNA vaccinations have been followed by secondary vaccination with 
inactivated virus particles have not been as effective in protecting macaques against 
SHIV challenge as vaccinia virus priming/DNA boosting or DNA priming/ vaccinia virus   60
boosting (Doria-Rose et al. 2003). Heterologous HA-DNA vaccine priming with 
inactivated trivalent influenza vaccine (TIV) boost was more effective in eliciting 
antibody responses against H1 or H3 serotype influenza viruses in rabbits than 
homologous prime/boost (DNA/DNA or TIV/TIV) (Wang et al. 2008a). 
Mice mucosally primed with recombinant viral vector and boosted with DNA vaccine, 
both encoding the gB protein of HSV, elicited better mucosal and systemic responses (Eo 
et al. 2001). Recombinant vaccinia virus priming and DNA boosting provided significant 
protection from SHIV mucosal challenge in macaque models (Doria-Rose et al. 2003). 
1.4.3.6 CpG motif-based adjuvants  
Three main approaches have been taken to use the adjuvant effects of CpG motifs in 
DNA vaccines and these are currently being investigated (Aguilar and Rodriguez 2007). 
They include immunostimulatory ODNs ( co-administered in vivo) (Marshall et al. 2005), 
ODN antigen conjugates (an ODN chemically conjugated to an antigen) (Datta et al. 
2004) and DNA vaccine vectors with enhanced immunostimulatory sequences (ISS) 
sequences (engineering the CpG motifs into the plasmid DNA backbone) (Rodriguez et 
al. 2003). A number of studies showed that plasmid DNAs in combination with CpG-
containing sequences enhanced immune responses to plasmid immunogens, although co-
delivery of CpG-containing ODNs with DNA vaccines appeared to have a negative effect 
(Weeratna et al. 1998).  
1.4.4 Second-generation DNA vaccines  
In addition to consideration of plasmid vectors, immunization regime and adjuvant 
systems to enhance immune responses and protection from DNA vaccines, consideration   61
has been given recently to optimizing the part of the target gene to be expressed and also 
to the use of some novel delivery systems with the aim of getting more consistent and 
robust immune responses. This is leading to the development of second-generation DNA 
vaccines (as compared to classic full-length gene-expressed plasmid DNA) and some 
examples are described below. 
1.4.4.1 Truncated DNA vaccines  
In some cases, full-length genes have not been found to be  suitable as DNA vaccine 
candidates because they either express highly immunogenic protein sequences that are 
not specific or protective (Chen et al. 1998a), are toxic for the host (Barry and Johnston 
1997) or are immunosuppressive in  the host (Levy 1993). However, use of a DNA vector 
containing a truncated gene has given enhanced immune response. An example is a 
plasmid vector vaccine containing the soluble or membrane-bound truncated forms of the 
neu oncogene, after the removal of the cytoplasmic kinase domain from the full-length 
gene, which generated better protective antitumor immunity than the vector encoding the 
full-length gene (Chen et al. 1998a). 
1.4.4.2 Epitope-based vaccines  
Multi-epitope DNA vaccines, sometimes referred to as polyepitope or polytope vaccines, 
have been constructed by linking well-defined epitope areas of genes together with 
appropriate nucleotide spacers (An et al. 2000; Leifert et al. 2004; Suhrbier 1997; 
Thomson et al. 1998; Tian et al. 2008). Compared to traditional full-length gene DNA 
vaccines, epitope-based DNA vaccines have advantages of increased ‘safety’ in that they 
are highly unlikely to integrate into the host genome; demonstrate ‘flexibility’ in epitope   62
selection, which should permit induction and optimisation of the desired type of 
immunity; have the potential to induce more potent immunoreaction than whole protein 
vaccines; and show the potential for induction of a broad spectrum of immune responses 
simultaneously targeting multiple antigens (Jackson et al. 2002). For instance, GG 
immunization of mice with a minigene coding for single epitopes derived from mutant 
p53 (an endogenous oncoprotein), or from HIV gp120 resulted in efficient induction of 
tumor protective CTL (Ciernik et al. 1996). 
A polytope DNA plasmid containing multiple contiguous minimal murine CTL epitopes 
was developed. Protective CTL responses in immunized mice were demonstrated in 
recombinant vaccinia virus, influenza virus, and tumor challenge models. Moreover, CTL 
responses generated by this plasmid immunization lasted for one year. The ability to 
deliver large numbers of CTL epitopes using relatively small polytope constructs and 
DNA vaccination technology holds promise in the design of human epitope-based CTL 
vaccines, in particular, in vaccines against Epstein-Barr virus, HIV and certain cancers 
(Thomson et al. 1998). 
IM injection of a multi-epitope DNA vaccine carrying three CTL epitopes of NP gene 
fused to the truncated HA from A/goose/Guangdong/1/96 (H5N1) did not produce 
haemagglutination inhibition (HI) antibody before challenge, but the percentages of 
CD4
+ and CD8
+ T lymphocytes in peripheral blood of immunized chickens increased 
significantly in comparison with chickens inoculated with a blank vector control. This 
vaccine also provided partial protection from homologous virus challenge (Peng et al. 
2003).   63
1.4.4.3 DNA vaccines delivered by bacterial vectors  
Some attenuated bacteria such as Salmonella spp. (Pan et al. 2009; Tacket et al. 2000), 
Shigella spp. (Fennelly et al. 1999; Sizemore et al. 1995) and Listeria monocytogenes 
(Frankel et al. 1995) are being used as delivery systems for plasmid DNA vaccines and as 
heterologous expression systems. Bacterial vectors can potentially be used via oral 
administration and may elicit mucosal immune response, but there are concerns regarding 
reversion to virulence of these bacteria and also whether preexisting immunity to the 
bacteria will preclude their use (Srivastava and Liu 2003).      
1.4.4.4 Self-replicating genetic vaccines 
In order to avoid the short intracellular half-life of RNA and its degradation by ubiquitous 
RNases, and to overcome the poor efficacy of some DNA-based and RNA-based 
vaccines, self-replicating replicons derived from the genomes of positive-stranded RNA 
viruses have been explored. Some alphaviruses, such as Sindbis virus (SIN), Semliki 
Forest virus (SFV), and Venezuelan equine encephalitis virus (VEE) are being developed 
as genetic vaccine vectors. In such a system, the structural protein region of the viral 
RNA genome is replaced with an antigen-encoding gene, while the enzymatic non-
structural protein genes, known collectively as the viral “replicase,” are retained. These 
replicon vectors can still direct their self amplification in an infected host cell and lead to 
high-level antigen expression (Chang et al. 2008; Dubensky et al. 2000; Vignuzzi et al. 
2001). 
A single IM injection of a SIN replicase-based vector expressing the glycoprotein B of 
HSV-1 induced virus-specific antibody and CTL responses, as well as protective   64
immunity in two different murine models. Moreover, 100- to 1,000-fold-lower doses of a 
SIN-based vector were required to induce comparable immune responsiveness to that 
achieved with a conventional plasmid DNA vector (Hariharan et al. 1998). 
Mice immunized with a SFV-based vaccine expressing PR8 virus NP produced NP-
specific antibody, a CTL response to NP epitopes and the level of protection from the 
replicon vector vaccine was comparable to that induced by plasmid DNA immunization 
(Vignuzzi et al. 2001). 
1.5 Avian and human influenza DNA vaccines 
Influenza DNA vaccines have been well studied with some of the earliest DNA vaccine 
development in mice conducted using influenza as a model (Ulmer 2002).  
1.5.1 Plasmid vectors used in influenza DNA vaccines 
Over the years various DNA expression vectors have been used in mice, chickens, or 
other animals as indicated below:  
  The pcDNA 3.1 vector, a non-fusion vector containing CMV/IE promoter and 
neomycin resistance gene for cloning HA and M gene from 
A/chicken/Italy/1067/99 (H7N1) (Cherbonnel et al. 2003);  
  The pCI vector, under the control of the CMV/IE promoter,  for cloning HA gene 
from A/goose/Guangdong/1/96 (H5N1) (Chen et al. 2001); 
  The pCI-neo vector, which contains theCMV/IE promoter, for cloning HA gene 
from A/turkey/Wisconsin/68 (H5N9) (Suarez and Schultz-Cherry 2000a); 
  The pSI vector containing the SV40 early promoter, for cloning HA gene from 
A/turkey/Wisconsin/68 (H5N9) (Suarez and Schultz-Cherry 2000a);   65
  The pCAGGS/MCS vector, which contains the chicken β-actin promoter element 
and the SV40 origin of replication, for cloning full-length HA, NA, Ml, NP or 
NSl gene from PR8 virus (Chen et al. 2005; Chen et al. 1999a; Chen et al. 
1998b) , HA and NA gene from A/chicken/Jiangsu/7/2002 (H9N2) (Qiu et al. 
2006), HA gene from A/HK/156/97 (H5N1) (Kodihalli et al. 1999),  HA gene 
from A/chicken/Victoria/1/85 (H7N7) and NP gene from A/turkey/Ireland/1/83 
(H5N8) (Kodihalli et al. 2000); HA gene from A/turkey/Ireland/1/83 (H5N8) 
(Kodihalli et al. 1997), A/turkey/Wisconsin/68 (H5N9) (Suarez and Schultz-
Cherry 2000a), and A/goose/Guangdong/1/96 (H5N1) (Jiang et al. 2007); In 
addition, HA, NA, M2, and NP genes from A/Hanoi/30408/2005 (H5N1) were 
cloned into pCAGα derived from a pCAGGS expression vector following a 
deletion of 829 bp between the Eco47III/XbaI sites (Patel et al. 2009); 
  The VR1012 vector, which contains CMV/IE promoter, bovine growth hormone 
(BGH) polyadenylation site, and Kan
r gene in a modified pUC backbone, 
encoding NP and M gene from PR8 virus (Epstein et al. 2005; Epstein et al. 2000; 
Epstein et al. 2002);  encoding HA from A/turkey/Wisconsin/68 (H5N9) (Suarez 
and Schultz-Cherry 2000a); VR10551, which is derived from VR1012 by 
replacing the BGH polyadenylation signal with a synthetic rabbit β-globin 
consensus polyadenylation signal, for cloning consensus NP, M1, and M2 
sequences from human H3N2 and H1N1 influenza viruses (Jimenez et al. 2007), 
and HA, NP, and M2 gene of A/Vietnam/1203/04 (H5N1) virus (Lalor et al. 
2008);   66
  The pRC/CMV vector, for cloning HA gene of A/WSN/33 (H1N1) influenza 
virus (Bot et al. 1997);  
  The pRC/RSV vector, which  contains the RSV long terminal repeat (LTR)   
promoter, for cloning HA from A/turkey/Wisconsin/68 (H5N9) (Suarez and 
Schultz-Cherry 2000a); 
  The pHW2000 vector, containing the human pol I promoter and the murine 
terminator sequence which are flanked by a truncated CMV/IE promoter and by 
the BGH polyadenylation signal, for cloning HA gene from A/Hong Kong/1/68 
(H3N2), A/Victoria/3/75 (H3N2), and A/Leningrad/360/86 (H3N2) (Huber et al. 
2009); 
  The pRSV vector, containing the RSV LTR promoter, the SV 40 virus t-intron, 
and the SV 40 polyadenylation site, for cloning NP gene from PR8 virus (Raz et 
al. 1994);   
  The pI.17 vector, which is a pUC-based plasmid carrying a bacterial origin of 
replication, Amp
r gene, a truncated enhancer region, full promoter and full intron 
A gene from human CMV and a CMV terminator sequence, for cloning full-
length HA gene of A/Sichuan/2/87 (H3N2) (Johnson et al. 2000); 
  The pGA, which consists of CMV/IE promoter, BGH polyadenylation site, and 
Kan
r gene, for cloning NP or HA gene of  PR8 virus (Sasaki et al. 2004); 
  The pJW4303 vector, under the control of a CMV/IE promoter, for cloning HA, 
NP gene from PR8 virus (Feltquate et al. 1997; Pertmer et al. 2000), HA gene 
from A/turkey/Ireland/1/83 (H5N8) (Kodihalli et al. 1997);   67
  The pBC12/CMV/IL-2 vector, which contains CMV/IE promoter and SV40 
origin of replication, rat preproinsulin II sequences (including an intron and a 
polyadenylation site), for cloning HA gene from PR8 and A/seal/Mass/1/80 
(H7N7) (Fynan et al. 1993a);  
  The V1J vector, which contains the CMV IntA enhancer, promoter, intron A for 
transcription initiation, the BGH terminator for transcription termination and 
ployadenylation in a modified pUC19 backbone, for cloning NP gene from PR8 
(Bender et al. 1998; Deck et al. 1997; Montgomery et al. 1993; Ulmer et al. 1994; 
Ulmer et al. 1993; Ulmer et al. 1998);  
  The pME18S vector, for cloning M and NP gene from PR8 (Okuda et al. 2001); 
  The pRCAS, containing a nonpermuted proviral form of a replication-competent, 
derivative of the Schmidt-Ruppin-A strain of RSV (Hughes et al. 1987), and the 
p188,  a defective-retroviral-based vector, for cloning HA gene of 
A/seal/Mass/1/80 (H7N7) (Robinson et al. 1993).   
1.5.2 Effect of different influenza virus genes on protective immunity 
DNA vaccination induced by different genes of AIV has been extensively explored and 
has shown promising, yet variable protective immune responses against homologous and 
heterologous AIV challenge. Cross-strain protective immunity against influenza based on 
CMI responses has been observed in mice, chickens and ferrets, and non-human primates 
as described in the following sections (Kodihalli et al. 2000; Laddy et al. 2008; Patel et al. 
2009).  
1.5.2.1 DNA vaccines encoding various viral genes in the murine model   68
1.5.2.1.1 HA-DNA 
Plasmid DNAs encoding HA from influenza A viruses have been extensively 
investigated. A number of studies have demonstrated that immunization via parenteral, 
mucosal, or gene-gun delivery with plasmid DNA encoding HA from PR8 virus (Bender 
et al. 1998; Bot et al. 1997; Chen et al. 1999a; Chen et al. 1998b; Chen et al. 1999b; 
Deck et al. 1997; Fynan et al. 1993b; Montgomery et al. 1993; Pertmer et al. 2000; 
Robinson et al. 1997; Ulmer et al. 1994), A/Sichuan/2/87 (H3N2) (Johnson et al. 2000), 
A/HK/156/97 (H5N1) and A/turkey/Ireland/1/83  (H5N8) (Kodihalli et al. 1999), 
A/Hanoi/30408/2005 (H5N1) (Patel et al. 2009), A/seal/Mass/1/80 (H7N7) (Fynan et al. 
1993b), and A/chicken/Jiangsu/7/2002 (H9N2) (Qiu et al. 2006) was able to produce cell-
mediated and humoral immunity and protect mice against lethal challenge with 
homologous virus. Nonethless, a single dose of HA-DNA from PR8 virus administered 
by EP could not protect mice against homologous influenza virus challenge (Chen et al. 
2005). Of note, immunization with plasmid DNA encoding A/HK/156/97 (H5N1) HA 
gene delivered via GG provided protective immunity against homologous A/HK/156/97 
(H5N1) and antigenic variant A/Chicken/HK/258/97 (H5N1) viruses. However, plasmid 
DNA encoding HA gene from A/turkey/Ireland/1/83 (H5N8), which differs from 
A/HK/156/97 (H5N1) by 12% in the HA1 region at the amino acid level, prevented death 
but did not fully protect immunized mice against A/HK/156/97 (H5N1) challenge 
infection (Kodihalli et al. 1999). This highlights that AIV vaccines may induce limited 
cross-protection among the same HA subtypes. Moreover, immunization of mice via EP 
with a plasmid encoding synthetic consensus HA gene of H5N1 AIVs provided 
heterosubtypic protection against pathogenic human and H5N1 AIV infection (Laddy et 
al. 2008).   69
1.5.2.1.2 NP-DNA  
As NP-DNA vaccines can induce immunity to conserved epitopes, it was hypothesized 
that such vaccines may protect the host against a broad range of viral variants (Epstein et 
al. 2000). Some studies showed that the plasmid DNAs encoding NP from PR8 virus 
failed to protect against challenge with homologous influenza virus (Chen et al. 1998b; 
Chen et al. 1999b; Pertmer et al. 2000; Robinson et al. 1997). Others have demonstrated 
that the plasmid DNAs encoding NP from PR8 virus induced CTL responses and 
partially protected mice from challenge with heterologous A/HK/68 (H3N2) influenza 
virus when dosed by GG or IM injection (Bender et al. 1998; Fu et al. 1997a; 
Montgomery et al. 1993; Ulmer et al. 1994; Ulmer et al. 1993; Ulmer et al. 1998). 
Intramuscular injection of a plasmid encoding NP gene from A/Hanoi/30408/2005 
(H5N1) failed to protect mice against homologous virus challenge (Patel et al. 2009), 
while immunization of mice via EP with a plasmid encoding synthetic consensus NP 
gene of H5N1 AIVs provided heterosubtypic protection against A/Hanoi/30408/2005 
(H5N1) challenge (Laddy et al. 2008). In particular, DNA priming-recombinant 
adenoviral boosting with NP generated strong antibody and T cell responses and hence 
conferred protection against challenge with multiple influenza A subtypes such as PR8, 
A/Philippines/2/82/X-79 (H3N2), H5N1 viruses A/HK/156/97 (H5N1) and A/HK/483/97 
(H5N1) (Epstein et al. 2005).  
Although the results of NP-DNA vaccination appear to be inconsistent in a number of 
studies, it did elicit NP-specific CTL responses in mice. Therefore, NP gene is being 
evaluated for potential development of broad spectrum influenza DNA vaccines. 
1.5.2.1.3 NA-DNA   70
Mice vaccinated with NA-expressing DNA(NA-DNA) from PR8 virus by GG (Chen et al. 
2005; Chen et al. 2000b; Chen et al. 1998b; Chen et al. 1999b), and NA-DNA from 
A/Aichi/2/68 (H3N2), A/Guizhou/54/89 (H3N2) (Chen et al. 2000b), and 
A/chicken/Jiangsu/7/2002 (H9N2) by EP (Qiu et al. 2006) showed significant protection 
against lethal challenge with the homologous virus. A single dose administration, even as 
low as 5 μg per mouse, of NA-DNA from PR8 virus by EP could protect mice from lethal 
challenge with homologous influenza virus and provided long-term protection against 
homologous virus infection (Chen et al. 2005). 
Immunization with plasmid NA-DNA, prepared from A/Guizhou/54/89 (H3N2), 
A/Aichi/2/68 (H3N2) or PR8 virus by GG or EP, afforded protection or cross-protection 
against a homologous or variant virus infection within the same subtype, but failed to 
confer protection against a different subtype (Chen et al. 2000b). Intramuscular injection 
of a plasmid encoding NA gene from A/Hanoi/30408/2005 (H5N1) failed to protect mice 
against homologous virus challenge (Patel et al. 2009), while EP with a plasmid encoding 
synthetic consensus NA gene of H5N1 AIVs provided partial protection against 
A/Hanoi/30408/2005 challenge (Laddy et al. 2008). In comparison with HA-DNA and 
NP-DNA, although information that NA-DNA vaccine induced detectable antibodies and 
provided protection against influenza virus challenge was limited, NA may also be an 
effective viral component for the development of AI DNA vaccines (Chen 2004). 
1.5.2.1.4 M-DNA and NS1-DNA 
Due to the ongoing antigenic variation of influenza viruses, especially on the surface 
glycoproteins, efficacy of vaccines based on HA and NA can fluctuate over time.  
However, the viral matrix protein (M) protein is nearly invariant in all influenza A strains   71
and hence has potential as a broad spectrum immunogen (Ito et al. 1991; Slepushkin et al. 
1995). 
Mice given a DNA plasmid vaccine encoding M1 gene of PR8 virus were not protected 
against homologous challenge although they did produce a detectable antibody response 
(Chen et al. 1998b). Intramuscular injection of a plasmid encoding M2 gene from 
A/Hanoi/30408/2005 (H5N1) failed to protect mice against homologous virus challenge 
(Patel et al. 2009). However, a pME18S-M construct encoding M1 and M2 genes of PR8 
virus provided 70% to 80% protection in the mice against challenge with not only 
homologous (PR8) but also heterologous (A/WSN/33) (H1N1) influenza viruses (Okuda 
et al. 2001). When this vaccine was applied topically together with cholera toxin or a 
synthesized CpG ODN as adjuvant, it conferred cross-protection against challenge with 
A/Udorn/72 (H3N2) virus (Ozaki et al. 2005). These studies suggested that M-DNA can 
provide some cross-protective immunity and this is being considered further in relation to 
the development of broad spectrum influenza vaccines. Alternatively, in mice 
administered plasmid encoding NS1 gene (NS1-DNA) there was no evidence of 
protection after homologous challenge (Chen et al. 1998b). 
1.5.2.1.5 Co-administration of mixed plasmids encoding different genes 
Promising results with some of the single gene-expressing DNA vaccines against 
influenza A viruses in mice encouraged further investigations using combinations of 
genes especially to produce broader spectrum protection. The following combinations 
have been investigated. 
1.5.2.1.5.1 NP-DNA and M-DNA   72
BALB/c mice dosed with a mixture of NP-DNA and M-DNA from PR8 virus gave a 
modest reduction in virus replication in lung which showed some correlation with 
improved survival after homologous challenge compared with unvaccinated controls 
(Epstein et al. 1997; Levi and Arnon 1996). Mice vaccinated with NP-DNA and M-DNA 
combination survived after lethal challenge with A/Philippines/2/82/X-79 (H3N2) 
influenza virus whereas B6-β2m (-/-) mice (defective in normal MHC class I complexes) 
that received identical vaccination died following lethal virus challenge (Epstein et al. 
2000).  
Vaccination of a mixture of NP-DNA and M-DNA from PR8 virus reduced replication of 
A/Hong Kong/486/97 virus (a nonlethal H5N1 strain) in the lungs compared to controls, 
protected mice against lethal challenge with A/Hong Kong/156/97 (intermediate 
virulence), but failed to protect against challenge with A/Hong Kong/483/97 (highly 
virulent strain) challenge. Additionally, all mice primed with a mixture of NP-DNA and 
M-DNA and subsequently exposed to A/Hong Kong/156/97 challenge survived after re-
challenge with A/Hong Kong/483/97 (Epstein et al. 2002).  
Compared to single plasmid vaccines expressing NP, M1, M2, or other combinations of 
them from consensus sequences of human H3N2 and H1N1 influenza viruses, 
intramuscular injections of a cationic lipid-formulated NP-DNA and M2-DNA plasmid 
combination gave the highest level of protection against lethal challenge with A/HK/8/68 
(H3N2) or PR8 viruses in mice (Jimenez et al. 2007). 
A Vaxfectin-formulated vaccine containing NP-DNA and M2-DNA derived from highly 
pathogenic A/Vietnam/1203/04 (H5N1) influenza virus strain gave significant protection 
against death in mice and provided some protection in ferrets (Lalor et al. 2008).   73
Studies with plasmids encoding NP and/or M gene of H1N1, H3N2 or H5N1 influenza 
viruses suggested that immune responses against conserved internal proteins were likely 
to  provide some protection and could play a role in decreasing influenza transmission 
(Epstein et al. 2002; Lalor et al. 2008). 
1.5.2.1.5.2 Various combinations of HA-DNA, NA-DNA, M-DNA and NP-DNA 
Gene gun administration of plasmid DNA combinations either HA-DNA+ NA-DNA or 
HA-DNA + NA-DNA + M1-DNA, respectively encoding HA, NA and M1 genes from 
PR8 virus resulted in almost complete protection of mice against homologous virus 
challenge, whereas, mice that received either HA-DNA or NA- DNA alone showed only 
partial protection against challenge and mice given M1-DNA failed to show any 
protection. Moreover, both of the plasmid DNA mixtures (HA-DNA + NA-DNA) and 
(HA-DNA + NA-DNA + M1-DNA) exhibited a slight tendency to confer cross-
protection against an A/Yamagata/120/86 (H1N1) virus challenge, a drift mutant of the 
same virus subtype. The addition of the M- DNA to HA-DNA+ NA-DNA mixture did 
not appear to strengthen the degree of protection (Chen et al. 1999a). In another study, 
one-day-old or 12-week-old mice administered a combined HA-DNA and NP-DNAs 
from PR8 virus provided slightly better protection against the lethal PR8 challenge than 
HA-DNA or NP-DNA alone (Pertmer et al. 2000).   
Intramuscular immunization of a Vaxfectin-formulated vaccine containing consensus HA, 
NP, and M2-expressed plasmids from A/Vietnam/1203/04 (H5N1) conferred complete 
protection from lethal homologous H5N1 virus challenge in mice and ferrets (Lalor et al. 
2008).   74
As compared to vector-immunized controls, EP with combined  DNA vaccines 
respectively encoding  consensus HA, NP and NA genes of H5N1 AIVs provided 
protection against A/Vietnam/1203/2004 (H5N1) challenge, in terms of weight loss and 
reduction in viral load in ferrets (Laddy et al. 2008) and in terms of reduction in viral 
loads, and absence of histopathological changes in lungs (inflammation, infiltration, and 
edema) in  rhesus macaques (Laddy et al. 2009).  
In summary, protection studies of immunized mice challenged with homologous or 
heterologous influenza A viruses indicate that HA afforded better protection than the NA, 
NP or M2 DNA vaccines (Patel et al. 2009). Co-administration of mixed plasmids 
provides a better immune response than single plasmids alone. Inclusion of conserved NP 
and M2 influenza antigens in a HA-expressing plasmid vaccine may increase the cross-
protective antiviral response. Thus, DNA vaccination with conserved influenza genes 
may provide an alternative in the control of a rapidly spreading pandemic virus in the 
absence of antigenically matched HA-based vaccines (Epstein et al. 2002; Lalor et al. 
2008). 
1.5.2.2 DNA vaccines encoding various avian influenza genes in the chicken model  
In contrast to the extensive body of literature relating to DNA vaccines for influenza 
viruses in the murine model, relatively little is reported on DNA vaccines against AIVs in 
the chicken model. Available information is described below. 
1.5.2.2.1 HA-DNA  
DNA vaccines encoding HA gene from A/goose/Guangdong/1/96 (H5N1) (Chen et al. 
2001), A/turkey/Ireland/1/83 (H5N8) (Kodihalli et al. 1997; Kodihalli et al. 2000),   75
A/turkey/Wisconsin/68 (H5N9) (Suarez and Schultz-Cherry 2000a), 
A/chicken/Italy/1067/99 (H7N1) (Cherbonnel et al. 2003), A/seal/Mass/1/80 (H7N7) 
(Fynan et al. 1993a; Fynan et al. 1993b; Robinson et al. 1993), A/chicken/Victoria/1/85 
(H7N7) (Kodihalli et al. 2000), A/chicken/China/N/2005 (H9N2) (Pan et al. 2009) have 
been reported and these vaccines gave variable levels of protective immunity against  
lethal homologous virus challenge in chickens.  
Gene gun administration of HA-DNA from A/turkey/Ireland/1/83 (H5N8) provided 95% 
cross-protection against challenge with lethal antigenic variants that had 11 to 13% amino 
acid sequence difference in the HA1 region from A/turkey/Ireland/1/83 virus (Kodihalli 
et al. 1997). DNA vaccines encoding HA gene either from A/turkey/Ireland/1/83 (H5N8) 
or A/chicken/Victoria/1/85 (H7N7) administered via GG gave over 85% protection 
against homologous virus challenge, with minimal virus shedding in tracheal and cloacal 
swabs. However, both plasmids failed to elicit a cross-protective immunity against 
different subtypes of challenge virus (Kodihalli et al. 2000).   
Plasmid DNA vaccines have been considered as alternatives to inactivated influenza 
virus vaccine and fowlpox-vectored vaccines (Zheng et al. 2009). Studies showed that 
H1-, H3-, H5-, H7- and H9-encoding DNA vaccines have protected mice and chickens 
from homologous influenza A virus challenge (Chen et al. 1998b; Cherbonnel et al. 2003; 
Huber et al. 2009; Laddy et al. 2007; Qiu et al. 2006).  Some protection was also shown 
against challenge with heterologous viruses within the same subtype but not against 
different subtypes. To date there have been no reports on the efficacy of H6-HA DNA 
vaccines in mice or chickens.    76
1.5.2.2.2 NP-DNA 
Gene gun delivery of plasmid encoding NP gene from A/turkey/Ireland/1/83 (H5N8) 
reduced the severity of infection and conferred 50% protection on chickens from 
homologous challenge and 42% protection against heterologous A/chicken/Victoria/1/85 
(H7N7) virus challenge, suggesting that this NP-DNA vaccine did not induce substantial 
levels of protective immunity against either homologous or heterologous AIVs (Kodihalli 
et al. 2000).  
1.5.2.2.3 Combined plasmids 
As with DNA vaccines in mice, combination plasmid vaccines have also been used in 
chickens to investigate if this improved vaccine efficacy. Chickens inoculated via GG 
with a combination DNA vaccine consisting of two plasmids respectively encoding the 
HA genes from A/turkey/Ireland/1/83  (H5N8) or A/chicken/Victoria/1/85 (H7N7)  
acquired complete protection against challenge with the respective viruses and the 
vaccinated chickens showed no virus shedding in tracheal and cloacal swabs (Kodihalli et 
al. 2000). Immunization of chickens with a combination of HA-DNA and M-DNA 
plasmids respectively encoding HA and M gene from A/chicken/Italy/1067/99 (H7N1) 
using the Medijector device appeared to induce higher HI antibody titre than HA-DNA 
alone and gave improved protection against homologous challenge (Cherbonnel et al. 
2003). 
1.5.2.3 DNA vaccine encoding various influenza virus genes in other animal models 
African Green monkeys injected with a mixture of five DNAs encoding HA gene from 
A/Beijing/353/89 (H3N2), A/Texas/36/91 (H1N1), and B/Panama/45/90 and NP and M1   77
from PR8 virus induced HI antibodies to A/Beijing/353/89. Ferrets immunized with DNA 
encoding HA from PR8 virus and A/Georgia/03/93 (H3N2) also elicited HI antibodies 
and they were protected against homologous virus challenge (Donnelly et al. 1995a).  
Plasmid DNA vaccines encoding HA from A/Hawaii/01/91 (H3N2), and NP and Ml from 
A/Beijing/353/89 (H3N2) were investigated in ferrets and shown to provide protection 
against challenge with a divergent, drift variant virus A/Johannesburg/33/94 (H3N2) and 
the extent of protection conferred by the DNA vaccine was comparable to that provided 
by an inactivated A/Johannesburg/33/94 vaccine (Donnelly et al. 1997a). 
Itradermal immunization of pigs with an M2eNP DNA construct encoding NP gene of 
A/swine/Oedenrode/96 (H3N2) virus and M2 gene from A/swine/Best/96 (H1N1) virus 
induced an antibody response to M2 protein but failed to confer protection against 
A/swine/Best/96 (H1N1) virus challenge. Unexpectedly, the M2eNP DNA-vaccinated 
pigs displayed more severe clinical signs than were expected from challenge by this virus 
(Heinen et al. 2002). 
Immunization of rabbits via GG with a plasmid encoding codon optimized HA or 
truncated HA genes from A/NewCal/20/99 (H1N1) or A/Panama/2007/99 (H3N2) 
influenza virus elicited strong HI and neutralizing antibody responses (Wang et al. 2006).  
Intradermal and mucosal vaccination of ponies via GG with a plasmid DNA encoding 
HA gene A/equine/Kentucky/1/81 (H3N8) conferred complete protection from challenge 
with homologous virus infection, while ID vaccination alone only afforded partial 
protection (Lunn et al. 1999).  
1.5.3 Specific aspects of the humoral immune response to avian influenza DNA vaccines   78
Anti-HA antibody induced by plasmid DNAs encoding HA from AI virus strains played 
a key role in neutralizing virus and producing protective efficacy in mice, chickens,  
ferrets and nonhuman primates against challenge with homologous and heterologous 
HPAI viruses (Kodihalli et al. 1997; Laddy et al. 2008).  
1.5.3.1 Antibody response in chicken model 
The protocols that have been used for DNA vaccination in chickens are similar to those 
used in the murine model. The minimal and maximal doses of plasmid DNA used per 
bird have varied between 50 μg (Chen et al. 2001; Cherbonnel et al. 2003) to 300 μg 
(Fynan et al. 1993a) for saline-DNA injection, and from 0.4 ng (Fynan et al. 1993b) to 10 
μg (Kodihalli et al. 2000) for GG delivery. A few studies have employed a single 
vaccination (Feltquate et al. 1997), but most studies utilized booster immunizations 
(Fynan et al. 1993a; Jiang et al. 2007; Kodihalli et al. 1997; Robinson et al. 1993). 
Dosage intervals between vaccinations of two weeks (Chen et al. 2001), three weeks 
(Cherbonnel et al. 2003; Jiang et al. 2007; Le Gall-Recule et al. 2007; Suarez and 
Schultz-Cherry 2000a) and four weeks (Fynan et al. 1993a; Fynan et al. 1993b; Kodihalli 
et al. 1997; Lee et al. 2006; Robinson et al. 1993) have been successfully used.  
Various delivery routes for DNA inoculation have been examined in chickens and the 
effect of DNA delivery routes on protective immunity has been assessed. Intramuscular, 
IV and intratracheal administration of a H7-expressing DNA vaccine provided better 
protective immunity against lethal A/chicken/Victoria/1/85 (H7N7) challenge than SC, IP, 
intrabursal, and intraorbital inoculations (Fynan et al. 1993b). Nevertheless, 
immunization with 100 µg of a H7-expressing plasmid by each of three routes (IM, IP   79
and IV) followed by boosting with 300 µg DNA (100 µg IV, 100 µg IP, and 100 µg IM) 
showed that IM delivery did not improve the level of protection in comparison with the 
trials which did not include the IM route (Fynan et al. 1993a). Gene gun delivery of a 
H5-expressing plasmid conferred complete immune protection against lethal H5 virus 
challenge, but as discussed previously this delivery system is not practical in the chicken 
industry (Kodihalli et al. 1997).  
1.5.3.1.1 Anti-HA antibody  
Unlike immune response induced by HA-DNA in mice, some studies in chickens have 
demonstrated only low to undetectable levels of HA specific antibodies resulting from 
primary and booster immunization with DNA vaccine, although high antibody titres 
resulted from challenge with AI virus (Fynan et al. 1993a; Kodihalli et al. 1997; 
Kodihalli et al. 2000; Suarez and Schultz-Cherry 2000a). However, studies in chickens 
have also reported that other DNA vaccines generated acceptable antibody responses 
(Chen et al. 2001; Cherbonnel et al. 2003; Jiang et al. 2007; Suarez and Schultz-Cherry 
2000a).  
1.5.3.1.2 Anti-NP antibody responses  
Similar to the findings of poor HI antibody responses after the use of HA-expressing 
plasmids in some studies, chickens immunized via GG with a plasmid encoding the NP 
gene from A/turkey/Ireland/1/83 (H5N8) failed to induce detectable antibodies to NP as 
measured by ELISA. Following challenge with homologous influenza 
A/turkey/Ireland/1/83 (H5N8) virus or heterologous influenza A/chicken/Victoria/1/85 
(H7N7) virus, some birds survived and they produced high levels of HI antibodies to the 
challenge viruses (Kodihalli et al. 2000).    80
1.5.3.2 Antibody response in other animal models  
Immunization via EP with a combination of synthetic consensus plasmid DNAs encoding 
HA, NP and NA of H5N1 AIVs induced marked cross-reactive antibodies to divergent 
H5N1 viruses in ferrets (Laddy et al. 2008) and rhesus macaques (Laddy et al. 2009). 
1.5.4 Specific aspects of CMI response to avian influenza virus DNA vaccines  
Due to ongoing antigenic shift and drift of influenza A virus, strain-specific antibody 
response produced by protein-based vaccines do not remain effective and need to be 
regularly updated. For this reason intensive attention has focused on investigation of 
vaccines to induce CMI response which may have the potential to induce cross-protection 
against homosubtypic and heterosubtypic influenza A viruses.  Although each of the viral 
proteins (including HA, NA) can trigger a CTL response, the primary target of CMI 
responses typically focus on peptides from internal conserved proteins of the influenza A 
virus (Kodihalli et al. 2000; Laddy et al. 2008; Thomas et al. 2006).  
DNA vaccines encoding conserved antigens have been shown to protect against diverse 
influenza A subtypes in mice (Bender et al. 1998; Epstein et al. 2005; Epstein et al. 2002; 
Ulmer et al. 1993; Ulmer et al. 1998), chicken (Kodihalli et al. 2000) and ferrets 
(Donnelly et al. 1995a). This protection is mediated by both class I-restricted CTLs and 
Th1-type cytokine secreting helper T cells (Ulmer et al. 1993; Ulmer et al. 1998). 
The CTL response to NP is characterized by cross-reactivity between various subtypes of 
influenza A viruses and there is reduced sensitivity to antigenic drift with this viral 
protein (Kodihalli et al. 2000; Shu et al. 1993). Long-lasting anti-NP CTL activity has 
been observed in vivo (Raz et al. 1994; Yankauckas et al. 1993). In addition, CMI   81
responses induced by DNA vaccines were not inhibited by the presence of maternal 
antibody (Pertmer et al. 2000). 
Because many reagents defining surface markers on important cellular population are of 
murine origin, and numerous recombinant and congenic mouse strains, and more recently 
transgenic and knockout strains are available, much of the work on the celluar immunity 
to influenza A virus has been extensively conducted in mice as described in section 
1.4.1.3 (Epstein 2003).  In contrast, due to unavailability of monoclonal antibodies 
(mAbs) recognizing avian T cell-associated antigens as well as the very limited number 
of inbred lines of chickens with genetically defined MHC haplotypes, knowledge of the 
specifics of CMI against AIV in avian species is limited (Kapczynski 2008).  
Despite the absence of detectable antibodies to NP following immunization with the 
plasmid pCMVNP from A/turkey/Ireland/1/83 (H5N8), 42-50% chickens survived 
following homologous and heterologous virus challenge (Kodihalli et al. 2000). This 
partial protection may relate to the CMI activation and mobilization, which became 
functional in half of the chickens before the highly pathogenic H5 or H7 virus infection 
was well established and caused fatalities.  It is also possible that cytokines like IFN-γ 
production from virus specific T-memory cells, as observed by studies with NP-DNA in a 
mouse model (Bot et al. 1998), were effective in shutting virus infection down in half of 
the chickens before overwhelming H5 or H7 HPAI infection occurred. Unfortunately, 
cytokine measurement was not conducted in that study. In another chicken study using 
multi-epitope DNA vaccines against H5N1 AIV, CD4
+ and CD8
+ T lymphocyte in the 
peripheral blood of immunized chickens were reported to increase significantly in 
comparison to a blank vector control (Peng et al. 2003). In addition, real-time PCR   82
testing showed that the mRNAs for nine cytokines (IFN-α, IFN-β, IFN-γ, IL-4, IL-6, IL-8, 
IL-10, IL-15, and IL-18) were expressed in HPAI virus infected chickens, showing that 
HPAI infection quickly induced intensive antiviral and proinflammatory cytokine mRNA 
expressions in chickens as compared with  a LPAI strain (Suzuki et al. 2009). In addition, 
in vivo EP of a plasmid expressing consensus NP protein of H5N1 AIVs elicited IFN- γ-
based CMI responses in the rhesus macaque model (Laddy et al. 2009). 
1.5.5 Protective efficacy related to both cellular and humoral immune responses to H5N1 
avian influenza viruses  
In a study on evaluation of DNA vaccines encoding conserved or variable influenza 
antigens against different isolates of H5N1 viruses in mice, the T cell response, as 
analyzed by ELISpots, induced by the HA-expressing plasmid was higher than those 
from those plasmids encoding NA, NP or M2 gene. The T cell responses were also 
directly proportional to the level of protection, with HA-expressing plasmid > NA- > NP- 
> M2- expressing plasmids. Despite the absence of a detectable B cell response, as 
measured by HI and neutralizing antibody, a T cell response was still detected after 
vaccination with low doses of HA-expressing plasmid and this was capable of giving 
protection (Patel et al. 2009).  
In another study in mice, ferrets and non-human primates, plasmids encoding synthetic 
consensus HA, NP and NA gene of H5N1 AIVs were administered via EP. In mice, the 
HA-DNA vaccine provided complete protection against A/Hanoi/30408/2005 (H5N1) 
virus challenge, and there was partial protection shown by the NP-DNA vaccine and NA-
DNA vaccine, but this was greater for the NP-DNA vaccine than for the NA-DNA 
vaccine. With regards to CMI response, all three plasmids induced IFN-γ-based cellular   83
immune responses in mice, largely dependent upon CD8
+ T cells, with responses to  NP> 
HA > NA. In terms of antibody response, HA-DNA elicited a strong antibody response in 
mice, as determined by ELISA and HI assays whereas neither NA-DNA nor NP-DNA 
induced detectable antibody responses in mice. In ferrets and rhesus macaques, the 
combination of HA-DNA, NP-DNA and NA-DNA induced strong antigen-specific CMI 
responses and cross-reactive antibody responses to HA. Despite the absence of NP 
antibody response NP-DNA induced potent CMI responses and conferred a statistically 
significant degree of protection with reduction in average weight loss (Laddy et al. 2008). 
In another study, single immunization of mice with a plasmid expressing HA gene of 
A/Chicken/Henan/12/2004 (H5N1) induced acceptable levels of circulating anti-
influenza virus antibodies and also a potent systemic CMI response with high level of 
IFN-γ-producing cells and low levels of IL-4-producing cells (Zheng et al. 2009).  
Taken together, plasmid DNA-induced protective immunity involves interaction between 
B cells and T cells (either CD4
+ or CD8
+ cells). It is necessary to assess the relationship 
between both arms of the plasmid-induced immune responses in evaluating DNA 
vaccines with regards to protective efficacy against influenza A virus (Patel et al. 2009). 
1.6 Hypotheses of the thesis  
1. That H6-DNA vaccines are immunogenic and can induce a protective immune 
response in vaccinated chickens against specific H6N2 AI viruses.  
2. That enhancement of DNA vaccines in chickens against AIVs can be achieved by 
approaches such as selection of DNA expression vectors, incorporation of enhancer   84
sequences, codon optimization of the HA gene, optimization of the dose of injected 
plasmid DNA and the number of immunizations.   
3. That antibody responses to AI DNA vaccines can be further enhanced by different 
administration methods, and by the use of adjuvants including lipofectin and different 
chemical adjuvants, including a novel nanoparticle, Phema.  
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Chapter 2 
Biological and genetic characterization of the H6N2 influenza virus originating from 
a healthy Eurasian coot in Western Australia 
 
2.1 Introduction 
Avian influenza virus (AIV) infection in poultry can exhibit  various signs from an 
asymptomatic infection to an acute, fatal disease (Lee et al. 2007). Two surface 
glycoproteins, haemaggglutinin (HA) and neuraminidase (NA), responsible for 
attachment to cell receptors to initiate infection and the release of virus particles from 
host cell receptors respectively, are the most important protective components among the 
viral proteins (Hampson 2006). Internal nucleoprotein (NP), related to the switching of 
viral RNA polymerase activity from mRNA synthesis to cRNA and vRNA synthesis, is a 
major target of the host cytotoxic T-cell immune response (Tamura et al. 2005; Yewdell 
et al. 1985). 
Waterfowl are commonly believed to be a major reservoir of the type A influenza viruses 
which are antigenically and genetically diverse (Slemons et al. 1991; Slemons and 
Swayne 1995). These waterfowl-origin viruses are occasionally associated with outbreaks 
of severe avian influenza in domestic poultry, characterised by swollen kidneys and 
visceral urate deposits (Slemons and Swayne 1990, 1995). Chickens and turkeys 
experimentally challenged with waterfowl-origin type A influenza viruses became 
infected but remained clinically normal, even though high virus titres could be detected in 
kidney tissues and viral nucleoprotein was detectable in renal tubular epithelial cells and 
in intestinal mucosal epithelial cells, suggesting that these isolates could be nephrotropic 
and enterotropic (Slemons and Swayne 1990, 1995). More recently, there were reports on 
H6 subtype AIV outbreaks in commercial poultry (Abolnik et al. 2007; Woolcock et al.   86
2003; Yee et al. 2009). This highlighted that waterfowl-origin virus can present a 
potential threat to domestic poultry. 
The H6 subtype AIV was first isolated from a turkey in 1965, and other H6 viruses were 
subsequently isolated from shorebirds and wild ducks (Downie et al. 1977; Downie and 
Laver 1973; Sharp et al. 1993). The H6 subtype influenza viruses have received little 
attention until the first documented infection of humans with an H5N1 AIV occurred in 
Hong Kong in 1997.  An H6N1 influenza virus, A/teal/HK/W312/97 (H6N1) isolated 
during this outbreak was found to have the same internal gene and NA gene segments as 
this A/HK/156/97 (H5N1) virus. This indicated that this isolate seemed to be one 
progenitor of the A/HK/156/97 (H5N1) virus (Hoffmann et al. 2000).  Although natural 
human infection with H6 subtype has not yet been reported, a recent seroprevalence study 
showed that United States veterinarians who have been exposed to birds demonstrated 
significantly elevated antibody titers against H5, H6, and H7 AIVs (Myers et al. 2007). It 
raised the possibility that H6 viruses could become novel human pathogens (Chin et al. 
2002). 
In addition, H6 viruses are one of the most commonly recognized subtypes in domestic 
ducks in southern China (Cheung et al. 2007)  and in migratory birds in North America 
and Europe (Munster et al. 2007; Spackman et al. 2005). Surveillance has demonstrated 
that the continued co-circulation of H5N1, H6N1, and H9N2 AIVs in southern China has 
led to frequent reassortment in minor poultry species (Cheung et al. 2007; Chin et al. 
2002). This in turn greatly increases the genetic diversity of influenza A viruses in this 
region and highlights the potential for H6 viruses and H6 reassortants to cross the species 
barrier to infect humans. Understanding the epidemiology, ecology and evolution of H6   87
viruses will be helpful to further understand the molecular evolution of H5N1 AIV and 
may help in the development of future control measures.  
The objective of the work described in this chapter was to provide baseline information 
on the biological and genetic properties of an H6N2 AIV isolate (A/coot/WA/2727/79), 
which was isolated from a healthy Eurasian coot (Fulica atra) in Western Australia 
(Mackenzie et al. 1984), as well as the potential pathogenicity before its use as a model 
virus for a proof-of-concept DNA vaccine research. 
2.2 Materials and Methods 
2.2.1 H6N2 avian influenza virus, replication and identification 
Avian influenza virus A/coot/WA/2727/79 (H6N2) was kindly provided by Prof. John 
Mackenzie, University of Western Australia, Australia from virus stocks held at the 
Animal Virology laboratory, DAFWA. The virus stock was propagated at DAFWA using 
9-11 day-old specific pathogen-free (SPF) chicken embryonated eggs (White Leghorn, 
SPAFAS Inc., VIC, Australia) according to the standard method provided by the World 
Organisation for Animal Health (OIE)(OIE 2008). Briefly, 0.1 mL volumes of 10-fold 
dilutions of virus stock in sterile PBS (NaCl 8 g, KCl 0.2 g, Na2HPO4 1.15 g, KH2PO4 
0.2 g, add distilled water (dH2O) up to 1L, pH7.4) were inoculated into the allantoic 
cavity of 9-11day-old embryonated chicken eggs. The eggs were incubated at 35–37°C 
for 4–5 days. Following chilling at 4°C overnight, the allantoic fluid of these eggs was 
harvested and tested for haemagglutination (HA) activity. The stock virus was passaged 
two additional times to compare HA titres after passage. Individual aliquots of HA 
positive allantoic fluid were also tested to ensure bacterial sterility before pooling. The 
pooled HA positive virus was tested to confirm presence of H6 activity by a   88
haemagglutination inhibition (HI) test using in-house H6 reference positive sera from 
DAFWA. The virus with HA activity was stored at -70°C as working stocks for later 
experiments. This new viral stock, amplified in SPF or specific antibody negative (SAN) 
chicken embryonated eggs (Altona Hatchery Pty. Ltd., WA, Australia) from 1-2 passages, 
was used to  conduct infectivity titrations in chicken embryos, provide antigen for 
inactivated vaccine preparation and challenge virus for subsequent studies.  
Confirmatory H subtyping of A/coot/WA/2727/79 (H6N2) was performed at Tai Lung 
Veterinary Laboratory, AFCD, Hong Kong. The reference H6 antiserum to 
A/Ost/RSA/946/98 (H6N8) virus was provided by Veterinary Laboratories Agency, 
Weybridge, Surrey, UK. The HI test was performed as per the OIE standard protocol. 
The HI titre against 4 HA units of inactivated virus antigen was 1:160, which was 
consistent with other H6 viruses in the collection at Tai Lung Veterinary Laboratory. The 
N subtype of this H6N2 virus was identified as N2 subtype by neuraminidase inhibition 
testing at AAHL, Australia. This information was provided by Dr Paul Selleck at AAHL. 
2.2.2 HA antigen preparation 
A/coot/WA/2727/79 (H6N2 was amplified by inoculating 0.1 mL virus (approximately 
10
3 EID50) into the allantoic cavity of 10-day-old SAN eggs and harvesting allantoic fluid 
from the eggs on day 5. Following confirmation of HA activity by a spot HA test, the 
infectious allantoic fluids were harvested and clarified by centrifugation. The virus was 
inactivated by adding a final concentration of 0.1% (v/v) formaldehyde (37% formalin, 
Sigma, MO, USA) and stirring the allantoic fluid for 20 hr at 37°C. Effectiveness of 
inactivation was evaluated by inoculating 0.2 mL of undiluted and 1/10 diluted allantoic 
fluid respectively into each of five 10-day-old eggs, incubating for 1 week, and testing   89
allantoic fluid for HA activity. The completely inactivated allantoic fluid was aliquotted 
and stored at -20°C until required. 
2.2.3 Haemagglutination (HA) and Haemagglutination Inhibition (HI) tests 
2.2.3.1 Preparation of 0.5% chicken red blood cells (CRBC)  
The SPF or SAN chicken blood was collected and mixed with an equal volume of 
Alsever’s solution (citric acid 0.055 g, sodium citrate 0.8 g, D-Glucose 2.05 g, NaCl 0.42 
g, add dH2O to make up to 100 mL; sterilize by autoclaving at 116°C for 10 min). The 
blood was centrifuged in a graduated conical tube at 800 g for 5 min. Following removal 
of the supernatant and the buffy coat, the red cells were resuspended in PBS, and mixed 
with a Pasteur pipette gently, before a further centrifugation step for 5 min at 800 g. This 
process was repeated twice. The red cell pellet was diluted to a concentration of 0.5% 
(packed cell v/v) in PBS containing 0.1% foetal calf serum (FCS) (Gibco, Melbourne, 
Australia). 
2.2.3.2 HA test 
HA assays were performed as per the OIE procedure (OIE 2008). Briefly, 25 µL volumes 
of PBS were aliquotted across a 96-well U plate (Greiner Bio-One, Frickenhausen, 
Germany). Then 25 µL of antigen was added to the first well and two-fold serial dilution 
was made across the plate to the last well. Finally 25 µL of PBS and 25 µL of 0.5% 
CRBC were added to all wells and the plate was shaken on the plate shaker. The plate 
was incubated at room temperature for 40 min before being examined for HA activity. 
The endpoint was the highest dilution at which complete hemagglutination occurred and 
this was considered as 1 HA unit. The HA titre of the antigen was then calculated.   90
2.2.3.3 HI test 
HI assays were performed as per the OIE procedure (OIE 2008). In brief, 25µL of PBS 
was added across to all wells of a 96-well U-bottomed plate. Then 25µL of serum was 
added to the first well, and two-fold serial dilutions were made across the plate to the last 
well, with the last 25µL mixture being discarded. Finally, 25µL of antigen (containing 4 
HA units) was added to all diluted serum wells. The plate was mixed briefly and then 
incubated at room temperature for 30 min to 60 min, before 25 µL of 0.5% CRBC was 
added to the wells. After shaking, the plate was incubated at room temperature for a 
further 40 min until a positive haemagglutination reaction developed in non-serum 
containing control wells. The HI titre was the reciprocal of the highest serum dilution 
fully inhibiting haemagglutination.  
The same procedure was used with H6 reference antiserum to determine the presence of 
H6 virus in inoculated allantoic fluid. 
2.2.4 Cell culture for virus growth 
2.2.4.1 Cell passage, storage and resuscitation 
Madin-Darby Canine Kidney cells (MDCK), provided by DAFWA, were grown in 25 or 
75cm
2 plastic flasks (Nalge, Nunc International, Denmark) in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco BRL, Auckland, New Zealand)(make up 1 packet 
(~10g) powdered medium to 1L and 23.8 mM NaHCO3, filter-sterilised) supplemented 
with 10% (v/v) FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-
glutamine at 37°C in a 5% CO2 humidified incubator. When monolayers were confluent 
in the flask, the media was removed and the cells were washed with sterile PBS, then 5   91
mL of 0.25% trypsin (Difco, NJ, USA), 1 mM EDTA, Hank’s balanced salt solution 
(HBSS, Invitrogen, Melbourne, Australia) were added to the flask and incubated for 2-5 
min at 37°C to dislodge the cells from the plastic. The cells were passaged in DMEM 
containing 10% FCS, using a split ratio of 1:3, and incubated in flasks at 37°C in a 5% 
CO2 humidified incubator, or maintained in DMEM with 2% FCS. 
Cells in monolayers were washed and trypsinised during mid-log phase of growth. 
DMEM containing 10%FCS was added and the cell suspension was centrifuged at 1000g 
for 5 min at 4 °C. The supernatant was removed and the pellet was gently resuspended in 
5mL DMEM containing 20% FCS. An equal volume of DMEM containing 20% DMSO 
was added very slowly. The cell suspension was then aliquoted into 1mL cryovials (Nunc 
International), and stored at 4°C for 2 hr, followed by -80°C overnight. Subsequently, the 
cryovials were placed into liquid nitrogen for long term storage.   
Once a cell cryovial was taken out from liquid nitrogen it was thawed rapidly in a 
container with 37-40°C water. Five milllitres of pre-warmed DMEM with 10% FCS was 
slowly added to the cells. Cells were then centrifuged at 1,000g for 5 min and 
resuspended in 10 mL DMEM with 10% FCS. The cells were placed into a flask 
followed by incubation at 37°C with 5% CO2 for a few days to form a monolayer.  
2.2.4.2 Virus propagation 
Virus growth in MDCK cells was performed according to the standard WHO protocol  
(WHO 2002).Cells were propagated in 25 cm
2 tissue culture flasks (T-25 flask, BD 
Biosciences, NSW, Australia) or 6-well culture plates (Nunc International). When the 
MDCK cells formed a monolayer, the medium was discarded and the cells were washed   92
three times with 6 mL (flask) or 2mL (6-well plate) of virus growth medium consisting of 
DMEM supplemented with antibiotics, L-glutamine, 0.2 % bovine serum albumin 
fraction V (Gibco BRL), with or without the addition of 2 μg/mL TPCK-trypsin (Sigma, 
MO, USA). Aliquots of 100 μl undiluted (for T-25 flask) or 1/10 diluted (plate) infective 
allantoic fluid virus were inoculated into the monolayer cells. The inoculum was 
adsorbed for 30 min at 37°C followed by the addition of 6mL (flask) or 2mL (plate) of 
virus growth medium with or without 2 μg/mL of TPCK trypsin. The cells were observed 
daily for 1 week for a cytopathic effect (CPE). CPE was confirmed to be virus specific by 
HA and immunofluorescent testing.  
2.2.5 Immunofluorescent Test (IFT) 
MDCK cells were propagated on microscope cover slips in a 6-well plate, and inoculated 
with H6 virus. At 36-72 hr post-inoculation the medium was removed.  Fixing solution, 
consisting of 2 mL of ice cold methanol/acetone (1:1) was added into the 6-well plate and 
left at room temperature for 10 min. The plate was then stored at 4°C overnight or at -
20°C for long term storage. Following air-drying, the plate was washed once with PBS 
before 1 mL anti-H6 serum (made from chickens vaccinated with inactivated whole 
H6N2 virus) with a dilution of 1:100 was added and incubated at 37°C for 45 min. The 
plate was washed three times for 5 min each using PBST (0.05% Tween-20 in PBS). This 
was followed by the addition of 0.5 mL fluorescein isothiocyanate (FITC)-conjugated 
anti-chicken immunoglobulin G (IgG) at a dilution of 1:250 (Sigma). After incubation at 
room temperature for 30 min, the plate was washed three times with PBST. The cover 
slip was inverted onto a glass slide and observed for fluorescent staining under a 
fluorescent microscope (Olympus BX50, Tokyo, Japan).   93
2.2.6 Infectivity titration of the virus  
Serial 10-fold dilutions of A/coot/WA/2727/79 (H6N2) virus stock were made using PBS. 
Aliquots of 0.1 mL of diluted fluid were inoculated into the allantoic cavity of five 
embryonated eggs of between 9 days and 11 days of age, or onto monolayers of MDCK 
cells in 96-well plates. Embryos or plates were incubated at 37°C for 7 days and observed 
daily to check for mortalities or CPE. The allantoic fluid of each egg or culture medium 
from each well was assayed for HA activity to determine the presence or absence of virus 
infection.  The titre expressed as 50% egg-infective dose/0.1 mL (EID50 /0.1 mL)  or 50% 
tissue culture infective dose/0.1 mL (TCID50 /0.1 mL) was calculated by the method of 
Reed-Muench (Anon 2000). 
2.2.7 Intravenous pathogenicity index (IVPI) test  
The IVPI test was performed in an isolation animal house room at the Murdoch 
University campus by injecting virus with an HA titer > 2
4 intravenously into10 chickens 
as described in the OIE Manual (OIE 2008). A virus with an IVPI of greater than 1.2 or 
higher was considered a HPAI. Briefly, the infectious virus (grown in SPF embryonated 
eggs) with a HA titre 1/512 (2
9, EID5010
6.5/0.1 mL) was diluted 1/10 in sterile 0.9% 
NaCl. Aliquots of 0.1 mL of the diluted virus were injected intravenously into ten 6-
week-old SAN chickens (Altona Hatchery Pty. Ltd.). Birds were examined for signs of 
illness at 24-hr intervals for 10 days and scored as follows: 0 if normal, 1 if sick, 2 if 
severely sick, or 3 if dead.  The IVPI score is taken as the average score per bird per 
observation over the 10-day period, namely the total of all individual chicken scores 
divided by the total number of observations.    94
Oropharyngeal and cloacal swabs (OS and CS) were taken on days 1, 3, 5 and 7 and were 
placed into 1mL of Viral Transport Medium (VTM) (0.1% (w/v) yeast extract (Difco), 
0.5% (w/v) lactalbumin hydrolysate, 1x HBSS (Invitrogen), 4000 U/mL penicillin, 10 
mg/mL streptomycin, 0.1mg/mL fungizone, 0.035% (w/v) NaHCO3,  0.03% (w/v) 
glutamic acid, 0.01% (w/v) glutamine, 0.01% (w/v) methionine, 0.015% (w/v) arginine, 
0.0001% (w/v) biotin, 0.0001% (w/v) folic acid) provided by DAFWA.  These were 
frozen at -70°C until tested. The birds were bled for the last time and then euthanased by 
cervical dislocation 10 days post challenge.    
2.2.8 Virus challenge 
Six 8-week-old SAN chickens were subjected to virus challenge in an isolation animal 
house room at the Murdoch University campus. Each chicken received 0.5 mL H6N2 
virus (10
6.5 EID50 /0.1 mL) by nasal instillation (0.1 mL), eyedrop (0.1 mL) and oral route 
(0.3 mL). Following challenge all chickens were observed daily. In addition to collecting 
OS, CS and blood as above, kidney was also taken after the birds were euthanased and a 
20% (w/v) homogenate was prepared in VTM for virus isolation.   
2.2.9 Virus isolation 
Virus isolation was based on standard procedures (OIE 2008; WHO 2002). Each swab 
was thawed at room temperature, vigorously mixed for 30 sec with a vortex mixer, held 
at room temperature for 30 to 60 min followed by a clarifying centrifugation at 900 g for 
10 min at 4°C. Aliquots of 0.2 mL supernatant fluid from each swab were injected into 
the allantoic sac of two to four 9 to 11-day-old SAN chicken embryonated eggs. After 
incubation at 37°C for 6–7 days with periodic candling to remove and store sick or dead   95
embryos (4°C), harvested allantioc fluids were tested individually for HA activity. The 
allantoic fluids that gave a negative reaction were re-passaged in chicken embryonated 
eggs to confirm that a low titre of virus was not present. HA positive eggs were 
confirmed as H6N2 virus by HI testing as described above (OIE 2008).  The frequency of 
virus shedding was recorded as the number of days, on which positive CS or OS were 
obtained, divided by the total number of swabs collected post challenge for each group. 
2.2.10 Amplification of the H6N2 virus genes of interest   
2.2.10.1 Primer design  
The 102 AIV H6 sequences from GenBank were aligned using Bioedit (version 5.0.9.1) 
(Hall 1999). The consensus sequences were used to design the primers for amplification 
of HA, NP and NA genes of A/coot/WA/2727/79 (H6N2). Recognition sites for 
restriction endonuclease were added to the 5’ ends of the primers as outline in bold in 
Table 2.1. The feasibility of the designed primers was tested using Amplify 1.2. The 
primers were synthesized by GeneWorks Pty Ltd (SA, Australia). 
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Table 2.1 Primers used for amplification and sequencing of A/coot/WA/2727/79 (H6N2) in 
different vectors. 
 
Primer    Sequence (5’to 3’)*    Genome   Nt 
position** 
HAF aaCTGCAGCAAAAGCAGGGGAAAATG*** HA  gene 3-20 
HAR    cgcGGATCCTTTCTAATTATATACATATYYTGC HA  gene  1702-1725 
NPF tgcTCTAGAAGCAAAAGCAGGGTAKAT NP  gene  1-18 
NPR cgcGGATCCAGTAGAAACAAGGGTATTTTTC NP  gene  1543-1565 
NAF tgcTCTAGAAGCAAAAGCAGGAGTBNAAA NA  gene 1-15 
NAR cgcGGATCCAGTAGAAACAAGGAGTTTTT NA  gene  1400-1509 
M13F GTTTTCCCAGTCACGAG  pGEM-T  vector  2956-3012 
M13R CAGGAAACAGCTATGAC  pGEM-T  vector  176-197 
VRF TAGTCTGAGCAGTACTCGTTG  VR1012 1772-1792 
VRR CAATGCGATGCAATTTCCTC  VR1012  2031-2050 
* Degenerate nucleotide code Y refers to C or T, K refers to G or T, and N refers to A, C, G or T. 
** The nucleotide (nt) numbering system was adopted according to GenBank accession No. CY004515 
(HA), CY004518 (NP) and CY004517(NA) ( Influenza A virus (A/coot/ALB/134/1987(H6N2)).                                                      
*** Restriction endonuclease sequence is in bold. Protective nucleotide bases in lower case were added 
before recognition sites for restriction endonuclease in order to obtain accurate and efficient digestion. 
 
2.2.10.2 RNA extraction  
Viral RNA was extracted using an RNeasy Mini Kit (Qiagen,VIC, Australia) according 
to the manufacturer’s instructions. In brief, H6N2 AIV infected allantoic fluid was 
centrifuged at 2,000 g at 4°C for 30 min. The supernatant was then centrifuged at 
180,000 g at 4°C for 3 hr. The pellet was subsequently dissolved in a 1/10 volume of TE 
buffer (10 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0) before being mixed with an equal 
volume of RLT Buffer (plus β-mercaptoethanol). Following centrifugation at 13,000 g 
for 1 min, the supernatant was transferred to a new microcentrifuge tube. An equal 
volume of 70% ethanol was added to the supernatant followed by transfer to an RNeasy 
spin column placed in a 2 mL collection tube. The column was subsequently centrifuged 
for 15 sec at 10,000 g. After discarding the flow-through, 700 μL Buffer RW1 was added 
to the RNeasy column followed by centrifugation for 15 sec at 10,000 g and the flow-
through discarded. Following this, 500 μL Buffer RPE was added onto the RNeasy   97
column and subsequently centrifuged for 15 sec at 10,000 g and the flow-through 
discarded. After the RNeasy column was washed again with 500 μL Buffer RPE, it was 
centrifuged for 2 min at 10,000 g to remove any residual wash buffer. The RNeasy 
column was then transferred to a new 1.5 mL collection tube and 50 μL of RNase-free 
water was added onto the RNeasy silica-gel membrane and allowed to sit  at room 
temperature for 10 min. RNA was eluted by  centrifugation for 1 min at 10,000 g . The 
RNA concentration was measured using a nanodrop ND-1000 spectrophotometer 
(Thermo Scientific, MA, USA), and then stored at -70 °C until use.  
2.2.10.3 Reverse Transcription (RT)  
cDNA was synthesized using a high-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, CA, USA) following the protocol recommended by the manufacturer. 
Briefly, in a total volume of 50 μL, 25 μL RNA was mixed with 13.5 μL nuclease-free 
dH2O, 5.0 µL of 10x RT buffer, 2.0 µL of 25x dNTP Mix (100 mM), 2 μL of 20 μM 
forward primer and 2.5 µL (50 U/μL) MultiScribe
TM Reverse Transcriptase. Following 
gentle mixing, RT was performed in a thermal cycler using the following cycle protocol: 
25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, and 4°C hold. The reaction was kept 
at 4°C for short term storage or -20°C for long term storage. 
2.2.10.4 Gradient PCR for determining optimal annealing temperature  
Gene fragments of interest were amplified by gradient PCR using a PCR Thermal Cycler 
(Eppendorf  Mastercycler Gradient PCR Thermal Cycler, NY, USA). Briefly, in a 50 μL 
volume, 29.75 μL dH2O was mixed with 10 μL of 5 x Green GoTaq® Flexi Buffer, 5 μL 
of 5 mM MgCl2 , 1 μL of dNTP mix (10 mM each), 1 μL of 30 μM forward primer, 1 μL   98
of 30 μM reverse primer, 2 μL cDNA and 0.25 μL GoTaq®  DNA polymerase (5 U/μL) . 
After aliquoting 10 μL per PCR tube, amplification was performed in a PCR thermal 
cycler using the following parameters:  one cycle of 95°C for 2 min; 40 cycles of 95°C 
for 40 sec, different annealing temperatures for 30 sec, 72°C for 4 min, and a final 
extension step of  72°C  for 7-10 min. 
2.2.10.5 PCR using proof-reading polymerase 
PCR reactions were performed in a 50 μL volume containing 37.25 μL dH2O, 5 μL Pfu 
DNA polymerase 10 x buffer with MgSO4, 1 μL of dNTP mix (10 mM each), 1 μL of 30 
μM forward primer, 1 μL of 30 μM reverse primer, 4 μL cDNA template, 0.5 μL of Pfu 
DNA polymerase (3 U/μL, Promega Corp., Sydney, Australia), 0.25 μL GoTaq® DNA 
polymerase (5 U/μL, Promega). Amplification was conducted under the following 
thermal cycling conditions:  one cycle of 95°C for 2 min; 40 cycles of 95°C for 40 sec, 
52.5°C for 30 sec, 72°C for 4 min, and a final extension step of 72°C  for 7-10 min. 
2.2.11 Agarose gel electrophoresis 
PCR products were visualized in a 1-1.2% agarose gel with ethidium bromide (EB) added 
to give a final concentration of 0.5 μg/ mL.  Prior to loading, samples were mixed with 6x 
loading buffer (Promega). Size markers (100 bp DNA ladder plus (Fermentas, QLD, 
Austrlia), or 1 kb DNA ladders (Promega) were added to separate lanes. Electrophoresis 
was conducted in TAE buffer (242 g Tris base, 57.1 mL glacial acetic acid, 100 mL of 
0.5 M EDTA (pH 8.0) in 1000 mL dH2O) at a constant voltage of 60-120 kV for 40 min 
to 2 hr depending on the resolution required. Gels were checked with an ultraviolet 
transilluminator to visualize DNA bands.   99
2.2.12 Estimation of nucleic acid concentration 
The concentration of DNA was estimated photometrically by measuring absorption of the 
sample at 260 nm using a NanoDrop ND-1000 Spectrophotometer. The purity of nucleic 
acid was determined by the OD260/OD280 ratio. Pure DNA has an OD260/OD280 ratio of 
~1.8 whereas pure RNA has an OD260/OD280 ratio of ~2.0.  
2.2.13 Recovery of DNA from agarose gels  
Following agarose gel electrophoresis, DNA bands of interest were recovered using 
MiniElute gel extraction kit (Qiagen) according to the manufacturer’s instructions. 
Briefly, following electrophoresis at 70 V for 60- 90min, the bands were cut using a clean 
scalpel blade under long UV light/ illuminator if EB was used or under Safe Imager blue-
light transilluminator if the SYBR green I dye (Invitrogen) was used.  
Following excision 3 times the gel volume of buffer QG was added and incubated at 50°C 
for 10 min. Following the addition of 1 gel volume of isopropanol, the mixture was 
loaded onto a QIAquick spin column in a 2 mL collection tube provided. After 
centrifugation at 13,000 g for 60 sec, the flow-through was discarded and 0.5 mL QG was 
added followed by the same centrifugation as before. The column was washed twice with 
750 μL buffer PE by centrifugation (13,000 g for 60 sec and then 2min). The column was 
transferred to a 1.5 mL tube before 10-30 μL of dH2O was added and incubated at room 
temperature for 10 min. The DNA was eluted from the membrane by centrifugation at 
13,000 g for 60 sec. 
2.2.14 Cloning of PCR products  
2.2.14.1 Ligation reactions   100
The pGEM
®-T Easy vector (Promega) was used to clone PCR products and served as a 
holding vector for PCR products. Molar ratios of gene of interest versus vector of 
approximately 3:1 to 5: 1 were used in the ligation reactions. The ligation followed the 
protocol of the pGEM-T Easy vector kit. The reaction mixture containing 5 μL of 2x 
rapid ligation buffer, 3 μL of DNA fragment, 1 μL T4 DNA ligase (3 U/μL, Promega), 1 
μL pGEM-T Easy vector (50 ng/μL) was gently mixed and incubated at 4°C overnight. 
2.2.14.2 Transformation  
Transformation was conducted using JM109 competent Escherichia coli (E. coli) cells 
(Promega). Briefly, the cells were thawed on ice after which a 5 μL of ligation reaction 
was added to 50 μL of competent cells followed by gentle mixing and incubating on ice 
for 15-20 min. The reaction was subsequently placed at 42°C for 45-50 sec and 
immediately put back on ice for 2 min. Following the addition of 900 μL Luria-Bertani 
(LB) media (10 g bacto-tryptone, 5 g bacto-yeast extract, 10 g NaCl, adjust the pH to 7.0 
with 5N NaOH and the volume to 1 L with dH2O) the mixture was incubated at 37°C 
with shaking (225 rpm) for 1 hr. During this period, 1.2% agar (1.2% bacto agar added to 
LB media) plates containing100 μg/mL ampicillin, 100 μL of 100 mM IPTG and 20 μL 
of 50 mg/mL X-gal were prepared for selective blue-white screening. Following 
incubation, 100 μL and 200 μL culture were spread onto plates, followed by incubation at 
37°C overnight. White colonies were subsequently chosen for PCR screening.  
2.2.14.3 PCR for screening of recombinant plasmids 
A single white colony was randomly picked and re-streaked on a new plate supplemented 
with 100 μg/mL ampicillin, 0.5 mM IPTG and 80 μg/mL X-gal, followed by incubation   101
at 37°C overnight. Replicate colonies were then picked into 20 μL dH2O. Following 
boiling for 10 min, the mixture was used as a template for PCR. 
PCR was conducted with a volume of 20 μL PCR reaction containing 4 μL of 5 x PCR 
buffer, 2 μL of 25 mM MgCl2, 1 μL of 10 mM dNTP, 0.25 μL of 30 μM  M13F, 0.25 μL 
of 30 μM M13R, 0.1 μL Taq polymerase(5 U/μL),  5 μL template DNA, and 7.4 μL 
dH2O. The thermal cycle conditions were as follows: 95 °C for 4 min; 94 °C for 40 sec, 56 
°C for 30 sec, 72 °C for 90 sec, 35 cycles; 72 °C for 7 min. After electrophoresis, positive 
clones were identified by visualization of bands of expected size. Sequencing of these 
positive clones was used to further confirm their identity.                                                  
2.2.15 Plasmid DNA purification  
A QIAprep
®Spin Miniprep kit (Qiagen) was used for purifying plasmid DNA. In brief, 
one colony was inoculated into 3-5 mL LB with100 μg/mL ampicillin followed by 
incubation at 37°C overnight. The culture was centrifuged at 13,000 g for 1 min and the 
resulting pellet dissolved in 250 μL of Buffer P1. The cells were lysed with 250 μL 
Buffer P2, followed by addition of 350 μL Buffer N3 until a precipitate formed. After the 
mixture was centrifuged at 13,000 g for 10 min at room temperature, 800 μL of 
supernatant containing plasmid DNA was transferred to a spin column. After 
centrifugation at 13,000 g for 40-60 sec, the flow-through was discarded. The column 
was washed once with 0.5 mL of Buffer PB and twice with 750 μL of buffer PE by 
centrifugation at 13,000g for 40-60 sec. Following centrifugation at 13,000 g for 2 min to 
remove residue buffer PE, the column was placed into in a 1.5 mL tube. 50 μL dH2O was 
added and left for 10 min at room temperature. The DNA was eluted by centrifugation at 
13,000 g for 60 sec before being quantified and finally stored at -20 °C.   102
2.2.16 Sequencing 
Nucleotide sequencing was conducted using ABI PRISM
TM Big Dye Terminator Version 
3.1 ready reaction kit with AmpliTaq DNA polymerase (Perkin-Elmer Applied 
Biosystems, Conn., USA) in an ABI 377 automatic DNA sequencer (Applied Biosystems, 
USA). In brief, 10 μL reactions containing 1 μL of 5X sequencing buffer, 1 μL of 3.2 
pmoles/μL M13F or M13R primer, 5 μL template (80 ng/μL plasmid DNA), 2 μL of Dye 
terminator mix, 1 μL dH2O were subjected to thermal cycling conditions of 96 °C for 2 
min; followed by 25 cycles of 96°C for 10 sec, 56°C for 5 sec and 60°C for 4 min, with a 
14°C final hold. DNA was precipitated by adding 25 μL of 100% ethanol, 1 μL of 125 
mM EDTA and 1 μL of 3M NaOAc (pH 4.8) on ice for 20 min followed by 
centrifugation at 14,000 g for 30 min at room temperature. Pellets were rinsed with 125 
μL of 70% ethanol and dried for 5-10 min at room temperature. The pellet was stored at   
-20 °C until sequencing by qualified SABC personnel.  Sequence data was analysed using 
SeqEd
TM version 1.0.3 (Applied Biosystem Inc.).  
2.2.17 Sequence analysis and construction of phylogenetic tree 
The HA amino acid sequence of A/coot/WA/2727/79 (H6N2) was deduced by EMBOSS 
Transeq (http://www.ebi.ac.uk/Tools/emboss/transeq/) and then aligned with selected 
LPAI or HPAI  isolates by Clustal W (http://www.ebi.ac.uk/Tools/clustalw2/index.html) 
to analyse the cleavage region sequence. 
Phylogenetic analysis of the nucleotide sequences obtained from this study and from the 
GenBank database was performed using the Molecular Evolution Genetics Analysis 
program (MEGA, version 4.0)(Tamura et al. 2007). Reference viruses were selected from   103
representative isolates of H1-H16 and N1-N9 subtype as well as some Australian isolates, 
for which corresponding complete sequences of three genes were available from 
GenBank. The estimated evolutionary distances between DNA sequences were displayed 
by Maximum Composite Likelihood model with the neighbor-joining method with 1,000 
bootstrap replications. 
2.2.18 Data analysis 
All statistical analysis of HI antibody titres was conducted as geometric mean titres 
(GMT). Statistical analyses of experimental data and controls were conducted by using 
the paired-sample T-test, and one way analysis of variance (ANOVA) (Mann-Whitney 
Test was used as homogeneity of variance testing showed statistical significance) with 
SPSS statistical software version 15 as well as Chi-square (Fisher's exact test was used 
when the sample number was less than 5) using Statistix. Statistical significance was 
defined at the level of p<0.05. 
2.3 Results  
2.3.1 Virus growth in cell cultures 
Monolayers of MDCK cells in the 6-well plate inoculated with 100 μL of 1/10 dilution of 
allantoic fluid containing A/coot/WA/2727/79 (H6N2) showed morphological changes 
consistent with virus induced cytopathic effect (CPE), including rounding and shrinkage 
of cells, plaque formation and finally detachment of cells from the surface of culture plate. 
In contrast, uninfected cells showed no sign of cell damage (Figure 2.1 and 2.2).  
Interestingly, this H6N2 LPAI virus grew in MDCK cells in the absence of exogenous 
trypsin. The virus titre in the supernatant of infected cells was 10
6.5 TCID50/0.1mL (HA   104
titre 2
8) in the presence of TPCK and 10
5.5/0.1mL TCID50 (HA titre 2
6) in the absence of 
TPCK.     
         
  
Figure 2.1 Morphological changes postinoculation of A/coot/WA/2727/79 virus in MDCK. 
A, MDCK with CPE; B, uninfected control cells (x10). 
 
 
 
      
 
Figure 2.2 Immunofluorescent staining of virus infected MDCK cells. 
A, cultures with TPCK trypsin; B, cultures without TPCK trypsin; C, uninfected control cells, 
(x20). 
 
2.3.2 Intravenous pathogenicity index  
After IV inoculation of the H6N2 virus the unvaccinated challenged chickens consumed 
less feed during the first 7 days but their appetite returned to normal after that. 
Correspondingly, these birds looked smaller compared to the vaccinated and naïve 
control groups, however, body weight measurements were not conducted. This suggested 
that virus intravenous inoculation resulted in mild growth suppression. No birds showed 
any other clinical signs during a 10-day observation period. One out of ten birds died on   105
day 6 following IV injection. Thus, the IVPI score of this virus was 0.15. According to 
the criteria of the World Organisation for Animal Health (OIE 2008), the isolate was 
classified as a LPAI virus. 
2.3.3 Comparison of virus shedding by different challenge routes 
Following IV challenge, the remaining nine birds showed a HI GMT of 2
7 (titres ranging 
from 2
5 to 2
8) by 10 days post inoculation whereas six birds showed HI GMT of 2
6 (titres 
ranging from 2
4 to 2
9) after combined oral and oculonasal challenge (Figure 2.3). 
Moreover, there was no significant difference in the GMT (ANOVA, P=0.219) post-
challenge between IV route, and combined oral and oculonasal routes, however, there 
was a significant difference (ANOVA, P=0.000) in the GMT between prior and post-
challenge in both IV challenge group and the combined oral and oculonasal groups, 
indicating that this virus can replicate in chickens along with an absence of clinical signs. 
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Figure 2.3 HI titre after virus challenge via intravenous route (group1) and combined oral 
and oculonasal routes (group2). 
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Table 2.2  Virus shedding in swabs post challenge via intravenous as well as combined oral and oculonasal route. 
 
 Intravenous  challenge  Oral and oculonasal challenge 
  241  242  243*  244 245 266 267 268 269 270 231 232 233 234 235 236 
  O * *  C  O  C  O  C  O  COCOCOCOCOCO  C  OCOCOCOCOCOC
D1 +*** – – – – + – – – – – – – – – – – – + – + – + – + – + – + – + – 
D3  +  – – – + – – – + – – – + – – + – – + – + – + + + – + – – – + – 
D5  –  – – – + + – – – – + + – – – – – – – – – – + – + – + + – – + – 
D7  –  – – – – + – + – – + – – + – – – + – – – – + – – – – + – – + – 
       * The bird died on day 6 post challenge. Swabs on day 7 referred to that on day 6. ** O represents oropharyngeal swabs and C represents cloacal swabs. 
       *** + positive and  –  negative for virus isolation. 
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As shown in Table 2.2, the virus shedding rate post-challenge in OS was 25% (10/40) 
and 70.8% (17/24) whereas the rate in CS was 20% (8/40) and 12.5% (3/24) respectively 
for the IV route, and the oral/oculonasal routes. There was a highly significant difference 
(Chi-square, P=0.0003) in virus shedding via OS and no significant difference (Fisher 
exact tests, P=0.51) in virus shedding via CS between the IV route and the oral/ 
oculonasal routes. Moreover, no virus was detected in the kidneys 10 days post-challenge. 
2.3.4 Cloning and sequencing of avian influenza virus gene 
The viral HA, NP and NA genes of  the H6N2 virus were amplified from infective 
allantoic fluid by RT and PCR (Figure 2.4), showing expected sizes, 1.7 kb for HA, 1.5 
kb for NA and 1.6 kb for NP. These three genes were cloned into pGEM-T easy vector to 
generate pT-HA, pT-NP and pT-NA, and the cloned genes were respectively amplified 
by M13 and virus primers as shown in Figure 2.4.  
             
 
Figure 2.4 A RT-PCR amplification of HA, NP and NA gene of the H6N2 virus. 
Lane 1, 1kb marker (Promega); lane 2, HA; lane 3, NA; lane 4, NP fragment (arrow indicates 
specific fragment). B PCR amplification of HA, NP and NA genes in pGEMT-easy vector 
using M13 and virus primers. Lane 1, 100bp marker (Fermentas); lane 2, NA-M13 primers; 
lane 3, NA-virus primers; lane 4, NP-M13 primers; lane 5, NP-virus primers; lane 6, HA-M13 
primers; lane 7, HA-virus primers. 
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Three segments of genomes of A/coot/WA/2727/79 (H6N2) have been sequenced and are 
shown in Appendix 2.1. The complete open reading frame (ORF) of A/coot/WA/2727/79 
(H6N2) virus HA gene was determined to be 1701 nucleotides long, capable of encoding 
a protein of 567 amino acids. The deduced amino acid sequence showed no multiple 
basic amino acid motif in the cleavage site of the HA, which is characteristic of HPAI 
viruses (Figure 2.5).  In comparison with the presence of leucine (L) and serine (S) at 
residues 226 and 228 considered as conserved amino acid sites for receptor binding for 
human influenza viruses, this isolate had respectively glutamine (Q) and glycine (G) 
residues (Figure 2.6). The HA sequence was 1723 bp long. The HA ORF sequence is the 
same as that in GenBank accession number (CY028243) (1709 bp).    109
 
Figure 2.5 Alignment of the HA cleavage region among A/coot/WA/2727/79 and reference isolates. 
AF474035(A/chicken/ California/6643/2001(H6N2)), D90303(A/shearwater/Australia/1/1972(H6N5)), CY005691 (A/black 
duck/AUS/4045/1980(H6N5)), CY004515 (A/coot/ALB/134/1987(H6N2)), AF028709 (A/Hong Kong/156/97(H5N1)), AY577314 
(A/Thailand/3(SP-83)/2004(H5N1)), AY497096 (A/chicken /Mexico/232/94 (H5N2)), AY497093 (A/chicken/El Salvador/102711-1/01 (H5N2)). 
 
          
Figure 2.6 Comparison of amino acid at position 226 and 228 of HA. 
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The NP gene of A/coot/WA/2727/79 (H6N2) was 1565 bp whereas the NCBI sequence 
(accession No. CY028246) was 1530 bp. The ORF of NP gene was determined to be 
1494 nucleotides long, capable of encoding a protein of 498 amino acids. The NP 
sequence in the ORF region is the same as that in NCBI. 
The NA gene of A/coot/WA/2727/79 (H6N2) was 1468 bp whereas the NCBI sequence 
(accession No. CY028245) was 1434 bp. The ORF of NA gene was determined to be 
1407 nucleotides long, capable of encoding a protein of 469 amino acids. There were six 
base differences between our sequence and the NCBI sequence, which resulted in five 
amino acid differences (Figure 2.7).  
                          
 
 
Figure 2.7 Comparison of NA gene sequence between this study and the GenBank. 
 
2.3.5 Phylogenetic analysis 
Phylogenetic trees based on HA, NA and NP genes of the A/coot/WA/2727/79 (H6N2) 
virus are shown in Figure 2.8.  Phylogenetic analysis of the HA gene demonstrated that 
A/coot/WA/2727/79 (H6N2) shared the highest sequence identity with influenza A virus 
(A/black duck/AUS/4045/1980 (H6N5)) (Genbank accession CY005691). There were 
wide differences between this H6N2 virus and  the other Australian isolates of different 
subtypes prevalent in Australian wild birds at that time in the database, including A/red-
necked stint/AUS/4500/1980 (H3N8) (CY005705), A/gray teal/AUS/3/ 1979 (H4N6) 
gi|162373910|gb|CY028245.1|      -------------AGTGAAAATGAATCCAAATCAGAAGATAATAACAATT 37 
NA_29Mar07_                      AGCAAAAGCAGGAGTTGAAAATGAATCCAAATCAGAAGACAACAACAATT 50 
                                                ************************ ** ******* 
 
gi|162373910|gb|CY028245.1|      GGCTCTGTCTCTCTAACCATCGCAACAATATGCTTTCTCATGCAGATTGC 87 
NA_29Mar07_                      GGCTCTGTCTCTCCAACCATCGCAACAACATGCTTTCTCATGCAGATTGC 100 
                                 ************* ************** *********************   111
(CY005682), A/red-necked stint/AUS/5745/1981 (H12N9) ( CY005711), A/wedge-tailed 
shearwater/Western Australia/2576/1979 (H15N9) ( CY005408). This isolate was also 
closely related to other H6 avian influenza viruses, especially isolates from Alberta.  
From the phylogenetic tree the H6 avian influenza virus group appeared to be closer in 
virus evolution to H1, H2 and H5 virus groups than to H3, H4, H7, H8,H9, H11,H12, 
H13, H15 (there was insufficient data available in Genbank to extend these relationships 
to  H10, H14 and H16 viruses).     
Four groups can be assigned from the phylogenetic analysis of NA genes: (i) N1, N4; (ii) 
N5, N8; (iii) N3, N6, N7, N9; and (iv) N2, which was consistent with the previous 
grouping of NA genes (Harley et al. 1989). The phylogenetic analysis of NA genes 
clearly supported the subtyping of the A/coot/WA/2727/79 virus as H6N2. All the N2 
subtype viruses examined showed close phylogenetic relationships to each other 
including North American and Asian isolates. N2 groups showed substantial 
phylogenetic differences from other N subgroups. In an evolutionary sense the N1 
subtype appeared to be closer to N4 subtype, N5 appeared closer to N8 subtype and N6 
appeared closer to N9 subtype.    
The phylogenetic analysis of the NP genes demonstrated that A/coot/WA/2727/79 (H6N2) 
shared the highest sequence identity with Influenza A virus A/black duck/AUS/4045/ 
1980 (H6N5) (Genbank accession CY005694). It also had a closer relationship with other 
Australian isolates than those from Asia, North America or Europe.  
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A/shorebird/DE/12/2004(H6N8)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
A/Chicken/California/6643/01(H6N2)
A/quail/Hong Kong/1721-20/99(H6N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00(H6N1)
A/laughing gull/NJ/276/1989(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/Hong Kong/d134/1977(H6N2)
A/chicken/Taiwan/G2/87(H6N1)
A/duck/Taiwan/0526/72(H6N1)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/04(H6N2)
A/Shearwater/Australia/1/72(H6N5)
A/coot/WA/2727/79(H6N2)
A/black duck/AUS/4045/80(H6N5)
A/pintail duck/Alberta/1360/1979(H6N2)
A/mallard duck/ALB/205/1978(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/widgeon/ALB/256/82(H6N6)
A/blue-winged teal/ALB/685/82(H6N4)
A/mallard duck/ALB/289/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/coot/ALB/134/1987(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/85(H6N2)
A/Puerto Rico/8/34(H1N1)
A/Japan/305/57(H2N2)
A/tern/South Africa/61(H5N3)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/pintail duck/Alberta/114/1979(H8N4)
A/red-necked stint/Aus/5745/81(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/mallard duck/ALB/797/1983(H11N3)
A/red-necked stint/Aus/4189/1980(H4N8)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/red-necked stint/Aus/4500/1980(H3N8)
A/Hong Kong/1/68(H3N2)
A/chicken/Germany/N/1949(H10N7)
A/chicken/British Columbia/04(H7N3)
A/duck/Australia/341/83 (H15N8)
A/wedge-tailed shearwater/WA/2576/79(H15N9)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/1983(H15N9)
99
100
93
100
100
100
100
100
100
86
100
100
100
100
58
100
99
100
90
68
74
100
99
60
55
98
99
99
100
100
99
98
100
100
85
45
100
100
100
96
95
92
89
100
60
79
64
45
23
32
0.2
A/shorebird/DE/12/2004(H6N8)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
A/Chicken/California/6643/01(H6N2)
A/quail/Hong Kong/1721-20/99(H6N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00(H6N1)
A/laughing gull/NJ/276/1989(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/Hong Kong/d134/1977(H6N2)
A/chicken/Taiwan/G2/87(H6N1)
A/duck/Taiwan/0526/72(H6N1)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/04(H6N2)
A/Shearwater/Australia/1/72(H6N5)
A/coot/WA/2727/79(H6N2)
A/black duck/AUS/4045/80(H6N5)
A/pintail duck/Alberta/1360/1979(H6N2)
A/mallard duck/ALB/205/1978(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/widgeon/ALB/256/82(H6N6)
A/blue-winged teal/ALB/685/82(H6N4)
A/mallard duck/ALB/289/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/coot/ALB/134/1987(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/85(H6N2)
A/Puerto Rico/8/34(H1N1)
A/Japan/305/57(H2N2)
A/tern/South Africa/61(H5N3)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/pintail duck/Alberta/114/1979(H8N4)
A/red-necked stint/Aus/5745/81(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/mallard duck/ALB/797/1983(H11N3)
A/red-necked stint/Aus/4189/1980(H4N8)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/red-necked stint/Aus/4500/1980(H3N8)
A/Hong Kong/1/68(H3N2)
A/chicken/Germany/N/1949(H10N7)
A/chicken/British Columbia/04(H7N3)
A/duck/Australia/341/83 (H15N8)
A/wedge-tailed shearwater/WA/2576/79(H15N9)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/1983(H15N9)
99
100
93
100
100
100
100
100
100
86
100
100
100
100
58
100
99
100
90
68
74
100
99
60
55
98
99
99
100
100
99
98
100
100
85
45
100
A/shorebird/DE/12/2004(H6N8)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
A/Chicken/California/6643/01(H6N2)
A/quail/Hong Kong/1721-20/99(H6N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00(H6N1)
A/laughing gull/NJ/276/1989(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/Hong Kong/d134/1977(H6N2)
A/chicken/Taiwan/G2/87(H6N1)
A/duck/Taiwan/0526/72(H6N1)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/04(H6N2)
A/Shearwater/Australia/1/72(H6N5)
A/coot/WA/2727/79(H6N2)
A/black duck/AUS/4045/80(H6N5)
A/pintail duck/Alberta/1360/1979(H6N2)
A/mallard duck/ALB/205/1978(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/widgeon/ALB/256/82(H6N6)
A/blue-winged teal/ALB/685/82(H6N4)
A/mallard duck/ALB/289/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/coot/ALB/134/1987(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/85(H6N2)
A/Puerto Rico/8/34(H1N1)
A/Japan/305/57(H2N2)
A/tern/South Africa/61(H5N3)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/pintail duck/Alberta/114/1979(H8N4)
A/red-necked stint/Aus/5745/81(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/mallard duck/ALB/797/1983(H11N3)
A/red-necked stint/Aus/4189/1980(H4N8)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/red-necked stint/Aus/4500/1980(H3N8)
A/Hong Kong/1/68(H3N2)
A/chicken/Germany/N/1949(H10N7)
A/chicken/British Columbia/04(H7N3)
A/duck/Australia/341/83 (H15N8)
A/wedge-tailed shearwater/WA/2576/79(H15N9)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/1983(H15N9)
99
100
93
100
100
100
100
100
100
86
100
100
100
100
58
100
99
100
90
68
74
100
99
60
55
98
99
99
100
100
99
98
100
100
85
45
100
100
100
96
95
92
89
100
60
79
64
45
23
32
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A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/1985(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail duck/ALB/1360/1979(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/mallard duck/Alberta/205/1978(H6N2)
A/coot/ALB/134/1987(H6N2)
A/chicken/California/6643/01(H6N2)
A/duck/Hong Kong/d134/1977(H6N2)
A/Japan/305/57(H2N2)
A/Hong Kong/1/68(H3N2)
A/coot/WA/2727/79(H6N2)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/2004(H6N2)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/chicken/British Columbia/04(H7N3)
A/mallard duck/ALB/797/1983(H11N3)
A/tern/South Africa/1961(H5N3)
A/chicken/Germany/n/1949(H10N7)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/83(H15N9)
A/wedge-tailed shearwater/WA/2576/79(H15N9) 
A/red-necked stint/AUS/5745/1981(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/mallard duck/ALB/289/1982(H6N6)
A/widgeon/ALB/256/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/laughing gull/NJ/276/1989(H6N8)
A/shorebird/DE/12/2004(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/AUS/341/1983(H15N8)
A/red-necked stint/Aus/4189/80(H4N8)
A/red-necked stint/Aus/4500/80(H3N8)
A/black duck/AUS/4045/1980(H6N5)
A/shearwater/Australia/1/1972(H6N5)
A/blue-winged teal/ALB/685/1982(H6N4)
A/pintail duck/ALB/114/1979(H8N4)
A/duck/Taiwan/0526/72(H6N1)
A/chicken/Taiwan/G2/87(H6N1)
A/Puerto Rico/8/34(H1N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00 (H6N1)
A/quail/Hong Kong/1721-20/99 (H6N1)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1) (H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
75
100
100
99
100
94
64
93
99
100
100
99
53
98
100
100
99
56
47
78
100
99
82
61
57
47
31
99
100
99
83
100
99
89
48
98
100
100
85
99
71
45
27
99
38
83
82
46
100
0.1
A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/1985(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail duck/ALB/1360/1979(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/mallard duck/Alberta/205/1978(H6N2)
A/coot/ALB/134/1987(H6N2)
A/chicken/California/6643/01(H6N2)
A/duck/Hong Kong/d134/1977(H6N2)
A/Japan/305/57(H2N2)
A/Hong Kong/1/68(H3N2)
A/coot/WA/2727/79(H6N2)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/2004(H6N2)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/chicken/British Columbia/04(H7N3)
A/mallard duck/ALB/797/1983(H11N3)
A/tern/South Africa/1961(H5N3)
A/chicken/Germany/n/1949(H10N7)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/83(H15N9)
A/wedge-tailed shearwater/WA/2576/79(H15N9) 
A/red-necked stint/AUS/5745/1981(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/mallard duck/ALB/289/1982(H6N6)
A/widgeon/ALB/256/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/laughing gull/NJ/276/1989(H6N8)
A/shorebird/DE/12/2004(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/AUS/341/1983(H15N8)
A/red-necked stint/Aus/4189/80(H4N8)
A/red-necked stint/Aus/4500/80(H3N8)
A/black duck/AUS/4045/1980(H6N5)
A/shearwater/Australia/1/1972(H6N5)
A/blue-winged teal/ALB/685/1982(H6N4)
A/pintail duck/ALB/114/1979(H8N4)
A/duck/Taiwan/0526/72(H6N1)
A/chicken/Taiwan/G2/87(H6N1)
A/Puerto Rico/8/34(H1N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00 (H6N1)
A/quail/Hong Kong/1721-20/99 (H6N1)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1) (H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
75
100
100
99
100
94
64
93
99
100
100
99
53
98
100
100
99
56
47
78
100
99
82
61
57
47
31
99
100
99
83
100
99
89
48
98
100
100
A/pintail/Alberta/113/85(H6N2)
A/shoveler/ALB/114/1985(H6N2)
A/blue-winged teal/ALB/69/1985(H6N2)
A/mallard/Alberta/98/85(H6N2)
A/pintail duck/ALB/1360/1979(H6N2)
A/pintail duck/ALB/367/1978(H6N2)
A/mallard duck/Alberta/205/1978(H6N2)
A/coot/ALB/134/1987(H6N2)
A/chicken/California/6643/01(H6N2)
A/duck/Hong Kong/d134/1977(H6N2)
A/Japan/305/57(H2N2)
A/Hong Kong/1/68(H3N2)
A/coot/WA/2727/79(H6N2)
A/guillemot/Sweden/3/00(H6N2)
A/duck/Hainan/4/2004(H6N2)
A/Quail/Hong Kong/G1/97 (H9N2)
A/Hong Kong/1073/99(H9N2)
A/chicken/British Columbia/04(H7N3)
A/mallard duck/ALB/797/1983(H11N3)
A/tern/South Africa/1961(H5N3)
A/chicken/Germany/n/1949(H10N7)
A/wedge-tailed shearwater/WA/2327/83(H15N9)
A/sooty tern/WA/2190/83(H15N9)
A/wedge-tailed shearwater/WA/2576/79(H15N9) 
A/red-necked stint/AUS/5745/1981(H12N9)
A/gull/Maryland/704/1977(H13N6)
A/duck/England/1/1956(H11N6)
A/gray teal/AUS/3/1979(H4N6)
A/Swine/Ontario/01911-1/99 (H4N6)
A/mallard duck/ALB/289/1982(H6N6)
A/widgeon/ALB/256/1982(H6N6)
A/blue-winged teal/MN/993/1980(H6N6)
A/laughing gull/NJ/276/1989(H6N8)
A/shorebird/DE/12/2004(H6N8)
A/mallard/ALB/206/1996(H6N8)
A/duck/AUS/341/1983(H15N8)
A/red-necked stint/Aus/4189/80(H4N8)
A/red-necked stint/Aus/4500/80(H3N8)
A/black duck/AUS/4045/1980(H6N5)
A/shearwater/Australia/1/1972(H6N5)
A/blue-winged teal/ALB/685/1982(H6N4)
A/pintail duck/ALB/114/1979(H8N4)
A/duck/Taiwan/0526/72(H6N1)
A/chicken/Taiwan/G2/87(H6N1)
A/Puerto Rico/8/34(H1N1)
A/Teal/Hong Kong/W312/97(H6N1)
A/pheasant/Hong Kong/SH39/99 (H6N1)
A/chukka/Hong Kong/FY295/00 (H6N1)
A/quail/Hong Kong/1721-20/99 (H6N1)
A/HongKong/156/97(H5N1)
A/Thailand/16/2004(H5N1) (H5N1)
A/Brown-headed Gull/Qinghai/3/05(H5N1)
A/duck/Korea/S17/03(H6N1)
A/duck/Hong Kong/3461/99 (H6N1)
A/partridge/Taiwan/LU1/99(H6N1)
75
100
100
99
100
94
64
93
99
100
100
99
53
98
100
100
99
56
47
78
100
99
82
61
57
47
31
99
100
99
83
100
99
89
48
98
100
100
85
99
71
45
27
99
38
83
82
46
100
0.1  114
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2.4 Discussion  
This study describes the biological and genetic properties of A/coot/WA/2727/79 (H6N2) 
isolated from an apparently healthy coot in 1979. This virus was classified as LPAI based 
on an IVPI score of 0.15 and a motif of 
321PQAETRG
328 at the HA cleavage site, which 
did not present the multiple basic acid motif found in HPAI viruses. Moreover, this 
isolate is able to grow on commonly used MDCK cells in the absence of exogenous 
TPCK trypsin. 
Accumulated data has indicated that new pandemic human influenza viruses arising 
every 10-15 years are derived from AIVs isolated from lower mammals or birds either by 
direct transmission or by genetic recombination between human and animal viruses 
(Alexander and Brown 2000; Downie et al. 1977; Hobson 1973).  As AIVs of wild birds 
may serve as progenitors of human pandemic influenza viruses, investigation and 
analysis of these viruses can provide useful information on the spectrum of AIVs existing 
in wild bird populations around the world.  This may assist in identifying viruses with the 
potential to evolve into human pandemic influenza viruses. Moreover, identifying and 
assessing the biological properties and potential pathogenicity of waterfowl-origin type A 
influenza viruses in chickens could help identify viruses that present an increased threat 
to domestic poultry.  
The HA glycoprotein for influenza A viruses is responsible for virus attachment to host 
cells and then fusion between the host cell membrane and the virus membrane 
(Alexander 2008). This glycoprotein is synthesized as a precursor, HA0, which requires 
post-translational cleavage by host proteases before it is able to induce membrane fusion 
and before infectious virus particles can be produced (Rott 1992). In general, the HA0   116
precursor in LPAI viruses is cleaved only in certain environments where trypsin-like 
enzymes are present or exogenous trypsin is added for the efficient replication of the 
virus in cell culture (Lee et al. 2008). In the current study the H6N2 virus replicated in 
MDCK cells without addition of exogenous trypsin, although replication, as measured by 
TCID50 and HA titre in the supernatant, was more efficient in the presence of trypsin.  In 
this regard the H6N2 isolate behaved more like an HPAI virus in cell culture despite 
being clearly LPAI by the gold standard IVPI tests. The reason for this was not 
determined in this study. Possible causes could include the presence of residual trypsin 
during cell passage, however the growth media used included sufficient FCS to inactivate 
any remaining trypsin. Alternatively, the MDCK cells may have sufficient protease 
activity that permitted cleavage of the HA0 of this particular H6N2 virus.  In an 
experiment with in vitro cultivation of swine influenza virus, HA titers in the presence of 
trypsin reached a maximum of 1: 2048 (average titer, 1: 870) whereas the titres were 1: 4 
to 1: 8 (average titre, 1:2.6) without trypsin (Herman et al. 2005). This indicated that 
some low pathogenic viruses have ability to grow without trypsin. 
Some studies showed that all H6 AIVs examined contained the amino acid motif 
PQIETR↓G at the cleavage site (arrow) between HA1 and HA2 (Chin et al. 2002; 
Webster and Rott 1987). However, the current H6N2 virus and the closely related 
A/black duck/AUS/4045/1980(H6N5) and A/coot/ALB/134/1987(H6N2) viruses 
possessed PQAETR↓G (Figure 2.5). Possibly this motif allowed HA0 cleavage by weak 
cellular proteases for these viruses. 
The HA of influenza type A viruses is responsible for binding of the virus to the cell 
surface of sialic acid (SA) containing oligosaccharide receptors (Connor et al. 1994;   117
Vines et al. 1998).  The amino acids at the receptor-binding site (RBS) of HA are highly 
conserved among AIVs. In H2 and H3 influenza virus strains (human viruses), the 
presence of leucine at position 226 and serine at 228 in the HA was correlated with 
preferential recognition of SAα2,6Gal, whereas among equine and avian influenza 
viruses,  the presence of glutamine at residue 226 and glycine at residue 228  
preferentially recognize SAα2,3Gal (Connor et al. 1994)). Moreover, the HA is 
responsible for host range restriction of influenza A virus. Amino acid residue analysis of 
this isolate further highlights that this virus has a specificity for avian and inability to 
bind SAα2,6Gal despite an ability to grow on MDCK cells in the absence of Trypsin.  
Waterfowl are considered to be the principal reservoir of Influenza A viruses. Variations 
in pathogenicity may exist among AIVs isolated from wild birds. Slemons et al.(1991) 
assessed the pathogenicity potential of 29 wild duck-origin influenza A viruses with a 
range of HA-NA combinations (including H5N1, H5N2, H5N9, H7N8). IVPI indices of 
all these viruses ranged from 0.0 to 0.49. A total of seven out of 232 chickens died 
following IV challenge with 29 waterfowl-origin influenza A viruses. All deaths fell 
within 3-7 days postinoculation. For the IVPI conducted on the H6N2 virus in this study 
only one bird died on day 6. The OIE criteria for classifying an AIV as HPAI is any virus 
with an IVPI greater than 1.2 or where six or more out of eight inoculated chickens die 
(OIE 2008).  Thus, the H6N2 virus tested in the present study was classified as an LPAI 
virus. Growth suppression may be an objective measure of the pathogenicity potential of 
LPAI (Karunakaran et al. 1988).  In our experiment, a period of inappetance and apparent 
growth suppression but no other clinical signs were observed. In view of these 
observations the H6N2 virus used in these studies was classified as an LPAI virus.   118
H6 antibody responses appeared in the chickens after administering this virus via either 
the IV route or the combined oral and oculonasal routes. This further verified previous 
studies that waterfowl-origin Influenza A viruses are capable of infecting domestic 
chickens under experimental conditions but without causing clinical illness (Condobery 
and Slemons 1992; Slemons et al. 1991; Slemons and Swayne 1990, 1995). Moreover, 
virus shedding following virus challenge via different routes presented obvious 
differences. Relatively even levels of excretion via the cloaca and oropharynx occurred 
following IV challenge. However, a higher shedding rate from the oropharynix resulted 
from oral and oculonasal inoculation, which implied a high level and sustained virus 
growth in the upper respiratory tract.  
The NP gene of A/coot/WA/2727/79 (H6N2) was more closely related to other 
Australian isolates than isolates from Asia, North America or Europe, indicating that 
these Australian isolates may have common ancestral nucleoprotein genes. The H6 HA 
and NP phylogenetic trees revealed that this H6N2 virus isolate was closely related to 
A/black duck/AUS/4045/80(H6N5) and to other AI strains isolated from shearwaters in 
Australia from 1979 to 1983. This suggested that this genetic type was prevalent in 
Australian wild birds during that time. The H6 HA and NA phylogenetic trees revealed 
that this isolate was related to North America lineage viruses (e.g. A/pintail 
duck/Alberta/1360/1979 (H6N2) and A/coot/ALB/134/1987 (H6N2)) and also to 
Eurasian lineage viruses (e.g. A/duck/Hong Kong/d134/1977 (H6N2), 
A/guillemot/Sweden/3/00 (H6N2)), indicating that interaction may have been occurring 
among migratory wild birds between two geographic regions at that period. The isolation   119
of a similar virus from pelagic birds in Australia showed how widely these AIVs are 
spread around the world. 
Since this H6N2 strain itself was not further purified before cloning the genes of interest, 
the possibility that the virus stock was polyclonal was not eliminated. It is possible that 
minor differences in sequences could have resulted from the clones chosen for 
sequencing. The sequences for the genes from this virus lodged in Genbank resulted from 
sequencing after different passage histories in embryonated chicken eggs in different 
laboratories. All these factors may have contributed to the six nucleotide differences in 
the NA gene between the sequence obtained in this study and the GenBank sequence for 
this virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   120
Chapter 3 
Development and evaluation of haemagglutinin- or nucleoprotein-expressing DNA 
vaccines in a VR1012 expression vector against avian influenza H6N2 virus in 
chickens 
 
3.1 Introduction 
DNA vaccines offer some distinct advantages over traditional protein-based vaccines due 
to their safety, effectiveness, stability and lack of reliance on egg or cell culture-based 
production (Doria-Rose and Haigwood 2003; Forde 2005). DNA vaccines expressing the 
HA or NP gene of AIVs have provided solid immune protection against influenza virus 
infections in chickens (Chen et al. 2001; Cherbonnel et al. 2003; Fynan et al. 1993a; 
Fynan et al. 1993b; Jiang et al. 2007; Kodihalli et al. 1997; Kodihalli et al. 2000; Suarez 
and Schultz-Cherry 2000b). However, immunogenicity of DNA vaccines in chickens has 
been variable depending on expression vector, insert gene (antigenicity of encoded insert) 
and the delivery method and route of inoculation (Kodihalli et al. 1997; Kodihalli et al. 
2000; Robinson et al. 1993). In addition, the experimental procedures that are normally 
used in these studies, which include either administering large doses of plasmid DNA 
multiple times (Suarez and Schultz-Cherry 2000a) or using application methods such as 
GG (Kodihalli et al. 1997), are not likely to be applied in the field for routine 
administration to poultry as they are not practical. Therefore, this new technology for use 
in poultry is still being developed and improvements in DNA vaccine technology are 
needed before the vaccines can be made commercially available (Suarez and Schultz-
Cherry 2000a). 
H6 subtype AI viruses have not only caused sporadic outbreaks of AI in the poultry 
industry worldwide, but also have been shown to constitute a potential threat to public   121
health (Chen et al. 2009; Myers et al. 2007). This highlights the need to develop an H6 
vaccine. Live attenuated influenza A virus H6 vaccines generated using the eight-plasmid 
reverse genetics system were recently developed and evaluated in mice and ferrets (Chen 
et al. 2009). Numerous studies on DNA vaccines have shown that HA-expressing 
plasmids from H1, H3, H5, H7 and H9 subtypes of influenza A viruses protected mice 
and chickens against homologous virus challenge (Cherbonnel et al. 2003; Kodihalli et al. 
1999; Kodihalli et al. 1997; Kodihalli et al. 2000; Lee et al. 2003; Ljungberg et al. 2002; 
Ljungberg et al. 2000; Qiu et al. 2006). To our knowledge, there is no publication 
detailing similar studies on the efficacy of an H6-DNA vaccine.  
This  chapter describes investigations of the DNA expression vector VR1012 encoding 
the HA (VR-HA) or NP (VR-NP) genes of A/coot/WA/2727/79(H6N2) virus with 
respect to induction of immune responses in chickens, protection from infection and 
reduction in virus shedding. 
3.2 Materials and Methods 
3.2.1 Preparation of VR1012 plasmid DNA   
The expression vector VR1012 (Vical Inc., CA, USA) (Figure 3.1) and the competent E. 
coli cells DH 5α (Invitrogen) were provided from stocks available in the School of 
Veterinary and Biomedical Sciences, Murdoch University, Australia.  
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Figure 3.1 Schematic diagram of DNA expression vector VR1012. 
(http://www.vical.com/). 
 
3.2.1.1 Preparation of electrocompetent cells 
The competent cells were prepared according to the protocol by Dower et al.(1988). 
Briefly, a fresh colony of DH 5α bacterial cells was inoculated into 10 mL SOB medium 
(2% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl) 
and incubated with vigorous aeration at 250 rpm overnight at 37°C. The overnight culture 
was diluted into 1 L pre-warmed SOB medium and incubated at 37°C with vigorous 
aeration at 250 rpm to an optical density at 600 nm wavelength (OD600) of 0.8. The 
culture was transferred into a chilled sterile centrifuge tube and centrifuged in a cold rotor 
at 3,000 g for 10 min. The pellets were gently resuspended in 1 L of 4°C cold sterile 10% 
glycerol. The tube was centrifuged as above. The pellets were resuspended in 0.5 L of   123
cold sterile 10% glycerol. Following further centrifugation, the pellet was resuspended in 
2-3 mL of 10% glycerol. The cells remained on ice and the suspension was dispensed in 
aliquots of 50 μL/ tube and frozen on dry ice. The cell concentration (approximately 1 x 
10
10 cells/mL) was measured by a spectrophotometer. Finally the cells were stored at       
-70 °C until required. 
3.2.1.2 Transformation of plasmid DNA into E. coli by electroporation 
The Gene Pulser (Bio-Rad, NSW, Australia) was used to perform transformation as per 
the instructions (Dower et al. 1988). The Gene Pulser (Bio-Rad) was set at 25 μF 
capacitor, 2.5 kV, and 200 Ω. One microlitre of VR1012 stock plasmid DNA was added 
into a thawed 50 μL tube of DH 5α cells followed by transfer into a chilled, 0.2 cm 
electroporation cuvette and insertion into the safety chamber. A pulse of 12.5 kV/cm with 
a time constant of about 4.0 msec was used. Following removal of the cuvette from the 
chamber, 1 mL of pre-cooled SOC medium (2% bacto-tryptone, 0.5% bacto-yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was 
quickly but gently added  to resuspend the cells. The cell suspension was subsequently 
transferred to a sterile polypropylene tube and incubated, with shaking at 225 rpm, for 
about 1 hr at 37°C. Then 10-100 μL of transformed DH 5α culture was spread on 1.2% 
agar LB plates supplemented with 50 μg/mL kanamycin. The plate was incubated at 37°C 
overnight until colonies were formed.  
3.2.1.3 Identification of VR1012 
Single colonies were picked from the plate, inoculated into 5 mL LB for incubation at 
37°C overnight. The plasmid DNA was extracted using QIAprep
®Spin Miniprep kit    124
(Qiagen) as described in section 2.2.15.  
The presence of plasmid DNA was confirmed by HindIII digestion as follows: 5 μL of 10 
x Tango buffer (Fermantas), 1 μg plasmid DNA, 0.5 μL HindIII (10 U/μL) and dH2O 
were added to give a final volume of 50 μL. Following incubation at 37°C for 2-3 hr, the 
digestion products were visualised by agarose gel electrophoresis as described in section 
2.2.11. 
3.2.2 Subcloning of viral HA and NP genes into expression vectors 
The recombinant pGEM-T vectors (pT-HA, pT-NP) containing the full-length HA or NP 
gene of A/coot/WA/2727/79 (H6N2) were described in Chapter 2. The full coding 
sequences of HA or NP genes were subcloned from the pT-HA or pT-NP  into the 
expression vector VR1012 with PstI or XbaI and BamHI restriction enzymes used to 
generate the final plasmids VR-HA or VR-NP that were used for immunizations. 
3.2.2.1 Restriction endonuclease reaction 
 A 50μL restriction endonuclease reaction mixture consisting of 5 μL of 10 x Tango 
buffer (Fermantas), 1 μg pT-HA DNA or VR1012 DNA, 1 μL BamHI (10 U/μL), 1 μL 
PstI (10 U/μL) and dH2O added up to 50 μL was prepared and  incubated at 37°C for 2-3 
hr. Similarly, another reaction mixture of 5 μL of 10 x Tango buffer (Fermantas), 1 μg 
pT-NP or VR1012 plasmid DNA, 1 μL BamHI (10 U/μL), 1 μL XbaI (10 U/μL) and 
dH2O  added up to 50 μL was prepared and incubated at 37°C for 2-3 hr. After checking 
for complete digestion by agarose gel electrophoresis, the digestion products containing 
HA or NP genes were fractionated and recovered as per section 2.2.11 and 2.2.13.    125
3.2.2.2 Ligation, transformation and screening 
The ligation was performed as per section 2.2.14.1 using pGEM-T Easy vector kit. The 
molar ratio of the gene of interest versus vector was approximately 3:1 to 5:1. 
Transformation was performed according to section 3.2.1.2 (above) and screening of 
positive clones was conducted as per section 2.2.14.3. The VR-HA or VR-NP constructs 
were purified using Qiagen columns and sequenced to verify the fidelity of the sequences 
as per the procedures described in section 2.2.15.  
3.2.3 Large-scale preparation of plasmid DNA for use as a DNA vaccine 
A single colony of the VR-HA or VR-NP construct was inoculated into 10 mL LB with 
50 μg/mL kanamycin and kept at 37°C overnight with shaking at 250 rpm. The following 
day, 1 ml fresh culture was inoculated into 1L LB with 50 μg/mL kanamycin and 
incubated at 37°C overnight with shaking at 220 rpm. The bacterial cells were harvested 
by centrifugation at 2,500 g for 10 min at 4°C.  The pellet was fully resuspended in 100 
mL NTE buffer (100 mM NaCl, 10 mM Tris (pH 7.4), 1 mM EDTA(pH 8.0)) followed 
by centrifugation at 3,500 g for 10 min at 4°C. The pellet was resuspended in 50 mL pre-
cooled solution I (25 mM Tris (pH 8.0), 10 mM EDTA (pH 8.0), 0.9% (w/v) glucose).  
This was followed by addition of 100 mL of freshly prepared solution II (0.2 M NaCl, 
1%SDS), gently mixing and holding on ice for 10 min.  Then 75 mL high salt 
neutralization buffer (2.5M KOAc, 5% (v/v) formic acid) was added to the mixture and 
thoroughly mixed until a white precipitate was observed.  After centrifugation at 3,500 g 
for 15 min at 4°C, the supernatant was filtered through four layers of sterile gauze before 
the addition of an equal volume of isopropanol.  The suspension was centrifuged at 2,500 
g for 15 min at 4°C. The pellet was resuspended in 15 mL dH2O and an equal volume of   126
LiCl solution (5M LiCl, 1% (w/v) 3-(N-Morpholino) propanesulfonic acid (MOPS), pH 
to 8.0, kept at 4°C) was added. The mixture was kept on ice for 10 min before 
centrifugation at 3,500 g for 15 min at 4°C. The supernatant was mixed with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) followed by centrifugation at 
1,900 g for 5 min at 20°C. The aqueous phase was transferred to a polypropylene tube 
followed by the addition of an equal volume of isopropanol. The mixture was centrifuged 
at 2,500 g for 15 min at 4°C and the pellet was dissolved in dH2O followed by the 
addition of 10 μL RNase A (10 mg/mL, Fermantas) at 37°C for 30 min. The DNA was 
precipitated by addition of 1/10 volume 3 M NaOAc (pH 4.8) and 2.5 volumes 100% 
ethanol followed by incubation at   -20°C for overnight and centrifugation at 15,000 g for 
20 min at room temperature. The pellet was washed in 75% ethanol by centrifugation at 
15,000 g for 5 min at room temperature. The DNA pellet was dried briefly, resuspended 
in dH2O and stored at -20°C until required. DNA concentration was determined by 
spectrophotometric analysis at 260 nm and 280 nm.  
3.2.4 In vitro expression of DNA plasmid in eukaryotic cells 
Cos-7 (African green monkey kidney) cells, supplied by the Department of Microbiology, 
University of Western Australia, were grown as per section 2.2.4.1. Approximately 60-
80% confluenct Cos-7 cells were used for transfection. An aliquot of 30 μg plasmid DNA 
was added to 0.5 mL of 0.25 M CaCl2 followed by dropwise addition to 0.5 mL 2xBBS 
(50 mM BES(N,N-bis(hydroxyethyl)-2-aminoethanesulfonic acid), 280 mM NaCl, 1.5 
mM Na2HPO4, pH 6.95) with aeration using a glass pasteur pipette attached to a pipette-
man. After incubating for 10 min at room temperature, the DNA mixture was trickled 
over the cells and the flask was incubated overnight at 37°C. The control flask was   127
similarly inoculated with the 0.25 M CaCl2/2xBSS mixture without plasmid DNA. After 
18 hr the media was removed and the cells were washed twice using about 5 mL of 
DMEM with 10% FCS. Following the addition of 5 mL DMEM with 10% FCS, the 
flasks were incubated at 37°C for another 48 hr. After discarding the supernatant the cells 
were harvested by freezing (-20°C) and thawing, and resuspended in 200-500 μL PBS for 
Western blotting. Similarly, Cos-7 cells transfected with 200 μL plasmid DNA mixture in 
6-well plates were used to conduct IFT using fluorescent microscope (Olympus BH-2, 
Tokyo, Japan) as per section 2.2.5.  
3.2.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting (WB) 
3.2.5.1 SDS-PAGE 
Protein samples were analysed by SDS-PAGE on discontinuous gels (Laemmli 1970). 
One dimensional gel electrophoresis was conducted under reducing conditions using a 
mini-protein electrophoresis apparatus (Bio-Rad). A 12.5% resolving gel (5 mL) 
containing 2.17 mL dH2O, 1.25 mL of 1.5 M Tris (pH 8.8), 0.05 mL of 10% SDS, 1.5 
mL of 40% acrylamide/bis (37.5:1), 25 μL of 10% ammonium persulfate (APS) and 5 μL 
TEMED was prepared in the gel apparatus, followed by addition of 0.5 mL dH2O or 
butanol to level the resolving gel surface. Once the resolving gel became solid, a 4% 
stacking gel (2.5 mL) containing 1.58 mL dH2O, 630 μL of 0.5 M Tris (pH 6.8), 25 μL of 
10% SDS, 250 μL 40% acrylamide/bis, 12.5 μL of 10% APS and 2.5 μL TEMED was 
then added, followed by insertion of an electrophoresis comb to create loading wells. 
Prior to electrophoresis, transfection product was mixed with an equal volume of 2x 
loading buffer (2 mL dH2O, 0.5 ml 0.5 M Tris pH6.8, 400 μL glycerol,  800 μL of 10%   128
SDS, 200 μL β-mercaptoethanol and 100 μL 0.05% bromophenol blue) followed by 
boiling for 10 min. Then 20 μL samples were added to the wells and the electrophoresis 
was conducted at 150 V for 1.5-2 hr at room temperature in running buffer (2.9 g/L Tris 
base, 14.4 g/L glycine, and 1 g/L SDS).  
3.2.5.2 Coomassie blue staining 
Following electrophoresis, the protein bands were visualized by staining with Coomassie 
brilliant blue dye at room temperature overnight, with rocking. The gel was destained for 
about 2 hr in a solution containing 10% acetic acid and 40% methanol, and destaining 
was stopped with 7% glacial acetic acid when protein bands were clearly evident. 
3.2.5.3 Western blotting 
The separated protein bands were transferred from gels onto Hybond
TM nitrocellulose 
membrances (Bio-Rad) using a mini trans-blot apparatus (Bio-Rad). Transfer was 
performed in transfer buffer (3.03 g Tris base, 14.4 g glycine, 200 mL methanol per L) 
overnight at 30 V at 4°C. The membrane was blocked in PBST containing 5% (w/v) skim 
milk powder for 1 hr at room temperature.  Chicken anti-H6 hyperimmune serum at a 
dilution of 1:100 was added to the membrane followed by incubation at room 
temperature for 1 hr. After washing 3 times with PBST (5 min per time), the membrane 
was incubated with horseradish peroxidase (HRP) conjugated anti-chicken 
immunoglobulin (Ig) (Sigma) at a dilution of 1:500 for 1 hr at room temperature. 
Following washing 3 times in PBST, the colour was developed with a 4-chloronaphthol 
(4-CN) substrate solution (100 mL of TBS [0.02 M Tris base, 0.385 M NaCl (pH 7.5)], 
60 μL H2O2, 20 mL methanol, and 60 mg 4-CN (Bio-Rad) at room temperature for 10   129
min as described by the manufacturer. After the colour developed, the reaction was 
stopped by rinsing the membrane in dH2O and the membrane was then allowed to dry.   
3.2.6 Measurement of antibodies to H6 avian influenza A proteins  
3.2.6.1 HI test  
The HI tests were conducted on serum from vaccinated and control chickens using the 
procedures described in section 2.2.3.3. 
3.2.6.2 Enzyme-linked immunosorbent assay (ELISA) 
3.2.6.2.1 Indirect ELISA 
 
ELISA antigen was prepared as described previously (Fatunmbi et al. 1989; Johansson et 
al. 1989; Qiu et al. 1992). Briefly, infective allantoic fluid was centrifuged at 3,000 g for 
20 min and the supernatant was then centrifuged at 180,000 g for 2 hr at 4°C. The pellet 
was resuspended in NTE buffer.  The concentrated virus was centrifuged through 30% 
sucrose onto a 60% sucrose cushion and at 160,000 g for 1.5 hr at 4°C.  Virus was 
removed from the interface and diluted 1:5 in NTE buffer. Following centrifugation at 
150,000 g for 1 hr at 4°C, the pellet was suspended in a small volume of NTE buffer. The 
concentrated virus was inactivated by adding a final concentration of 0.5% SDS for 60-
min incubation at 37°C. This ELISA antigen was assayed for protein concentration by a 
spectrophotometer and stored at -70°C. Similarly, a negative antigen was prepared from 
SPF chicken embryonated allantoic fluids. 
Checkerboard titrations were performed using different antigen, control serum and 
conjugate concentrations to determine the optimal antigen concentration, and conjugate 
and serum dilutions. The indirect ELISA procedure was as follows: The 96-well ELISA   130
microplates (Greiner Bio-one) were coated with 100 μL per well of antigen diluted in 
0.05 M carbonate-bicarbonate coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) 
at 4°C overnight. After washing  three times (5 min per time)  with PBST, 100 μL 
blocking solution (PBST containing 5% skim milk powder) was added followed by 
incubation at 37°C for 30 min. Then 100 μL of diluted test sera, anti-H6 positive control 
serum or SPF chicken serum were added followed by incubation at 37°C for 30 min. 
Following washing, 100 μL of diluted HRP-conjugated rabbit anti-chicken IgG 
(Chemicon International Inc., Melbourne, Australia) was added and the plate was 
incubated at 37°C for 30 min. After the last washing 100 μL of TMB substrate (Promega) 
was added and plates were incubated at room temperature for 5 min, when the reaction 
was stopped by adding 50 μL of 2 M H2SO4. The optical density (OD) was read at 450 
nm using a Multimode detector (DTX880 Beckman Coulter Inc., CA, USA). Results 
were expressed as a test to negative (T/N) ratio equal to the OD of the test sample divided 
by the OD of negative control; with T/N ratio over 2.0 considered as positive. 
3.2.6.2.2 Competitive ELISA (c-ELISA) 
 
Competitive ELISA reagents and test procedures were supplied by Dr Paul Selleck, 
CSIRO, AAHL, Geelong, Australia. Competitive Influenza type A ELISA was performed 
as follows: ELISA plates (Greiner Bio-one) were coated with 50 μL of influenza A 
nucleoprotein antigen  per well in carbonate-bicarbonate coating buffer diluted as 
directed followed by incubation for 1 hr at 37°C on a microplate shaker at a speed of 400 
rpm. After washing 3 times with PBST, 50 μL of test serum (diluted 1:10 in sample 
diluent (PBST containing 1% skim milk powder) was added to appropriate wells. The 
negative serum diluted 1:10 and positive serum diluted 1:10 and 1:100 as the high and   131
low positive controls, as well as monoclonal antibody (mAb) control (sample diluent only) 
were added respectively. Subsequently, 50 μL mAb that specifically binds AIV 
nucleoprotein diluted as directed, was added followed by incubating at 37°C for 30 min 
on a plate shaker. After washing, 50 μL of optimally diluted anti-mouse IgG HRP 
conjugated antibody (Silenus, VIC, Australia) was added followed by incubating at 37 °C 
for 30 min on a plate shaker. Following washing, 50 μL TMB substrate were added and 
incubated for 5 min with shaking followed by 50 μL of 1 M H2SO4 stopping solution. The 
OD results were read on a multiscan ELISA reader at 450 nm and then calculated as the 
percentage inhibition of binding of mAb in the absence of any serum. The test was 
acceptable if OD of mAb average was more than 0.8, and inhibition percentage of high 
positive, low positive and negative control were more than 80%, more than 40%, and  
less than 40%, respectively.  The results were calculated using the following formula (Av 
refers to average): 
(Av OD of sample  % inhibition =  100- (  Av OD of mAb  X 100) 
 
Test sera giving inhibitions of less than 40% were negative, and those giving greater than 
60% inhibitions were positive. Sera giving inhibitions of between 40% to 60% were 
considered equivocal.  
The indirect ELISA was used to detect antibody in VR-HA vaccinated chickens and the 
competitive ELISA was used for the detection of antibody in VR-NP vaccinated chickens.  
3.2.6.3 Immunoblot assay 
The immunoblot assay was performed as described for WB in section 3.2.5.3 above. The 
above-mentioned inactivated purified virus was equally mixed with non-reducing loading   132
buffer (2% SDS, 20% sucrose, 0.01% (v/v) bromophenol blue, 0.125M Tris (pH 6.8)) 
followed by boiling for 5 min (Qiu et al. 1992). The virus samples were applied to an 
SDS-PAGE gel in a single gel wide well, producing a continuous band of antigen across 
the gel. Protein bands in the unstained SDS-PAGE gel were then transferred to Hybond
TM 
nitrocellulose membrances. The blotted membrane was then cut in longitudinal strips and 
WB was performed on strips using sample sera (including positive and negative control 
antisera) at appropriate dilutions, followed by anti-chicken IgG, HRP conjugate and 
developed with Bio-Rad colour development reagent.  
3.2.7 Preparation of inactivated H6N2 vaccine as a control vaccine  
HA antigen was prepared as per section 2.2.2.  To mimic currently used commercial 
water-in-oil (W/O) AI vaccine formulations for poultry, the oil-based adjuvant 
Montanide
 TM ISA-70 VG (Seppic, Paris, France) was used. According to the 
manufacturer’s recommended protocols, 2.6 mL inactivated undiluted allantoic fluid (HA 
titre 2
7)  was added dropwise into 7.4 mL Montanide 
TM ISA-70 VG adjuvant by stirring 
with magnetic stirrers and mixed for 5-6 hr until a W/O emulsion was formed.   
3.2.8 Preparation of DNA vaccine formulations  
3.2.8.1 DNA vaccine  
Various dilutions containing the required quantity of plasmid DNAs (as shown in Tables 
3.1 and Table 3.2) were made in sterile PBS (pH 7.2) or 0.9% NaCl solution as described 
below.  
3.2.8.2 DNA vaccine with lipofectin adjuvant   133
For the DNA vaccines using lipofectin as adjuvant 20 μL lipofectin (Invitrogen) was 
mixed with 100 μL PBS and kept for 30 min at room temperature to form liposomes as 
described (Lee et al. 2006). As indicated in Table 3.1 and 3.2, various concentrations of 
plasmid DNAs were diluted into a total volume of 280 μL and then mixed with the 
liposome. The plasmid-liposome mixture was allowed to stand for 15 min at ambient 
temperature before injection. 
3.2.9 DNA immunization of chickens  
The chickens were 6-week-old layer pullets (Hy-Line) supplied by Altona Hatchery Pty. 
Ltd., Australia.   
3.2.9.1 Experiment 1   
 
Birds were housed in steel mesh cages with one bird per cage and fed commercial poultry 
feed and water ad lib at the animal house, Murdoch University, Australia. The 
immunization protocol is shown in Table 3.1. Four groups of five 6-week-old chickens 
were all intramuscularly injected twice, 3 weeks apart, with the appropriate amount of 
VR-HA or blank vector (VR) plasmid DNA dissolved in 0.2 mL 0.9% NaCl, with a 0.1 
mL injection in each leg. The control group was intramuscularly injected with 1 mL of 
inactivated H6N2 virus vaccine (IVV). All the chickens were shifted to an AEC-
approved free-range pen at Jandakot, Western Australia, 2 weeks after the second 
injection.   
Six weeks after the second injection, three chickens from each group were randomly 
selected to receive a third IM injection of their respective dose of plasmid DNA plus   134
lipofectin adjuvant. Seventeen weeks later, selected groups received a fourth vaccination 
using the same regimen as the third one.  
Chickens were bled by venepuncture from the wing veins at the initial vaccination and at 
intervals of 2 weeks post-vaccination to measure the H6-specific antibodies using HI, 
ELISA and immunoblotting assay. 
Homologous virus challenge was conducted 30 weeks following the last vaccination for 
chickens that did not receive booster vaccination with lipofectin adjuvant (non-
adjuvanted chickens) and 7 weeks following the last vaccination for those receiving 
booster vaccinations with adjuvant (adjuvanted chickens). 
3.2.9.2 Experiment 2   
 
 A second vaccination experiment was conducted using a similar immunization regimen 
as experiment 1. Each group of 3 SAN chickens, reared at an AEC-approved free-range 
pen at Jandakot, Australia, was intramuscularly administered VR-HA, VR-NP or VR 
plasmid DNA in 0.2 mL PBS, with or without lipofectin adjuvant, at the doses indicated 
in Table 3.1. Three weeks later the birds received a second injection of the same dose and 
then a third injection was given 6 weeks later. The birds were bled and tested as 
described for experiment 1. Selected groups were subjected to virus challenge at 7 weeks 
following the last vaccination. 
3.2.10 Virus challenge and virus isolation 
Virus challenge was performed as per section 2.2.8 using EID5010
7.25/0.1 mL H6N2 virus. 
OS and CS were collected daily from the chickens. Serum was separated from the 
collected blood for further serological testing.   135
Table 3.1 Number of birds used in experiment 1 and experiment 2. 
 
  Experiment 1  Experiment 2 
Vaccine type  VR  IVV VR-HA  VR  VR-HA  VR-NP 
Dose (µg)  300    50  100  300  100
 a 100
 a 500 500
 a 100 100
 a 500  500
 a
1
st, 2
ndvaccination  5  5  5  5  5  3  3 3 3 3 3 3  3 
3
rdvaccination 3
a   3
 a     3
 a 3
 a    3  3 3 3 3 3 3  3 
4
th vaccination 3
 a   3
 a       3
 a              
Virus challenge  4
b  5  3  2 1    3 2  3  3  1  3    3    3 
Group  for analysis   1  6  2  4 4    3 5 11  7  5  8    9    10 
              a - Adjuvant; b - One bird died.VR, IVV, VR-HA and VR-NP refer to the empty vector VR1012, inactivated H6N2 virus vaccine, HA-expressing 
              construct, NP-expressing construct respectively. 
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Virus isolation was performed as per section 2.2.9.  The virus titre in selected positive 
samples was measured by serial dilution and inoculation in chicken embryos as per 2.2.6. 
3.2.11 Data analysis 
Statistical analyses were conducted as per section 2.2.17. 
3.3 Results  
3.3.1 In vitro expression of the VR-HA and VR-NP constructs 
Restriction enzyme analysis of the inserted of HA or NP genes in VR1012 vector showed 
inserts of expected size (1.7 kb for HA and 1.6 kb for NP) (Figure 3.2). The expression of 
recombinant VR-HA or VR-NP in Cos-7 cells was confirmed by WB (Figure 3.3). As 
shown in Figure 3.3, the intensity of approximately 66 kD (HA protein) or 56 kD (NP 
protein) bands became correspondingly darker when the dose of transfected plasmid 
DNA was increased from 20 μg to 40 μg. No specific band was observed at the 
corresponding site in both Cos-7 and blank vector controls. The expression of VR-HA or 
VR-NP in Cos-7 cells was also confirmed by IFT (Figure 3.4). Compared to the blank 
vector control, bright fluorescence in the cytoplasm was observed in both HA and NP 
vector transfected cells. No specific fluorescence was observed in the blank vector 
control.   137
  
 
Figure 3.2 Identification of insert genes in VR1012 vector. 
Lane 1, 1 kb marker; lane 2, HA (BamHI/PstI); lane 3, NP (BamHI/XbaI); lane 4,  NA 
(BamHI/XbaI); lane 5, HA (undigested); lane 6, NP (undigested); lane 7, NA (undigested); lane  
8, VR1012 (BamHI/PstI); lane 9, VR1012 (BamHI/XbaI); lane 10, VR1012 (uncut) (Arrow 
represents HA, NP and NA, respectively). 
 
 
 
 
Figure 3.3 Transient expression of recombinant HA and NP in Cos-7. 
Lanes 1-3, 20, 30, 40 μg VR-HA plasmid DNA; lane 4, virus control; lane 5, Cos-7; lane 6, 
VR1012; lane 7, Marker (Bio-Rad, 250, 150, 100, 75, 50, 37 kD, from top to bottom); lanes 8-10, 
40, 30, 20 μg VR-NP DNA. Arrow refers to specific band.  
 
 
 
          
 
Figure 3.4 Expression of HA and NP in transfected Cos-7 cells by IFT. 
 A, VR-HA; B, VR-NP; C, blank vector control (x10). 
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Figure 3.5 Virus band indicated by arrow following sucrose gradient ultracentrifugation. 
 
3.3.2 Optimal parameters of indirect ELISA  
ELISA antigen was prepared from the collected virus band (Figure 3.5). The graphs 
showing optimization of ELISA parameters are shown in Figure 3.6. Positive/negative 
(P/N) ratio was the optical density at 450 nm wavelength (OD450) from virus antigen 
coated wells divided by the OD450 of the negative antigen wells. ELISA plates were 
coated with different concentrations of virus or negative control antigen and a 
checkerboard titration was performed with different dilutions of conjugate. The 50 
ng/well antigen showed higher P/N ratio at the conjugate dilution of either 1/2000 or 
1/4000. Dilutions of H6-specific chicken antiserum were reacted against different antigen 
concentrations. The higher P/N ratio was under 50 ng/well antigen and serum dilution of 
1/100 or 1/200. Thus, the optimal ELISA parameters that were used for subsequent 
testing were 50 ng/well (0.5 ng/μL) antigen, serum at a dilution of 1/200, conjugate at a 
dilution of 1/4000.    139
 
Figure 3.6 Optimization of ELISA parameters. P/N ratio refers to the optical density from 
virus antigen coated wells divided by the OD450 of the negative antigen wells. 
A  Different conjugate dilution versus different antigen concentration under constant serum 
dilution. B  Different antigen concentration versus different serum dilution under fixed conjugate 
dilution. 
 
3.3.3 Effect of different doses and vaccination times on VR-HA antibody response 
3.3.3.1 Antibody response elicited by VR-HA in experiment 1  
The chickens vaccinated twice 3 weeks apart with either the 50, 100 or 300 µg dose of 
VR-HA elicited no measurable antibody using HI, ELISA and immunoblotting assays 
during the 6 week period post-vaccination. One remaining bird from the100 µg group 
transiently showed a low HI titre (2
1) at 24 weeks following the second vaccination.  
In an attempt to induce an antibody response by VR-HA, three chickens from the 50 µg, 
100 µg and 300 µg dose groups above were randomly selected to be given a booster with 
VR-HA plus lipofectin as adjuvant, using the same dose and delivery route. As shown in 
Table 3.2, only one chicken (identification number 50A in Figure 3.7) from the 50 μg 
group produced a low level of HI antibody (titre 2
2) and this was confirmed by 
immunoblotting assay and ELISA. The highest immunoblotting titres for chicken 50A 
were at 2 weeks post-vaccination with a titre of 1/320 and at 4 weeks with a titre of 1/640 
after three vaccinations (Figure 3.7). Another chicken (100A) from the 100 μg group 
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gave a low HI antibody titre (2
2) but this could not be confirmed by immunoblotting 
assay.  No HI and immunoblotting antibody in any other vaccinated chickens was 
observed over the 17-week period following three vaccinations.  
 
 
Figure 3.7 Antibody detection by immunoblotting assay. 
Lane1, marker (Bio-Rad), Lanes 2-9, VR-HA vaccinated chicken 50A serum 4 weeks post-
vaccination at dilutions 1/40, 1/80, 1/160, 1/320, 1/640, 1/1280,1/2560, 1/5120 dilution; Lanes 
10-18, VR1012 vector control vaccinated chicken serum 4 weeks post-vaccination at dilutions of 
1/5, 1/10, 1/20, 1/40, 1/80, 1/160, 1/320, 1/640, 1/1280 dilution; Lane 19, H6 positive serum at 
1/125 dilution; Lane 20, pre-vaccination serum at 1/5 dilution. 
 
 
In an attempt to further enhance the antibody response, 17 weeks following the three 
vaccinations, the 50 µg and 300 µg dose groups were boosted a fourth time with their 
respective dose of VR-HA with lipofectin adjuvant, identical to the third vaccination. As 
shown in Table 3.2, a total of three out of six chickens that received the VR-HA vaccine 
generated detectable HI antibody. One chicken from the 50 µg group that showed a low 
HI titre following three vaccinations had a HI titre of 2
8 after four vaccinations, which 
was confirmed by immunoblotting assay. The other two from each of the 50 μg and 300 
μg group showed lower HI titres (2
2).   141
Table 3.2 Antibody conversion in chickens immunized with VR-HA construct in experiment 1 and 2. 
 
Experiment 1  Experiment 2 
Vaccine type  VR  IVV VR-HA VR  VR-HA  VR-NP 
Dose (µg)  300    50  100  300  100
a 100
a 500 500
a 100 100
a 500 500
a 
2
ndvaccination 0/5
b 5/5 0/5  1/5
c  0/5  0/3  0/3 0/3 0/3  1/3
d 0/3 0/3 0/3 
3
rdvaccination 0/3    1/3
a 0/3 0/3
 a 0/3  1/3  0/3  1/3
e 0/3 0/3 0/3 0/3 
4
th vaccination 0/3   2/3
 a ND
f 1/3
 a               
                       a - Adjuvant   
                       b - Number of sero-conversions / total number of vaccinated chickens    
                       c - Antibody appeared at 24 weeks following the second vaccination 
                       d - Competitive ELISA   
                       e - Immunoblotting antibody 
                       f - Not done.   142
3.3.3.2 Antibody responses post virus challenge in experiment 1 
All vaccinated chickens sero-converted by 10 days after virus challenge and the antibody 
range within the groups were shown in Table 3.3. There was no significant difference in 
GMT of HI antibody between pre- and post-virus challenge in the blank vector group 
(Group 1), Group 2 (50 µg VR-HA group with adjuvant) or Group 5 [300 µg (2 birds) or 
500 µg (1 bird) VR-HA without adjuvant] but statistically significant differences in 
Group 3 (300 µg VR-HA group with adjuvant)(P=0.044), Group 4  [50 µg (2 birds) and 
100 µg (1 birds) VR-HA without adjuvant] (P=0.028) and Group 6 (inactivated vaccine 
group) (P=0.033). Moreover, there was no significant difference in HI GMT before or 
after virus challenge between any of the VR-HA groups and the blank vector control 
group.  
 
Table 3.3 HI antibody titre and statistical analysis pre-challenge (PRC) and post-challenge 
(POC) for vaccine groups in experiment 1 
                                 
  Group 1*  Group 2  Group 3  Group 4  Group 5  Group 6 
PRC  0**
Aa 2
0-8(2
3.3)
 Aab 2
0-2(2
0.7)
 Aa 2
0-2(2
0.7)
 Aa 0
Aa 2
4-7(2
6)
 Ab 
POC  2
3-8 (2
5.7)
 A a 2
7-7(2
7)
 Aa 2
5-10(2
7.7)
 Bab 2
8-13(2
10.3)
 Bab 2
3-10(2
6.3)
 Aab 2
8-12(2
9.6)
 Bb 
*Groups 1, 2 and 3 were vaccinated with either 300 µg blank vector plasmid DNA, 50 µg VR-HA or 300 
µg VR-HA respectively with two vaccinations without adjuvant followed by two vaccinations with 
adjuvant. Group 4, 50 µg VR-HA (2 birds), and 100 µg VR-HA (1 birds) given two vaccinations without 
adjuvant. Group 5, 300 µg VR-HA (2 birds) given two vaccinations and one bird given 500 µg VR-HA for 
three vaccinations. Group 6, inactivated virus vaccine given two vaccinations. 
** HI titre for the groups shown as range with GMT.  
Within the column for Groups 3, 4 and 6 the different uppercase superscript letter indicates statistical 
differences (P < 0.05) using the Paired-sample T test. There were no significant differences in GMT 
between pre- and post-challenge for the other groups.  
For the row groups with different lowercase superscript letter are significantly different (P < 0.05) using 
ANOVA or Mann-Whitney test. Except for significant difference between Group 6 and Group 1 or 2, there 
were no significant differences in HI GMTin other groups after virus challenge.  
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The GMT of Group 6 pre-challenge was significantly higher than the blank vector 
controls (Group1) and three of the four VR-HA groups (Groups 3, 4 and 5), but Group 6 
was no significantly different from Group 2 (50 µg VR-HA with adjuvant) (P=0.45) prior 
to challenge. However there was a significant difference (P=0.02) in GMT between 
Group 2 and Group 6 post challenge. In addition, there was a significant difference in 
GMT pre- and post-challenge between Group1and Group 6. 
3.3.3.3 Antibody response induced by VR-HA in experiment 2 
In experiment 2, chickens administered 100 μg or 500 μg VR-HA twice with or without 
lipofectin adjuvant for the initial vaccinations also did not induce measurable antibody. 
As shown in Table 3.2, following three vaccinations, only one chicken from the group 
inoculated with the 100 μg VR-HA and the adjuvant produced a low level of HI antibody 
(2
1), which was confirmed by immunoblotting assay, at 4 weeks after the third 
vaccination. Another chicken from the 500 μg adjuvanted group did not develop HI 
antibody but its immunoblotting antibody titre was 1/20. No HI or immunoblotting 
antibody was detected in any other chickens during the 7 week period following three 
vaccinations.  
3.3.3.4 Antibody responses post viral challenge in experiment 2 
In order to assess whether VR-HA developed a protective immune response, six chickens 
vaccinated with VR-HA and adjuvant were challenged with the homologous virus. As 
illustrated in Table 3.4, the HI titre in VR-HA vaccinated chickens ranged from 2
5 to 2
14 
in the VR-HA vaccinated groups after virus challenge. There was a significant difference 
(P=0.009) in the GMT in the adjuvanted 100 μg VR-HA group (Group 7) before and after   144
challenge but there was no significant difference (P=0.086) in the adjuvanted 500 μg VR-
HA group (Group 8) between pre-and post challenge. In the adjuvanted empty vector 
group (Group 11), there was no significant difference (P=0.081) in the GMT between 
pre-and post-challenge. Furthermore, there was no statistical difference in the GMT both 
prior to and after virus challenge between each of the VR-HA groups and the blank 
vector group.  
Table 3.4   HI antibody titre and statistical analysis pre-challenge (PRC) and post-challenge 
(POC) for vaccine groups in experiment 2. 
 
  Group 6*  Group 7  Group 8  Group9  Group 10  Group 11 
PRC  2
4-7(2
6)
 ** Aa 2
0-2(2
0.7)
 Ab 0
Ab 0
Ab 0
Ab 0
Ab 
POC  2
8-12(2
9.6)
 Ba 2
6-7(2
6.7)
 Bbf 2
5-14(2
8.7)
 Aabc 2
4-6(2
4.7)
 Bbc 2
3-5(2
3.7)
 Bc 2
3-10(2
7.7)
 Aacf 
*Group 6, inactivated virus vaccine given two vaccinations. Group 7and 8, 100 µg and 500 µg VR-HA 
given three vaccinations with adjuvant respectively. Group 9 and 10, 100 µg and 500 µg VR-NP given 
three vaccinations with adjuvant respectively. Group 11, 100 μg blank vector plasmid DNA given three 
vaccinations with adjuvant.  ** HI titre for the groups shown as range with GMT. 
Within the column the different uppercase superscript letter indicates statistical differences (P < 0.05) using 
the Paired-sample T test. For the row groups with different lowercase superscript letter are significantly 
different (P < 0.05) using ANOVA or Mann-Whitney test. 
 
3.3.3.5 Antibody response induced by VR-NP  
Following VR-NP vaccination, three out of 12 VR-NP vaccinated chickens (one weak 
positive and 2 equivocal) induced a weak antibody response to the NP of the H6 virus by 
cELISA. One chicken from the 100 µg VR-NP group without lipofectin gave a weak 
positive result using cELISA at 4 weeks after the second vaccination (Table 3.2), but a 
equivocal ELISA result at 4 weeks following the third injection. One bird from the 
adjuvanted 500 µg VR-NP group showed an equivocal result by cELISA following the 
second injection. Another chicken from the adjuvanted 100 µg VR-NP group showed a 
equivocal result by cELISA after three vaccinations. No antibody was detected in any 
other vaccinated chickens for the 7 week period following three vaccinations.    145
As shown in Table 3.4 following virus challenge, HI titre in six chickens vaccinated with 
adjuvanted VR-NP showed a range of HI titres from 2
3 to 2
6 with an average of 2
4.17. 
There was significant difference (P<0.05) in GMT between pre- and post-challenge in 
either 100 µg or 500 µg VR-NP groups. However, in comparison with the blank vector 
group, there was no statistical difference in GMT in both pre- and post-challenge in either 
100 µg or 500 µg VR-NP group.  
In addition, there was no significant difference (Mann-Whitney Test, P=0.32) before 
virus challenge but a significant difference (ANOVA, P=0.031) post-challenge between 
the combined VR-HA groups and the combined VR-NP groups in experiment 2. 
3.3.3.6 Effect of lipofectin adjuvant on numbers of chickens showing seroconversion  
As illustrated in Table 3.2, three out of nine chickens that received the VR-HA and 
adjuvant and one out of six chickens that received the VR-HA alone showed sero-
conversion in experiment 1.  Also two out of 12 chickens vaccinated with the VR-HA or 
VR-NP plus adjuvant and one out of nine chickens that received the VR-HA or VR-NP 
alone showed sero-conversion in experiment 2. Overall, there were seven sero-
conversions out of 36 vaccinated birds, with five seroconversions out of 21 from groups 
given DNA vaccines with lipofectin adjuvant and two out of 15 from groups given 
vaccines without adjuvant, but there was not a significant difference (Fisher’s extract test, 
P=0.67) between the adjuvanted and non-adjuvanted groups. 
3.3.4 Effect of DNA vaccines on virus shedding following virus challenge 
No clinical signs were observed during 10 days following H6N2 LPAI virus challenge 
except for one chicken that received two doses of the empty vector that died on day 5   146
after virus challenge from parasitism associated with a heavy intestinal nematode 
infection unrelated to the study. 
3.3.4.1 Virus shedding in blank vector control group 
All swabs from the 7 blank vector vaccinated chickens over the 10 days after challenge 
were subjected to virus isolation. As shown in Table 3.5, virus shedding occurred 
intermittently during this period, with a positive rate of 26.15% (17/65) in CS and 
47.69% (31/65) in OS respectively. Most virus excretion occurred within the first 7 days 
following virus challenge. The virus isolation rate in the OS was 65.96% (31/47) from 
day 1 to day 7 following virus challenge, whereas, the positive rate in CS was 27.66% 
(13/47) for the same period, indicating that the respiratory tract was an important route 
for this LPAI virus shedding. As shown in Figure 3.8, the highest titre in OS fell between 
day 3 and day 4 post-challenge, with the peak titre of 10
3 EID50/0.1 mL. 
 
Table 3.5 Frequency of virus shedding from individual birds in the blank vector control 
group*. 
 
1a** 1b  1c 1d
*** 11a  11b  11c  Day 
OS CS OS CS OS CS OS CS OS CS OS CS OS CS
Day  1 + – + – + – + – + – + – + – 
Day  2 + – + – + – – – + – + – + – 
Day  3 – – + – – – – – + – + + + – 
Day  4 – – + – + + + – + + + + + + 
Day  5 – – + – – – – + + – – + + + 
Day  6 – – + – – +      + – – + – + 
Day  7 – – + – – –      + – – + + + 
Day  8 – – – – – –      – – – + – – 
Day  9 – – – – – –      – – – – – + 
Day  10  – – – + – –      – – – – – + 
        * + refers to positive and – refers to negative for virus isolation. ** Number refers to group number 
        as described in text and in Table 3.1 and individual birds are designated a, b, and d within the groups. 
        *** This chicken died 5 days after virus challenge.   147
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Figure 3.8  Level of virus shedding post-challenge in blank vector groups in experiments 1 
and 2. 
Number refers to group number as described in text and in Table 3.1 and individual birds are 
designated a, b, c and d within the groups.   
 
3.3.4.2 Comparison of virus recovery between VR-HA, inactivated vaccine and blank 
vector groups in experiment 1 
The rate of virus recovery in both OS and CS for the VR-HA vaccinated groups, the 
inactivated H6N2 vaccine group and the blank vector control group is illustrated in Table 
3.6. For the OS swabs, there were no significant differences in virus shedding rates 
between the blank vector controls and any of the four VR-HA groups. However, there 
was a significant reduction in virus shedding (Fisher’s exact tests, P=0.035) for the 
inactivated vaccine group (Group 6) compared with the blank vector group (Group 1) and 
also compared with the groups vaccinated with VR-HA without adjuvant (Groups 4 and 5) 
(P< 0.05). Group 6 was not significantly different in virus shedding in OS from the 50 µg 
adjuvanted VR-HA group (Group 2) or 300 µg adjuvanted VR-HA group (Group 3). For 
the CS results Groups 3 and 4 showed a significantly higher (P< 0.05) level of virus 
shedding compared with the other VR-HA group (Group 2), blank vector controls and   148
inactivated vaccine groups. There were no significant differences in virus recovery in CS 
between the other VR-HA groups, the inactivated vaccine group, or the blank vector 
control group. In terms of virus titre being shed, the virus titre in OS in the VR-HA 
groups on day 4 after virus challenge was shown in Table 3.7. There was no significant 
difference in the GMT of virus shedding between Group 2 and Group 3, between Group 4 
and Group 5, and between Group1 and any of the four VR-HA groups. However, there 
was a significant difference between Group 1 and Group 6 (Mann-Whitney Test, 
P=0.029). 
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Table 3.6 Virus recovery from VR-HA vaccinated chickens for six consecutive days post-challenge in experiment 1. 
 
  Group 1  Group 2  Group 3  Group 2+ Group3  Group 4  Group 5  Group 4+ Group 5  Group 6 
OS 10/22(45.5)
 a 5/18(27.8)
 ac 8/18(44.4)
 ac 13/36(36.1)
 ac 9/18(50.0)
 a 10/18(55.6)
 a 19/36(52.8)
 a 2/18(11.1)
 bc 
CS 3/22
 (13.6)
 acg 0/18(0)
 a 5/18(27.8)
 bcdf 5/36(13.9)
 af 7/18(38.9)
 bcd 4/18(22.2)
 adg 11/36(30.6)
 bfg 0/18(0)
 a 
* Group 1, 2 and 3 referred to 300 µg blank vector plasmid DNA, 50 µg and 300 µg VR-HA respectively with two vaccinations without adjuvant followed by 
two vaccinations with adjuvant. Group 4, 50 µg (2 birds), and 100 µg (1 birds) VR-HA given two vaccinations without adjuvant. Group 5, 300 µg VR-HA (2 
birds) given two vaccinations and one bird given 500 µg VR-HA for three vaccinations. Group 6, inactivated virus vaccine given two vaccinations. 
**HA positive numbers/total sample numbers. Percentages are shown in parenthesis.  
For the row groups with different lowercase superscript letter are significantly different (P < 0.05) using Chi-square or Fisher’s exact tests. 
 
 
 
Table 3.7 Peak virus titre in OS in individual chickens on day 4 post-challenge. 
 
VR-HA VR-NP  VR-NP  IVV  No. 
Bird  Group2* Group3 Group4 Group5 Group  7 Group  8 Group  9 Group10 Group1 Group11 Group 6 
1 10
1 <1**  10
1.5 10
1.5 10
0.03 <1 10
0.03 10
1 10
1.75 10
2.5  <1 
2 <1 <1  10
0.03 10
0.5 <1 10
0.5 10
1.5 <1 10
2 10
0.5  <1 
3 10
0.3 10
0.5 10
0.3 10
1 10
2 10
1.5 10
2.5 10
1.5 10
0.3 10
1.5  <1 
4                <1   <1 
5                     <1 
GMT 10
0.44 10
0.17 10
0.61 10
1 10
0.68 10
0.67 10
1.34 10
0.83 10
1.35 10
1.5  10
0.001 
* Group  2 and 3 referred to 50 µg and 300 µg VR-HA respectively with two vaccinations without adjuvant followed by two vaccinations with  
adjuvant. Group 4, 50 µg (2 birds), and 100 µg (1 bird) VR-HA given two vaccinations without adjuvant. Group 5, 300 µg VR-HA (2 birds) given two 
vaccinations and one bird given 500 µg VR-HA for three vaccinations. Group 6, inactivated virus vaccine given two vaccinations. Group 7and 8, 100 µg 
 and 500 µg VR-HA given three vaccinations with adjuvant respectively. Group 9 and 10, 100 µg and 500 µg VR-NP given three vaccinations 
 with adjuvant respectively. Group 11, 100 μg blank vector plasmid DNA given three vaccinations with adjuvant. 
** For calculation of GMT in those groups with swabs with no detection, the titre of those birds was normally ascribed as an EID50 titre of 10
0.001.   150
3.3.4.3 Comparison of virus recovery between VR-HA, inactivated vaccine and blank 
vector groups in experiment 2 
As illustrated in Table 3.8, there was a highly significant difference in the level of virus 
shedding in OS (Fisher’s exact test, P=0.0001) and CS (Fisher’s exact test, P=0.0003) 
between Group 6 (inactivated vaccine) and Group 11 (blank vector control).  
In comparison with Group 11, there was a highly significant decrease in virus shedding in 
OS (Fisher’s exact test, P=0.0006) and CS (Fisher’s exact test, P=0.0003) in Group 7 
(100 µg VR-HA) whereas there was no significant difference in OS (Fisher’s exact test, 
P=0.29) and CS (Chi-square, P=0.09) in Group 8 (500 µg VR-HA). In comparison with 
Group 6, there was no significant difference in virus shedding in both OS and CS for 
Group 7 but there were significant increases in virus shedding in OS and CS for Group 8. 
Furthermore, there was a highly significant decrease in virus shedding in OS (Chi-square, 
P=0.0084) and CS (Chi-square, P=0.0013) in combined VR-HA group (Groups 7 and 8)  
compared to Group 11 whereas there was no significant difference in virus shedding in 
OS and CS between the combined VR-HA group and Group 6. In terms of virus titre in 
OS, Group 7 or Group 8 were not statistically significant from each other or from Group 
11.   151
Table 3.8 Level of virus shedding from the VR-HA, VR-NP and control groups post-challenge*. 
  
  Group 6**  Group 7  Group 8  Group7+Group 8  Group 9  Group 10  Group9+Group10  Group 11 
OS   2/18(11.1)
 a  3/18(16.7)
 a c 10/18(55.6)
 bde  13/36(36.1)
 ace  13/18(72.2)
 bd 8/18(44.4)
 ad  21/36(58.3)
 bde 14/18(77.8)
 bd 
CS  0/18(0)
 a  0/18(0)
 ac 5/18(27.8)
 bde  5/36(13.9)
 ace  0/18(0)
 ac 0/18(0)
 ac  0/36(0)
 ac 10/18(55.6)
 bd 
* HA positive numbers/total sample numbers. Percentages are shown in parenthesis. 
** Group 6, inactivated virus vaccine given two vaccinations. Group 7and 8, 100 µg and 500 µg VR-HA given three vaccinations with adjuvant respectively. 
Group 9 and 10, 100 µg and 500 µg VR-NP given three vaccinations with adjuvant respectively. Group 11, 100 μg blank vector plasmid DNA given three 
vaccinations with adjuvant.  
  For the row groups with different lowercase superscript letter are significantly different (P < 0.05) using Chi-square or Fisher exact tests. 
 
 
 
 
Table 3.9 Proportion of challenged birds that shed virus under each vaccine regime. 
 
VR-HA without adjuvant 
(Group 4+Group5) 
VR-HA with adjuvant 
(Group2+Group3+Group7+Group8)
VR-NP with adjuvant 
(Group 9+Group10) 
VR with or without adjuvant 
(Group1+Group11) 
IVV(Group6) 
OS CS  OS  CS  OS  CS  OS  CS OS  CS 
6/6 (100)
*  3/6 (50)  10/12 (83.3)  5/12 (41.7)  5/6(83.3) 0/6 (0)  7/7 (100)  6/7 (85.7)  2/5(40)  0/5(0) 
* Number of birds shedding virus /total number of birds tested (percentage). 
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As shown in Table 3.8, there were significant differences in virus shedding from OS 
(Chi-square, P= 0.035) and CS (Chi-square, P=0.046) between the low dose (Group 7) 
and high dose (Group 8) VR-HA groups. This was consistent with the result for CS 
between the low dose VR-HA with lipofectin adjuvant (Group 2) and high dose VR-HA 
with lipofectin adjuvant (Group 3) in experiment 1. However, there was no statistical 
significant difference (Mann-Whitney Test, P=1.0) in GMT of virus shedding from OS 
between Group 7 and Group 8 (Table 3.7).  
There was also no significant difference in virus shedding in both OS and CS between the 
combined groups  (Groups 2 and 3) given 4 vaccinations of  VR-HA from experiment 1 
and those (Groups 7 and 8 ) given 3 vaccinations of VR-HA in experiment 2. Nor was 
there any significant difference in the virus GMT between these two combined groups.  
3.3.4.4 Comparison of virus recovery between the blank vector control and VR-NP 
groups in experiment 2 
As illustrated in Table 3.8, no virus shedding occurred in the cloaca in both VR-NP 
groups over 6 consecutive days. Compared to the empty vector group (Group11), there 
was a 55.6% decrease in virus shedding in CS and a 19.5% decrease in shedding in OS 
for the combined VR-NP vaccinated group. There was a highly significant decrease in 
virus shedding in CS but no significant difference for OS between the (combined or 
single) VR-NP groups and Group11. There was no significant difference in virus 
shedding in OS and CS between lower dose VR-NP (Group 9) and higher dose VR-NP 
(Group10) groups. Neither was there any significant difference in the virus GMT in OS 
between Group 9 and Group 10, and between the combined VR-NP groups and Group 11.   153
3.3.4.5 Proportion of challenged birds that shed virus under each vaccine regime 
As summarized in Table 3.9, by comparison with the empty vector controls, in terms of 
the proportion of birds that shed virus, there was a decrease of 44% and 85.7% 
respectively in virus shedding in CS in the adjuvanted VR-HA and the VR-NP group, and 
a decrease of 16.7% in virus shedding in OS in both groups. However, there was no 
decrease in the proportion of birds shedding virus in the oropharynx but a decrease of 
35.7% in the proportion shedding virus in the cloaca in the non-adjuvanted VR-HA group. 
In contrast, there was a decrease of 60% in virus shedding in OS and 85.7% in CS in the 
inactivated vaccine group. 
3.4 Discussion  
In this chapter, the vaccination of chickens by inoculation of VR1012 plasmid DNAs 
encoding HA or NP genes from H6N2 AIV was evaluated. Although immunization with 
VR-HA or VR-NP together with lipofectin adjuvant induced only minimal antibody 
responses, the vaccinated birds showed some evidence of protection against AIV 
infection, with a 44% and 85.7% decrease respectively in the number of birds shedding 
virus via the cloaca but only16.7% reduction in virus shedding via the oropharynx in both 
groups compared with empty vector vaccinated controls. More interestingly, no virus 
shedding was observed in CS from both lower dose VR-HA groups and VR-NP groups. 
3.4.1 Evaluation of antibody response to DNA vaccines 
Both VR-HA vaccines in experiment 1 and experiment 2 and VR-NP vaccines in 
experiment 2 showed similar results in that they all gave no or poor antibody responses to 
the H6 virus HA, or NP, even with more sensitive test methods such as ELISA and   154
immunoblotting assay developed in an attempt to detect marginal antibody levels to HA, 
in addition to HI test. All DNA vaccinated groups showed rapidly increasing antibody 
responses to virus challenge as expected, but the post-challenge antibody titres were not 
statistically different from the blank vector controls. There were statistically significant 
increases in antibody titre in five out of eight DNA vaccinated groups and the inactivated 
vaccine group pre- and post-challenge but no significant difference for two blank vector 
control groups, suggesting that VR-HA, VR-NP or inactivated vaccine vaccination may 
result in an anamnestic antibody response after challenge. It should be noted that the 
small group sizes may have resulted in statistical aberrations and this cannot be ruled out.  
The post-challenge HI titres for VR-NP were significantly lower than those for VR-HA 
in experiment 2, indicating that the VR-HA vaccine did appear to prime a H6 HA 
antibody response whereas the VR-NP, as expected, did not. Taken together, the VR-HA 
DNA vaccines at least provided some evidence of playing a priming role in the antibody 
response. 
The backbone of a DNA vaccine vector carries CpG motifs, which may or may not have 
an adjuvant effect for DNA vaccines (Doria-Rose and Haigwood 2003). Inoculation of 
naked plasmid DNA can induce immune responses due to the CpG motif in a regular 
expression vector (Cantlon et al. 2000; Krieg et al. 1998a). Although no naive chickens 
were challenged in the present experiment, in testing post-challenge chicken sera by 
immunoblotting assay, some blank vector vaccinated chickens gave much stronger non-
specific bands than those in VR-HA and VR-NP vaccinated chickens (data not shown). 
This suggested that the blank vector itself may elicit non-specific immune responses. In 
fact, the empty VR1012 vaccinated birds also gave strong antibody responses after   155
challenge, from no antibody pre-challenge to levels equivalent to VR-HA and VR-NP 
vaccine after challenge and marginally lower than killed vaccine responses. Presumably, 
the empty vector could non-specifically stimulate immune responses and resulted in 
enhanced antibody response post virus challenge.  
The observation that the HA-expressing DNA vaccines elicited no to very low HI titres in 
chickens post-vaccination in this study was in an agreement with results using the same 
VR1012 vector expressing the HA gene of A/turkey/Wisconsin/68(H5N9) virus (Suarez 
and Schultz-Cherry 2000a). Some studies reported that HA-expressing DNA vaccines 
elicited no to very low detectable antibody in chickens (Fynan et al. 1993a; Kodihalli et 
al. 1997; Kodihalli et al. 2000; Robinson et al. 1993), mice (Kodihalli et al. 1999) and 
ferrets (Webster et al. 1994). But IM injection of plasmid DNA encoding the HA gene of 
A/HK/156/97(H5N1) in chickens reportedly elicited high HI antibody titres (Chen et al. 
2001). Chickens administered with a plasmid encoding HA of a LPAI virus (H7N1) by 
the Medijector device also developed detectable HI titres with the highest geometric titre 
of  2 
6.8 (Cherbonnel et al. 2003). The reasons for these differences in efficacy of HA-
DNA vaccines are complicated. Many factors, such as DNA expression vector used 
(Suarez and Schultz-Cherry 2000a), gene inserted (Barry and Johnston 1997; Doria-Rose 
and Haigwood 2003), animal species (Babiuk et al. 2003) or mouse strain (Chen et al. 
1999a), injected DNA dose (Davis et al. 1993b; Doria-Rose and Haigwood 2003; Galvin 
et al. 2000), volume (Dupuis et al. 2000), application methods and delivery route (Barry 
and Johnston 1997; Wang et al. 2008b) may all have an effect on the antibody response 
induced by a DNA vaccine.  
3.4.2 Evaluation of the effect of DNA vaccines on virus shedding   156
AI vaccination has been shown to reduce virus shedding but may not stop it altogether in 
vaccinated birds (Capua and Marangon 2007a). Robinson et al.(1997) demonstrated that 
post-challenge protection was associated with reduced viral replication in the lungs of 
mice.  Kodihalli et al.(2000) showed that the high protection rate induced by either a 
plasmid encoding HA of A/Turkey/Ireland/83 (H5N8) or a plasmid encoding HA of 
A/Chick/Victoria/1/85(H7N7) correlated well with  a low virus detection rate in tracheal 
swabs and cloacal swabs as well as low virus titre on day 3 or day 5 following virus 
challenge of chickens. In the present study, no deaths or clinical signs were expected 
from an LPAI challenge so reduction of virus shedding in OS and CS was used as an 
indicator of protection. This reduction in virus shedding was evident in the inactivated 
vaccine group in these studies. 
Two separate trials using VR-HA vaccination with adjuvant showed similar findings. 
Compared to the inactivated vaccine group, there was no significant difference in the 
level of virus shedding in OS and CS for the combined adjuvanted VR-HA groups (either 
the combined group 2 and 3 or the combined group 7 and 8) in both experiments. As 
compared with the blank vector controls, there was a highly significant decrease in virus 
shedding in OS and CS in experiment 2, but no significant difference in experiment 1. 
This indicated that VR-HA vaccination elicited some protective immune response as 
demonstrated by reduction in virus shedding.  However, the reduction rate in virus 
shedding was greater in the inactivated vaccine group, indicating that this VR-HA 
vaccine was inefficient at reducing virus shedding following virus challenge in 
comparison with the inactivated vaccine. Although there was no significant difference in 
virus titre shed via oropharynx between lower doses and higher doses of the VR-HA   157
vaccine, the level of virus shedding in CS in the two experiments and in OS in 
experiment 2 was significantly lower in the lower dose group than in the higher dose 
group. This suggested that lower doses (either 50 or 100µg) of VR-HA vaccine appeared 
to induce better protective responses than higher doses (either 300µg or 500µg).  
As with the inactivated vaccine, no virus shedding was observed in CS in VR-NP groups 
or in the lower dose of VR-HA groups. With respect to virus recovery, in comparison 
with the empty vector group, significant reduction in virus shedding from the VR-NP 
groups occurred only in CS whereas for the VR-HA groups reduction in virus shedding 
was apparent in either OS or CS.  The reason why VR-HA vaccine had more impact on 
reducing virus shedding via oropharynx or cloaca whereas VR-NP had more impact on 
reducing virus shedding via cloaca was not determined from these experiments. This was 
possibly related to the function of the HA and NP genes. The HA gene plays a more 
important role in protective immunity than the NP gene (Suarez and Schultz-Cherry 
2000b), although NP-mediated CTL response against NP was reportedly vital for limiting 
the dissemination of the virus, and promoting its clearance in humans (McMichael et al. 
1983) as well as in mice (Wells et al. 1981). However the level of virus shedding via the 
cloaca after challenge for the empty vector group in this study was low and this may have 
contributed to no cloacal virus shedding in the adjuvanted VR-NP groups.   
As shown in Table 3.6 and Table 3.8, the level of virus shedding via oropharynx or 
cloaca from VR-HA vaccinated groups without adjuvant (Groups 4 and 5) was not 
significantly different from the empty vector vaccinated group, indicating that primary 
immunization induced by two naked VR-DNA vaccinations was not sufficient to 
generate an effective immune response.    158
When compared with the unvaccinated controls, HA-DNA vaccinated chickens showed 
more than 2 log10 EID50 reduction in virus GMT in tracheal and cloacal swabs collected 
on day 3 and day 5 after highly pathogenic H5 and H7 AIV challenge and hence 
conferred good protection (Kodihalli et al. 2000). In the current H6N2 LPAI virus study 
using a high dose challenge, the virus did not seem to replicate well in chickens, resulting 
in low titre of virus shedding via respiratory and alimentary route in controls but the 
frequency and titre of virus shedding were variably reduced in either VR-HA or VR-NP 
vaccinated chickens.  
Taken together, using VR-HA or VR-NP constructs at different doses, different numbers 
of boosters and with or without lipofectin adjuvant did not give good protection against 
LPAI virus infection in terms of reduction in virus shedding. However, no virus shedding 
was observed in CS in both lower dose VR-HA groups as well as two VR-NP groups and 
a reduction in virus shedding in OS in the low dose VR-HA groups. This gives some 
encouragement for the further development of DNA vaccines against H6N2 AI virus.  
3.4.3 Parameters affecting efficacy of DNA vaccines 
In early DNA vaccine studies, the dose of the DNA vaccine was considered to be an 
important factor for the efficacy of DNA vaccines (Robinson et al. 1993; Ulmer et al. 
1994; Ulmer et al. 1993). The amount of plasmid DNA used could have as much effect 
on the strength and character of immune responses as the route of inoculation (Barry and 
Johnston 1997). A study of pathogenic simian-human immunodeficiency virus (SHIV) in 
macaques and HIV phase I clinical studies in humans showed that higher doses of 
plasmid DNA administered gave better antigen-specific immune responses than lower 
doses (Amara et al. 2001; Boyer et al. 2000; MacGregor et al. 1998). But in another HIV   159
DNA vaccine study, increasing the vaccine DNA dose did not achieve increased immune 
responses (Galvin et al. 2000). Different levels of DNA vaccine initiated protection were 
achieved in different experiments in the current study. Lower doses of an HA-expressing 
DNA vaccine elicited a better reduction in virus shedding, suggesting that the protective 
immune response of DNA vaccines did not have a direct linear correlation with the dose 
of inoculated plasmid DNA. This implies that generation of better immune responses to 
H6 virus cannot be achieved by just increasing the vaccine DNA dose and may require 
high protein expression by a high-efficiency expression vector or by the use of other 
boosting agents. This also highlighted that optimization of plasmid DNA dose delivered 
was necessary for evaluating the efficacy of DNA vaccines. Encouragingly, if lower 
DNA doses were optimal, the cost of DNA vaccines may potentially be reduced.  
In an early HIV experiment, higher amounts of plasmid encoding CTL epitopes of HIV 
gp160 gave lower CTL responses after single GG immunization (Barry and Johnston 
1997). The reason why the lower dose induced better immune response is unknown as the 
mechanism by which IM injection DNA is introduced into the extracellular spaces of 
muscle followed by internalization of DNA is as yet fully unidentified (Ulmer et al. 
1994). Nevertheless, there is some evidence that the level of expression is more crucial 
for cellular responses. Presumably, large amounts of plasmid might generate too vigorous 
cellular immune response which perhaps kills off the transfected cells too early to 
maintain immune stimulation, resulting in attenuated vaccine responses (Barry and 
Johnston 1997). Moreover, it is believed that in excess of 90% of the DNA by IM 
injection never enters the cytoplasm and of this 10% less than 1% gets into the nucleus 
where gene expression occurs (Babiuk et al. 2003; Barry and Johnston 1997). Thus, the   160
possibility that high dose DNA is introduced into extracellular spaces by IM route, 
potentially leading to a more rapid clearance of DNA, cannot be ruled out.  
Lipofectin is generally used for transfection of cells in vitro. It has also been used to 
produce AI HA subtype–specific reference antisera via DNA vaccination of chickens 
(Lee et al. 2006). As illustrated in Table 3.2, in a total of 36 vaccinated birds, 23.8% 
(5/21) sero-conversion occurred in the lipofectin adjuvant group whereas 13.3% (2/15) 
seroconversion occurred in the non-adjuvanted group. One chicken developed a low HI 
titre after the third VR-HA booster given with lipofectin and after a fourth booster given 
with lipofectin this bird developed a similar HI antibody level to the inactivated vaccine 
group chickens. This suggested that lipofectin was effective as an adjuvant to improve the 
level of antibody production in chickens. This is consistent with findings elsewhere of an 
increase in the percentage of birds that responded to DNA vaccinations given with 
lipofectin (Suarez and Schultz-Cherry 2000a). Moreover, in experiment 2, 100 µg 
adjuvanted VR-HA groups showed significant reductions in virus shedding in both OS 
and CS when compared with the empty vector control group. However, this was not 
achieved in experiment 1, suggesting that the protocol of three vaccinations with adjuvant 
in experiment 2 was superior to the protocol with two vaccinations without adjuvant and 
then with two vaccinations with adjuvant in experiment 1. In comparison with the 
adjuvanted groups, the IM administration of naked VR-HA plasmid DNA alone two 
times was not sufficient to induce antibody or to give significant reduction in virus 
shedding. This supported the use of lipofectin as an adjuvant to provide some 
enhancement of the immune response induced by the VR-HA or VR-NP DNA vaccines.    161
DNA vaccinations in other studies required multiple injections before they demonstrated 
detectable antibody response (Barnett et al. 2001; Boyer et al. 2000). In this study, one 
chicken with multiple injections generated a moderate H6 HI antibody titre comparable to 
that induced by the inactivated vaccine. In two VR-HA experiments, the number of birds 
showing sero-conversion increased after the third immunization, in contrast to sero-
conversion following two vaccinations. This suggests that the number of vaccinations 
may also play a role in induction of measurable antibody response by DNA vaccines.  
3.4.4 LPAI challenge model 
A number of studies have evaluated DNA vaccines against HPAI virus. Much less 
research has been focused on the LPAI model. Because LPAI viruses typically do not 
cause disease or clinical signs in chickens, assessment of vaccine efficacy is more 
difficult with an LPAI virus challenge model. A defined challenge model has not been 
described for LPAI viruses as yet. Cherbonnel et al.(2003) and Le Gall-Reculé et 
al.(2007) used a co-infection model with Mycoplasma gallisepticum and Salmonella spp. 
in addition to high doses of LPAI virus in an attempt to increase the virus replication and 
shedding.  Prel et al.(2007) challenged vaccinated ducks by nasal instillation and eyedrop 
with a high dose of LPAI virus A/Duck/France/02166/2002(H5N3). In our experiments 
virus challenge involved a high dose of H6N2 avian influenza virus administered via 
nasal instillation, eyedrop and oral routes. The results in the blank vector group revealed 
that the virus was recovered from 100% (7/7) of challenged chickens via OS and 85.7% 
(6/7) of challenged chickens via CS, indicating that there was sufficient challenge virus 
for assessment of reduction in virus shedding and that this LPAI virus challenge model 
was successful in chickens.    162
In conclusion, two vaccinations with naked plasmid DNA in a VR1012 vector without   
adjuvant were insufficient to induce an effective immune response against the 
homologous virus challenge. However, by increasing the number of vaccinations, and 
with incorporation of lipofectin adjuvant, an enhanced immune response could be 
induced by VR-HA and VR-NP DNA vaccines. The results described in this chapter 
provide some encouragement for the further development of a H6 DNA vaccine. In the 
following chapters we evaluated alternative vectors and adjuvants in attempts to enhance 
immune response to the H6 DNA vaccines. 
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Chapter 4 
Effect of alternative expression vectors and administration methods on HA-
expressing DNA vaccines 
 
4.1 Introduction  
In the experiments reported in Chapter 3, a mammalian expression vector VR1012 was 
used to generate DNA constructs encoding HA or NP genes of A/coot/WA/2727/79 
(H6N2) virus. Both VR-HA and VR-NP constructs induced low to no detectable antibody 
response despite the use of multiple booster injections, lipofectin as adjuvant and a high 
dose of plasmid DNA. Nevertheless, following homologous virus challenge, vaccination 
by both VR-HA and VR-NP constructs were able to reduce virus shedding via cloaca and 
oropharynx to some extent in chickens. Thus, the immunity induced by these DNA 
vaccines was not sufficiently protective and alternative approaches needed to be 
investigated.  
Selection of an appropriate vector was one major factor that needed to be considered.  
The DNA expression vector is an important factor affecting the efficacy of DNA 
vaccines by facilitating expression of the target genes at the transcriptional and post-
transcriptional levels (Fattori et al. 2002).  Characteristics of the nucleotide sequence of 
the vector itself, e.g. negative regulatory elements, can influence expression levels of the 
target gene and therefore affect the immunogenicity of DNA vaccines (Montgomery et al. 
1993). To date, a number of expression vectors have been used in DNA vaccine research.  
The pCI or pCI-neo vector have been used to generate vaccine plasmid pCI HA or pCI-
neo HA which elicited measurable antibody titres in chickens against 
A/Goose/Guangdong/1/96 (H5N1) or A/turkey/Wisconsin/68 (H5N9) respectively (Chen 
et al. 2001; Suarez and Schultz-Cherry 2000a). The pVAX1 vector was employed to   164
clone HA, NA and M1 consensus sequences from circulating H5 AIV to generate 
recombinant constructs, which induced highly cross-reactive cellular immune responses 
against H5 influenza antigens in mice (Laddy et al. 2007). 
Another strategy to improve the potency of DNA vaccines is to manipulate the method of 
plasmid delivery. DNA immunization using conventional needle methodologies, such as 
IM or ID injections, appeared less successful in non-human primates and humans, 
however, physical methods, such as GG and electroporation (EP), have been shown to 
elicit better immune response in large animals and humans (Pertmer et al. 1995; Wang et 
al. 2008b). Although IM vaccination has been widely used (Perrie et al. 2001), it does not 
appear particularly efficient at inducing immune responses by DNA vaccination as 
plasmid DNA administered by IM route was poorly distributed, inefficiently expressed, 
and rapidly degraded (Otten et al. 2000; Ulmer et al. 2006; Wang et al. 2008b).Gene gun 
technology, which delivers the DNA coated onto metal carrier beads, usually gold, into 
epidermal skin cells, was regarded as an effective method for DNA vaccination. But this 
method is currently impractical for poultry due to the inability to vaccinate large numbers 
of birds and the high cost of the carrier beads (Fynan et al. 1993b; Kodihalli et al. 1997; 
Olsen et al. 1997).  
Electroporation, also called electropermeabilisation, was first reported for in vitro gene 
transfer in 1982 (Neumann et al. 1982). Subsequently, in vivo EP has been proven to be 
an efficient approach for delivering genes into muscle tissue (Mir et al. 1999; Rols and 
Teissie 1998). In comparison with simple muscle injection, EP has been proven to 
increase gene expression by several orders of magnitude and to significantly reduce inter-
individual variability (Fattori et al. 2002). This technology has been demonstrated to   165
increase the magnitude of the humoral and cellular responses induced by DNA vaccines 
in a range of animal models such as mice (Dupuis et al. 2000; Kadowaki et al. 2000; 
Laddy et al. 2007; Muthumani et al. 2008; Widera et al. 2000; Zucchelli et al. 2000), rats 
(Mathiesen 1999; Zucchelli et al. 2000),  rabbits (Wang et al. 2008b; Widera et al. 2000; 
Zucchelli et al. 2000), guinea pigs (Widera et al. 2000), goats and cattle (Tollefsen et al. 
2003), sheep (Babiuk et al. 2002; Babiuk et al. 2007) and non-human primates (Luckay 
et al. 2007). It also allowed a significant reduction in the DNA dose required (Widera et 
al. 2000; Zucchelli et al. 2000). 
This chapter describes investigations relating to two objectives to try to improve DNA 
vaccines against H6N2 LPAI virus in chickens.  
  To compare three different eukaryotic expression vectors expressing the same HA 
gene in an attempt to find an improved vector.  
  To employ EP to increase DNA uptake by cells and hence expression of the HA 
gene in chickens.  
4.2 Materials and Methods 
4.2.1 Subcloning of the H6N2 HA gene into three vectors 
The pCI and pCI-neo vector, were kindly provided by Dr David Suarez, Southeast 
Poultry Research Laboratory, Athens, USA. The pVAX1 vector was kindly provided by 
Professor Graham Wilcox, School of Veterinary and Biomedical Sciences, Murdoch 
University, Australia. A schematic showing the genetic maps of the three expression 
vectors is provided below (Figure 4.1).   166
                 
 
 
Figure 4.1 Map of the expression vectors used in this study. 
The full-length HA fragment was subcloned into the EcoRI/SmaI multiple cloning site of the vectors pCI, pCI-neo 
(http://www.promega.com/catalog/catalogproducts.aspx?categoryname=productleaf_8) and the EcoRI and HindIII sites of the pVAX1 
(http://tools.invitrogen.com/content/sfs/vectors/pVAX11.pdf), respectively.   
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The full-length HA gene of A/coot/WA/2727/79 (H6N2) from the pT-HA in Chapter 2 
was subcloned into the pCI or pCI-neo vectors at the EcoRI and XmaI sites to generate 
pCI-HA and pCI-neo-HA constructs and was similarly subcloned into the pVAX1 vector 
at the EcoRI and HindIII sites to generate the pVAX-HA construct. Proof-reading PCR 
was performed as per section 2.2.10.5 using the following primers. The protocol for the 
subcloning was described in detail in section 3.2.2. 
Table 4.1 Primers used for amplification and identification of HA gene from pT-HA. 
 
Primer  Sequence(5’to 3’)  Genome  Nt position* 
pCI-HAf ccgGAATTCCAAAAGCAGGGGAAAATG** HA  gene  3-20 
pCI-HAr tccCCCGGGTTTCTAATTATATACATATYYTGC HA  gene  1702-1725 
HA-pVAXf CccAAGCTTCAAAAGCAGGGGAAAATG HA  gene 3-20 
HA-pVAXr ccgGAATTCTTTCTAATTATATACATATYYTGC HA  gene  1702-1725 
pCIf TCCACTTTGCCTTTCTCTCCAC  pCI vector  966-987 
pCIr TCATCAATGTATCTTATCATG  pCI vector  1115-1136 
pVAXf TGGGAGGTCTATATAAGC  pVAX  vector  596-613 
pVAXr AGGGGCAAACAACAGATG pVAX  vector  849-867 
* The nucleotide (nt) numbering system of was adopted as per the HA gene of A/coot/WA/2727/79 (H6N2) 
virus. 
 **Restriction endonuclease sequence is in bold. 
 
4.2.1.1 Purification of PCR products  
PCR products were purified using a Qiaquick PCR purification kit (Qiagen) according to 
the manufacturer’s instructions. In brief, the PCR product was dissolved in 5 x volume 
Buffer PB. After mixing, the mixture was added into a spin column followed by 
centrifugation at 13,000 g for 60 sec at room temperature. After discarding the flow-
through, 750 μL buffer PE was added followed by two centrifugations at 13,000 g for 60 
sec. The column was then placed into a 1.5 mL Eppendorf tube and 30 μL dH2O was 
added. After standing for 1 min at room temperature DNA was eluted by centrifugation at 
13,000 g for 60 sec and stored at -20°C.   168
4.2.1.2 Restriction endonuclease reactions 
Restriction endonuclease reactions were performed as described in section 3.2.1.1 but 
different buffers and enzymes were used. For cloning into the pCI or pCI-neo vectors, 4 
μL of 10 x buffer B (Promega), 0.4 μL acetylated BSA (10 μg/μL), 2 μg plasmid DNA 
(pCI-neo, pCI or purified PCR product ), 1 μL EcoRI (12 U/μL, Promega), 2.0 μL XmaI 
(5 U/μL, Promega) were mixed with dH2O  made up to 40 μL. The reaction mix was 
incubated at 37°C for 2-4 hr.  
For cloning into the pVAX1 vector, 4 μL of 10 x buffer B (Promega), 0.4 μL acetylated 
BSA (10 μg/μL), 2 μg plasmid DNA (pVAX1 or purified PCR product), 1 μL EcoRI (12 
U/μL, Promega) , 1.0 μL HindIII (10 U/μL, Promega) were mixed with sterile, dH2O 
made up to 40 μL. The reaction mix was incubated at 37°C for 2-4 hr.  
For the pVAX-HA identification, 2 μL of 10 x NEBuffer (New England Biolabs Inc., 
Hertfordshire, UK), 0.2 μL acetylated BSA (10 μg/μL), 1 μg pVAX-HA DNA, 0.5 μL 
EcoR I (12 U/μL, Promega), 0.6 μL ApaLI (10 U/μL, NEB) were mixed with dH2O up to 
20 μL. The reaction mix was incubated at 37°C for 2 hr. 
4.2.1.3 Ligation and transformation  
Ligation and transformation were conducted as described in 3.2.2.2.  Plasmid DNA 
containing the recombinant constructs was prepared as described in section 3.2.3.  
4.2.2 Transient expression of recombinant plasmids in eukaryotic cells 
As described in section 3.2.4.1, Cos-7 cells were prepared without antibiotics until 
forming 80-90% confluency in a 6-well plate. The cells were transfected transiently using   169
FuGENE® HD Transfection Reagent (Roche Diagnostics Australia Pty. Ltd., NSW, 
Australia) following the manufacturer’s protocol. Briefly, 5 µg plasmid DNA was added 
into 100 µL opti-MEM (Gibco BRL) in a 1.5 mL Eppendorf tube. Then 15 µL 
transfection reagents were added into the DNA solution without contact with the tube 
wall followed by vortexing for 1-2 sec and incubating at room temperature for 15 min. 
The DNA mixture was dispensed into 6-well plates in a drop-wise manner then the plate 
was incubated at 37°C for 48 hr.  
The expression of recombinant constructs in Cos-7 cells was detected by WB as per 
section 3.2.5.  After the removal of the media, 90 µL non-reducing loading buffer was 
added into each well. The lysate was boiled for 10 min prior to loading into the 
electrophoresis gel. After WB, the nitrocellulose membrane was scanned in the 
ProXPRESS 2D Proteomic Imaging System (PerkinElmer, CT, USA). IFT was 
performed as per section 2.2.5 using a microscope (Olympus BX51, Tokyo, Japan). 
4.2.3 Experimental design of the vaccination and challenge study 
Three-week old Hy-Line layer pullets (Altona Hatchery Pty. Ltd.) were raised in a free-
range pen. DNA vaccine formulations were conducted as described in section 3.2.9. The 
immunization regime is shown in Table 4.2 according to the procedure described 
previously (Lee et al. 2003). Each group of 5 birds received two separate injections in the 
breast muscle of 0.2 mL plasmid DNA diluted in PBS. Birds were subsequently given 
booster vaccinations twice at 4-week intervals using the same DNA vaccine. The 
vaccinated birds were bled every two weeks to determine HI antibody titres.    170
Each chicken received 1 mL (10
6.25 EID50/0.1 mL) of the challenge virus 6-7 weeks after 
the third vaccination as described in section 2.2.8. Swabs were collected daily for virus 
isolation as described in section 2.2.9. 
 
Table 4.2 Immunization procedure for pCI-HA, pCI-neo-HA and pVax-HA DNA vaccine in 
chickens. 
 
Group Species Number 
of birds 
Vaccine Dose  Route*  Adjuvant  Number  of 
immunization
1 Hy-line  5  pCI-HA  50  IM  No  3 
2 Hy-line  5  pCI-HA 100  IM  No  3 
3 Hy-line  5  pCI-HA 300  IM  No  3 
4 Hy-line  5  pCI-neo-HA  50  IM  No  3 
5 Hy-line  5  pCI-neo-HA  100  IM  No  3 
6 Hy-line  5  pCI-neo-HA  300  IM  No  3 
7 Hy-line  5  pVAX-HA  50  IM  No  3 
9 Hy-line  5  pVAX-HA  100  IM  No  3 
9 Hy-line  5  pVAX-HA  300  IM  No  3 
10 Hy-line  4  pCI-HA  100  IM  Lipofectin  3 
11 Hy-line  4  pCI-neo-HA  100  IM  Lipofectin  3 
12 Hy-line  5  Inactivated  virus  1mL  IM  No  2 
13 Hy-line  4  PBS  1mL  IM  No  3 
14 White  Rock  8  pCI-HA  100  IM  No  2 
15 White  Rock  8  pCI-HA  100  EP  No  2 
* IM refers to intramuscular delivery and EP represents electroporation delivery. 
 
In a separate experiment, 3-week-old SPF White Rock chickens, from Harbin Veterinary 
Research Institute, China, were housed in HEPA-filtered isolators. Each group of 8 birds 
was inoculated twice with pCI-HA at a 3-week interval via IM route alone or by EP 
according to the manufacturer’s instructions. Briefly, following IM injection of plasmid 
DNA in a 200µL volume at two sites in the leg, a pair of surface plate electrodes was 
clipped to the leg at the DNA injection sites. The EP parameters used were as follows: 
voltage- 220V, discharge magnitude - 60ms and frequency -50HZ, using an electric pulse   171
generator (WJ-2002 Electrode Device for simultaneous injection of DNA and 
electrotransfer, Scientz Biotechnology Co., Ltd., Ningbo, China).  Some fasciculation of 
the chicken’s legs occurred with electroporation and the procedure was repeated using a 
pulse of the opposite polarity.  
4.3 Results 
4.3.1 Identification of recombinant constructs in three vectors 
The three constructs produced fragments of the expected sizes following restriction 
endonuclease digestions as shown in Figure 4.2.  As expected from the restriction sites of 
DNA constructs, the pCI-HA gave 1.7 kb and 4.0 kb fragments following EcoRI and 
XmaI digestion and 3.72 kb and 1.98 kb following EcoRI and BamHI digestion. The pCI-
neo-HA gave 1.7 kb and 5.4 kb fragments following EcoRI and XmaI digestion and 3.1 
kb and 4.0 kb following EcoRI and BamHI digestions. The pVAX-HA gave 1.7 kb and 
3.0 kb fragments following EcoRI and HindIII digestion, 1.9 kb and 2.8 kb fragments 
following EcoRI and ApaLI digestion, and 4.7 kb following EcoRI and XmaI digestion or 
EcoRI and BamHI digestion. These three constructs were also further characterized for 
the fidelity of the HA gene and insertional direction using sequencing and alignment by 
ClustalW as expected.         
4.3.2 In vitro expression of the three HA-expressing constructs 
The expression of the three HA-expressing constructs in Cos-7 cells by WB displayed an 
approximately 84 kD band (Figure 4.3, left). The pCI-HA gave the strongest band 
followed by the pCI-neo-HA. The pVAX-HA band was barely detectable. With an 
increase to the amount of plasmid DNA for transfection, the band intensity from both the   172
pCI-neo-HA and pVAX-HA constructs became denser (Figure 4.3, right). The ratio of 
FuGENE® HD Transfection Reagent (µl): pVAX-HA DNA of 10:5 gave the best 
transfection result.          
    
 
Figure 4.2 Electrophoresis gels showing restriction enzyme digestion patterns of DNA 
vaccine constructs. 
A Lane 1, 1kb DNA ladder (Promega); lane 2, 3 and 4, pCI neo-HA double digested with EcoRI 
and XmaI, EcoRI and BamHI, and undigested pCI-neo-HA plasmid DNA; lane 5, 6 and 7,  pCI-
HA double digested with EcoRI and XmaI, EcoRI and BamHI , and undigested pCI-HA; lane 8, 9 
and 10, pVAX-HA double digested with EcoRI and XmaI, EcoRI and BamHI, and undigested 
pVAX-HA. B Lane 1, 1kb DNA ladder, lane 2, pVAX-HA digested with EcoRI and HindIII, lane 
3, pVAX-HA digested with EcoRI and ApaLI. 
   
   
 
Figure 4.3 Transient expression of three DNA vaccine constructs by Western blotting. 
A Lane 1, Marker (Bio-Rad); lane 2 , pCI-HA; lane 3, pCI-neo-HA; lane 4, pVAX-HA; lane 5, 
pCI; lane 6, pCI-neo; lane 7,  pVAX1. B Lane 1, Marker, lane 2-5, FuGENE® HD Transfection 
reagent (µL): pVAX-HA DNA (µg) ratios: 6/3, 10/5, 15/5, 20/5;  lane 6-7, FuGENE® HD 
Transfection reagent (µL):pCI-neo-HA DNA (µg) ratios: 6/3, 10/5.   173
Cos-7 cells transfected with pCI-HA or pCI-neo-HA displayed bright fluorescence in the 
cytoplasm and cell membrane using anti-H6 serum and the IFT (Figure 4.4), however, the 
pVAX-HA transfected cells showed only limited fluorescence.  
   
   
 
 
Figure 4.4  Fluorescence occurring in three H6 HA-expressing DNA vaccine constructs 
expressed in Cos-7 cells. 
A, pCI-HA; B, pCI; C, pCI-neo-HA; D, ,pCI-neo; E,  pVAX-HA;  F, pVAX1 vector. (x10)   174
 4.3.3 Antibody responses in intramuscularly vaccinated chickens  
4.3.3.1 Comparison of antibody responses induced by three non-adjuvant DNA vaccines 
No HI titre was detected in any vaccinated chickens 6 weeks after the third vaccination.  
However, at 7 days post virus challenge the chickens showed a range of HI titres (Table 
4.3).  Except for the inactivated vaccine group, there was a significant increase in the 
GMT of HI antibody between pre- and post-challenge in all HA DNA vaccinated groups 
and the naïve control group using the paired-sample T test. There was no significant 
difference in the GMT of HI antibody post challenge between the naïve control group and 
each of the DNA vaccine groups (single or combined), whereas, the post-challenge GMT 
for the inactivated vaccine group was significantly higher than each of the non-
adjuvanted DNA vaccine groups. There was also a significantly higher (ANOVA, 
P=0.000) HI GMT post challenge in the inactivated vaccine group compared with the 
naïve control group. 
There was no significant difference in the GMT of HI antibody post challenge for 
different doses in each vaccine pCI-HA, pCI-neo-HA or pVAX-HA (ANOVA, P=0.073, 
0.41 and 0.086 respectively). Neither was there significant difference in the GMT of HI 
antibody post challenge between the three vaccines (ANOVA, P=0.53).  175
Table 4.3 Antibody response prior to challenge (PRC) and post challenge (POC) for naive controls, inactivated vaccine (IVV) and 
different DNA vaccine groups (pCI-HA, pCI-HA-neo and pVAX-HA) at the doses indicated (in μg). 
 
pCI-HA  pCI-HA-neo  pVAX-HA   
 
Naive 
control 
IVV 
50 100  300 100*  50 100  300  100*  50 100  300 
PRC    0**
 Aa 8.6±1.1
 A b 0
 Aa 0
 Aa 0
 Aa 0
 Aa 0
 Aa 0
 Aa 0
 Aa 0
 Aa  0
 Aa 0
 Aa  0
 Aa 
POC 4.5±0.6
Ba 9.8±0.5
 Ab 3.2±1.3
 Bac 5.2±1.6
 Bac 5.2±1.3
 Bac 8.3±1.3
 Bdf 4.4±2.6
 
Bac 
5.4±1.1
 
Bac 
6.2±2.2
 
Bacf 
4.8±1.0
 
Bae 
4.9±2.1
 
Bac 
3.6±1.1
 
Bac 
6.4±2.1
 
Bacf 
* Adjuvant group. 
** HI titre of each group shown as GMT(log2) ± standard deviation (SD). 
Within the column the different uppercase superscript letter indicates statistical differences (P < 0.05) using Paired-sample T test. For the row groups with 
different lowercase superscript letter are significantly different (P < 0.05) using ANOVA or Mann-Whitney test.  
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4.3.3.2 Effect of adjuvant on antibody response   
As shown in Table 4.3, the HI titre in 100 µg pCI-HA vaccinated chickens ranged from 
2
3 to 2
7 with a GMT of 2
5.2 after virus challenge. The HI titre in 100 µg adjuvanted pCI-
HA vaccinated chickens ranged from 2
7 to 2
10 with a GMT titre of 2
8.3. There was a 
significant difference (ANOVA, P=0.019) in the GMT of HI antibody between non-
adjuvanted and adjuvanted pCI-HA groups. There was also a statistically significant 
difference in GMT post challenge between the 100µg pCI-HA adjuvanted group and the 
naive control group (ANOVA, P=0.002), the 100µg pCI-HA adjuvanted group and the 
inactivated vaccine control group (ANOVA, P=0.036). 
The HI titre in 100 µg pCI-neo-HA vaccinated chickens ranged from 2
4 to 2
7 with a GMT 
of 2
5.4 after virus challenge whereas the HI titre in 100 µg adjuvanted pCI-neo-HA 
vaccinated chickens ranged from 2
4 to 2
6 with a GMT of 2
4.8. There were no significant 
differences (ANOVA P=0.39) in the GMT of HI antibody between the non-adjuvant and 
adjuvant pCI-neo-HA groups. Neither was there a statistically significant difference 
(ANOVA, P=0.67) in GMT post challenge between 100µg pCI-neo-HA adjuvanted 
group and the naive control group. 
4.3.3.3 Effect of poultry breed on antibody response   
The HI antibody GMT induced by pCI-HA vaccines in White Rock SPF chickens are 
shown in Table 4.4.  Two out of eight SPF chickens gave  weak, transient HI titres 
following two vaccinations with pCI-HA, but there was no significant difference (Mann-
Whitney Test, P=0.24) in the GMT of HI antibody at two weeks after the second   177
immunization between White Rock (SPF) and Hy-Line (commercial) chickens 
intramuscularly vaccinated with 100µg pCI-HA. 
Table 4.4 Comparison of HI antibody GMT in SPF chickens immunized with 100 µg pCI-
HA vaccine administered by intramuscular injection (IM) or electroporation (EP). 
 
HI titre (weeks post vaccination)  Group Route 
1  2  3*  4  5 6 7  8 
1 IM  0  0 0  0 0.1±0.2  0.06±0.2 0  0 
2  EP 0  0  0.3±0.7  0.6±1.8  1.3±2.1 1.1±2.1 0.8±1.9  0.8±1.9 
    * The second vaccination. HI titre for each group showed as GMT (log2) ± SD. 
 
4.3.3.4 Antibody response in chickens vaccinated using electroporation 
The antibody response curve induced by pCI-HA administered with EP is shown in 
Figure 4.5. One out of eight birds showed a low HI titre following the first vaccination. 
Two weeks following the booster, four out of eight birds seroconverted and the highest 
HI titre reached 2
6. However, there was no significant difference (Mann-Whitney Test, 
P=0.182) in the GMT of HI antibody between the IM and EP groups at 5 weeks post-
vaccination (Table 4.4).  
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Figure 4.5 Temporal anti-H6 HI responses in chickens immunized with 100µg pCI-HA by 
EP. 
The curve represents the HI antibody GMT of eight birds.  Each icon number refers to one bird.    178
Table 4.5 Virus shedding post challenge in oropharyngeal (OS) and cloacal swabs (CS) in unvaccinated chickens and chickens vaccinated 
with inactivated vaccine (IVV) or different DNA vaccine groups (pCI-HA, pCI-neo-HA and pVAX-HA) at the doses (μg) indicated. 
 
pCI-HA pCI-neo-HA  pVAX-HA    Naive 
control 
IVV 
50 100  300  Sub- 
total 
100
**  50 100  300 Sub- 
total 
100
**  50 100 300 Sub- 
total 
O 
S 
13/28 
(46.4)
* a 
0/35
 
bc 
 
15/35 
(42.9)
 
ade 
14/35 
(40.0)
 
ade 
25/35 
(71.4)
 
bcf 
54/105 
(51.4) 
9/28 
(32.1)
 
ad 
19/35 
(54.3)
 
ac 
17/35 
(48.6)
 
ad 
12/35 
(34.3) 
ad 
48/105 
(45.7)
 
 
9/28 
(32.1)
 
ad 
16/28 
(57.1)
 
ac 
19/35 
(54.3)
 
ac 
15/35 
(42.9)
 
ad 
50/98 
(51.0) 
C 
S 
9/28 
(32.1)
 a 
4/35 
(11.4)
 
ac 
3/35 
(8.57)
 
bc 
0/35
 bc 3/35 
(8.57)
 
bc 
9/105 
(8.57) 
0/28
 bc 3/35 
(8.57)
 
bce 
0/35
 
bc 
7/35 
(20.0) 
aef 
10/105 
(9.52) 
 
1/28 
(3.57) 
bcf 
0/28 
bc 
4/35 
(11.4) 
ac 
6/35 
(17.1)
 a 
10/98 
(10.2) 
* No. of bird swabs positive for virus /total number of swabs tested from birds in the group (percentage), ** Adjuvant group. 
For the rows groups, statistical analysis is performed only in each of three HA-expressing construct groups, naïve control and inactivated vaccine 
group. Groups with different lowercase superscript letter in the row are significantly different (P < 0.05) using Chi-square or Fisher's exact test.  179
4.3.3.5 Virus shedding in vaccinated chickens following virus challenge 
The level of virus shedding in vaccinated and control groups after challenge with H6N2 
virus was summarized in Table 4.5.There was a highly significant difference (Fisher’s 
exact test, P=0.000) in the level of virus shedding in OS but no significant difference 
(Fisher’s exact test, P=0.062) in CS between the inactivated virus vaccine (IVV) and the 
naïve control groups.  
There was no significant difference in virus shedding in OS between the naïve control 
group and any of the HA-expressing DNA vaccine groups except for the 300µg pCI-HA 
group (Chi-square, P= 0.043). However, there were significant differences in the level of 
virus shedding in CS between the naïve control group and the groups vaccinated with 50, 
100 and 300 µg pCI-HA; 50 and100 µg pCI-neo-HA; or 50 µg pVAX-HA (P< 0.05). For 
adjuvanted groups, there were no significant differences in virus shedding in OS but 
significant differences in CS between the naïve control group and either the adjuvanted 
100 μg pCI-HA (Fisher's exact test, P=0.0018) or 100 μg pCI-neo-HA groups (Fisher's 
exact test, P=0.012).  
In comparison with the IVV group, there were no significant differences in virus 
shedding in CS in any of the HA-expressing DNA vaccine groups, but there were   
significant differences in virus shedding in OS  compared with the 50 µg, 100 µg pCI-HA, 
100µg, 300 µg pCI-neo-HA, 300 µg pVAX-HA, adjuvanted 100 µg pCI-HA and 
adjuvanted pCI-neo-HA groups (P< 0.05).   
There were significant reduction in virus shedding via the oropharynx in chickens 
between the 50 μg and 300 μg (Chi-square, P= 0.016), 100 μg and 300 μg (Chi-square,   180
P= 0.008) of the pCI-HA vaccine. Significant differences also occurred in cloacal 
shedding between 100 μg and 300 μg doses (Fisher's exact test, P=0.029) of the HA-pCI-
neo vaccine and between 50 μg and 300 μg doses (Fisher's exact test, P=0.011) of pVAX-
HA. The results from all these groups suggested that lower doses of these vaccines were 
more effective in reducing the level of virus shedding than the higher dose.   
Additionally, there was no significant difference in virus shedding between 100 μg non-
adjuvanted and adjuvanted pCI-HA groups (Chi-square, P= 0.52 in OS, Fisher's exact test, 
P=1.0 in CS) or pCI-neo-HA groups (Chi-square, P= 0.19 in OS, Fisher's exact test, 
P=0.44 in CS). There was no significant difference in virus shedding in OS or CS 
between the combined pCI-HA, pCI-neo-HA and pVAX-HA groups.  
4.4 Discussion  
Direct IM injection of plasmid DNA has been used extensively for immunization against 
a range of antigens but its mechanism is not clearly understood. Different DNA 
expression vectors that contain different combinations of natural and/or synthetic 
promoters, introns and transcriptional termination signals have been compared in an 
attempt to increase the transcriptional level in transduced muscle and hence improve the 
DNA expression (Fattori et al. 2002).  The first objective in investigations reported in this 
chapter was evaluation of three different plasmid vectors for induction of immune 
responses to H6N2 HA. Antibody titres in vaccinated chickens have been shown to 
correlate well with survivability after HPAI virus challenge (Suarez and Schultz-Cherry 
2000a). Alternatively, a decrease in viral shedding in the trachea and cloaca has also been 
identified as an excellent marker for determining protection from AIV challenge after 
vaccination (Crawford et al. 1999). Although the three DNA plasmid constructs did not   181
elicit measurable H6 HA antibody responses in vaccinated Hy-Line chickens, DNA 
vaccination significantly reduced virus shedding in CS post-virus challenge. This 
indicated that the three vaccines had induced some level of immunity in the vaccinated 
chickens. Moreover, in the 100 µg pCI-HA adjuvanted group the post-challenge HI 
antibody titres were significantly higher than post-challenge HI titres for the naïve control 
group, indicating an anamnestic antibody response after priming induced by the DNA 
vaccination. However, virus shedding was not significantly reduced in OS, indicating that 
these three DNA constructs were not effective in protecting the oropharynx against 
homologous H6N2 AIV infection. 
Although there was no significant reduction in virus shedding in OS for the different 
doses of each vaccine, the lower dose groups (50 or 100 μg) appeared to be more 
effective at reducing virus shedding in CS than the higher dose group (300 μg). This was 
consistent with the results reported in Chapter 3 with the VR-HA construct. It has been 
previously reported that expression of injected plasmid DNA was not directly 
proportional to delivery dose  and that optimization of DNA immunization is necessary 
(Davis et al. 1993b). 
The in vitro expression studies showed that pCI-HA gave the highest level of protein 
expression in Cos-7 cells among the three constructs. Although there was no statistical 
difference in reducing virus shedding in OS and CS between the three vaccine groups in 
vivo, both the 50 and 100 μg pCI-HA groups tended to have lower levels of virus 
shedding than the other two constructs (Table 4.5). Moreover, the adjuvanted pCI-HA 
group showed better priming immune responses, resulting in higher post-challenge 
antibody titres, than the adjuvanted pCI-neo-HA group. Thus, both the in vitro and in   182
vivo expression studies indicated that the pCI-HA construct was more effective as a 
vaccine than the pCI-neo-HA or pVAX-HA constructs.  
Although numerous vectors have been used in genetic immunization, little has been done 
to investigate the effect of different vectors on the generation of immune responses to 
DNA vaccines.  In a study with H5 HA-expressing DNA vaccines using four different 
promoters in five different plasmids (pSI, pCI-neo, VR1012, pCAGGS.MCS and 
pRC/RSV), the pCI-neo HA construct with the CMV-IE promoter afforded the best 
response on the basis of antibody titre and protection post-virus challenge (Suarez and 
Schultz-Cherry 2000a). In comparison with the pCI, the pCI-neo was designed to contain 
a β-globin/IgG chimeric intron located downstream of the enhancer/promoter region, 
which was considered to further increase gene expression (Promega 2007). However, 
results from our study did not demonstrate that the pCI-neo vector was more effective 
than the pCI vector. Possibly, due to low efficiency of gene uptake and/or expression for 
both constructs via IM route, the larger size of the pCI-neo-HA construct may have been 
more unfavorable for myofibre cell uptake or expression. The pVAX1 plasmid lacks an 
intron in its backbone in contrast to the pCI and pCI-neo plasmids. The addition of an 
intron to the plasmid is believed to cause enhanced protein expression (Manoj et al. 
2004). Intron A acted as an enhancer of the CMV-IE promoter and positively regulated 
expression from the CMV-IE promoter in transformed mammalian cells (Chapman et al. 
1991). Introns can also give rise to small regulatory mRNA molecules that regulate gene 
expression levels (Lin et al. 2006). Thus, absence of an intron in the pVAX 1 vector may 
have contributed to its lower gene expression level.    183
Spatial–temporal patterns of gene expression in mouse skeletal muscle revealed that the 
majority of DNA was degraded before entering muscle cells and an average of about 6% 
(up to 15%) of the myofibre cells surrounding the injection site took up and expressed 
DNA (Doh et al. 1997). Thus, a suggested approach to enhance the potency of DNA 
vaccines was to increase the proportion of transduced myofibre cells within a given 
muscle. In vivo electroporation has been demonstrated to increase both the number of 
muscle fibres taking up plasmid DNA and the copy number of plasmids introduced into 
the cells (Aihara and Miyazaki 1998). Comparison of IM and EP to induce immune 
responses to DNA vaccination was the second objective of the investigations reported in 
this chapter.  
Although GG is one of the most popular methods for DNA vaccine delivery, EP was 
chosen in this study as it appeared to be most suitable. Some studies have demonstrated 
that EP based DNA intramuscular delivery resulted in higher and more persistent levels 
of protein expression compared to GG or IM vaccination (Best et al. 2009; Bloquel et al. 
2006). Another study showed in an anti-tumor model in transgenic mice that GG seemed 
to be less effective than EP in controlling the incidence and the growth of spontaneous 
tumors albeit the overall antigen specific immune responses between GG and EP were 
very similar (Smorlesi et al. 2006). In addition, compared to GG, EP may be more 
practical for routine use as the preparation of DNA coated particle beforehand and pre-
treatment (depilation) at the injection site are unnecessary.   
In  the experiments with VR-HA via IM injection reported in Chapter 3, no or weak 
antibody responses were induced before virus challenge, and similar findings were shown 
with DNA vaccines using the three alternative HA-expressing constructs via IM injection.   184
However, in contrast to the IM vaccination groups, administration of 100 μg pCI-HA via 
EP resulted in 50% percent of vaccinated chickens showing evidence of sero-conversion, 
with HI titres in some birds reaching 2
6, although the GMT of HI antibody for the EP 
group was not significantly different from the group receiving this vaccine dose by IM 
injection. This is consistent with the results of studies in which a codon optimized H5 HA 
DNA vaccine administered via EP induced earlier and higher antibody titres in rabbits 
than via IM injection alone (Wang et al. 2008b).  The results reported here suggest that 
EP may also be effective in enhancing the efficacy of DNA vaccination in chickens. 
Another study showed that a HA-expressing DNA construct induced high, intermediate 
and low levels of ELISA antibody in BALB/c (H-2
d), C3H (H-2
k), and B10 (H-2
b) mice 
respectively and the HA-DNA conferred significant protection only in BALB/c mice 
(Chen et al. 1999b). Similarly, in a study with DNA plasmids encoding for five 
Plasmodium falciparum proteins, mouse strain affected antibody response (Sedegah et al. 
2004). Such variability between different strains of mice highlighted the importance of 
genetic background on immune response. In the current studies very low or no HI 
antibody titres were induced by the pCI-HA vaccine given IM in either White Rock or 
Hy-Line chickens. It appeared that there was no significant difference between the 
chicken breeds in the uptake and expression of the pCI-HA plasmid. 
Like the non-adjuvanted vaccine groups, the 100 μg pCI-HA and pCI-HA-neo 
adjuvanted groups showed significantly reduced virus shedding in the cloaca than naïve 
controls, although this reduction did not  occur with virus shedding in the oropharynx. 
Although there was no significant difference in virus shedding in the oropharynx and 
cloaca between the non-adjuvanted and adjuvanted groups, there was a significantly   185
higher GMT of HI antibody in the 100µg pCI-HA adjuvanted group post challenge, 
indicating more effective priming in the adjuvanted vaccine group and that lipofectin 
adjuvant played a role in improving the immune response for the pCI-HA vaccine.    
Although the three DNA constructs tested in this phase of the study did not inhibit 
replication of the challenge virus in the oropharynx after conjunctival, nasal and oral 
challenge, they were able to substantially reduce virus shedding from the cloaca. No 
challenge virus could be recovered from about 90% of CS from the birds receiving one of 
the three DNA constructs, whereas, challenge virus was isolated from about 32% of CS 
from the naïve control group (Table 4.5). Because cloacal shedding of infectious virus 
and subsequent contamination of litter or water is a major source of AI virus in the 
environment (Condobery and Slemons 1992; Crawford et al. 1998; Wood et al. 1994), 
DNA vaccines based on these plasmid-HA constructs should be effective at reducing 
transmission of AIV in the field even if no measurable antibody response was induced.  
Since HA plays a more important role in inducing antibody response to avian influenza 
than NP and the aim of this thesis was to addresses the low immunigenicity of plasmid 
DNA, this chapter and subsequent chapters only focused on the HA-expressing plasmid. 
This Chapter reported the results of experiments using three alternative eukaryotic 
vectors encoding the same HA gene of a H6N2 virus. The investigations showed that the 
pCI-HA construct was better than the other two constructs in terms of antibody response 
and reduction in the level of virus shedding, although all three vaccines were not very 
effective at inducing a protective immune response. However, it was encouraging to note 
that the use of lipofectin as an adjuvant and EP as the delivery regime were both shown 
to enhance the immune responses induced by the pCI-HA construct. This indicated that   186
further strategies were now needed to improve the potency of DNA vaccines for the 
protection of chickens against the H6N2 AI virus. 
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Chapter 5 
Enhanced efficacy of an HA-expressing DNA vaccine using Kozak sequence and an 
alternative pCAGGGS vector 
 
5.1 Introduction  
Although  immunogenicity and protective efficacy of DNA vaccines have been shown in 
numerous model systems, one of the problems hindering DNA vaccine development has 
been low immunogenicity (Abdulhaqq and Weiner 2008).  The development and 
evaluation of H6-HA DNA vaccines using four different DNA expression vectors, 
VR1012, pCI, pCI-neo and pVAX1, have been described in the two previous chapters. 
All these constructs containing a CMV promoter induced weak or no H6 antibody 
response in vaccinated chickens, even when co-administered with Lipofectin as adjuvant. 
However, some protective efficacy in terms of reduction in virus shedding after virus 
challenge was demonstrated.  Therefore, other parameters affecting the expression of the 
HA from the DNA construct needed to be explored.  
The appropriate design of the plasmid is crucial to high level expression of its encoded 
antigen and subsequent immune response induced by that antigen. Among many factors 
affecting the level of antigen expression in eukaryotic expression vectors, the promoter is 
regarded as an important variable (Davis et al. 1993b). Although the CMV promoter 
appeared to be the most efficient in a number of studies (Manoj et al. 2004), poor 
immune responses resulted from DNA constructs using CMV promoters in  the studies in 
chickens reported in Chapters 3 and 4.  Thus it was decided to use another expression 
vector containing a different promoter.  The vector pCAGGS, containing the chicken β-
actin promoter, has been shown to be effective in DNA vaccines for Nipah virus (Wang 
et al. 2008c), Rift Valley fever virus (Wang et al. 2007), H5 AIV (Jiang et al. 2007), HIV   188
(Bu et al. 2003), hepatitis B virus (Oka et al. 2001), influenza (Chen et al. 1998b), 
Japanese cedar pollinosis (Masuda 2005), and diabetes (Shigihara et al. 2005).  
A Kozak sequence is regarded as the consensus sequence for initiation of translation in 
vertebrates (Kozak 1987a, b). It functions by slowing down the rate of scanning by the 
ribosome and increasing the chance of ribosome recognising the start of translation at the 
AUG start codon. Insertion of a Kozak sequence into a gene of interest or into an 
expression vector has been used to develop DNA vaccines against Chikungunya virus 
(Muthumani et al. 2008), HIV (Kumar et al. 2006), duck hepatitis B (Xu et al. 2005), 
enterotoxigenic E coli (ETEC) infection (Melkebeek et al. 2007), and minigene DNA 
vaccines (An et al. 2000).  
In this study, we incorporated a Kozak sequence upstream of the initiation codon of the 
HA gene and then cloned this modified HA gene into the expression vector pCAGGS, 
resulting in a pCAG-HAk construct. This DNA vaccine construct was subsequently 
evaluated in vitro and by vaccination and challenge studies in chickens.  
5.2 Materials and methods 
5.2.1. Construction of the pCAG-HAk DNA vaccine  
5.2.1.1 Primer design 
The oligonucleotide primers shown in Table 5.1 were used for amplification and 
sequencing of the AIV HA gene. Primers were designed to permit amplification of the 
full-length ORF of the HA of A/coot/WA/2727/79 (H6N2) containing a Kozak sequence. 
Thus, a Kozak sequence (GCCGCCACC) was inserted before the ATG start codon, an 
EcoRI site was added upstream of the Kozak sequence and a SmaI site was added to the   189
5’end of the downstream primer (HAd). These primers were synthesized by GeneWorks 
(GeneWorks Pty. Ltd.). Primers for the HA sequencing and pCAGGS primers were 
synthesized by Shanghai Invitrogen Biotechnology Co., Ltd (Shanghai, China).  
 
Table 5.1  Primers used for amplification and sequencing of AIV HA gene. 
 
 Primer    Sequence (5’to 3’)    Genome         Nt position* 
HAu ATGATTGCAATCATAATATTC  HA  gene  16-36 
HAd    TTATATACATATCCTGCATTG  HA gene      1696-1716         
P1 CTGGGTAGCATATCCCATGT  HA  gene 340-321 
P2 AAATCCCCAATGTGACATCTTG  HA  gene  251-272 
P3  TGAGCAAAATACTCTGTATG    HA gene  620-639 
P4 TAAGACTGGCAACTGGTCTGAG HA  gene  1000-1021 
P5  ATGCCAATGTGAAGAACC    HA gene  1381-1398 
pCAG-F    GAGATCTCGGAGACGATTG  pCAGGS  71-89 
pCAG-R CAGAAGTCAGATGCTCAAG pCAGGS  97-78 
* The nt position was based on the HA gene of A/coot/WA/2727/79 (H6N2) in the Appendix 2.1.         
 
 
The pCAGGS expression vector was provided by Harbin Veterinary Research Institute, 
China and its structure is shown diagrammatically in Figure 5.1.     
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Figure 5.1 Schematic diagram of the pCAGGS vector. 
Modified from Kodihalli et al.(1997). Ori refers to simian virus 40 origin of replication, CMV-
IE/En refers to CMV/IE enhancer, β-actin refers to chicken β-actin promoter, rbg PA refers to 
rabbit β-globulin polyadenylation site, An refers to simian virus 40 antigen. 
 
5.2.1.2 RNA extraction 
Viral RNA was extracted using Trizol LS Reagent (Invitrogen) according to the 
manufacturer’s instructions. Briefly, 250 μL of viral allantoic fluid was added to 750 μL 
Trizol LS Reagent in a 1.5 mL eppendorf tube. Following mixing and incubation at room 
temperature for 5 min, 200 μL chloroform was added and the mixture was vigorously 
shaken for 15 sec.  After incubation for 10 min at room temperature, the mixture was 
centrifuged at 12,000 g for 10 min at 4°C. The supernatant (about 500 µL) was then 
transferred to a new tube followed by adding 500 µL isopropyl alcohol, and mixing and 
holding for 10 min at room temperature. After the centrifugation at 12,000 g for 10 min at 
4°C, the supernatant was discarded and 1 mL 75% alcohol was added to the pellet 
followed by centrifugation at 12,000 g for 5 min at 4°C. Subsequent to discarding the   191
supernatant, the pellet was dried at room temperature and resuspended in 20 µL DEPC-
treated dH2O and then stored at -70°C until needed. 
5.2.1.3 Reverse transcription 
Reverse transcription was performed using Moloney murine leukaemia virus reverse 
transcriptase (Invitrogen) as described by the manufacturer. In brief, 20 µL RNA was 
mixed with 2.0 µL of 20 µM HAu. The mixture was heated at 70°C for 5 min to disrupt 
the secondary structure of the RNA and then quickly chilled on ice. After brief 
centrifugation, the following components were added up to a total volume of 40µL: 
8.0µL of  5x first strand buffer, 4.0 µL of dNTP mix (2.5 mM each), 4.0 µL of 0.1M DTT, 
1 µL of  (40 U/µL) RNaseOUT (Invitrogen), and 1.0 µL( 200 U/µL) M-MLV RT. 
Following mixing the reaction was held at 37°C for 3 hr and then stored at -70°C until 
needed.  
5.2.1.4 Amplification of HA gene by proof-reading PCR 
Proof-reading PCR was performed using the Phusion
TM high-fidelity DNA polymerase 
protocol (Finnzymes OY, Espoo, Finland). Briefly, 50 μL PCR reactions contained 10 μL 
of 5x Phusion
TM HF reaction buffer, 4 μL of 2.5 mM dNTP mix, 3 μL cDNA template,  1 
μL of 20 μM HAu and 1 μL of 20 μM HAd,  0.5 μL ( 2U/μL) high-fidelity DNA 
polymerase, and 30.5 μL dH2O. The thermal cycler program included initial denaturation 
at 98°C for 30 sec, followed by 30 cycles of denaturation (10 sec at 98°C), annealing (1 
min at 60°C) and elongation (45 sec at 72° C), and a final elongation step at 72°C for 5 
min.    192
5.2.1.5 Restriction endonuclease digestion 
Following agarose gel electrophoresis, the predicted PCR product of 1.7 kb was excised 
and recovered using a QIAquick Gel Extraction Kit (Qiagen) as previously described in 
section 2.2.13. 
The recovered HA fragment and pCAGGS plasmid DNA was subjected to restriction 
endonuclease digestion with EcoRI (TaKaRa) and SmaI (Fermentas, Changsha, China) as 
described in section 4.2.1.2. The digestion product was purified using a PCR purification 
kit (Watson BioTechnologies Inc., Shanghai, China) and then quantified using Ultrospec 
3000 UV/Visible spectrophotometer (Pharmacia Biotech, Cambridge, UK). 
5.2.1.6 Construction of pCAG-HAk expression vector 
The EcoRI-SmaI digested HA fragment was ligated into the EcoRI-SmaI digested 
pCAGGS vector to generate pCAG-HAk as described in section 3.2.1.2.  
Transformation was conducted as described in section 2.2.14.2 using DH5α competent E. 
coli cells (TaKaRa). The positive clones were screened by PCR and further confirmed by 
sequencing using the vector-specific primers. 
5.2.1.7 Sequencing 
 
A Beckman CEQ
TM2000XL DNA analysis system was used to perform sequencing. For 
this, 400 ng plasmid DNA and ddH2O was added into a 0.2 mL thin-wall tube to a total 
volume of 7 μL, followed by denaturation at 96°C for 3 min. Subsequently 1 μL (5 
pmol/μL) viral primer and 2 μL DTCS Quick Start Master Mix (Premix) (Beckman 
Coulter, CA, USA) were added and PCR was performed using the thermal cycler   193
program: 96°C for 20 sec, 50°C for 20 sec, 60°C for 4 min, 30 cycles followed by 
holding at 4°C.  
The sequencing reaction was transferred to 2.5 μL stop solution (1 μL of 3 M NaAC (pH 
5.2), 1 μL of 100 mM EDTA (pH 8.0), 0.5 μL of 20 mg/mL glycogen). Then 60 μL cold 
95% (v/v) ethanol (-20°C ) was added and the mixture was held at -20°C for 20 min, 
followed by  centrifugation at 12,000 g at 4°C for 20 min. The pellet was subsequently 
washed twice with 200 μL cold 70% (v/v) ethanol (-20°C), followed by centrifugation at 
12,000 g at 4°C for 10 min. The pellet was re-suspended in 30 μL formamide by holding 
at 4°C for 20 min. It was then transferred to the appropriate wells of the CEQ sample 
plate followed by overlaying with one drop of light mineral oil. The sample plate was 
loaded into the Beckman CEQ800 sequencer (Beckman Coulter).  
After sequencing, Seqman from DNASTAR was used to edit and analyse the sequence 
and MegAlign was used to compare the result with previous HA sequencing results. 
5.2.2 Large-scale preparation of plasmid DNA for use as a DNA vaccine 
 
A large quantity of plasmid DNA was prepared according to the classical protocol 
(Sambrook and Russell 2001). Briefly, 1L bacterial culture was harvested by 
centrifugation at 5, 000 g for 15 min at 4°C. The pellet was dissolved in 100 mL STE 
(100 mM NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA (pH 8.0)) buffer (4°C) followed by 
centrifugation at 5,000 g for 10-15 min at 4°C. The pellet was resuspended in 18 mL of 
solution I (4°C) followed by the addition of 2 mL of 10 mg/mL lysozyme (in 10 mM Tris 
(pH 8.0) buffer) (Bgi Life Tech Co., Ltd., Beijing, China). Then 40 mL of solution II was 
added to the suspension followed by gently mixing and incubation on ice for 10 min. 
Subsequently 30 mL of solution III (60 mL of 5 M KOAc, 11.5 mL glacial acetic acid   194
and 28.5 mL dH2O) was added to the mixture and thoroughly mixed until a white 
precipitate was observed. After centrifugation at 8,000 g for 20 min at 4°C, the 
supernatant was filtered through 4-layers of sterile gauze. The filtered supernatant was 
mixed with 0.6 volume isopropanol followed by centrifugation at 8,000 g for 20 min at 
room temperature. The pellet was dissolved in 10 mL TE buffer (10 mM Tris-HCl (pH 
8.0), 1 mM EDTA (pH 8.0)) and then mixed with 10 mL of 5 M LiCl solution (4°C). The 
mixture was held on ice for 10 min before centrifugation at 10,000 g for 15 min at 4°C. 
The supernatant was mixed with an equal volume of isopropyl alcohol followed by 
holding at room temperature for 10 min. After centrifugation at 12,000 g for 10 min at 
4°C, the pellet was rinsed with 70% ethanol. The pellet was then dissolved in 500 μL TE 
containing 20 µg/mL RNase A (Genebase Gene-Tech Co., Ltd., Shanghai, China) and 
held at 37°C for 30 min. The supernatant was mixed with an equal volume of 
phenol:cholorform:isoamyl alcohol (25:24:1) followed by centrifugation at 10,000 g  for 
5 min at room temperature. The aqueous phase was transferred to a polypropylene tube 
followed by the addition of an equal volume of cholorform. The supernatant was 
precipitated by addition of 1/10 volume 3M NaOAc (pH4.8) and 2.5 volumes 100% 
ethanol followed by incubation at -20°C for 30 min. After centrifugation at 15,000 g for 
20 min at 4°C, the pellet was dissolved in 1 mL dH2O followed by adding 0.5 mL PEG-
MgCl2 solution (40% (w/v) PEG8000, 30 mM MgCl2), and the mixture was held at room 
temperature for 10 min. Following centrifugation at 12,000 g for 20 min at room 
temperature, the pellet was washed twice using 1 mL 70% ethanol followed by 
centrifugation at 12,000 g for 5 min. The pellet was dried at 37°C for 10 min, dissolved 
in 500 μL TE and stored at -20°C until required.   195
5.2.3 In vitro expression of pCAG-HAk 
Transfection was conducted with Lipofectamine
TM 2000 (Invitrogen Corp., CA, USA) 
following the manufacturer’s instructions. Human embryonic kidney cell line 293T cells 
were grown in DMEM (Gibco BRL, CA, USA) supplemented with 10% FCS in a 6-well 
plate pre-coated with poly-lysine (Greiner-Bio One) until the cells were approximately 
70-80% confluent.  Then 5 μg plasmid DNA was added to 100 μL Opti-MEM (Gibco 
BRL) in a sterile tube and 10 μL (1mg/mL) Lipofectamine
TM 2000 was added to 200μL 
Opti-MEM in another tube followed by gently mixing and holding at room temperature 
for 5 min. Subsequently, the Lipofectamine solution was added to the DNA solution 
followed by gently mixing and holding at room temperature for 30 min. During this 
period, the 6-well plate was washed twice with 2 mL Opti-MEM followed by the addition 
of 1.2 mL Opti-MEM into each well.  The DNA-Lipofectamine mixture was then added 
to the cells, followed by incubation at 37°C for 6-10 hr. After the medium was removed, 
the cells were washed twice with Opti-MEM. The wells were filled with 1.5 mL Opti-
MEM and the plate was incubated at 37°C for another 24 hr.  
Thirty six to forty eight hours post-transfection the cells were fixed using 70% alcohol at 
room temperature for 30 min. Then the IFT was performed using chicken anti-H6 serum 
and rabbit anti-chicken FITC (Sigma-Aldrich, Beijing, China) as described in section 
2.2.5. The monolayers were observed for specific green fluorescence under a Leica 
DMIRES2 microscope (Leica, Wetzlar, Germany). 
The expression of pCAG-HAk in Cos-7 cells and subsequent detection of HA antigen 
bands by WB was previously described in sections 3.2.4 and 3.2.5.     196
5.2.4 Animals and immunizations  
Chicken vaccination and challenge studies were conducted as described in section 4.2.3 
using SPF chickens at the Harbin Veterinary Research Institute, China.  
For the vaccinations, plasmid DNA was diluted in PBS to deliver the doses indicated in 
Table 5.2 and 5.3 as a 200 µL volume administered in the leg muscles by either IM 
injection or EP, as described in section 4.2.3. Three groups of 8 chickens received either 
10, 100 or 300 µg pCAG-HAk by IM injection (Groups 1-3); one group of 8 chickens 
received 100 µg pCAGGS by IM injection (Group 4) and one group of 8 chickens 
received 100 µg pCAG-HAk by electroporation (Group 5). Three weeks later, these five 
groups of birds were given booster vaccinations using the same dose and delivery route. 
Another group of 15 chickens (Group 6) received only a single vaccination of 100 µg 
pCAG-HAk by IM injection. 
5.2.5 Virus challenge  
In preparation for challenge studies with pCAG-HAk-vaccinated chickens, a pilot study 
was conducted to determine clinical signs and virus shedding in control chickens using 
the H6N2 LPAI challenge virus available in Harbin, since A/coot/WA/2727/79 (H6N2) 
virus was unavailable. Six 8-week-old naïve SPF chickens were challenged with a 10
6.17 
EID50/0.1 mL dose (HA titre 2
6) of A/duck/Anhui/269/2002 (H6N2) virus in a 0.2 mL 
volume via nasal instillation.  
OS and CS were collected from all chickens at 1, 3, 5 and 7 days post-challenge for virus 
isolation in chicken embryonated eggs. The chickens were observed daily for clinical 
signs and death over a 2-week period.    197
Sera were collected at day 10 post-vaccination for detection of HI antibody as described 
in section 2.2.3.3.  
Statistical analysis of data was conducted as per section 2.2.18. 
 
5.3 Results 
5.3.1 Confirmation of the pCAG-HAk construct 
Because no antibodies or marginal antibody response in vaccinated chickens in previous 
chapters may have been due to mutation of the HA gene, the new HA DNA construct was 
developed directly from the H6N2 virus.  The HA fragment was subsequently amplified 
by proof-reading PCR, using an annealing temperature of 60°C, to yield a product of 1.7 
kb. After cloning of the HA gene into the pCAGGS vector, the inserted gene was 
sequenced using the primers (P1-P5) in Table 5.1.  The HA sequence was consistent with 
that achieved in Chapter 2. 
5.3.2 In vitro expression of the pCAG-HA construct  
Forty eight hours after transfection of 293T cells with pCAG-HAk and pCAGGS, the cell 
monolayers were stained by IFT. Specific fluorescence was mainly distributed in the cell 
membranes of cells transfected with pCAG-HAk as shown in Figure 5.2.  
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Figure 5.2 Immunofluorescence in 293T cells after transfection with the pCAG- HAk (A) 
and absence of specific staining with pCAGGS (B).(x100). 
 
 
The HA protein expression in pCAG-HAk transfected Cos-7 cells was detected by WB, 
displaying a strong band of approximately 78 kDa (Figure 5.3).  
 
 
 
Figure 5.3 HA expression in Cos-7 cells detected by WB. 
Lane 1, protein markers (Bio-Rad); lane 2, pCAG-HAk transfected cells; lane 3, pCAGGS 
transfected cells. 
 
5.3.3 Antibody response induced by two vaccinations of pCAG-HAk construct    199
As shown in Table 5.2 (Groups 1 to 3), the earliest time of sero-conversion appeared two 
weeks after vaccination. The H6 HI test sero-conversion rates three weeks after initial 
vaccination were 37.5%, 12.5% and 0 in the 10, 100 and 300 µg pCAG-HAk vaccinated 
groups respectively. After the booster vaccination the sero-conversion rate increased to 
87.5%, 75% and 75% respectively, indicating that a second vaccination increased the 
sero-conversion rate in all three groups. 
The profile of HI antibodies induced by different doses of pCAG-HAk (Groups 1 to 3) 
during the 8-week study period was similar (Table 5.3 and Figure 5.4). After one dose, 
the vaccinated birds in the 10 µg and 100 µg pCAG-HAk groups demonstrated HI 
antibody, but those in the 300 µg group did not. However, the H6 HI titre rose 
significantly in the three different dose groups following booster vaccination and reached 
a plateau 2-3 weeks post-booster. No H6 HI titre was observed in the pCAGGS 
vaccinated group. The GMT of HI antibody was significantly different (Mann-Whitney 
Test, p<0.05) between the combined pCAG-HAk groups and the pCAGGS group at 
weeks 4, 5, 6, 7 and 8 following initial vaccination, but there was no significant 
difference at week 3 after vaccination. There was no significant difference in GMT 
between the three doses of pCAG-HAk vaccine (ANOVA, P = 0.963).   200
Table 5.2 Sero-conversion rate by H6 HI test in chickens immunized with pCAG-HAk or pCAGGS. 
 
Sero-conversion rate (weeks post vaccination)  Group Vaccine Dose 
(µg) 
Route
1  2 3* 4  5  6  7  8  9 10  11  12 
1  pCAG-HAk  10  IM 0/8** 1/8 3/8 4/8  6/8  6/8 7/8 7/8         
2  pCAG-HAk 100  IM  0/8  1/8 1/8 2/8  6/8  5/8 5/8 6/8         
3  pCAG-HAk 300  IM  0/8  0/8 0/8 5/8  6/8  6/8 6/8 5/8         
4  pCAGGS  100  IM  0/8  0/8 0/8 0/8  0/8  0/8 0/8 0/8         
5  pCAG-HAk 100  EP  1/8  5/8 7/8 8/8  8/8  8/8 8/8 8/8         
6 pCAG-HAk  100  IM  0/15  6/15 5/15 7/15 10/15 8/15 8/15 8/15 8/15 8/15 8/15 8/15
                   *Time of booster vaccination for Groups 1 to 5; Group 6 was only vaccinated once.  
     **N/N represents HI antibody positive chickens/all vaccinated chickens.  
 
 
 
Table 5.3 HI titres in chickens immunized with pCAG-HAk or pCAGGS via IM or EP over an 8- or 12- week period after vaccination. 
 
HI titre (weeks post vaccination)  Vaccine Dose 
(µg) 
Route 
1 2  3*  4 5 6 7 8 9  10  11  12 
pCAG-HAk  10  IM  0**  0.4±1.1 0.9±1.4 1.6±2.1 2.4±2.1 2.8±2.1  3.1±2.0 3.2±2.1     
pCAG-HAk  100  IM  0  0.4±1.1 0.4±1.1 1.0±2.1 2.6±2.6 2.9±2.9  2.9±2.7 2.9±2.3     
pCAG-HAk  300  IM  0  0  0  1.5±1.7 2.6±2.2 2.6±2.0  2.3±1.7 1.9±1.8     
pCAGGS  100  IM  0 0 0 0 0 0 0 0         
pCAG-HAk  100  EP  0.1±0.4  3.3±3.4 3.8±2.8 6.7±3.0 7.1±3.0 6.6±2.3  5.8±2.4 5.6±2.1     
pCAG-HAk 100  IM  0  1.0±1.4 0.9±1.4 2.0±2.5 2.4±2.3 2.1±2.2  1.8±1.9 1.7±1.8 1.5±1.6 1.3±1.3 1.1±1.2 1.1±1.2
* Chickens in Groups 1-5 were given a booster 3 weeks after initial immunization; Group 6 was only vaccinated once.   
** H6 HI antibody represents GMT (log2) ± SD. 
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Figure 5.4 Temporal changes of H6 HI titers over an 8 week period post-vaccination in chickens immunized with 10 µg (A), 100 µg (B) 
and 300 µg (C) pCAG-HAk.The curve represents the mean antibody titre of the relevant group. Numbers refer to individual birds.(D) Average 
H6 HI antibody titres in the 10, 100, 300 µg pCAG-HAk groups via IM vaccination and the 100 µg pCAG-HAk group vaccinated with EP.   202
 5.3.4 Antibody response induced by a single vaccination of the pCAG-HAk construct  
Of 15 birds vaccinated with a single dose of 100 µg pCAG-HAk construct, 40 % (6/15) 
sero-converted at week 2 post-vaccination and 66.7% (10/15)  at week 5 post-vaccination 
(Group 6 in Table 5.2). The peak HI GMT occurred at week 5 post-vaccination and the 
HI titre slowly declined during the 3-month observation period (Figure 5.5). There were 
no significant differences (ANOVA, P>0.05) in the GMT of H6 HI antibody at weeks 2 
and 3 post-vaccination between  Group 6 and the pCAGGS vector group (Group 4). 
Neither was there a significant difference in the HI antibody GMT (ANOVA, P=0.43) or 
in the sero-conversion rate (Fisher's exact test, P=0.37) at week 3 following initial 
vaccination between Group 6 and Group 2 (Table 5.2 and Table 5.3). 
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Figure 5.5 Temporal changes in H6 HI titer over a 12-week post-vaccination period in 
chickens immunized with a single dose of 100 µg pCAG-HAk. 
The curve represents the mean antibody titre of the group. Each icon number refers to one bird. 
 
5.3.5 Antibody response induced by two vaccinations of pCAG-HAk construct via EP   203
Birds administered pCAG-HAk construct via EP showed 87.5% sero-conversion after the 
first vaccination and 100% sero-conversion after the second vaccination (Group 5 in 
Table 5.2).  The highest HI antibody GMT (2
7.1) occurred at week 5 post-vaccination then 
the antibody gradually declined. The highest HI titre for an individual bird was 2
11 
(Figure 5.6). 
There were significant differences (ANOVA/Mann-Whitney Test, P<0.05) in the  HI 
antibody GMT from week 2 to 8 between the IM and EP groups receiving 100 µg pCAG-
HAk (Figure 5.5d). 
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Figure 5.6 Temporal changes in H6 HI titer over an 8-week period post-vaccination in 
chickens immunized with 100 µg pCAG-HAk via EP. 
The curve represents the mean antibody titre of the group. Each icon number refers to one bird. 
 
 
5.3.6 Virus challenge  
Six naive SPF chickens challenged with A/duck/Anhui/269/2002 (H6N2) virus did not 
exhibit any clinical signs during the two-week period post-challenge. Only three birds 
shed the virus intermittently in OS in the first four days, whereas, no virus shedding was 
detected in CS during 7 consecutive days of sampling. The GMT of H6 HI antibody at   204
day 10 post-challenge was 2
4.67 (range from 2
2.5 to 2
 6) using homologous virus 
(A/duck/Anhui/269/2002) as antigen compared with 2
1.25 (range from 0 to 2
2.5) using 
heterologous virus (A/coot/WA/2727/79) as antigen.  
5.4 Discussion 
This study successfully demonstrated that a pCAG-HAk DNA vaccine was able to elicit 
measurable H6 HI antibody responses. Either one or two vaccinations of naked plasmid 
DNA induced sero-conversion in a substantial proportion of chickens vaccinated. In 
particular, 100% of chickens vaccinated with the pCAG-HAk DNA vaccine via EP 
generated high titres of H6 antibody, which is comparable to titres previously achieved 
with an inactivated whole virus H6N2 vaccine (Table 3.3 in Chapter 3). Nevertheless, the 
higher dose (300 µg) of pCAG-HAk DNA administered by IM injection did not produce 
any higher antibody responses than the lower doses used (either 10 µg or 100 µg). 
The temporal antibody response studies following pCAG-HAk vaccination with EP 
showed that the earliest detectable antibody was at one week post-vaccination, compared 
with two weeks after IM administration. However, in some IM vaccinated chickens the 
immune response was not detectable until five weeks post-vaccination. This long lag 
phase is probably related to poor DNA uptake into muscle fibers via IM delivery, the 
mechanism of which is poorly understood. It has been hypothesized that IM injection of 
naked DNA vaccines only causes the transfection of a limited number of muscle fibres 
however, due to the low rate of muscle fibre turnover, this can result in the expression of 
the plasmid DNA for an extended period of time (Pertmer et al. 1996; Wolff et al. 1990).    
In addition, myocytes are terminally differentiated, long-lived cells that cannot re-enter 
mitosis, and thus do not dilute out the internalized plasmids resulting in long-term   205
stability and transcriptional activity of plasmid DNA (Fattori et al. 2002; van Deutekom 
et al. 1998). 
The antibody titre peaked at approximately two weeks following two DNA vaccinations 
via either IM or EP, persisted for several weeks and gradually declined. With IM 
administration, two immunizations appeared to be better than one in terms of the strength 
and persistence of the antibody response. The effect of a single immunization via EP was 
not evaluated in this study due to an inadequate number of SPF isolators and the limited 
experimental period available. 
Dose–response studies demonstrated that IM injection of pCAG-HAk DNA at doses of 
10 µg, 100 µg or 300 µg could induce HI antibodies. Although the sero-conversion rate 
following two vaccinations was similar in the three different dose groups, both 10 µg and 
100 µg groups appeared to generate higher H6 HI geometric antibody titres than the 300 
µg group,  although this was not significantly different. This result suggested that lower 
dose DNA vaccination appeared to generate a better antibody response than vaccination 
with a higher dose and this is similar to observations made in Chapters 3 and 4. In 
addition, the observation that vaccination with the 10 µg DNA plasmid dose via the IM 
route appeared to induce similar H6 HI antibody titres to the 100 µg DNA plasmid dose 
has implications for the cost-effectiveness of such DNA vaccines.  
Although GG delivery system has been shown to reduce the dosage required to protect 
chickens against H5 AI to 1–10 µg plasmid DNA (Kodihalli et al. 1997), this method is 
impractical for field use. The present study indicated that IM injection at a dose of 10 µg 
induced a similar antibody response to 100 µg DNA vaccination. This was in agreement 
with a research report (Ulmer et al. 1994), in which IM injection of low doses of HA or   206
NP-expressing DNA at doses of 100 ng to1 µg was successful in generating antibodies to 
HA and CTL respectively, and in protecting mice against influenza virus challenge.  
 In the group receiving a single dose of the 100 µg pCAG-HAk DNA vaccine, the 
antibody response at week 3 post-vaccination appeared stronger in terms of the sero-
conversion rate than in the group with two injections of the same dose three weeks apart. 
However, the differences between the groups at week 3 post-vaccination were not 
significantly different and probably resulted from biological variation in individuals 
within the experimental groups. In addition, there was considerable individual variation 
in H6 HI antibody response among chickens receiving the pCAG-HAk vaccine 
intramuscularly. The highest H6 HI titre reached was 2
8, whereas, some birds had no 
measurable antibody response. Similarly, in the EP group, the highest titre achieved was 
2
11 and the lowest, after two doses, was 2
2. This variation has also been reported in other 
DNA vaccine studies in chickens (Suarez and Schultz-Cherry 2000a) and mice (Ulmer et 
al. 1994). The reason for the wide variation in individual HI antibody titres in vaccinated 
birds is not clear, but may be attributable to the poor efficiency of the delivery method 
(Wang et al. 2008b).  This inter-individual variation is another drawback of DNA 
vaccines and supports the need to fully elucidate the mechanism of the DNA-induced 
immune response. 
For this study the intention was to conduct a heterologous H6N2 challenge with pCAG-
HAk vaccinated chickens using A/duck/Anhui/269/2002 virus that was available in 
Harbin and then to conduct a homologous challenge in chickens vaccinated with pCAG-
HAk at Murdoch University. However, the pilot trial of the heterologous challenge in 
naive control birds with the H6N2 virus available in Harbin produced no clinical signs   207
and very limited virus shedding. Thus, group sizes would have to have been large to 
detect any differences in virus shedding between vaccinates and controls with this virus 
and as time constraints were in place the heterologous challenge study was not conducted 
at Harbin. This challenge would have been used to optimize the pCAG-HAk vaccine dose 
for the homologous challenge studies at Murdoch University.  
Although the 10 µg pCAG-HAk plasmid dose administered intramuscularly provided 
similar antibody responses to the 100 µg DNA dose in this study, it was decided to use 
100 µg pCAG-HAk plasmid dose for the DNA vaccine studies performed at Murdoch, 
reported in Chapters 7 and 8, because of the variability of plasmid uptake by muscle cells 
and the DNA plasmid dosage used by other DNA vaccine researchers (Chen et al. 2001; 
Cherbonnel et al. 2003).  
It has been established previously that chickens given inactivated vaccines  that reach a 
post-vaccination geometric mean HI titre of greater than 2
6.5 had good protection after 
challenge, based on disease signs and tracheal/cloacal virus isolation (Wood et al. 1985). 
However, in vaccine challenge studies using field vaccinated birds with a H5 HI titre of 
2
5 or higher there was complete protection against a high challenge dose of Asian H5N1 
HPAI (Ellis et al. 2004). A close relationship between HI titers  generated by plasmid 
DNA (greater than 1:40) and protection was observed previously in mice, ferrets and 
non-human primates immunized with a plasmid encoding consensus HA gene of H5 AIV 
(Laddy et al. 2008). Although LPAI virus challenge was not able to be conducted in the 
Harbin studies, if protection/reduction in virus shedding is equated with a HI titre of 2
5 or 
higher, at least six out of eight chickens in the 100 µg EP group and two out of eight   208
birds in the 100 µg IM group, with HI titres greater than 1:64, had achieved this level of 
protection. 
In vivo electroporation has been well documented to improve the efficacy of DNA 
vaccination in eliciting both humoral and cellular immune responses in several models 
including mice (Chen et al. 2005; Dobano et al. 2007; Dupuis et al. 2000; Hooper et al. 
2007; Widera et al. 2000), goats and cattle (Tollefsen et al. 2003), sheep (Babiuk et al. 
2002; Babiuk et al. 2007; Tsang et al. 2007), rabbits (Wang et al. 2008b) and non-human 
primates (Luckay et al. 2007). In this study, the mean H6 HI titre was ≥ 8-fold higher in 
the EP vaccinated group than in the IM vaccinated group from 2 to 8 weeks post-
vaccination. This indicated that vaccination with EP was significantly more effective than 
routine IM inoculation with the pCAG-HAk vaccine in chickens.  
The promoter driving gene expression was reported previously to be one of the factors 
affecting the efficacy of DNA vaccines (Xiang et al. 1995). Depending on their origin, 
promoters differ in tissue specificity and efficiency in initiating mRNA synthesis 
(Kodihalli et al. 1997; Xiang et al. 1995).  One study demonstrated that CMV and 
chicken β-actin promoters were equally suitable for use with a H5 HA-expressing DNA 
vaccine in chickens (Kodihalli et al. 1997), on the basis of protection against lethal 
challenge with H5N1 HPAI virus. However, in contrast to the previous CMV promoter-
driven HA-expressing constructs described in Chapters 3 and 4, the pCAG-HAk plasmid 
containing the chicken β-actin promoter was more effective at producing H6 HI antibody 
responses in chickens.  
The Kozak sequence plays a major role in the initiation of a translation process in 
mammalian cells (De Angioletti et al. 2004). As prokaryotic genes and some eukaryotic   209
genes do not have Kozak sequences, it has been postulated that the expression level of 
these genes might be augmented by the insertion of a Kozak sequence. Insertion of a 
Kozak sequence upstream of the gene in a pUC vector was shown to significantly 
increase in vitro expression of the human serum albumin gene in horse cells (Olafsdóttir 
et al., 2008). Thus, this approach would appear to be a useful and practical tool in the 
development of improved DNA vaccines.  
In this study, a pCAG-HAk DNA vaccine was constructed that incorporated a Kozak 
sequence upstream of the ATG initiation codon of the HA gene. Insertion of the Kozak 
sequence and use of the high-efficiency pCAGGS vector synergistically contributed to a 
higher level of H6 HA expression than other plasmid vectors evaluated in earlier chapters, 
resulting in a detectable antibody response. Analyzing the parameters which impact on 
DNA-induced antibody responses is important to successfully develop DNA vaccines. 
Further investigation of these factors in this DNA construct was carried out in the 
following chapters to identify which plays the more critical role in eliciting antibody 
responses.  
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Chapter 6 
Evaluation of codon usage on the immunogenicity of a HA DNA vaccine against 
H6N2 avian influenza  
 
6.1 Introduction  
DNA immunization has emerged as a promising new approach to vaccination. However, 
successful DNA vaccination requires high expression of genes derived from 
microorganisms in animals and humans. One of the barriers for expression of genes 
derived from microorganisms in mammalian cells may be attributable to the inter-specific 
difference of codon usage (Nagata et al. 1999). It is known that mammalian codon usage 
patterns are different from those of numerous microorganisms and yeasts (Ikemura 1985). 
Thus, differences in codon usage between a heterologous gene and the host organism 
may have an impact on expression of the gene, which may eventually affect the 
immunogenicity of an antigen-encoding DNA vaccine. 
A codon is a trinucleotide sequence encoding an amino acid residue. Most amino acids 
are encoded by more than one codon as the genetic code is degenerate. However, the 
choice of codons is not random and the frequency of synonymous codon usage is biased 
depending on the species (Makoff et al. 1989; Nagata et al. 1999). Thus, codon usage 
optimization of a gene, which substitutes a mammalian-biased codon for the codon 
preference of a microorganism, represents a novel strategy for engineering a DNA 
vaccine construct or enhancing the efficacy of DNA vaccination. Nagata et al.(1999) 
examined how codon optimization affected the translational efficiency in mammalian 
cells using plasmid DNA encoding a CTL epitope derived from Listeria monocytogenes 
and Plasmodium yoelii. It was reported that codon optimization of the green fluorescent 
protein gene (Zolotukhin et al. 1996) or human erythropoietin gene with human high-  211
frequency codons gave a considerably higher level of expression in mammalian cells. It 
was also reported that codon optimization was effective in enhancing the immunogenicity 
of DNA vaccines against influenza virus (Wang et al. 2006), H5 AIV (Jiang et al. 2007), 
HIV (Andre et al. 1998; Deml et al. 2001; Kumar et al. 2006), papillomavirus (Cheung et 
al. 2004);  Clostridium tetani (Stratford et al. 2000), Mycobacterium tuberculosis (Ko et 
al. 2005) and Plasmodium falciparum (Narum et al. 2001). Codon optimization was also 
used to develop DNA vaccines against emerging diseases such as Nipah virus (Wang et 
al. 2008c), Chikungunya virus (Muthumani et al. 2008) and severe acute respiratory 
syndrome (SARS) virus (Yang et al. 2004). 
The purpose of the study reported in this chapter was to construct a DNA plasmid 
encoding a codon optimized HA gene and to determine if it could maximise 
immunogenicity of a H6 HA-expressing DNA vaccine in chickens.  
6.2 Materials and Methods 
6.2.1 Preparation of a codon-optimized HA-expressing DNA vaccine construct 
The chicken biased codon information (the codon preference of Gallus gallus) was 
obtained from a codon usage database (http://www.kazusa.or.jp/codon/). The sequence of 
the full-length HA gene from A/coot/WA/2727/79 (H6N2) was shifted to the chicken-
biased codons using Editseq of DNASTAR. Despite DNA-level sequence changes, the 
final codon-optimized HA DNA sequence still produced the same HA amino acid 
sequences as those in the wild type AI virus. The Kozak sequence GCCGCCACC was 
added immediately before the start codon. For subcloning purposes the restriction 
endonuclease sites of EcoRI and SmaI were added immediately upstream of the Kozak 
sequence and downstream of the stop codon, respectively. This codon-optimized HA   212
gene was chemically synthesized and cloned into pUC57 (Figure 6.1) by GenScript 
Corporation (Beijing, P.R. China), with the addition of an EcoRV site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Plasmid construct map from GenScript Corporation (Beijing, China). 
The C09702-1 (optiHA gene) was cloned in pUC57 by EcoRV. Blue sequences refer to 
protective bases added by GenScript. 
 
 
 
The synthesized codon-optimized HA gene insert was subcloned into the expression 
vector pCAGGS to generate pCAG-optiHAk at the EcoRI and SmaI sites as described in 
Chapter 5. This ligation product was transformed into E. coli (H5α strain). The positive 
clone was selected based on the results of PCR and restriction enzyme digestion of the 
 
 
 
MCS: 
pUC57-C6a8
(4501bp)
TCTAGAT ATTGGAAGCTT 
Xba I  
TACCATTGG ATC GGATCC 
BamH I  
MCS
pUC57
(2710bp)
MCS
C09702 -1(1728bp)   213
DNA construct. Plasmid DNA was prepared for in vitro transfection using a 
QIAprep
®Spin Miniprep kit (Qiagen) as described in section 2.2.15 and for in vivo 
animal immunization using the classical alkaline lysis and subsequent PEG purification 
as described in section 5.2.2. 
6.2.2 Confirmation of in vitro-expressed HA antigens 
The pCAG-optiHAk construct was transiently transfected into 293T cells or BSR (a clone 
of BHK-21) using Lipofectamine
TM 2000, as described in section 5.2.3. The expression of 
HA antigens was verified by WB and IFT as described in sections 3.2.5.3 and 2.2.5 
respectively. The substrate for WB was 3, 3'-diaminobenzidine (DAB) (Boster 
Biotechnology Co. Ltd, Wuhan, China). 
6.2.3 DNA immunization of chickens 
Groups of 6-week-old SPF chickens housed in HEPA-filtered isolators, with 8 birds per 
group, were intramuscularly injected with either 10 µg or 100 µg pCAG-optiHA plasmid 
as per section 5.2.4. This experiment commenced three weeks after the study in Chapter 5 
using SPF chickens from the same batch as Chapter 5. Sera were collected on a weekly 
basis post-vaccination for HI assays as per section 2.2.3. Statistical analysis of data was 
conducted as per section 2.2.17. 
6.3 Results 
6.3.1 Effect of codon optimization on HA composition 
The chemically synthesized chicken codon-biased HA gene from A/ coot/WA/2727/79 
(H6N2) had the same HA amino acid sequences as the original virus, but the nucleotide 
homology between the wild-type HA gene and the codon-optimized HA gene was 74.8%.   214
The comparison at nucleotide sequence level between them is shown in Appendix 6.1 
using ClustalW software (http://www.ebi.ac.uk/Tools/clustalw/). A summary of the codon 
preference changes before and after codon optimization using EditSeq of DNASTAR is 
presented in Table 6.1. Codon optimization resulted in an increase in the G+C content 
from 41.3% in HA wild-type to 59.5% after optimization. 
 
Table 6.1 Comparison of the most frequently prevalent codons in the chicken and H6N2 
virus. 
 
Codon Codon  Amino acid 
Virus Chicken 
Amino acid 
Virus Chicken 
Ala GCA  GCC Met AUG  AUG 
Arg AGA  AGA Leu UUG  CUG 
Asn AAU  AAC Lys AAA  AAG 
Asp GAU  GAU Phe  UUC/UUU  UUC 
Cys UGU  UGC Pro CCA CCC 
Gln CAA  CAG Ser UCA  AGC 
Glu GAA  GAG Thr ACA  ACC 
Gly GGA  GGC Trp UGG  UGG 
His CAU  CAC Tyr UAU  UAC 
Ile AUA  AUC Val GUG  GUG 
 
 
6.3.2 Identification of insert gene by restriction endonuclease digestion and PCR 
The synthesized gene was sequenced by the company. For confirmatory identity, the 
synthesized codon optimized HA gene in a pUC57 vector was digested by EcoRI and 
SmaI, resulting in a 1.7 kb HA fragment and a 2.71 kb pUC57 fragment. The pCAG-
optiHAk construct was identified by PCR using virus primers and a vector/virus primer 
pair, and restriction endonuclease digestion (Figure 6.2).  
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Figure 6.2 A Identification of synthesized optiHA gene by restriction endonuclease digestion. 
Lane 1, DL2000 plus DNA marker (Beijing Tuoyingfang Biotech Co.,Ltd , Beijing, China); lane 
2, synthesized optiHA (EcoRI/SmaI). B Identification of optiHA gene by PCR. Lane 1, 
DL2000 marker; lane 2, optiHA fragment (1.7 kb) amplified by HAu/HAd primers; lane 3, 
optiHA fragment (1.8 kb) amplified by HAu/pCAG-R primers. C Restriction enzyme analysis 
of optiHA gene. Lane1, 1 kb marker; lane 2, pCAG-optiHAk (EcoRI/SmaI); lane 3, pCAG-HAk 
(EcoRI/SmaI); lane 4, pCAGGS. 
 
6.3.2 Transient expression of pCAG-optiHAk construct 
The pCAG-optiHAk construct and pCAGGS vectors transfected into 293T cells were 
fixed by alcohol at 48 hours and the encoded antigen expression was detected by IFT. 
Specific fluorescence was clearly observed, mainly distributed in the cell membrane in 
pCAG-optiHAk transfected 239T cells, but not in pCAGGS transfected cells (Figure 6.3). 
The outcomes of transient transfection of the synthetic and native HA genes in BSR cells 
were also compared by WB. As illustrated in Figure 6.4,  both the  pCAG-optiHAk  and 
the pCAG-HAk (wildtype) transfected BSR cells showed  approximately 84 kD  bands of 
the expected  size, but  the pCAG-optiHAk construct did not produce better antigen 
expression in vitro than the pCAG-HAk (wildtype).  
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Figure 6.3 293T cells transfected with pCAG-optiHA (A) and with pCAGGS (B) (x100). 
 
 
 
 
 
 
Figure 6.4 Western blotting analysis of HA protein expressed in BSR cells. 
Lane 1, marker (PageRulerTMPrestained Protein Ladder, Fermentas, MD, USA); lane 2,  pCAG-
optiHAk; lane 3, pCAG-HAk; lane 4, pCI-HAk;  lane 5, pCAGGS.  
 
6.3.3 Antibody response  
The kinetics of the antibody response induced by pCAG-optiHAk is shown in Figure 6.5 
and Table 6.3. Following booster vaccination, the seroconversion rate and HI titres 
increased in both groups. The higher dose groups generated better immune responses 
than the lower dose groups in terms of the seroconversion rate, although there were no 
significant differences (P>0.05) in the GMT of HI antibody between different doses of 
pCAG-optiHAk. This suggested that a 100 µg dose of pCAG-optiHAk was a more 
optimal dosage for induction of HI antibody responses.  
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Table 6.2 Sero-conversion rates in chickens immunized with pCAG-optiHAk, pCAG-HAk 
and pCAGGS*. 
 
Sero-conversion rate (weeks post vaccination)  Group Vaccine Dose 
(µg) 
Route
1  2  3**  4 5 6 7  8  9 
1 pCAG-optiHAk  10 IM  0/8***
 a 0/8
a 1/8
 a 1/8
 a 2/8
 a 3/8
 a 3/8
 a 2/8
 a 2/8
 a 
2 pCAG-optiHAk  100  IM 0/8
 a 2/8
 a 3/8
 a 3/8
 a 4/8
 a 4/8
 a 7/8
 a 7/8
 b 7/8
 b 
3 pCAG-HA  10  IM  0/8
 a 1/8
 a 3/8
 a 4/8
 a 6/8
 a 6/8
 a 7/8
 a 7/8
 b  
4 pCAG-HA  100  IM  0/8
 a 1/8
 a 1/8
 a 2/8
 a 6/8
 a 5/8
 a 5/8
 a 6/8
 ab  
5  pCAGGS  100  IM  0/8  0/8 0/8 0/8 0/8 0/8 0/8  0/8  0/8 
* Data from the Chapter 5 for comparison purposes. ** Time of booster vaccination. *** N/N represents HI 
antibody positive chickens in all vaccinated chickens. Within the column the different lowercase 
superscript letter indicates statistical differences (P < 0.05) using Fisher's exact test, group 5 excluded in 
statistical analysis.   218
Table 6.3 HI antibody in chickens immunized with pCAG-HAk, pCAG-optiHAk and pCAGGS. 
 
HI titre (weeks post vaccination)  Group Vaccine Dose 
(µg) 
Route
1 2  3*  4 5 6 7 8 9 
1 pCAG-optiHAk  10 IM  0 0 0.1±0.2** 0.4±1.1  1.3±2.5 1.4±2.5 1.1±2.0 1.2±2.2 1.2±2.2
2 pCAG-optiHAk  100  IM  0 1.1±1.5 0.8±1.3  1.4±1.9  2.5±2.7 2.6±2.8 3.2±2.3 2.9±2.2 3.0±2.1
3*** pCAG-HAk  10 IM  0 0.4±1.1 0.9±1.4  1.6±2.1  2.4±2.1 2.8±2.1 3.1±2.0 3.2±2.1  
4*** pCAG-HAk 100  IM  0 0.4±1.1 0.4±1.1  1.0±2.1  2.6±2.6 2.9±2.9 2.9±2.7 2.9±2.3  
5***  pCAGGS  100  IM  0 0  0  0 0 0 0 0 0 
              * Time of booster vaccination. ** GMT (log2) ± SD. *** Data from the Chapter 5. 
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Figure 6.5 Temporal anti-H6 HI responses in chickens immunized with 10 µg (A) and 100 µg (B) pCAG-optiHAk construct. 
The curve represents the mean antibody titre of the relevant group. Each icon number refers to one bird.  
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6.3.4 Comparison of HI titres between pCAG-HAk and pCAG-optiHAk groups 
The sero-conversion rate and level of antibody response were compared between pCAG-
HAk and pCAG-optiHAk groups (Tables 6.2 and 6.3) using data from this experiment 
and from the experiment in Chapter 5. There were no significant differences in the sero-
conversion rates from week 1 to week 7 after initial vaccination between either 10 or 100 
µg groups for pCAG-HAk and pCAG-optiHAk vaccines. Neither were there significant 
differences (ANOVA or Mann-Whitney, P>0.05) during an 8-week period in antibody 
GMT post vaccination between pCAG-HAk and pCAG-optiHAk vaccines. Only at week 
8 for the 10 µg dose groups was there a difference, with the pCAG-HAk group showing a 
higher sero-conversion rate than the pCAG-optiHAk group. This suggested that a codon-
optimized HA-expressing DNA vaccine was not able to achieve better immunogenicity 
than the wild type HA-expressing DNA vaccine.  
6.4 Discussion 
The HA protein of AIV is a natural target for vaccines. In the study reported in this 
chapter, the virus HA gene sequence was replaced by the chicken biased codon sequence 
to prepare the vaccine. As a result, there was 25.2% alteration at the nucleotide level in 
the codon-optimized HA DNA sequence, but no changes at the amino acid level. The GC 
ratio increased 18.2% in the codon optimized HA gene compared to the wild type virus 
sequence. The high GC content in the gene may be favorable for its mRNA stability, 
processing and nucleo-cytoplasmic transport (Haas et al. 1996; Jiang et al. 2007). This 
high GC rate could increase the number of CpG motifs in an optimized gene, which may 
act as an inherent adjuvant. Theoretically, the immunogenicity of the optimized HA-  220
encoding plasmid could be expected to have been improved. However, the codon 
optimized HA DNA vaccine did not achieve better antigen expression in terms of band 
intensity in WB in vitro, or with immunogenicity in terms of sero-conversion rate and HI 
titre in vivo, than the wild type HA-expressing DNA vaccine.  
The dose-response experiment showed that the 100 µg dose group elicited a better 
response than the 10 µg dose group and 87.5% birds vaccinated twice with a dose of 100 
µg produced a mean HI titre of 2
3. Although the age of vaccinated birds differed for 
logistical reasons between the pCAG-optiHAk study (6-week-old chickens) and the 
pCAG-HAk study (3-4 week-old chickens), both groups were SPF chickens of the same 
strain and batch and the age difference was considered unlikely to affect their antibody 
responses.  
Hass et al.(1996) reported that re-engineering the coding sequence with the most 
prevalent HIV-1 codons considerably impaired rat thymocyte protein (Thy-1) expression, 
but enhanced green fluorescent protein expression. Our experiment showed that either in 
vitro or in vivo expression of optimized HA gene was similar to that achieved by the wild 
type HA-expressing DNA vaccine. This result was different from other studies on 
optimized DNA vaccines, in which increased immunogenicity using a codon 
optimization strategy was shown (Deml et al. 2001; Jiang et al. 2007; Narum et al. 2001; 
Steinberg et al. 2005).  
Many factors regulate and influence gene expression levels. Although others who 
employed the same strategy for codon optimization as used in this study achieved the 
expected increased immune response (Jiang et al. 2007; Steinberg et al. 2005), 
introduction of host biased codons into a DNA vaccine backbone alone may not be   221
enough to increase vaccine immunogenicity. Some factors such as mRNA secondary 
structure, internal TATA boxes, cryptic splicing sites, premature PolyA sites, internal chi 
sites, ribosomal binding sites, negative CpG islands, RNA instability motif (ARE) and 
inhibition sites all may impact on ribosomal binding and stability of mRNA (Wang et al. 
2006). Thus, expression of a codon biased gene may still require further enhancement by 
RNA optimization. 
In addition, it has been widely assumed that translational initiation is responsible for 
translational efficiencies of mammalian gene products (Haas et al. 1996). The toeprinting 
assay used with mRNAs showed that the nucleotide G in position +4 augmented 
recognition of AUG and favored translation (Kozak 1987b). The first amino acid 
following ATG was Glu (GAG) in an optimized HA gene from A/goose/Guangdong/1/96 
(H5N1) (Jiang et al. 2007), in contrast, the current optimized HA gene presented Ile 
(ATC). The difference that the 4+ sequence was A rather than G in the current study may 
account for suboptimal expression in chicken cells. 
Considering the factors above, the codon optimization approach in this study needs to be 
further explored.    222
 Chapter 7 
Effect of different expression vectors with the Kozak sequence on HA-expressing 
DNA vaccines against H6N2 avian influenza 
 
7.1 Introduction 
DNA-based immunization has pioneered a new era of vaccine research. Efficient 
expression of heterologous genes in an appropriate eukaryotic vector is a prerequisite for 
the development of DNA vaccines. A promoter/enhancer, responsible for transcriptional 
initiation, is critical to successfully drive the expression of heterologous genes of interest. 
Davis et al. (1993b) reported that luciferase reporter gene expression driven by the RSV 
promoter was 1,000-fold higher using the SV40 promoter. Direct DNA injection of a 
HIV-1 gag/env multigenic DNA vaccine under the CMV/IE promoter/enhancer generated 
stronger humoral and T-cell proliferative responses in macaques than those produced 
using the endogenous AKV murine leukaemia viral long terminal repeat (Galvin et al. 
2000). The HA-expressing pCI-neo vector containing the CMV/IE promoter conferred 
better immune response to an H5 AIV in chickens in terms of antibody titre and 
survivability post virus challenge when compared with pSI containing the SV40 promoter, 
VR1012 containing CMV/IE promoter, pCAGGS.MCS containing the chicken β-actin 
promoter and pRC/RSV containing RSV promoter (Suarez and Schultz-Cherry 2000a). It 
is therefore important to select an effective vector with a strong promoter in an attempt to 
improve the efficacy of DNA vaccines.   
Sequences flanking the AUG initiation codon within mRNA have been proven to impact 
on its recognition by eukaryotic ribosomes. The consensus sequence surrounding the start 
codon, known as the Kozak consensus sequence, GCCA/GCCAUGG, has been shown to   223
be critical for efficient translation because lack of these nucleotide bases caused leaky 
scanning of ribosomes and hence reduced the efficiency of translation (Kozak 2005). The 
insertion of a Kozak sequence adjacent to the target gene in a vector has been shown to 
significantly enhance the level of gene expression (Melkebeek et al. 2007; Olafsdottir et 
al. 2008).  
In Chapters 3 and 4, a total of four eukaryotic vectors for expressing HA gene were 
investigated, however they did not elicit measurable HI antibody to H6 via the IM route 
in Hy-Line layer chickens. In Chapters 5 and 6, the pCAG-HAk and pCAG-optiHAk 
constructs generated using the pCAGGS vector, with the addition of a Kozak sequence, 
successfully induced measurable antibody responses in SPF chickens. Unfortunately, due 
to logistic reasons associated with the conduct of this work in Harbin, China, it was not 
possible to conduct homologous virus challenge. In view of the successful generation of 
H6 antibody with DNA vaccines using the pCAGGS expression vector and a Kozak 
sequence, experiments were conducted and reported in this chapter to determine whether 
the vector or the Kozak sequence played a more important role in antigen expression and 
generation of measurable antibody responses. It was believed that this might help to 
explain why the previous vectors did not induce detectable antibody responses.  
7.2 Materials and Methods 
7.2.1 Preparation of pCI-HAk DNA vaccine 
The HA gene was subcloned from the pCAG-HAk vector into the pCI vector at the 
EcoRI and SmaI sites to generate a pCI-HAk construct, using the procedures described in 
section 4.2.1. The pCAG-HAk, pCAG-optiHAk, pCI-HAk, pCI-HA, VR-HA, pCI and 
VR1012 plasmid DNAs were prepared using the protocol described in section 3.2.3.   224
7.2.2 Comparison of protein expression by the DNA vaccine constructs  
7.2.2.1 Preparation of primary chicken-embryo-fibroblast (CEF) cells   
Primary CEF cells were prepared using standard procedures. The head, feet, wings and 
viscera of 10-day-old SPF chicken embryos were removed and the remaining embryo 
material was washed once with HBSS. After the embryos were minced with scissors, 2.5 
mL of 0.25% trypsin was added and incubated at 37°C for 5 min. The digest was rinsed 
with 25 mL HBSS following removal of the supernatant. The cells were filtered through 
four layers of gauze, agitated and suspended in 30 mL DMEM with 6% FCS and then 
distributed into 100 mL flasks and incubated at 37°C until confluent. Primary cells were 
trypsinized, transferred to a 6-well plate as described in section 2.2.4.1 and cultured in 
DMEM supplemented with 5% FCS, 50 U/mL penicillin and 50 µg/mL streptomycin.  
7.2.2.2 In vitro expression of DNA vaccine constructs 
Chicken embryo fibroblast cells, human embryonic kidney cells (293T), African green 
monkey kidney cells (Cos-7) and hamster kidney cells (BSR) were grown in DMEM 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 4 mM L-glutamine and 
10% FCS as described in section 2.2.4. Transfection was performed as described in 
sections 4.2.2 and 5.2.3; expressed H6 HA protein was visualized by WB as described in 
section 4.2.3 and by IFT as described in section 2.2.5.  
7.2.3 Immunization of chickens  
Three-week old Hy-Line layer chickens were housed in free range animal house pens, 
with access to water and feed ad libitum. They were randomly assigned into three groups 
with five birds each and a naive control group with six birds. The three vaccinated groups   225
were vaccinated twice at 3-week intervals with the pCAG-HAk, pCAG-optiHAk or pCI-
HAk vaccine constructs using the same immunization procedure as in section 4.2.3. 
7.2.4 Virus challenge and virus isolation 
Three weeks following booster vaccination, each bird was subjected to challenge using a 
0.5 mL H6N2 virus challenge dose (10
6.5 EID50 /0.1 mL) as described in section 2.2.8. 
OS and CS were collected every second day over a seven-day period. Virus isolation was 
performed as described in section 2.2.9. 
7.3 Results 
7.3.1 Confirmation of the pCI-HAk DNA vaccine construct  
The pCI-HAk construct demonstrated the expected size fragments following restriction 
endonuclease digestion, as illustrated in Figure 7.1. These were 1.7 kb and 4.0 kb 
fragments after EcoRI and XmaI digestion and 2.0 kb and 3.7 kb fragments after EcoRI 
and BamHI digestion. This construct was further confirmed by sequencing the insert gene 
and its junction site (data not shown). 
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Figure 7.1 Restriction enzyme analysis of the plasmid pCI-HAk. 
A Lane 1, 1 kb DNA ladder (Promega); lane 2, pCI-HAk (EcoRI/XmaI); lane 3, pCI (EcoRI).  
B  Lane 1, DL2000 plus marker (Beijing Tuoyingfang Biotech Co., Ltd); lane 2, pCI-HAk 
(EcoRI/XmaI); lane 3, pCI-HAk (EcoRI/BamHI).  
 
 
7.3.2 Transient expression of different DNA vaccine constructs in vitro 
7.3.2.1 Expression in chicken-origin cells 
As shown in Figure 7.2, the pCAG-HAk and pCAG-optiHAk constructs showed similar 
intensity of fluorescence, but much better expression in terms of number of staining 
transfected cells, than the pCI-HAk construct. The pCI-HAk construct gave much 
brighter fluorescence and better expression in terms of number of transfected cells, than 
the pCI-HA construct. No specific fluorescence was observed in the blank vector, 
pCAGGS or pCI transfected CEF cells. 
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Figure 7.2 Photomicropgraphs of immunofluorescent staining for H6 avian influenza 
antigens in CEF cells transfected with (A) pCAG-optiHAk,  (B) pCAG-HAk, (C) pCI-
HAk ,(D) pCI-HA, (E) pCAGGS only, (F) pCI only. (Leica DMIRES2, x100). 
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7.3.2.2 Expression in human-origin cells 
Similar to the observations in chicken origin cells, the brightest H6 antigen 
immunofluorescence was present in 239T cells transfected with the pCAG-HAk and 
pCAG-optiHAk constructs, followed by the pCI-HAk and pCI-HA constructs. The 
pCAGGS or pCI transfected cells did not show specific fluorescence (Figure 7.3). 
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Figure 7.3 Photomicropgraphs of immunofluorescent staining for H6 avian influenza 
antigens in 293T cells transfected with (A) pCAG-optiHAk, (B) pCAG-HAk , (C) pCI-HAk,  
(D) pCI-HA, (E) pCAGGS only, (F) pCI only. (Leica DMIRES2, x100). 
 
7.3.2.3 Expression in monkey-origin cells 
Cos-7 cells were transfected with 5 µg of the different DNA constructs, as described in   230
section 3.2.3, using FuGENE® HD Transfection reagent (Roche). At 48 hr following 
transfection the transfected cells were lysed in 100 µL non-reducing buffer. Aliquots of 5 
µL of lysed cells for each of the pCI-HAk, pCAG-HAk and pCAG-optiHA constructs 
and 20 µL transfected cells for each of the other plasmids (pCI-HA, VR-HA, pCI, 
pCAGGS, VR1012) were loaded in their respective lanes for SDS-PAGE as described in 
section 3.2.5.3.  
Western blotting was conducted and gels were probed with antibody to H6 influenza 
virus. As shown in Figure 7.4 (A), the pCAG-HAk and pCAG-optiHA constructs gave 
the strongest bands. Next was the pCI-HAk construct. These three constructs were at 
least 4-fold stronger in band intensity than either the pCI-HA or VR1012-HA constructs 
and the band intensity for VR-HA was clearly stronger than that for pCI-HA. 
                     
 
 
 
 
Figure 7.4  (A) HA protein expression in DNA vaccine transfected Cos 7 cells by Western 
blotting.Lane 1, marker (Bio-Rad); lane 2, pCI-HAk; lane 3, pCAG-HAk; lane 4,  pCAG-
optiHAk; lane 5, pCI-HA; lane 6,  pCI; lane 7,  pCAGGS; lane 8,  VR-HA; lane 9, VR1012. (B) 
HA protein expression in transfected BSR cells by Western blotting. Lane 1, marker 
(Fermentas); lane 2, pCAG-optiHAk; lane 3, pCAG-HAk; lane 4, pCI-HAk; lane 5, pCAGGS.  
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Also, as shown in Figure 7.5, the intensity of H6 immunofluorescence and the level of 
expression in terms of number of transfected Cos-7 cells appeared to be marginally 
stronger for pCAG-HAk than for pCI-HAk, but for the pCI-HA and VR-HA constructs 
the intensity appeared similar. None of the negative control groups showed specific bands 
or immunofluorescence.  
7.3.2.4 Expression in hamster-origin cells 
 
Similarly to the outcome in the Cos-7 cells with WB, the expression of pCAG-optiHA 
and pCAG-HA constructs in BSR cells gave similar intensity bands, which were denser 
than those from the pCI-HAk construct (Figure 7.4, B).  
 
 
 
Figure 7.5 Photomicrographs of immunofluorescent staining of transfected Cos-7 cells with 
(A) pCAG-HAk, (B) pCI-HAk, (C) VR-HA, (D) Cos-7 cells. (Olympus BX51, x10).   232
7.3.3 Comparison of immune responses following administration of the pCI-HAk, 
pCAG-HAk and pCAG-optiHAk constructs in chickens  
As indicated in Table 7.1, no antibody production was measurable in Hy-line chickens 
vaccinated twice with the 100 µg pCI-HAk, pCAG-HAk or pCAG-optiHAk plasmids. 
However, all three vaccine groups and the naive control group showed a significant 
increase in GMT of HI antibody (P= 0.001) after challenge using the paired-sample T test. 
Although the HI GMT post-challenge in the pCI-HAk group was higher than the other 
two vaccinated groups, there were no significant differences in GMT between the pCI-
HAk, pCAG-HAk or pCAG-optiHAk groups and the naive control group.  Similarly 
there were no significant differences in HI GMT post challenge between the pCAG-HAk, 
pCAG-optiHA or pCI-HAk groups. 
Table7.1 Antibody response prior to and post virus challenge. 
 
 Naïve  control  pCAG-HAk pCAG-optiHA  pCI-HAk 
Prior to challenge  0  0  0  0 
Post  challenge 6.0±2.0* 5.6±1.7  5.0±3.4  8.2±2.2 
               * Values represent GMT (log2) ± SD of each group. 
 
As shown in Table 7.2, there appeared to be a reduction in virus recovery from OS and 
CS in all three vaccinated groups compared with the naive control group. However, the 
differences in the proportion of OS or CS positive for H6N2 virus between the naive 
control group and the pCAG-HAk, pCAG-optiHA or pCI-HAk vaccinated groups were 
not statistically significant.   
In terms of percentage of virus recovery from OS and CS, the pCAG-HAk group was 
lower than the pCAG-optiHAk or the pCI-HAk groups although there were no significant 
differences.    233
Table 7.2 Frequency of virus shedding in oropharyngeal and cloacal swabs. 
 
 Naïve  control  pCAG-HAk pCAG-optiHA  pCI-HAk 
OS 17/24(70.8)*  9/20(45) 12/20(60)  12/20(60) 
CS 3/24(12.5)  0/20(0) 0/20(0) 1/20(5) 
    * No. of swabs positive for virus isolation/total number of swabs tested. Percentages are shown 
    in parentheses. 
 
7.4 Discussion  
7.4.1 Comparison of in vitro expression for different HA-expressing constructs  
The in vitro studies reported in this chapter demonstrated that H6 HA gene expression in 
mammalian and avian cells could be maximally enhanced by use of an optimum 
expression vector, in this case pCAGGS, plus the use of a Kozak sequence in the 
construct. Additionally, the in vitro expression of the H6 HA gene using the expression 
vector pCI-HA, shown to be of lower efficiency in Chapter 4, was substantially enhanced 
by addition of a Kozak sequence to the construct. 
Four types of cells (monkey, hamster, human and chicken) were used to examine the in 
vitro HA expression of the DNA expression vectors by IFT and WB in the transfection 
experiments in this chapter. When the results are considered in conjunction with the in 
vitro comparisons in Chapter 4, the transfection experiments show a hierarchy in the in 
vitro expression efficiency in the order of pCAG-optiHAk/ pCAG-HAk > pCI-HAk > 
VR-HA > pCI-HA > pCI-neo-HA > pVAX-HA. 
DNA vaccines usually consist of bacterial plasmids that contain heterologous genes 
under the control of a eukaryotic promoter (Garmory et al. 2003). The selection of a 
promoter/enhancer element depends upon both the target cell type and the functional 
design of the vector construct (Harms and Splitter 1995). Furthermore, the   234
polyadenylation sequence used in a vector backbone, responsible for transcriptional 
termination, may also have a significant effect on foreign gene expression (Garmory et al. 
2003). In the pCAGGS vector, the CMV enhancer and the chicken β-actin promoter 
sequences are located upstream of the multiple cloning site (MCS) region and a rabbit β-
globin poly (A) sequence is located downstream from the MCS region (Galbiati et al. 
2000). In contrast, the pCI expression vector contains the CMV/IE enhancer/promoter 
region, a β-globin/IgG chimeric intron and an SV40 late polyadenylation signal. The 
VR1012 vector carries a CMV/IE promoter, a CMV intron A enhancer and a bovine 
growth hormone (BGH) polyadenylation sequence.  These differences in vector 
backbones between different expression vectors may explain why the pCAGGS vector 
had slightly stronger expression of the same HA gene in vitro than the pCI vector, and 
why the VR1012 vector showed better in vitro expression than the pCI vector. 
7.4.2 Effect of Kozak sequence on in vitro expression  
As illustrated in Figure 7.5, the difference in band intensity of expression between the 
pCI-HAk and the pCI-HA (Kozak effect) was much greater than that between the pCAG-
HAk and pCI-HAk (vector effect). This indicates that the Kozak sequence appeared to 
play a more important role in initiating protein expression among three efficient DNA 
vectors than the vector effect. It highlighted that the Kozak sequence can be used as an 
effective tool to increase the expression of target genes for DNA vaccine design in 
chickens. In vitro expression experiments with the pCAG-HAk vector also demonstrated 
that both the Kozak sequence and the pCAGGS expression vector were accountable for 
the increased level of expression, suggesting that both had a synergistic effect on the 
expression of DNA constructs. It also implies that mechanisms of improved antigen   235
expression for a Kozak sequence and modified vectors are different. Therefore, 
expression vector optimization and insertion of a Kozak sequence could synergistically 
enhance the expression of the gene of interest in vitro and hence potentially increase the 
efficacy of DNA vaccines in chickens. 
7.4.3 Comparison of DNA construct-induced immunity in chickens 
With all three vaccine constructs tested there appeared to be a reduction in virus shedding 
post-challenge compared to naive control chickens. Notably, with the pCAG-HA and 
pCAG-optiHA constructs there was no cloacal shedding of H6 virus. However, with the 
small group sizes and individual bird variation to DNA vaccination these differences 
were not shown to be significantly different (P>0.05) in contrast to the results with some 
of the vaccine constructs reported in Chapters 3 and 4 where similar reductions in virus 
shedding were observed and in some cases were statistically significant. The reduction in 
virus shedding via cloaca or oropharynx in the vaccinated chickens showed a hierarchy: 
pCAG-HAk > pCAG-optiHAk > pCI-HAk, which was similar to the hierarchy of gene 
expression in vitro.  
DNA vaccines have been demonstrated to elicit antibody responses since their first 
description in 1990 (Wolff et al. 1990), but their capacity to induce antibody responses 
has been shown to be quite variable in chickens (Chen et al. 2001; Kodihalli et al. 1997). 
In a previous study, chickens vaccinated with an H5 AI DNA vaccine by GG did not 
produce detectable pre-challenge antibodies, but produced high antibody titre and 
provided complete protection after homologous virus challenge (Kodihalli et al. 1997). 
Our results showed similarities with that study although the challenge was with LPAI 
virus rather than HPAI virus and we used reduction in virus shedding as our indicator of   236
protection. Using the less efficient delivery system of IM injection, the pCAG-HAk and 
pCAG-optiHAk vaccines did not induce measurable antibody before challenge in Hy-
Line chickens, but showed a reduction in oropharyngeal shedding and absence of cloacal 
shedding after challenge.  Evidence of protection after DNA vaccination in the absence of 
humoral immunity is considered an indicator of cellular immunity (Kodihalli et al. 1997).  
Examination of the impact of expression vectors on immune responses has generally 
compared only two plasmid configurations (Barry and Johnston 1997; Davis et al. 1993b; 
Galvin et al. 2000; Melkebeek et al. 2007; Uchijima et al. 1998; van Drunen Littel-van 
den Hurk et al. 1999; Xiang et al. 1995) or three plasmid vectors (Miller et al. 2004). 
Little has been reported on the comparison of multiple expression vectors (Suarez and 
Schultz-Cherry 2000a). Five expression vectors containing different combinations of the 
widely used CMV promoter, the chicken β-actin promoter and various enhancer and 
polyadenylation sequences were investigated to provide useful information on the 
selection of an appropriate vector for the development of a DNA vaccine in chickens. 
7.4.4 Analysis of the absence of detectable antibody responses using these DNA vaccines 
In the vaccination and challenge study conducted with the three vaccine constructs 
(pCAG-HAk, pCAG-optiHAk and pCI-HAk) in Hy-Line chickens, none of the constructs 
induced a H6 HI antibody response prior to challenge. This was in marked contrast to the 
results reported in Chapters 5 and 6 where both pCAG-HAk and pCAG-optiHAk 
constructs elicited measurable HI antibody responses in intramuscularly vaccinated SPF 
(White Rock) chickens. The reasons for this unexpected result are unclear, but possible 
reasons are considered below and highlight potential areas for future investigation.    237
Although the mechanisms of induction of immunity by DNA vaccines remain poorly 
understood, it is accepted that DNA vaccines are more effective in producing protective 
immunity in mice than in larger animals and non-human primates (Hirao et al. 2008). 
Some studies showed that the efficiency of responses to plasmid DNAs was highly 
related to the genotype of mice (Barry and Johnston 1997; Doolan et al. 1996). For 
example, immunization of different strains of mouse with plasmid DNAs encoding 
influenza virus HA, NA and NP genes showed that the ELISA antibody titres to HA or 
NA molecules in BALB/c, C3H and B10 mice were high, intermediate and low, 
respectively. HA-DNA afforded effective protection against lethal virus challenge only in 
BALB/c mice, whereas, NA-DNA provided significant protection in all strains of mouse. 
NP-DNA failed to provide protection in any strain of mouse (Chen et al. 1999b). This 
genetic control of antibody response among mouse strains was also observed using 
influenza virus HA subunit vaccines (Hirabayashi et al. 1991). Furthermore, considerable 
variation in antiviral antibody titres occurs in humans who received a conventional 
inactivated influenza vaccine and this may be partly explained by genetic factors (Kasel 
et al. 1969). In the current studies, since two chicken breeds were used for evaluating the 
potency of the same vaccine in two separate experiments, and one breed gave no post-
vaccinal antibody response, one can speculate that chicken breed differences have an 
effect on antibody responsiveness to DNA vaccines. This will need to be further 
investigated.   
Another point to consider is that there were differences between the rations fed to the Hy-
Line chickens at Murdoch University and the White Rock SPF chickens at Harbin. The 
poultry rations fed to the Hy-Line chickens contained approximately 10% lupin seed   238
(Lupinus angustifolius) as a protein additive (Brenes et al. 1993). Australian sweet lupins 
are widely used as a source of protein and energy in livestock feeds. Some experimental 
studies have indicated that feed containing lupins was shown to lower or inhibit antibody 
responses to experimental subunit vaccines to spirochaetosis in chickens and pigs (Dr 
Song Yong, personal communication). This did not however appear to affect antibody 
response to the inactivated whole virus H6N2 vaccines used in Chapters 3 and 4. 
Whether the presence of lupins in the ration affected the antibody responsiveness to DNA 
vaccines in chickens needs further investigation.  
An additional factor differed in the pCAG-HAk and pCAG-optiHAk vaccination studies 
undertaken at Murdoch University and Harbin. This was the method for extraction of the 
plasmid DNA from the bacterial suspension to prepare a large quantity of plasmid DNA 
for the vaccine. The alkaline lysis plus PEG method (section 5.2.2) was used to prepare 
plasmid DNA for the SPF chicken vaccination, whereas, the modified simple alkaline 
lysis method (section 3.2.3) was used to prepare plasmid DNA for Hy-Line chicken 
immunization. This was due to the different protocols and the reagent availability in the 
two laboratories. The different methods used may have resulted in variations in the 
quality of the plasmid DNA, which in turn could affect the efficacy of DNA vaccines in 
vivo, even though expression of plasmid DNA prepared from the modified alkaline lysis 
method was successfully demonstrated in Cos-7 cells. The role of different extraction 
methods for HA-expressing DNA vaccines in Hy-Line chickens also needs further 
investigation. 
Other mechanisms, not identified in these studies, may also have contributed to the 
difference in antibody responses between the Hy-Line and SPF chickens.   239
7.4.5 Correlation between in vitro and in vivo expression  
Higher levels of antigen expression in vitro may not necessarily mean higher levels of 
protein expression in vivo and also the induction of immune responses depends on the 
induction of cytokines such as interferon and interleukin which may result from ISS in 
the plasmid DNA (Sato et al. 1996). Nevertheless, analysis of some DNA vaccination 
studies indicates that there was a direct correlation between the level of protein 
expression in vitro and immunogenicity in mice (Steinberg et al. 2005), pigs (Melkebeek 
et al. 2007) and chickens (Jiang et al. 2007; Suarez and Schultz-Cherry 2000a). In the 
present study, the pCAG-HAk construct showed a similar level of expression in 
mammalian cells to the pCAG-optiHAk construct and both constructs also induced 
similar antibody responses in SPF chickens (as described in Chapter 6) and gave a similar 
level of reduction in virus shedding in the current trial. There was also a correlation 
between in vitro and in vivo expression when comparing the pCAG-HAk with the pCI-
HAk construct. Interestingly, our results indicated that the pCAGGS construct was most 
efficient among the five DNA vectors evaluated, although the pCAG-HAk construct 
introduced two varaibles (i.e. a vector with different promotor and a Kozak sequence) at 
the same time. In other studies the pCI-neo vector induced the strongest H5 antigen 
expression in mink lung epithelial cells and CEF cells  among five vectors 
(pCAGGS.MCS, VR1012, pCI-neo, pSI, pRC/RSV ) and also provided the best antibody 
responses to H5 HA in chickens (Suarez and Schultz-Cherry 2000a). However, the 
current pCAGGS vector used in this study was possibly further modified from the 
pCAGGS.MCS backbone used in that study and the inserted HA gene was different 
between the two studies.    240
Overall it is considered that the level of protein expression following transfection into 
mammalian or avian cells by the DNA plasmid vaccines evaluated shows a direct 
relationship with the magnitude of immune responses in chickens receiving these DNA 
vaccines. Since the level of in vitro expression correlates with the level of immune 
response in vivo, it is also considered that in vitro expression levels of the plasmid 
vaccines can be used as an indicator for pre-selection of expression plasmids prior to 
development of a DNA vaccine. A separate issue that has also been highlighted in these 
studies is that even with the optimum vector and promoters from in vitro assessment of a 
plasmid construct, it will be necessary to optimize the factors leading to effective in vivo 
expression of the antigen in order to initiate immune responses in different breeds of 
chickens or other target species. 
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Chapter 8  
Evaluation of different chemical adjuvants on avian influenza DNA vaccines in 
chickens 
 
8.1 Introduction 
Rapid degradation and poor cellular uptake of plasmid DNA has significantly impacted 
on the efficacy of 'naked' plasmid DNA vaccines (Wilson et al. 2009). As adjuvants have 
historically played a major role in successful vaccine development (Scheerlinck et al. 
2006), a number of chemical adjuvants have been examined in an attempt to improve 
plasmid DNA immunogenicity. Conventional adjuvants, many of which are very 
effective for killed and subunit vaccines, have either not been tested for DNA vaccines or 
are not usually beneficial in the mouse model (van Drunen Littel-van den Hurk et al. 
2004). However, some studies have shown a beneficial effect with such adjuvants (Jin et 
al. 2004; Sasaki et al. 1998a; Sasaki et al. 1998b; Sasaki et al. 1998c). Thus, further 
investigation of conventional or novel adjuvants and their formulation technologies could 
improve the utility of plasmid DNA vaccination. 
Aluminum salts, referred to as alum, including aluminum phosphate, aluminum 
hydroxide and other aluminum-containing salts, have been extensively characterized and 
are commonly used as conventional adjuvants to increase the magnitude of humoral 
immune responses. They are currently licensed for human and animal use (Gupta 1998). 
However, their potential as DNA vaccine adjuvants has had limited investigation. Alum-
DNA formulations increased the capacity of some DNA vaccines to induce antibody 
responses up to 100-fold in mice and guinea pigs, and 5-10-fold in non-human primates 
(Ulmer et al. 1999). Also, the level of antibodies induced by a plasmid DNA-coated   242
PLG-CTABmicro-particles in mice was markedly enhanced by the addition of aluminum 
phosphate (Singh et al. 2000). 
Nano-particles, varying in size from 10 to 500nm, are solid particles made from inert 
materials (Aucouturier et al. 2001).  They are potentially biocompatible and 
biodegradable, are relatively stable in vivo, are relatively easy to link with immunogens, 
have straightforward delivery methods and show little or no side effects (Cui and 
Mumper 2002a; Scheerlinck and Greenwood 2006). As early as 1995, solid inert beads 
adsorbed with antigen were reported to prime CD8
+T cell responses (Falo et al. 1995). 
Inert nanoparticles have subsequently been shown to induce strong immune responses to 
protein and peptide antigens in mice (Fifis et al. 2004a; Fifis et al. 2004b), sheep 
(Scheerlinck et al. 2006), pigs (Aucouturier et al. 2001) and cattle (Aucouturier et al. 
2001).  In the context of DNA vaccines, a cationic nanoparticle formulated plasmid DNA 
encoding a reporter gene enhanced in vitro cell transfection efficiency and elicited 16-
200-fold greater immune responses in mice than naked plasmid DNA alone following 
multiple delivery routes (Cui and Mumper 2002a, b, c, 2003a). Co-administration of 
cholera toxin (CT) and lipid A with a nanoparticle-based plasmid DNA showed a 
synergistic effect and hence further enhanced immune responses (Cui and Mumper 
2003a). Thus, nanoparticles, as a novel class of adjuvants, have the potential to induce 
immune responses to protein or plasmid DNA immunogens without the side effects 
typically associated with local tissue damage caused by conventional chemical adjuvants. 
Though the microparticle formulated plasmid DNA encoding the NP gene of A/PR/8/34 
(H1N1) virus was shown to enhance immune response in mice (Hartikka et al. 2008),   243
there has been no reports on nanoparticle-based avian influenza DNA vaccines in 
chickens.  
Seppic (Paris, France) produces a well-known range of adjuvants,  known as  Montanide 
ISA series, for human and veterinary vaccines.  For example, foot and mouth disease 
(FMD) recombinant protein adjuvanted with Montanide-ISA 50V elicited an FMD-
specific humoral immune response and provided protective immunity in guinea pigs 
(Balamurugan et al. 2005). Most recently the company has developed and provided a 
polymeric adjuvant, Essai 849101 for DNA vaccination. 
Genetic control of antibody responses have been observed in mice (Barry and Johnston 
1997; Chen et al. 1999b; Doolan et al. 1996; Hirabayashi et al. 1991) and probably in 
humans (Kasel et al. 1969). However, co-administration of cholera toxin B subunit (as 
adjuvant) with influenza HA vaccine not only markedly augmented the antibody 
responses to HA in all mouse strains tested, but also the degree of enhancement was 
similar among the strains (Hirabayashi et al. 1991). In Chapter 7, Hy-Line chickens 
receiving the pCAG-HAk vaccine construct did not produce a measurable antibody 
response in contrast to White Rock SPF chickens which did produce a measurable 
response to this vaccine (Chapters 5 and 6). Therefore, it was also of interest to determine 
whether the use of adjuvants could modify this possible genetic effect on antibody 
response to the same DNA vaccine.  
In Chapter 3 the chemical adjuvant lipofectin was evaluated in chickens and showed 
some enhancement of the immune response in terms of increasing the seroconversion rate 
of vaccinated birds and the level of antibody production and reducing virus shedding in 
both oropharyngeal and cloacal swabs.  However, it is prohibitively expensive for routine   244
use in poultry. Thus, an experimental adjuvant for poultry DNA vaccines (Essai), a new 
nanoparticle (Phema) and two variations of conventional alum were investigated as 
adjuvants with a plasmid DNA vaccine in chickens and the results are reported and 
discussed in this Chapter. 
8.2 Materials and Methods  
8.2.1 Plasmid DNA used for the vaccine 
The pCAG-HAk plasmid DNA used as the vaccine for combination with the various 
adjuvants was prepared as described in section 3.2.3.    
8.2.2 Formulation of plasmid DNA vaccines with adjuvants 
8.2.2.1 Preparation of DNA-coated alum 
Aluminum hydroxide (Al(OH)3 ) (AH) gel was prepared from aluminum potassium 
sulphate (AlK(SO4)2.12H2O) (BDH Chemicals Ltd, Victoria, Australia) as described by 
Scheerlinck et al. (2006). Briefly, 10 mL of 10% aluminium potassium sulphate was 
added to a 50 mL conical tube then 22.8 mL of 0.25N NaOH (BDH) was added drop-
wise while vortexing. Following incubation for 10 min at room temperature, the 
precipitate was collected by centrifugation at 1,000 g for 10 min. Following removal of 
the supernatant, 50 mL dH2O was added to re-suspend the AH gel by vortexing. The gel 
was washed once in 50 ml of water followed by centrifugation at 900 g for 20 min. Two 
versions of the AH adjuvant gels were prepared at a concentration of 400 µg/µL. One 
was suspended in 0.9% NaCl (referred to as alum-NaCl) and the other in PBS (referred to 
as alum-PBS). Then 1mL of  the 400 µg/µL AH suspensions was mixed with equal 
volumes of 0.9% NaCl or PBS solutions containing 0.2mL plasmid DNA (9.3 µg/µL)   245
respectively. These were incubated for the various times and temperatures indicated 
below, followed by centrifugation at 3,000 g for 10 min at room temperature. The DNA 
concentration in the supernatant was measured using a Nanodrop spectrophotometer. The 
precipitate was dissolved in either 0.9% NaCl or PBS respectively.  The amount of bound 
DNA in the precipitate was calculated by subtracting the amount of DNA in the 
supernatant from the total DNA used to prepare the suspension. The emulsions were then 
diluted to a concentration of 0.5 µg/µL DNA in their respective solutions for direct IM 
injection.   
To obtain the optimal DNA-binding to the alum adjuvants, different concentrations of 
alum (400, 200, 100, 50 µg/µL), different diluting buffers (PBS or 0.9% NaCl), different 
binding times (0.5, 1, 3, 5, 8, 27 hr) and different temperatures (4°C and 22°C) were used 
to prepare the adjuvants, using a constant concentration of plasmid DNA (2.4 µg/μL). 
8.2.2.2 Preparation of DNA-coated Essai 
Essai 849101, a high molecular weight water soluble copolymer, was kindly provided by 
Seppic, France. Formulation of the plasmid DNA using Essai 849101 was carried out 
according to the manufacturer’s instructions. Briefly, DNA was diluted in PBS and then 
Essai was added dropwise with gentle stirring to the DNA preparation to give final 
concentrations of 0.5 µg/µL for DNA and 10% (v/v) for Essai. Following initial mixing, 
the mixture was stirred for a further 10 min at room temperature.   
8.2.2.3 Preparation of the DNA-conjugated nano-beads  
A novel polymer (2-hydroxyethyl-methacrylate) (Phema), which formed a 150-300 nm 
hydrophilic nanoparticle suspension, was provided by the Nanotechnology Group,   246
Murdoch University. The DNA-coated nano-beads were prepared as follows. 
Optimization of the solvent for mixing the Phema and DNA was determined using 100% 
dH2O, dH2O/ethanol (50:50) and 100% ethanol and calculation of the level of DNA 
binding.  Consequently 2 mL of 1% Phema (w/v in ethanol) was added into chilled 10 
mL tubes on ice and sonicated for a few seconds. Then 1 mL of 1% polyvinyl alcohol 
(PVA) (w/v in dH2O) was added and the mixture was sonicated for 1 min on ice. 
Subsequently 200 µL of plasmid DNA (9.3 µg/µL) was added and sonicated for 2 min on 
ice. The resultant solution was then filtered through a 0.2 µm membrane to remove the 
surfactant. The flow-through was centrifuged at 15,000 g for 20 min at room temperature. 
The pellet was dissolved in PBS and the amount of DNA present was calculated by 
subtracting the amount of DNA in the supernatant, measured by a Nanodrop 
spectrophotometer, from the total DNA added.  
8.2.3 Vaccination regime used in chickens 
Three-week old Hy-Line chickens were housed in free-range pens with access to water 
and feed ad libitum. The experimental protocol used is shown in Table 8.1. Birds 
received two 0.2 mL IM injections of each vaccine combination at 3 week intervals, with 
0.1 mL per dose in each leg. 
Table 8.1 Immunization regime used in chickens. 
 
Group  Vaccine type  Dose (µg )  Adjuvant  No. of  birds 
1 pCAG-HAk  100  No  5 
2 pCAG-HAk  100  alum-NaCl  5 
3 pCAG-HAk  100 alum-PBS  5 
4 pCAG-HAk  100  Essai  5 
5 pCAG-HAk  200  Phema  4 
6 pCAG-HAk  100  Phema  3 
7 pCAG-HAk  10  Phema  5 
8 PBS  100  No  6   247
8.2.4 Virus challenge and virus isolation 
Three weeks following the booster vaccination, all birds in each group were subjected to 
virus challenge.  Subsequently, OS and CS were collected every second day for virus 
isolation as described in section 7.2.4. 
8.3 Results  
8.3.1 Optimization of DNA vaccine adjuvant formulations 
As shown in Table 8.2, the DNA binding rate increased with the increase of alum-NaCl 
concentration. DNA binding with alum-NaCl occurred within the first 1 hr. Temperature 
did not affect DNA binding rate after 3 hr. The 400 µg/µL alum-NaCl absorbed nearly 
100% plasmid DNA at either room temperature or 4°C after 1 hr following mixing. Thus, 
400 µg/µL alum-NaCl and binding for 2 hr at room temperature was used for the 
formulation of the DNA vaccine. In contrast, alum-PBS did not bind plasmid DNA even 
after overnight incubation. 
As shown in Table 8.4, Phema adjuvant prepared with 100% ethanol as solvent gave the 
highest DNA binding rate. Thus, 100% alcohol was used for the preparation of the Phema 
adjuvant vaccine. Subsequently, the maximal plasmid DNA-Phema binding rate, 
determined using a constant Phema concentration and different DNA concentrations, was 
approximately 30%.   248
Table 8.2 Plasmid DNA concentration remaining in supernatant after plasmid DNA binding with alum/0.9%NaCl diluent. 
 
Time  0.5 hr  1 hr  3 hr  5 hr  8 hr  27 hr 
Concentration 4°C 22°C  4°C 22°C  4°C 22°C 4°C 22°C 4°C 22°C 4°C 22°C 
400  µg/µL ND  131.8* ND 3.1 12.5 2.8  6.3  1.1 20.2 2.1  4.6  3.4 
200  µg/µL  ND 294.6 ND 91.4  103.8 58.2 43.6 48.1 62.8 35.6 80.0 55.2 
100 µg/µL  ND  727.7  ND  511.7 518.6 487.0 500.7  502.4 407.9 489.5 495.2 479.6
50  µg/µL  ND  859.8  ND  729.0 742.0 738.3 732.9  785.4 739.9 641.4 768.5 718.8
                                  * DNA concentration (ng/μL) in the supernatant following centrifugation. ** ND: not done.  
 
 
 
 
Table 8.3 Plasmid DNA concentration remaining in supernatant after plasmid DNA binding with alum/PBS diluent. 
 
Time  0.5 hr  1 hr  3 hr  5 hr  8 hr  27 hr 
Concentration  4°C 22°C 4°C 22°C  4°C 22°C 4°C 22°C 4°C 22°C 4°C 22°C 
400  µg/µL  ND 1267.3 ND 1279.1 1283.6 1187.3 1191.1 1194.5 1179.4 1189.1 1201.2 1193.7 
200  µg/µL  ND 1301.1 ND 1204.5 1190.1 1192.5 1199.1 1196.6 1200.9 1204.3 1214.4 1228.0 
100  µg/µL  ND 1274.8 ND 1188.2 1176.7 1164.0 1175.5 1176.5 1173.6 1153.5 1179.5 1195.1 
        *  DNA concentration (ng/μL) in the supernatant following centrifugation. ** ND: not done  
 
 
 
 
Table 8.4 Effect of solvent on plasmid DNA concentration remaining in the supernatant after plasmid DNA binding with Phema adjuvant. 
 
Solvent 100%  dH2O  50% alcohol/50% dH2O 100%  alcohol 
DNA concentration (ng/μL) 505.9  208.8  28.3   249
8.3.2 Effect of adjuvants on antibody response 
No HI titre was detected in any Hy-Line chickens 3 weeks post the second vaccination. 
By 10 days post virus challenge, all birds sero-converted with a range of HI titres as 
shown in Table 8.5.  There was a statistically significant difference (P<0.05) in the GMT 
of HI antibody between pre- and postchallenge in all vaccinated groups and the naïve 
control group using the paired-sample T test. 
There was no significant difference (ANOVA, P>0.5) in HI antibody GMT post-
challenge between the naïve control group and any of the vaccinated groups, nor was 
there any significant difference (ANOVA, P>0.5) between the pCAG-HAk group and 
any of six pCAG-HAk adjuvanted groups. 
 
Table 8.5 Antibody response prior to and post virus challenge. 
 
pCAG-HAk 
Alum Essai  Phema 
 Naive 
control  No 
adjuvant  NaCl  PBS  subtotal   200µg  100 µg  10 µg  subtotal
Prior    0  0 0 0 0 0 0 0 0 0 
Post 6.0±2.0* 5.6±1.7 6.8±2.4 5.4±2.0 6.1±2.2 6.8+2.6 5.3±1.5 5.3±1.5 6.6±2.1 5.8±1.8 
* Values represent GMT (log2) ± SD of each group. The data in the naïve control and pCAG-HAk groups 
was taken from Chapter 7.  
 
8.3.3 Effect of adjuvants on virus shedding 
As shown in Table 8.6, in comparison with the naïve control group, the pCAG-HAk 
vaccinated group reduced the virus excretion rate from 70.8% to 45% in OS post 
challenge and from 12.5% to 0 in CS. However, the pCAG-HAk vaccinated group was 
not significantly different from the naïve control group in OS and CS. Possibly, the   250
pCAG-HAk vaccine may have elicited some borderline level of protective immunity in 
the oropharynx (Chi square, P= 0.083).  
In comparison with the naïve control group, the alum-NaCl adjuvanted pCAG-HAk 
group showed a reduction in virus shedding rate from 70.8% to 40% in OS post challenge 
and showed no virus shedding in CS. There was a significant difference (Chi square, P= 
0.04) for OS between the naïve control group and the alum-NaCl adjuvanted pCAG-HAk 
group. The alum-PBS adjuvanted pCAG-HAk group was also significantly (Chi square, 
P= 0.018) different from the naïve control group in frequency of virus shedding in OS. 
However, there was no significant difference in virus shedding in OS and CS between the 
pCAG-HAk vaccinated and either the alum-NaCl or alum-PBS adjuvanted groups. 
Neither was there a significant difference between the alum-NaCl and alum-PBS groups. 
Although the Essai adjuvanted pCAG-HAk group showed less virus shedding in both OS 
and CS than the naïve control group, there was no significant difference between  them. 
Neither was there a significant difference between the pCAG-HAk and the Essai 
adjuvanted groups.   
There was a significant difference (Fisher’s exact test, P=0.014) between the naïve 
control group and the 100µg Phema adjuvanted pCAG-HAk group in the rate of virus 
shedding in OS but no significant difference in CS. However, the 200µg or 10 µg Phema 
adjuvanted pCAG-HAk groups was not significantly different in virus shedding from the 
naïve control group. Furthermore, there was no significant difference in virus shedding 
between the pCAG-HAk group and the 200µg, 100 µg or 10 µg Phema adjuvanted 
groups.    251
Table 8.6 Level of virus shedding in chickens vaccinated with pCAG-HAk plasmid with 
various adjuvants following virus challenge*. 
 
pCAG-HAk 
Alum Essai  Phema 
 Naïve 
control  No 
adjuvant  NaCl  PBS    200µg  100 µg  10 µg 
OS  17/24
a(70.8)  9/20
ab(45)  8/20
bc(40) 7/20
bc(35) 10/20
ab(50) 8/16
ab(50)  3/12
bc(25) 9/20
ab(45)
CS  3/24
 (12.5)  0/20
 (0)  0/20
 (0)  3/20
 (15)  2/20
 (10)  1/16
 (6.3)  0/12
 (0)  1/20
 (5) 
* Number of swabs positive for virus isolation/total number of swabs tested. Percentage rate is shown in 
parentheses.  OS and CS refer to oropharyngeal and cloacal swabs respectively. 
The data in the naïve control and pCAG-HAk groups was taken from Chapter 7.  
For the OS row, different lowercase superscript letters indicate statistical differences (P < 0.05) within the 
row using Chi square or Fisher’s exact test. There were no significant differences between groups for the 
CS. 
 
 
 
8.4 Discussion 
Following the previous trial using lipofectin as the adjuvant, another attempt was made to 
compare different chemicals as DNA vaccine adjuvants, namely alum, Phema and Essai. 
Although no statistical differences in virus shedding in OS and CS occurred between the 
pCAG-HAk group and its corresponding adjuvanted groups, a significant reduction in 
virus shedding in the oropharynx was evident in both alum groups and the 100 µg Phema 
group compared with the naïve control group which was not shown by the non-
adjuvanted pCAG-HAk group. This suggested that either alum or Phema as adjuvant 
further augmented the immune response induced by the pCAG-HAk construct.  However, 
Essai did not show any apparent effect. In an H5 avian influenza DNA vaccine study on 
adjuvant comparisons, two different cationic liposomes (lipofectin and lipotaxi) improved 
antibody titres, whereas, the other chemical adjuvants (including 25% sucrose, 
diethylaminoethyl dextran, calcium phosphate, polybrene) decreased the antibody 
response (Suarez and Schultz-Cherry 2000a). These results also illustrated that chemical   252
adjuvants for DNA vaccines are not always effective.  However, the effectiveness of 
Phema or other nanoparticles as new adjuvants warrants additional investigation. 
Aluminum hydroxide has a net positive charge in 0.9% NaCl (pH 7.0) and hence alum-
NaCl binds to the negatively charged plasmid DNA. Aluminum hydroxide in PBS 
possibly reacted to produce aluminum phosphate, which would have conferred a net 
negative charge to the surface of alum and prevented binding to DNA. This explains why 
alum-NaCl binds DNA and alum-PBS does not. Ulmer et al.(1999) reported that non-
DNA-binding aluminum salts (DNA-aluminum phosphate formulations) significantly 
enhanced antibody titres in mice, guinea pigs and Rhesus monkeys compared with naked 
DNA. In contrast, DNA/aluminum hydroxide formulations (DNA binding aluminum salt) 
were less potent than naked DNA. Our results showed that both DNA-binding (alum-
NaCl) and non-DNA-binding (alum-PBS) aluminum-based adjuvants enhanced immune 
responses initiated by the pCAG-HAk DNA vaccine in terms of frequency of virus 
shedding in the oropharynx, although there was no significant difference between these 
two groups. The difference in the effectiveness of the different alum adjuvants between 
these two experiments may be due to the differences in the indicators used to determine 
efficacy of DNA vaccines. In Ulmer’s study antibody titre was used, whereas, virus 
shedding frequency was used in this study. Direct comparison of the effect of these 
adjuvants on antibody responses could not be carried out due to the problem encountered 
with the Hy-Line chickens which did not produce antibody responses to the pCAG-HAk 
vaccines, even though reduction in virus shedding was evident in vaccinated chickens.  
Aluminum compounds are currently the most commonly used adjuvants for protein 
vaccines due to their good safety record and low cost. However, their exact mechanisms   253
of action are not yet fully understood. They may act via several mechanisms. Aluminum 
compounds precipitate protein antigens to form a “depot” at the site of injection, which 
allows for a slow release of antigen (Cox and Coulter 1997; Gupta 1998). This hypothesis 
was supported by a pharmacokinetic experiment using aluminum adjuvants in rabbits in 
which it took 28 days to dissolve about 50% of the aluminum phosphate at an IM 
injection site (Flarend et al. 1997). Presumably this may be the case for a DNA/alum-
NaCl formulation but the depot effect would not apply for the non-binding DNA/alum-
PBS adjuvant.   
Aluminum salts/DNA formulations could protect plasmid DNA from degradation by 
nucleases in vivo and thus enhance immunogenicity. This protection was confirmed in 
vitro using aluminum phosphate (Ulmer et al. 1999), but this was challenged by the 
observations that other compounds, such as heparin or aurin tricarboxylic acid, did not 
enhance DNA vaccine immunogenicity in vivo, although they protected DNA in vitro. 
Considering that aluminum phosphate/DNA formulations did not cause increased 
expression levels or longevity of antigen expression in muscle (Ulmer et al. 1999), the 
mechanism of action possibly involved targeting of aluminum-adsorbed DNA particles to 
APC due to the particle aluminum salt size (<10 µm) and its capacity to convert DNA 
immunogens to particulate forms.  
Moreover, aluminum compounds also stimulate immune-competent cells possibly by 
activation of complement, induction of eosinophilia, release of inflammatory cytokines, 
and activation of macrophages. This may lead to a local inflammatory response and thus 
non-specifically activate the whole immune system (Gupta 1998).    254
The use of particulate carriers as novel vaccine delivery systems is an area currently 
receiving a high level of interest. Micro- and nano-size particle characteristics, such as 
size and surface properties, including surface charge and hydrophobicity, affect vaccine 
efficacy (Xiang et al. 2006). Recently, micro- and nano- size particles have been used as 
experimental adjuvants in animal models.  Some studies have shown that nanoparticles 
might be more successful in stimulating immune responses in vivo than microparticles 
(Evans et al. 2004; O'Hagan et al. 2004; Singh et al. 2000). A range of inert nanoparticles 
have been tested and shown to be effective delivery vehicles for protein and peptide 
antigens. Nevertheless, application of nanoparticles with DNA vaccines is only at the 
exploratory stage (Cui and Mumper 2003a; Minigo et al. 2007). A biodegradable 
copolymer Phema has been used in a drug delivery system (Piotrowicz and Shoichet 
2006; Rao 1998). However, there appears to be no previous reports using Phema for 
vaccine adjuvant purposes. 
Due to the hydrophilicity of Phema, it is suspected that the ethanol solvent used in the 
current study may have imparted positive surface charges and allowed more absorption of 
the plasmid DNA than with water as a solvent. Plasmid DNA was possibly absorbed to 
the surface of Phema through electrostatic interaction or covalent binding and this did not 
appear to damage the DNA’s biological functions. The interaction also appeared to be 
complex because the optimum effect was achieved with the 100µg dose group and the 
response was poorer with both the 10 and 200µg dose groups. The mechanisms behind 
the observed adjuvant effect have not yet been resolved. Possible mechanisms are that 
these nanocarriers prevent DNA degradation and facilitate targeted delivery to APC 
(Khatri et al. 2008; Singh et al. 2000).   255
Effective adjuvants are able to facilitate uptake of antigen by DCs and to promote the 
activation of these cells in vivo (Scheerlinck et al. 2006). The size of nanoparticles used 
as DNA carriers has been shown to be of importance for DNA vaccine efficacy (Fifis et 
al. 2004a; Minigo et al. 2007; Scheerlinck et al. 2006). Conjugation of antigen to 40–50 
nm nanoparticles elicited 2- to 10-fold higher CD8
+ T cell responses in mice than those 
induced by other bead sizes (Fifis et al. 2004a). One possible explanation was that 
particles of different sizes may target different APCs. This was verified in an experiment 
showing that the 40–50 nm particles targeted DCs, whereas, the smaller 20 nm particles 
localized preferentially in CD40+ cells and large particles (1.0 µm) predominantly 
localized in F4/80+CD80+ cells.  Since DCs are the only APC capable of T cell priming 
(Banchereau and Steinman 1998), this size-dependent particle uptake might explain the 
higher efficacy of DNA/50 nm nanoparticles. In the current study, we did not measure the 
effect of Phema on cellular immune response, such as interferon production, although in 
other studies nanoparticles have potentiated cell mediated responses induced by DNA 
vaccines (Scheerlinck et al. 2006). Additionally, in this study the physicochemical 
characterization of Phema, such as particle size, surface charge, detergent content, release 
rate of DNA-nanoparticles and DNA integrity was not able to be conducted due to time 
and resource constraints. It was also clear that the DNA loading efficiency for Phema 
needs to be increased above the 30% estimated in this pilot study. Whether the use of 40 
to 50 nm Phema nanoparticles (rather than the larger particles used in this study) would 
further enhance immune responses should be further investigated.  
The pCAG-HAk vaccines with or without adjuvants did not induce a measurable 
antibody response in the Hy-Line chickens, however, the pCAG-HAk vaccines with alum    256
or Phema adjuvants gave some enhanced reduction in virus shedding from the 
oropharynx. The problem of lack of antibody response in Hy-Line chickens to DNA 
vaccines will require further investigation.  
In the present study it has been shown for the first time that Phema has provided some 
evidence of an enhancing or adjuvant effect when used with a DNA vaccine in chickens.  
This study also appears to be the first to report that traditional aluminum hydroxide 
adjuvants, either binding or non-binding, show evidence of enhancement of immune 
responses in chickens, resulting in reduction of virus shedding in the oropharynx from 
chickens challenged with an H6N2 influenza A virus.  
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Chapter 9 
 General Discussion and Conclusions 
 
 
Since the first DNA vaccines were described,  they began to enjoy great scientific 
popularity with largely two focuses: applying DNA vaccination to various model systems 
and improvement of DNA vaccine efficacy (Bergmann-Leitner and Leitner 2004). 
Despite a number of approaches addressing parameters that limit immune responses to 
DNA vaccines, there is little data to indicate which of these approaches will be most 
useful and practical for use with commercial vaccines (Greenland and Letvin 2007). 
This study focused on the development of a DNA vaccine for chickens and improvement 
of vaccine efficacy of the DNA vaccine based on AIV A/coot/WA/2727/79 (H6N2) as a 
proof-of-concept study for DNA vaccines against AI viruses.  Initial biological and 
genetic characterization of this virus, which was to be used for virus challenge studies in 
vaccinated chickens, was conducted and described in Chapter 2. Different approaches to 
enhance the immunogenicity of the DNA vaccine in a chicken model were assessed and 
reported in Chapters 3 to 8. The study evaluated the effectiveness of different DNA 
vectors encoding HA or NP genes of the virus in chickens and demonstrated synergistic 
effects from various manipulations of the DNA vaccines. In particular, selection of an 
appropriate expression vector, the insertion of an enhancer sequence into a vector 
backbone, and the use of electroporation as the method of delivery were the most 
effective strategies. Use of chemical adjuvants such as lipofectin, alum and nanoparticles 
further enhanced plasmid-induced immune responses.      258
Specific findings from the study are discussed below. Although different approaches 
were used and discussed in each chapter, some issues need to be emphasized with a view 
to indicating future directions that could be followed with this research. 
The ability of AI viruses to produce CPE in MDCK cells in the absence of trypsin 
correlates positively with pathogenicity (Shankar et al. 2009). Low pathogenic AI viruses 
cannot form plaques in the absence of trypsin, but the addition of trypsin to the cells will 
allow the cleavage of HA and produce plaquing (Bosch et al. 1981). In conducting the 
characterization of the LPAI A/coot/WA/2727/79 (H6N2) virus, it was observed that this 
virus was able to replicate moderately well in MDCK cells in the absence of exogenous 
trypsin, although the addition of trypsin did allow the virus to replicate to a higher titre in 
the cells. This adaption of a LPAI H6N2 virus from a wild bird to grow readily in MDCK 
cells was interesting and raised the question of how easily such a virus could change to 
replicate in vivo in mammalian species. It should be noted, however, that this adaption 
did not translate into a higher level of virulence for chickens challenged with the virus in 
this study.  
Initially, the study evaluated five commercial plasmid vectors for the preparation of DNA 
construct vaccines encoding the HA of the virus and the immunogenicity of the resultant 
constructs were compared. The potential of a DNA vaccine construct to induce an 
immune response in vivo has been shown to correlate positively with the level of 
expression of the encoded protein in vitro (Jiang et al. 2007; Melkebeek et al. 2007; 
Steinberg et al. 2005). This is likely to be used as an indicator for selection of potential 
DNA vaccines before in vivo assessment, which is useful in terms of time-saving, cost 
reduction and animal welfare considerations. These studies supported this selection   259
process as the level of in vitro expression measured by IFT or WB did correlate with the 
level of in vivo response to the vaccines.   
A variety of factors determine the magnitude and type of immune response induced by 
plasmid DNA vaccines. With analogy to conventional vaccines, the main factors 
affecting the efficacy of a DNA vaccines are the nature of a plasmid-expressed antigen, 
and the intrinsic adjuvant properties of the DNA expression vector (Bergmann-Leitner 
and Leitner 2004; Deml et al. 2001). In addition to these two major factors, other 
parameters, such as immunization methods and route, dose of plasmid DNA, number of 
vaccinations and vaccination intervals all play an important but less critical role in the 
context of the plasmid-induced immune response (Leitner et al. 1999). In the current 
studies involving the evaluation of different approaches to enhance immunity, selection 
of different expression vectors, together with incorporation of a Kozak sequence were 
shown to be important factors in increasing the expression of transgenes in DNA 
immunized animals. Codon optimization of target gene has been explored to improve the 
immunogenicity of DNA vaccines due to the codon bias of the hosts. Although codon 
optimization of the HA gene did not in itself enhance the immune response over the level 
achieved by the pCAGGS vector with a Kozak sequence,  it may still be worth further 
investigation to improve the expression of DNA vaccines in some host sytems. However, 
this approach is difficult, time-consuming, and expensive.  
Optimization of dose rates, vaccination times and intervals and combination with 
adjuvants have largely played a secondary role in successful vaccination. In this study, 
different doses for the five DNA constructs were assessed and although immune 
responses were generally poor for all vectors, it appeared that a dose of 100µg plasmid   260
DNA seemed to be the most effective in the chicken model. Increasing the number of 
vaccinations, in combination with an adjuvant, augmented plasmid-induced immune 
responses with the VR1012 vector as described in Chapter 3, but the effect on the level of 
immune response from multiple doses was variable and limited. Three-week vaccination 
intervals were used for the initial vaccinations reported in chapter 3 and in chapters  5, 6 
and 8; and a 4-week vaccination interval was used for the layer chickens vaccinated with 
three alternate plasmid vectors reported in Chapter 4.  No antibodies or a very low level 
of measurable antibody responses were detected in the Hy-Line layer chickens that were 
vaccinated in these studies, however, the SPF chickens vaccinated at a 3 week interval 
with the pCAG-HAk construct in Harbin gave moderate HA antibody responses. This 
variability of antibody response induced by the pCAG-HAk construct in the different 
chicken breeds may provide further insights into the efficacy of DNA vaccination and 
would have been followed up in this study if time and resources had permitted. 
The DNA vaccine studies in the Hy-Line chickens were disappointing as far as induction, 
or enhancement of antibody responses was concerned. Booster doses of the DNA vaccine 
using the VR1012 construct administered with lipofectin adjuvant did result in some 
chickens producing antibody responses to HA, although the subsequent studies using two 
doses of the more effective pCAG-HAk construct with three other adjuvants in Hy-Line 
chickens did not induce antibody to the HA. However, the use of the adjuvants lipofectin, 
alum and Phema nanoparticles did enhance the effectiveness of the vaccines in reducing 
virus shedding from the oropharynx after challenge. It is apparent from these studies that 
there needs to be an antibody response to the DNA vaccine itself before one can expect 
significant enhancement via the use of adjuvants. Unfortunately for logistical and   261
resource reasons it was not possible during these studies to conduct adjuvant studies with 
the pCAG-HAk vaccine in SPF chickens.  
DNA vaccines appear to act as their own adjuvant owing to the presence of ISS in their 
backbone (Davis 1997), thus DNA vaccines can be effective without adjuvants. However, 
incorporation of either chemical or genetic adjuvants to DNA vaccines does modulate or 
enhance their efficacy. In this study, lipofectin (liposome), aluminium hydroxide 
(traditional adjuvant), Essai (microparticle) and Phema (nanoparticle) were assessed. 
With the exception of Essai, all the chemicals demonstrated measurable adjuvant effects. 
Since lipofectin is too expensive to allow its routine use, the traditional aluminium 
hydroxide adjuvant, either binding or non-binding with DNA, may be useful as an 
adjuvant for enhancing DNA-induced immune responses in chickens owing to its low 
price and safety record. To our knowledge, nanoparticles have not been used for the 
development of AI DNA vaccines previously. In this study, a novel nanoparticle Phema 
used as an adjuvant showed promising results, comparable with alum adjuvants, for a 
DNA vaccine. The potential of nanoparticles as adjuvants has not been extensively 
explored with DNA vaccines and they are worthy of further investigation due to their 
biodegradability, biocompatibility, lack of side-effects and ease of delivery (Scheerlinck 
and Greenwood 2006). As DNA vaccination induced either Th1- or Th2-biased immune 
responses, use of nanomaterials of varying size, zeta potential and formulation could be 
developed and tested as alternative delivery systems to enhance or target the specific 
immune responses required (Fifis et al. 2004a; Minigo et al. 2007). Another alternative 
for future study is the use of genetic adjuvants whereby plasmid constructs expressing   262
different cytokines or co-stimulatory molecules can be combined with antigen specific 
DNA vaccines (Manoj et al. 2004; Scheerlinck 2001). 
Direct IM injection is a very practical and convenient method for vaccine administration 
in the field (Chen et al. 2001). Compared to the transfection rate in mice, IM injection of 
DNA vaccines in larger animals or humans is lower and thereby, has resulted in lower 
efficacy of DNA vaccines, although the reasons for this are not currently understood 
(Babiuk et al. 2003). Electroporation was shown to substantially intensify delivery of 
DNA to cells, leading to increased expression and elevated immune responses (Widera et 
al. 2000). In Chapters 4 and 5, higher efficacy of HA-expressing DNA vaccination was 
observed via EP than via IM injection. Although increasing the level of gene expression 
by manipulation or optimization of the plasmid vector, or by increasing the number of 
transfected cells through improved delivery systems, may separately result in improved 
efficacy of DNA vaccines, these two approaches are complementary and synergistic and 
a combination of these two approaches may be the most effective for achieving optimal 
DNA immunization (Babiuk et al. 2003). 
Although a large number of DNA vaccine studies have been conducted, many of the 
results are difficult to compare and are inconsistent (Leitner et al. 1999). Indeed, there is 
no universal protocol which applies to all DNA vaccines (Bergmann-Leitner and Leitner 
2004). From the results of these and other studies, one can conclude that it is necessary to 
optimize every newly developed DNA vaccine for maximum effectiveness and this 
appears to be a clear limitation for DNA vaccines. 
One attribute of DNA vaccines is that it is possible to manipulate and/or formulate the 
construct to induce immune responses that are most appropriate for specific pathogens   263
(Babiuk et al. 1999b).  Although DNA immunization, in most cases, induces a 
predominately Th1 response (Babiuk et al. 1999b; Raz et al. 1996), mixed Thl and Th2 
responses are recognised (Davis 1997). Whether a Thl or Th2 response predominates can 
be achieved by altering the method or route of DNA administration (Feltquate et al. 1997; 
Pertmer et al. 1996; Torres et al. 1997), altering the form of the antigen (secreted, 
cytoplasmic or membrane bound) (Lewis et al. 1996), the dose of antigen (Barry and 
Johnston 1997) or by co-administration of plasmids encoding various cytokines or co-
stimulatory molecules (Lewis et al. 1997). 
The experiments with five DNA construct vaccines encoding the H6 HA gene reported in 
this thesis showed that these vaccines gave low to undetectable levels of HA antibody but 
produced evidence of protective immunity in chickens challenged with the homologous 
LPAI virus, as demonstrated by reduction of virus shedding from the oropharynx and 
cloaca in challenged chickens. Similar results with poor antibody responses, but 
protection from challenge have been reported in other studies with influenza viruses in 
mice or chickens (Fynan et al. 1993a; Fynan et al. 1993b; Kodihalli et al. 1997; Robinson 
et al. 1993). Immune responses to antigens expressed by the plasmid DNA transfected 
host cells are mediated by the synergistic activity of B cells and T cells. Antibody 
responses to HA protein are critical for virus neutralization and prevention of influenza 
virus infection (Brown et al. 1992; Webster et al. 1991), whereas, CTL responses play a 
role in the clearance of influenza virus infection (McMichael et al. 1983). Intramuscular 
immunization of mice with an HA-expressing plasmid demonstrated that neutralizing 
antibodies and not CTLs mediated protection against lethal virus challenge (Operschall et 
al. 2000).  In murine studies it is hypothesized that DNA immunization induces a   264
memory response, and protection appears to be mediated by the priming of both T-helper 
and B-cell memories, resulting in a secondary immune response in response to the 
challenge (Fynan et al. 1995). Both cellular and humoral responses contribute to 
protection against influenza virus infection (Robinson et al. 1997). The low 
immunogenicity of DNA vaccines, demonstrated by the presence of low antibody levels, 
is not always an indicator of protective immunity (Scheerlinck 2001). In fact, DNA 
vaccines were particularly effective in priming anamnestic immune responses and the B-
cell memory response was often sufficient to protect animals from challenge (Babiuk et 
al. 1999b; Fynan et al. 1993a; Kodihalli et al. 1999; Kodihalli et al. 1997; Kodihalli et al. 
2000; Robinson et al. 1993). This characteristic of DNA vaccines makes challenge of 
vaccinated animals with the relevant pathogen imperative when evaluating these vaccines 
(Scheerlinck 2001). Indeed, in the majority of studies of DNA immunization so far, 
animals were challenged to measure the level of plasmid-induced protection generated by 
DNA vaccination (Babiuk et al. 1999b). For logistical reasons it was not possible to 
conduct studies of CMI responses to the DNA vaccines post-challenge in the chickens in 
this study, however with the very limited HA antibody responses to the DNA vaccines 
with four of the five vectors, yet evidence of protection from challenge demonstrated by 
reduced virus shedding, one can speculate that the vaccines had stimulated cellular 
immune responses to a certain degree.  
The pCAG-HAk construct generated measurable HI titres in SPF chickens (Chapter 5). 
Nonetheless, in all experiments using Hy-Line chickens, two immunizations with either 
VR-HA, pCI-HA, pCI-neo-HA, pCI-HAk or pCAG-HAk plasmids showed no antibody 
response or the production of a very low level of HI antibody. This important difference   265
in chicken strain effect was discussed in detail in Chapter 7 and would have been the 
focus for further investigation if time and resources had permitted. However, with the 
most efficient pCAG-HAk construct evaluated in SPF chickens, there was only 75% - 
87.5% seroconversion rate following two immunizations (Chapter 5). This highlighted 
that DNA vaccines containing the basic plasmid construct only induced low or moderate 
antibody responses in chickens and that other factors such as the delivery route and 
adjuvants may be necessary to produce strong antibody responses. Other DNA vaccine 
studies such as AI in chickens (Fynan et al. 1993b; Kodihalli et al. 2000; Robinson et al. 
1993), canine parvovirus in dogs (Babiuk et al. 1999b), haematopoietic necrosis virus in 
fish (Corbeil et al. 2000) and influenza in mice  (Fynan et al. 1993b; Johnson et al. 2000; 
Kodihalli et al. 1999) are consistent with this conclusion. 
The prevention of clinical disease and death in vaccinated chickens challenged by various 
HPAI viruses is well documented (Swayne 2009). However, few studies have addressed 
LPAI challenge. It was reported previously that some waterfowl-origin influenza virus 
strains were nephrotropic and enterotropic following intravenous challenge (Slemons and 
Swayne 1990, 1995). However, no virus was recovered from kidneys in naïve chickens 
via oral and oculonasal challenge with the H6N2 virus in the current studies (Chapter 2). 
In some studies with LPAI vaccines, in order to increase LPAI virus multiplication and 
shedding in chickens after challenge, co-infection with Mycoplasma spp. and Salmonella 
spp., as well as high doses of oculonasally inoculated LPAI virus have been used to 
assess the vaccine potency (Cherbonnel et al. 2003; Le Gall-Recule et al. 2007; Rousset 
et al. 2003). In another study, vaccinated ducks were only subjected to high dose of LPAI 
virus challenge by nasal and intraocular instillation (Prel et al. 2007). As these proof-of-  266
concept studies were conducted using a H6N2 LPAI virus which was shown in initial 
characterization studies to cause no clinical or pathological changes, it was decided to use 
level of virus shedding after challenge with homologous virus as an indicator of 
protection in the current studies.  
The frequency and titre of virus shedding after challenge is consistently used as an 
indicator to assess the potency and efficacy of viral vaccines. With vaccines against 
HPAI viruses, challenge studies use both protection rate and measurement of virus 
shedding after HPAI virus challenge to evaluate the potency of vaccines, but with LPAI 
challenge, virus shedding gives an option to measure protection. In a number of HPAI 
challenge studies in chickens,  the post challenge shedding is reported on day 3 
(Kodihalli et al. 1997; Swayne et al. 2000b) or day 7 post-challenge (Chen et al. 2001) 
whereas in these challenge studies with the H6N2 LPAI virus, shedding was assessed by 
collection of cloacal and oropharyngeal swabs on a daily or alternate day basis. Virus 
shedding through the cloaca and oropharynx is a major source of AI virus contamination 
of the environment (Condobery and Slemons 1992; Crawford et al. 1998; Wood et al. 
1994). Effective vaccine strategies to control AI require generation of specific immunity 
to preclude or clear virus replication in the respiratory and gastrointestinal tracts at the 
mucosal level and hence prevent virus shedding and bird-to-bird horizontal transmission 
(Swayne et al. 1997). 
In this study, a total of three virus challenge experiments for assessment of the efficacy of 
DNA vaccines were performed through simultaneous intraocular, intranasal and oral 
inoculation. The challenge doses in the experiments described in Chapters 3, 4 and 7 
were 10
7.25 (0.5 mL), 10
6.25 (1 mL), and 10
6.5 (0.5 mL) EID50 /0.1 mL, respectively. Our   267
three separate challenge protocols produced comparable results. Either the naïve or empty 
vector vaccinated control birds intermittently shed virus following H6N2 virus infection. 
The virus shedding for unvaccinated controls gave similar results across the three 
experiments with the frequency of virus recovery from the oropharynx (58.7% - 54 
chickens positive for virus shedding out of a total of 92 chickens tested) higher than that 
from the cloacal swabs (27.2% - 25/92). In comparison with occasional virus shedding in 
either oropharyngeal or cloacal swabs in the inactivated vaccine control group, the naïve 
control or empty vector control groups displayed higher frequencies of virus shedding. 
However, in the LPAI challenge study in Harbin that used a challenge dose of 0.2 mL 
(EID5010
6.17) of A/duck/Anhui/269/2002 (H6N2) by intranasal instillation, three out of 
six SPF chickens intermittently excreted virus in oropharyngeal swabs only in the first 
four days, whereas, no virus shedding was present in cloacal swabs during the seven 
consecutive days over which swabs were collected. This suggested that high dose 
inoculation of LPAI via multiple routes into chickens was necessary to induce cloacal 
virus shedding. 
In live recombinant vector-based vaccine studies with HPAI virus challenge, survival of 
chickens did not coincide with complete lack of virus shedding from the oropharynx or 
cloaca (Crawford et al. 1999; Swayne et al. 2000a). In an HA-expressing DNA vaccine 
study, GG immunization of chickens with DNA vaccines afforded high levels of 
protection against homologous H5 virus and its antigenic variants with the absence of 
virus shedding in either the trachea or cloaca at day 3 after virus challenge. However, 
whether vaccinated birds occasionally shed virus on other days was unknown (Kodihalli 
et al. 1997). With vaccination against H5N1 HPAI viruses, protection of chickens from   268
disease correlated with approximately 1000-fold reduction in the titre of virus shed from 
the oropharynx compared with unvaccinated controls on day 2 post-challenge (Ellis et al. 
2006). In a murine study with plasmid DNA encoding influenza viral proteins, virus titre 
in the lung of surviving mice after a lethal A/PR/8/34 (HlNl) virus challenge still reached 
10
3.1 EID50/mL (Chen et al. 1998b). The statistically significant difference in virus titre in 
lungs between the vaccinated and control groups directly correlated with the survival of 
mice subjected to a lethal A/PR/8/34 (HlNl) virus challenge. In other words, the 
vaccinated group was regarded as protected even though surviving mice had low levels of 
virus in lung tissue for a period after challenge. In the context of LPAI challenge 
therefore, it is reasonable to presume that a significant reduction of virus shedding in 
vaccinated birds compared to unvaccinated controls is consistent with a degree of 
protection.  
Comparison of the level of virus shedding between groups was made on the basis of 
frequency of positive swabs over the whole post-challenge period rather than comparison 
of virus titres because the titres of virus shed even in unvaccinated controls were very 
low. As compared with the control group, the groups receiving the VR-NP and VR-HA 
constructs as outlined in Chapter 3, and the pCAG-HAk construct outlined in Chapter 8, 
showed significant  reduction in virus shedding in oropharyngeal swabs while the pCI-
HA, pCI-neo-HA and pVAX-HA constructs described in Chapter 4 showed significant 
reduction in virus shedding in cloacal swabs. Therefore, although all the DNA construct 
vaccines gave some reduction in virus shedding following challenge, the extent of 
reduction in virus shedding was inconsistent. However, the adjuvanted 100 µg VR-HA 
group showed a similar reduction in virus shedding to the inactivated virus vaccine group   269
(55.6% reduction for cloacal swabs and 66.7% reduction for oropharyngeal swabs), 
which also gave a significant anti-H6 HA antibody response pre-challenge.  Moreover, 
the adjuvanted VR-NP group, the 100 µg naked or adjuvanted 100 µg pCI-HA group, the 
naked 100 µg pCI-neo-HA group, the 50 µg pVAX-HA, as well as the naked 100 µg 
pCAG-HAk, and alum-NaCl adjuvanted  or phema adjuvanted pCAG-HAk groups 
showed no virus shedding in cloacal swabs,  as was the case for the inactivated vaccine. 
Therefore, it appears possible that immunization with an effective HA-expressing DNA 
vaccine could provide equivalent protection to an inactivated virus vaccine and this 
would potentially reduce or prevent transmission of AIV under field conditions.       
Another strategy that has been used with DNA vaccines is DNA vaccine priming 
followed by boosting with a protein-based vaccine (prime-boost strategy) and this has 
proven to be successful in improving the efficacy of DNA vaccines (Huber et al. 2009; 
Lo et al. 2008; McConkey et al. 2003; McShane 2002; Sedegah et al. 2003; Sedegah et al. 
1998). Evaluation of a prime-boost strategy to enhance immune responses to the H6 HA 
DNA vaccine was planned to be undertaken in the study trip to the Avian Influenza 
Reference Laboratory in Harbin, China. The HA open reading frame (ORF) from the 
A/coot/WA/2727/79 (H6N2) was inserted into the intergenic region between the P and M 
genes of the LaSota Newcastle Disease Virus (NDV) vaccine strain using procedures 
described previously (Ge et al. 2007) and recombinant NDV expressing the H6 influenza 
virus HA was successfully rescued using reverse genetics. This live recombinant vaccine 
was ready to provide HA antigen boosting as part of a prime-boost strategy with the H6 
HA DNA vaccine, but due to time and logistical difficulties this could not be completed 
as part of this thesis.    270
In conclusion, as a proof-of concept study, DNA immunization with various H6 HA gene 
constructs was shown to be variably effective in inducing immune responses in chickens 
and with one construct, pCAG-HAk, in inducing moderate levels of antibody to H6 HA 
in SPF chickens. Different strategies had to be explored before the development of a 
DNA vaccine capable of generating significant levels of H6 HA antibody was achieved.  
The factors investigated to enhance immune responses included the type of plasmid 
vector, the target gene, modifications of the gene insert, the dose of plasmid DNA used, 
optimization of the immunization protocols, evaluation of different delivery methods and 
the use of adjuvants.  Some synergistic effects that improved the efficacy of the H6 HA 
DNA vaccines were demonstrated. Nonetheless, low and variable antibody responses, 
variable levels of protection and considerable inter-individual variability in responses 
were evident. DNA vaccination does provide a new and valuable approach to the 
development of AI vaccines, and offers advantages in safety, speed, simplicity, and the 
ability to target both cellular and humoral immune responses with a broader reactivity 
than the currently used inactivated whole virus vaccines or recombinant vectored 
vaccines. If the disappointing potency of DNA vaccines can be improved and safety can 
be established, this technology platform could become an important tool in combating 
influenza, other infectious diseases and cancers in animals and humans.  
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Appendix 2.1 Sequencing results of avian influenza A/coot/WA/2727/79 (H6N2) virus. 
 
HA gene (1723 bp) 
 
       1 CAAAAGCAGGGGAAAATGATTGCAATCATAATATTCGCGATAGTGGCCTCTACCAGCAAATCAGATAAGATCTGC 
       1          10        20        30        40        50        60        70     
      76 ATTGGATACCATGCCAACAACTCGACAACGCAAGTGGACACAATATTAGAAAAGAATGTGACAGTGACGCATTCA 
      76     80        90        100       110       120       130       140         
     151 ATTGAGCTCCTAGAGAGTCAAAAGGAGGAGAGATTATGCAGAGTATTAAATAAAGCCCCTTTGGATCTAAAGGGT 
     151          160       170       180       190       200       210       220    
     226 TGCACTATTGAAGGTTGGATTCTTGGAAATCCCCAATGTGACATCTTGCTTGGAGACCAAATTTGGTCTTACATA 
     226     230       240       250       260       270       280       290         
     301 GTGGAGAGACCTGGAGCCCAACATGGGATATGCTACCCAGGGGCATTAAATGAATTGGAAGAGTTGAAAGCACTC 
     301          310       320       330       340       350       360       370    
     376 ATTGGATCTGGAGAAAGAGTACAGAGATTTGAAATGTTTCCCAAAAGCACATGGACCGGAGTGGACACTGGCAGT 
     376     380       390       400       410       420       430       440         
     451 GGAGTTACGAAAGCCTGTTCCTACAACAGTGGCTCATCTTTCTACAGAAACCTTTTGTGGATAATAAAAACAAAA 
     451          460       470       480       490       500       510       520    
     526 TCTGCTGCATATCCAGTGATTAGGGGAACATACAATAATACTGGCTCCCAATCAATTCTATATTTCTGGGGTGTA 
     526     530       540       550       560       570       580       590         
     601 CACCATCCTCCTGATACCAATGAGCAAAATACTCTGTATGGTTCTGGTGATAGATATGTTAGAATGGGTACTGAG 
     601          610       620       630       640       650       660       670    
     676 AGCATGAACTTTGCCAAAAGTCCAGAAATAGCAGCGAGACCAGCTGTAAATGGGCAAAGAGGGAGGATTGATTAC 
     676     680       690       700       710       720       730       740         
     751 TATTGGTCTATATTGAAGCCAGGAGAAACCTTAAATGTAGAATCCAATGGCAACTTGATAGCTCCTTGGTATGCT 
     751          760       770       780       790       800       810       820    
     826 TACAAATTCATCAGTTCCAATAACAAGGGAGCTGTCTTCAAATCAAACCTTCCAATTGAAGATTGTGACACTGCC 
     826     830       840       850       860       870       880       890         
     901 TGTCAGACAGTAGCTGGAGCACTAAGGACAAACAAAACTTTCCAAAATGTTAGCCCTCTCTGGATTGGAGAATGT 
     901          910       920       930       940       950       960       970    
     976 CCCAAGTATGTTAAAAGTGATAGCCTAAGACTGGCAACTGGTCTGAGAAATGTCCCACAGGCAGAGACGAGAGGA 
     976     980       990       1000      1010      1020      1030      1040        
    1051 TTGTTCGGGGCCATAGCTGGGTTTATAGAAGGAGGATGGACAGGCATGATAGATGGATGGTATGGCTACCACCAC 
    1051          1060      1070      1080      1090      1100      1110      1120   
    1126 GAGAACTCACAGGGATCAGGCTATGCAGCAGACAAAGAAAGTACCCAGAAAGCAATTGACGGGATCACCAATAAA 
    1126     1130      1140      1150      1160      1170      1180      1190        
    1201 GTCAATTCCATTATTGACAAAATGAACACACAATTTGAGGCAGTAGAGCATGAGTTCTCAAATCTAGAAAGAAGA 
    1201          1210      1220      1230      1240      1250      1260      1270   
    1276 ATAGACAACCTAAACAAGAGAATGGAAGATGGATTTCTAGATGTGTGGACCTACAATGCTGAACTTTTAGTTCTA 
    1276     1280      1290      1300      1310      1320      1330      1340        
    1351 CTGGAAAATGAGAGAACCTTGGACCTGCATGATGCCAATGTGAAGAACCTATATGAAAAAGTGAAATCACAATTG 
    1351          1360      1370      1380      1390      1400      1410      1420   
    1426 AGAGACAATGCAAAGGATTTGGGTAATGGGTGTTTTGAATTTTGGCATAAATGTGATGATGAATGCATCAACTCA 
    1426     1430      1440      1450      1460      1470      1480      1490        
    1501 GTTAAGAATGGCACGTATGACTACCCAAAATACCAAGACGAAAGCAAACTTAATAGGCAGGAAATAGATTCAGTG 
    1501          1510      1520      1530      1540      1550      1560      1570   
    1576 AAACTGGAAAATCTGGGTGTATATCAAATCCTTGCTATTTATAGTACGGTATCGAGCAGTCTAGTTTTGGTGGGA 
    1576     1580      1590      1600      1610      1620      1630      1640        
    1651 CTGGTCATTGCCATGGGTCTTTGGATGTGCTCGAATGGTTCAATGCAATGCAGGATATGTATATAATTAGGAA 
    1651          1660      1670      1680      1690      1700      1710      1720   
 
 
NP gene (1565 bp) 
 
       1 AGCAAAAGCAGGGTAGATAATCACTCACCGAGTGACATCCACATCATGGCGTCTCAAGGCACCAAACGATCTTAT 
       1          10        20        30        40        50        60        70     
      76 GAACAGATGGAAACTGGTGGAGAACGCCAGAATGCTACTGAGATCAGAGCTTCCGTTGGAAGAATGGTTGGTGGA 
      76     80        90        100       110       120       130       140         
     151 ATTGGAAGATTCTACATACAGATGTGCACTGAACTCAAGCTCAGTGACTATGAAGGAAGGCTGATCCAAAATAGC 
     151          160       170       180       190       200       210       220    
     226 ATAACAATAGAGAGAATGGTCCTTTCAGCATTTGATGAAAGGAGGAACAAATACCTGGAGGAGCATCCCAGTGCT 
     226     230       240       250       260       270       280       290         
     301 GGGAAAGATCCTAAGAAGACTGGAGGTCCAATCTACAGAAGGAGAGATGGAAAATGGATTAGAGAACTGATCCTA 
     301          310       320       330       340       350       360       370    
     376 TACGACAAAGAGGAGATCAGGAGAATCTGGCGCCAAGCGAATAATGGGGAGGATGCAACTGCTGGCCTTACCCAT 
     376     380       390       400       410       420       430       440         
     451 TTGATGATATGGCATTCCAACCTCAATGATGCCACTTACCAGAGGACAAGAGCCCTTGTGCGTACTGGGATGGAC 
     451          460       470       480       490       500       510       520    
     526 CCTAGAATGTGCTCTCTGATGCAAGGCTCAACTCTCCCAAGAAGGTCTGGAGCTGCTGGCGCTGCAGTAAAAGGA 
     526     530       540       550       560       570       580       590         
     601 GTCGGAACAATGGTGATGGAACTGATTCGGATGATAAAACGGGGAATCAATGATCGAAATTTCTGGAGAGGCGAA 
     601          610       620       630       640       650       660       670    
     676 AATGGAAGAAGAACAAGGATTGCCTATGAGAGAATGTGCAACATTCTCAAAGGGAAATTCCAAACAGCAGCACAA 
     676     680       690       700       710       720       730       740         
     751 AGAGCAATGATGGACCAGGTGCGAGAAAGCCGGAATCCCGGGAATGCTGAAATTGAAGATCTCATATTTCTGGCG 
     751          760       770       780       790       800       810       820    
     826 CGATCTGCACTCATCCTGAGAGGGTCAGTGGCCCACAAGTCCTGCCTACCTGCTTGTGTGTATGGACTGGCTGTA   272
     826     830       840       850       860       870       880       890         
     901 GCCAGTGGATATGACTTTGAGAGAGAAGGATACTCCCTAGTTGGAATAGATCCTTTCCGCCTACTCCAGAACAGC 
     901          910       920       930       940       950       960       970    
     976 CAAGTATTCAGCCTCATCAGGCCCAACGAAAATCCAGCACACAAGAGTCAATTGGTCTGGATGGCATGCCACTCT 
     976     980       990       1000      1010      1020      1030      1040        
    1051 GCAGCATTTGAAGACCTGAGGGTGTCAAGCTTCATCAGAGGGACAAGGGTGGTCCCAAGAGGACAACTGTCCACC 
    1051          1060      1070      1080      1090      1100      1110      1120   
    1126 AGAGGAGTCCAAATCGCATCAAATGAGAACATGGAAACAATGGACTCTAGCACTCTTGAACTGAGAAGCAGGTAC 
    1126     1130      1140      1150      1160      1170      1180      1190        
    1201 TGGGCTATAAGGACCAGAAGCGGAGGGAACACAAATCAGCAGCGGGCATCAGCTGGACAAATCAGCGTACAACCC 
    1201          1210      1220      1230      1240      1250      1260      1270   
    1276 ACTTTCTCTGTGCAGAGGAGTCTCCCATTCGAGAGAGCAACCATTATGGCAGCATTTACCGGGAACACTGAAGGC 
    1276     1280      1290      1300      1310      1320      1330      1340        
    1351 AGAACATCTGACATGAGAACTGAGATCATAAGAATGATGGAGAGTGCCAGACCAGAAGACGTGTCCTTCCAAGGG 
    1351          1360      1370      1380      1390      1400      1410      1420   
    1426 CGGGGAGTCTTCGAGCTCTCGGACGAAAAGGCAACGAACCCGATCGTGCCTTCCTTTGACATGAGTAACGAGGGA 
    1426     1430      1440      1450      1460      1470      1480      1490        
    1501 TCTTATTTCTTCGGAGACAATGCAGAGGAGTATGACAATTAAAGAAAAATACCCTTGTTTCTACT 
    1501          1510      1520      1530      1540      1550      1560       
 
 
NA gene (1468 bp) 
 
       1 AGCAAAAGCAGGAGTTGAAAATGAATCCAAATCAGAAGACAACAACAATTGGCTCTGTCTCTCCAACCATCGCAA 
       1          10        20        30        40        50        60        70     
      76 CAACATGCTTTCTCATGCAGATTGCTATCCTAGTAACAACTGTGACACTACACTTCAAACAAAGTGAATGCAAAA 
      76     80        90        100       110       120       130       140         
     151 TCCCCTCGAACAATCAAGTAGTTCCATGTGAGCCGATCATAATAGAAAGGAACATAACCGAGATAGTGTATTTAA 
     151          160       170       180       190       200       210       220    
     226 ACAATACTACCATAGAAAAAGAAATTTGTCCAAAAGTAGTAGAATACAGGAATTGGTCAAAACCGCAATGTCAAA 
     226     230       240       250       260       270       280       290         
     301 TTACAGGGTTTGCTCCTTTCTCCAAGGACAACTCAATTCGGCTTTCTGCTGGTGGGGACATTTGGGTAACAAGAG 
     301          310       320       330       340       350       360       370    
     376 AACCTTATGTGTCATGCAGCCCCAATAAATGTTATCAATTTGCGCTTGGGCAGGGGACCACACTGGACAACAAAC 
     376     380       390       400       410       420       430       440         
     451 ACTCAAATGGCACAATACATGATAGAATCCCTCATAGAACCCTTTTAATGAACGAATTGGGTGTTCCGTTTCACT 
     451          460       470       480       490       500       510       520    
     526 TGGGAACAAAGCAAGTGTGCATAGCGTGGTCCAGCTCGAGCTGTCATGATGGGAAAGCATGGCTACATATTTGTG 
     526     530       540       550       560       570       580       590         
     601 TCACTGGGGATGATAGGAATGCAACTGCTAGTTTCATTTATGACGGGATGCTTGTTGATAGTATTGGTTCATGGT 
     601          610       620       630       640       650       660       670    
     676 CTCAAAATATTCTCAGAACTCAAGAGTCAGAATGTGTTTGCATTAATGGGACTTGTACTGTAGTAATGACTGATG 
     676     680       690       700       710       720       730       740         
     751 GAAGTGCTTCAGGAGTGGCTGACACTAGGATACTATTCATTAGAGAAGGGAAGATCGTTCATATCAGCCCATTAT 
     751          760       770       780       790       800       810       820    
     826 CAGGAAGTGCTCAGCATATAGAAGAATGTTCTTGTTATCCCCGATATCCAGACGTCAGATGTGTTTGCAGAGACA 
     826     830       840       850       860       870       880       890         
     901 ACTGGAAAGGTTCAAATAGGCCCGTTATAAATATAAATATGGCAGATTATAGCATTGATTCCAGTTACGTATGCT 
     901          910       920       930       940       950       960       970    
     976 CAGGACTTGTCGGCGACACACCAAGGAACGATGATAGCTCTAGCAGCAGCAACTGCAGAGATCCTAATAATGAAA 
     976     980       990       1000      1010      1020      1030      1040        
    1051 GAGGGAACCCAGGAGTGAAAGGATGGGCCTTTGACAATGGAAATGATGTTTGGATGGGTAGAACAATCAGCAAAG 
    1051          1060      1070      1080      1090      1100      1110      1120   
    1126 ATTCGCGCTCAGGTTATGAGACATTCAGAGTTATTGGTGGTTGGGCCACAGCTAATGCCAAGTCACAGATCAATA 
    1126     1130      1140      1150      1160      1170      1180      1190        
    1201 GGCAGATCATAGTTGACAATAATAACTGGTCTGGTTACTCTGGTATTTTCTCTGTTGAAGGCAAAAGCTGTATCA 
    1201          1210      1220      1230      1240      1250      1260      1270   
    1276 ATAGGTGTTTTTATGTGGAGTTGATAAGAGGGAGGCCGCAGGAAACTAGAGTATGGTGGACCTCAAACAGTATTG 
    1276     1280      1290      1300      1310      1320      1330      1340        
    1351 TCGTATTTTGCGGCACTTCAGGTACTTATGGAACAGGCTCATGGCCTGATGGGGCAAATATCAATTTCATGCCTA 
    1351          1360      1370      1380      1390      1400      1410      1420   
    1426 TATAAGCTTTCGCAATTTTAGAAAAAAACTCCTTGTTTCTACT 
    1426     1430      1440      1450      1460       
 
 
*Underlined areas refer to extra sequence outside that listed in GenBank. Underlined bold sequence refers to cleavage 
site in HA.  
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Appendix 6.1 Comparison of HA and optiHA sequences.  
 
 
HA              ATGATTGCAATCATAATATTCGCGATAGTGGCCTCTACCAGCAAATCAGATAAGATCTGC 60 
OptiHA          ATGATCGCCATCATCATCTTCGCCATCGTGGCCAGCACCAGCAAGAGCGATAAGATCTGC 60 
                ***** ** ***** ** ***** ** ******   ********    ************ 
 
HA              ATTGGATACCATGCCAACAACTCGACAACGCAAGTGGACACAATATTAGAAAAGAATGTG 120 
OptiHA          ATCGGCTACCACGCCAACAACAGCACCACCCAGGTGGATACCATCCTGGAGAAGAACGTG 120 
                ** ** ***** *********   ** ** ** ***** ** **  * ** ***** *** 
 
HA              ACAGTGACGCATTCAATTGAGCTCCTAGAGAGTCAAAAGGAGGAGAGATTATGCAGAGTA 180 
OptiHA          ACCGTGACCCACAGCATCGAGCTGCTGGAGAGCCAGAAGGAGGAGAGACTGTGCAGAGTG 180 
                ** ***** **    ** ***** ** ***** ** ************ * ********  
 
HA              TTAAATAAAGCCCCTTTGGATCTAAAGGGTTGCACTATTGAAGGTTGGATTCTTGGAAAT 240 
OptiHA          CTGAACAAGGCCCCCCTGGATCTGAAGGGCTGCACCATCGAGGGCTGGATCCTGGGCAAC 240 
                 * ** ** *****  ******* ***** ***** ** ** ** ***** ** ** **  
 
HA              CCCCAATGTGACATCTTGCTTGGAGACCAAATTTGGTCTTACATAGTGGAGAGACCTGGA 300 
OptiHA          CCCCAGTGCGATATCCTGCTGGGCGATCAGATCTGGAGCTACATCGTGGAGAGACCCGGC 300 
                ***** ** ** *** **** ** ** ** ** ***   ***** *********** **  
 
HA              GCCCAACATGGGATATGCTACCCAGGGGCATTAAATGAATTGGAAGAGTTGAAAGCACTC 360 
OptiHA          GCCCAGCACGGCATCTGCTACCCCGGCGCCCTGAACGAGCTGGAGGAGCTGAAGGCCCTG 360 
                ***** ** ** ** ******** ** **  * ** **  **** *** **** ** **  
 
HA              ATTGGATCTGGAGAAAGAGTACAGAGATTTGAAATGTTTCCCAAAAGCACATGGACCGGA 420 
OptiHA          ATCGGCAGCGGCGAGAGAGTGCAGAGATTCGAGATGTTCCCCAAGAGCACCTGGACCGGC 420 
                ** **    ** ** ***** ******** ** ***** ***** ***** ********  
 
HA              GTGGACACTGGCAGTGGAGTTACGAAAGCCTGTTCCTACAACAGTGGCTCATCTTTCTAC 480 
OptiHA          GTGGATACCGGCAGCGGCGTGACCAAGGCCTGCAGCTACAACAGCGGCAGCAGCTTCTAC 480 
                ***** ** ***** ** ** ** ** *****   ********* ***      ****** 
 
HA              AGAAACCTTTTGTGGATAATAAAAACAAAATCTGCTGCATATCCAGTGATTAGGGGAACA 540 
OptiHA          AGAAACCTGCTGTGGATCATCAAGACCAAGAGCGCCGCCTACCCCGTGATCAGAGGCACC 540 
                ********  ******* ** ** ** **    ** ** ** ** ***** ** ** **  
 
HA              TACAATAATACTGGCTCCCAATCAATTCTATATTTCTGGGGTGTACACCATCCTCCTGAT 600 
OptiHA          TACAACAACACCGGCAGCCAGAGCATCCTGTACTTCTGGGGCGTGCACCACCCCCCCGAT 600 
                ***** ** ** ***  ***    ** ** ** ******** ** ***** ** ** *** 
 
HA              ACCAATGAGCAAAATACTCTGTATGGTTCTGGTGATAGATATGTTAGAATGGGTACTGAG 660 
OptiHA          ACCAACGAGCAGAACACCCTGTACGGCAGCGGCGATAGATACGTGAGAATGGGCACCGAG 660 
                ***** ***** ** ** ***** **    ** ******** ** ******** ** *** 
 
HA              AGCATGAACTTTGCCAAAAGTCCAGAAATAGCAGCGAGACCAGCTGTAAATGGGCAAAGA 720 
OptiHA          AGCATGAACTTCGCCAAGAGCCCCGAGATCGCCGCCAGACCCGCCGTGAACGGCCAGAGA 720 
                *********** ***** ** ** ** ** ** ** ***** ** ** ** ** ** *** 
 
HA              GGGAGGATTGATTACTATTGGTCTATATTGAAGCCAGGAGAAACCTTAAATGTAGAATCC 780 
OptiHA          GGCAGAATCGATTACTACTGGAGCATCCTGAAGCCCGGCGAGACCCTGAACGTGGAGAGC 780 
                ** ** ** ******** ***   **  ******* ** ** *** * ** ** **   * 
 
HA              AATGGCAACTTGATAGCTCCTTGGTATGCTTACAAATTCATCAGTTCCAATAACAAGGGA 840 
OptiHA          AACGGCAACCTGATCGCCCCCTGGTACGCCTACAAGTTCATCAGCAGCAACAACAAGGGC 840 
                ** ****** **** ** ** ***** ** ***** ********   *** ********  
 
HA              GCTGTCTTCAAATCAAACCTTCCAATTGAAGATTGTGACACTGCCTGTCAGACAGTAGCT 900 
OptiHA          GCCGTGTTCAAGAGCAACCTGCCCATCGAGGATTGCGATACCGCCTGCCAGACCGTGGCC 900 
                ** ** *****    ***** ** ** ** ***** ** ** ***** ***** ** **  
 
HA              GGAGCACTAAGGACAAACAAAACTTTCCAAAATGTTAGCCCTCTCTGGATTGGAGAATGT 960 
OptiHA          GGCGCCCTGAGAACCAACAAGACCTTCCAGAACGTGAGCCCCCTGTGGATCGGCGAGTGC 960 
                ** ** ** ** ** ***** ** ***** ** ** ***** ** ***** ** ** **  
 
HA              CCCAAGTATGTTAAAAGTGATAGCCTAAGACTGGCAACTGGTCTGAGAAATGTCCCACAG 1020 
OptiHA          CCCAAGTACGTGAAGAGCGATAGCCTGAGACTGGCCACCGGCCTGAGAAACGTGCCCCAG 1020 
                ******** ** ** ** ******** ******** ** ** ******** ** ** *** 
 
HA              GCAGAGACGAGAGGATTGTTCGGGGCCATAGCTGGGTTTATAGAAGGAGGATGGACAGGC 1080 
OptiHA          GCCGAGACCAGAGGCCTGTTCGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACCGGC 1080 
                ** ***** *****  ******* ***** ** ** ** ** ** ** ** ***** *** 
 
HA              ATGATAGATGGATGGTATGGCTACCACCACGAGAACTCACAGGGATCAGGCTATGCAGCA 1140 
OptiHA          ATGATCGATGGCTGGTACGGCTACCACCACGAGAACAGCCAGGGCAGCGGCTACGCCGCC 1140 
                ***** ***** ***** ******************   *****    ***** ** **  
 
HA              GACAAAGAAAGTACCCAGAAAGCAATTGACGGGATCACCAATAAAGTCAATTCCATTATT 1200   274
OptiHA          GATAAGGAGAGCACCCAGAAGGCCATCGATGGCATCACCAACAAGGTGAACAGCATCATC 1200 
                ** ** ** ** ******** ** ** ** ** ******** ** ** **   *** **  
 
HA              GACAAAATGAACACACAATTTGAGGCAGTAGAGCATGAGTTCTCAAATCTAGAAAGAAGA 1260 
OptiHA          GATAAGATGAACACCCAGTTCGAGGCCGTGGAGCACGAGTTCAGCAACCTGGAGAGAAGA 1260 
                ** ** ******** ** ** ***** ** ***** ******   ** ** ** ****** 
 
HA              ATAGACAACCTAAACAAGAGAATGGAAGATGGATTTCTAGATGTGTGGACCTACAATGCT 1320 
OptiHA          ATCGATAACCTGAACAAGAGAATGGAGGATGGCTTCCTGGATGTGTGGACCTACAACGCC 1320 
                ** ** ***** ************** ***** ** ** ***************** **  
 
HA              GAACTTTTAGTTCTACTGGAAAATGAGAGAACCTTGGACCTGCATGATGCCAATGTGAAG 1380 
OptiHA          GAGCTGCTGGTGCTGCTGGAGAACGAGAGAACCCTGGATCTGCACGATGCCAACGTGAAG 1380 
                ** **  * ** ** ***** ** ********* **** ***** ******** ****** 
 
HA              AACCTATATGAAAAAGTGAAATCACAATTGAGAGACAATGCAAAGGATTTGGGTAATGGG 1440 
OptiHA          AACCTGTACGAGAAGGTGAAGAGCCAGCTGAGAGATAACGCCAAGGATCTGGGCAACGGC 1440 
                ***** ** ** ** *****    **  ******* ** ** ****** **** ** **  
 
HA              TGTTTTGAATTTTGGCATAAATGTGATGATGAATGCATCAACTCAGTTAAGAATGGCACG 1500 
OptiHA          TGCTTCGAGTTCTGGCACAAGTGCGATGATGAGTGCATCAACAGCGTGAAGAACGGCACC 1500 
                ** ** ** ** ***** ** ** ******** *********   ** ***** *****  
 
HA              TATGACTACCCAAAATACCAAGACGAAAGCAAACTTAATAGGCAGGAAATAGATTCAGTG 1560 
OptiHA          TACGATTACCCCAAGTACCAGGATGAGAGCAAGCTGAACAGACAGGAGATCGATAGCGTG 1560 
                ** ** ***** ** ***** ** ** ***** ** ** ** ***** ** ***   *** 
 
HA              AAACTGGAAAATCTGGGTGTATATCAAATCCTTGCTATTTATAGTACGGTATCGAGCAGT 1620 
OptiHA          AAGCTGGAGAACCTGGGCGTGTACCAGATCCTGGCCATCTACAGCACCGTGAGCAGCAGC 1620 
                ** ***** ** ***** ** ** ** ***** ** ** ** ** ** **    *****  
 
HA              CTAGTTTTGGTGGGACTGGTCATTGCCATGGGTCTTTGGATGTGCTCGAATGGTTCAATG 1680 
OptiHA          CTGGTGCTGGTGGGCCTGGTGATCGCCATGGGCCTGTGGATGTGCAGCAACGGCAGCATG 1680 
                ** **  ******* ***** ** ******** ** *********   ** **    *** 
 
HA              CAATGCAGGATATGTATATAA 1701 
OptiHA          CAGTGCAGAATCTGCATCTRR 1701 
                ** ***** ** ** ** *   
 
 
* refers to the same nucleotide by alignment.  
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